DRAFT - DO NOT CITE OR QUOTE

NCEA-S-3010 www.epa.gov/iris



TOXICOLOGICAL REVIEW

OF

ETHYLENE GLYCOL MONOBUTYL ETHER (EGBE)

NOTICE (CAS No. 111-76-2)

In Support of Summary Information on the Integrated Risk Information System (IRIS)

APRIL 2008

This document is an **External Review draft**. This information is distributed solely for the purpose of pre-dissemination peer review under applicable information quality guidelines. It has not been formally disseminated by EPA. It does not represent and should not be construed to represent any Agency determination or policy. It is being circulated for review of its technical accuracy and science policy implications.

> U.S. Environmental Protection Agency Washington, DC

Disclaimer

This document is a preliminary draft for review purposes only. This information is
 distributed solely for the purpose of pre-dissemination peer review under applicable information
 quality guidelines. It has not been formally disseminated by EPA. It does not represent and
 should not be construed to represent any Agency determination or policy. Mention of trade
 names or commercial products does not constitute endorsement or recommendation for use.

ii

Contents

Toxicological Review of Ethylene Glycol Monobutyl Ether (CAS NO. 111-76-2)

1	List of Tables	vi
2	List of Figures	viii
3	List of Acronyms	ix
4	Foreword	xi
5	Authors, Contributors, and Reviewers	xii
6	Chemical Managers/Authors	xii
7	Internal EPA Reviewers	xii
8	1. Introduction	1
9	2. Chemical and Physical Information	3
10	3. Toxicokinetics	4
11	3.1. Absorption and Distribution	4
12	3.2. Metabolism and Elimination	5
13	4. Hazard Identification	12
14	4.1. Studies in Humans: Epidemiology, Case Reports, Clinical Controls	12
15	4.2. Subchronic and Chronic Studies and Cancer Bioassays in Animals: Oral and Inhalation	15
16	4.2.1. Subchronic Studies	15
17	4.2.1.1. Oral	15
18	4.2.1.2. Inhalation	20
19	4.2.2. Chronic Studies and Cancer Bioassays	
20	4.2.2.1. Inhalation	25
21	4.3. Reproductive and Developmental Studies: Oral and Inhalation	
22	4.4. Other Studies	
23	4.4.1. Acute and Short-Term Exposure Studies	
24	4.4.2. Dermal Exposure Studies	
25	4.4.3. Ocular Exposure Studies	39
26	4.4.4. Genotoxicity	39
27	4.4.5. Immunotoxicity	42
28	4.4.6. Other In Vitro Studies	44
29	4.5. Synthesis and Evaluation of Major Noncancer Effects and Mode of Action: Oral and Inhala	ation 46
30	4.6. Evaluation of Carcinogenicity	51
31	4.6.1. Summary of Overall Weight of Evidence	51
32	4.6.2. Synthesis of Human, Animal, and Other Supporting Evidence	51
33	4.6.3. Mode of Action Information	53
34	4.6.3.1. Hypothesized Mode of Action for Liver Tumor Development in Male Mice	53

iii

1	4.6.3.1.1. Temporal association and species specificity	56
2	4.6.3.1.2. Dose-response relationships	56
3	4.6.3.1.3. Biological plausibility and coherence of the database	57
4	4.6.3.1.4. Relevance of the hypothesized MOA to humans	58
5	4.6.3.1.5. Other possible MOAs for liver tumor development in male mice	59
6	4.6.3.2. Hypothesized Mode of Action for Forestomach Tumor Development in Female Mi	ce 62
7	4.6.3.2.1. Temporal association	64
8	4.6.3.2.2. Dose-response relationships	64
9	4.6.3.2.3. Biological plausibility and coherence of the database	65
10	4.6.3.2.4. Relevance of the hypothesized MOA to humans	66
11	4.6.3.2.5. Other possible MOAs for forestomach tumor development in female mice	66
12	4.6.3.3. Conclusions About the Hypothesized Modes of Action	67
13	4.7. Susceptible Populations	68
14	4.7.1. Possible Childhood Susceptibility	70
15	4.7.2. Possible Gender Differences	71
16	5. Dose-Response Assessments	73
17	5.1. Inhalation Reference Concentration (RfC)	73
18	5.1.1. Choice of Principal Study and Critical Effect, with Rationale and Justification	73
19	5.1.2. Methods of Analysis, Including Models (PBPK, BMD, etc.)	77
20	5.1.2.1. Derivation of the POD Using PBPK Modeling and the NOAEL/LOAEL Method	77
21	5.1.2.2. Derivation of the POD Using PBPK Modeling and BMD Modeling Methods	80
22	5.1.2.2.1. BMD approach applied to hematological data.	80
23	5.1.2.2.2. BMD approach applied to hemosiderin staining data	82
24	5.1.2.3. Selection of the POD	85
25	5.1.3. RfC Derivation, Including Application of Uncertainty Factors (UFs)	86
26	5.1.4. RfC Comparison Information	87
27	5.1.5. Previous Inhalation Assessment	89
28	5.2. Oral Reference Dose (RfD)	89
29	5.2.1. Choice of Principal Study and Critical Effect, with Rationale and Justification	89
30	5.2.2. Methods of Analysis, Including Models (PBPK, BMD, etc.)	92
31	5.2.2.1. Derivation of POD Using PBPK Model and NOAEL/LOAEL Method	92
32	5.2.2.2. Derivation of POD Using PBPK and BMD Methods	94
33	5.2.2.2.1. BMD approach applied to hematological data.	94
34	5.2.2.2. BMD approach applied to hemosiderin endpoint	96
35	5.2.2.3. Route-to-Route Extrapolation from Inhalation Data	96
36	5.2.2.4. Selection of the POD	96
37	5.2.3. RfD Derivation, Including Application of Uncertainty Factors (UFs)	97
38	5.2.4. Previous Oral Assessment	98
39	5.3. Uncertainties in the Derivation of the Inhalation Reference Concentration (RfC) and Oral	
40	Reference Dose (RfD)	99
41	5.3.1. Choice of endpoint	99

iv

1	5.3.2. Choice of dose metric	
2	5.3.3. Use of BMC approach	
3	5.3.4. Choice of model for BMCL derivations	
4	5.3.5. Choice of animal to human extrapolation method	
5	5.3.6. Route-to-route extrapolation	
6	5.3.7. Statistical uncertainty at the POD	
7	5.3.8. Choice of bioassay	
8	5.3.9. Choice of species/gender	
9	5.3.10. Human relevance of noncancer responses observed in mice	
10	5.3.11. Human population variability	
11	5.4. Cancer Assessment	
12	5.4.1. Uncertainties in Cancer Risk Assessment	
13	5.1.1.1. Choice of low-dose extrapolation method	
14	5.4.1.2. Human relevance of cancer responses observed in mice	
15	5.5. Potential Impact of Select Uncertainties on the RfC	
16	6. Major Conclusions in the Characterization of Hazard and Dose Response	
17	6.1. Human Hazard Potential	
18	6.2. Dose Response	
19	Appendix A	
20	Appendix B	

v

21 Appendix C

List of Tables

1 2	Table 4-1. Hematology and hemosiderin data from the 13-week drinking-water exposure EGBE in F344 rats.	
3 4	Table 4-2. Incidence [*] and severity of selected histopathological lesions from the 13-wee drinking water exposure to EGBE in F344 rats.	
5 6	Table 4-3. Hematology and hemosiderin data from a 14-week inhalation study of EGBEF344 rats.	
7 8	Table 4-4. Hematology and hemosiderin data from a 14-week inhalation study of EGBE B6C3F1 mice.	
9 10	Table 4-5. Selected Female and Male Rat and Mouse Non-neoplastic effects from the 2- Chronic EGBE Inhalation Study	•
11 12	Table 4-6. Comparison of Female and Male Rat and Mouse Hct (Manual) Values from 3 and 12-month Inhalation Exposures to EGBE.	
13	Table 4-7. Summary of genotoxicity studies on EGBE, BAL, and BAA.	41
14 15	Table 4-8. Incidence of liver hemangiosarcomas and hepatocellular carcinomas in studie NTP chemicals that caused increased hemosiderin in Kupffer cells in male minimum	
16	Table 5-1. Results of candidate studies	74
17 18	Table 5-2. Female and male rat and mouse liver hemosiderin staining incidence and RB from subchronic and chronic EGBE inhalation studies.	
19	Table 5-3. Summary of PBPK models.	79
20 21	Table 5-4. Model estimates of BAA blood levels in female rats following inhalation exposures.	81
22 23 24	Table 5-5. Comparison of BMC/BMCL values for female rat RBC count data from a 14 week subchronic inhalation study, using modeled blood Cmax (3 months) of the EGBE metabolite BAA as a common dose metric.	the
25 26	Table 5-6. AUC BAA blood concentrations measured at 12 months in both sexesgenderB6C3F1 mice and F344 rats.	
27 28 29	Table 5-7. Comparison of BMC/BMCL values for male and female rat liver hemosiderin staining data from inhalation chronic study using measured blood AUC (12 months) of the EGBE metabolite BAA as a common dose metric.	
30 31 32	Table 5-8. Comparison of BMC/BMCL values for male and female mouse liver hemosiderin staining data from inhalation chronic study using measured blood AUC (12 months) of the EGBE metabolite BAA as a common dose metric	
33 34	Table 5-9. Summary of the application of UFs for RfC derivations using NOAEL/LOAI and BMC modeling approaches for male rat liver hemosiderin staining	
35	Table 5-10. Subchronic 91-day drinking water studies in rats and mice	90
36	Table 5-11. Modeled estimates of BAA in human blood exposed to EGBE in water	93
	April 2008 vi DRAFT-DO NOT CITE OR	QUOTE

1	Table 5-12. Model estimates of BAA blood levels in female rats following oral exposures	94
2 3 4	Table 5-13. Comparison of female rat RBC count and MCV BMD/BMDL values from an oral subchronic study using modeled blood Cmax (3 months) of the EGBE metabolite BAA as a common dose metric.	95
5 6	Table 5-14. Summary of the application of UFs for RfD derivations using NOAEL/LOAEL and BMD modeling approaches.	97
7	Table 5-15. Summary of uncertainty in the EGBE noncancer and cancer risk assessments	105
8 9	Table 5-16. Illustrative potency estimates for tumors in mice, using a linear analysis approach.	106

List of Figures

1	Figure 3-1. Proposed metabolic scheme of EGBE in rats and humans.	6
2 3	Figure 4-3. Simulated concentrations of EGBE, BAL, and BAA in liver tissues of female mice exposed via inhalation for 6 hours to 250 ppm EGBE.	61
4 5	Figure 5-5. Points of departure for selected endpoints with corresponding applied UFs and derived RfC.	88
6	Figure 5-7. Potential impact of select uncertainties on the RfC for EGBE.	108

List of Acronyms

1	ADH	alcohol dehydrogenase
2	AIC	Akaike Information Criterion
3	ALD	aldehyde dehydrogenase
4	AUC	area under the curve
5	BAA	butoxyacetic acid
6	BAL	butoxyacetaldehyde
7	BMC	benchmark concentration
8	BMCL	benchmark concentration, 95% lower bound
9	BMD	benchmark dose
10	BMDL	benchmark dose, 95% lower bound
11	BMDS	benchmark dose software
12	BMR	benchmark response
13	CASRN	Chemical Abstracts Service Registry Number
14	CHR	contact hypersensitivity response
15	CI	confidence interval
16	Cl _S	clearance rate
17	con-A	concanavalin-A
18	C_{max}	peak concentration
19	CYP450	cytochrome P450
20	DNA	deoxyribonucleic acid
21	EA	ethyl acrylate
22	EG	ethylene glycol
23	EGBE	ethylene glycol monobutyl ether
24	EGEE	ethylene glycol ethyl ether
25	EGME	ethylene glycol methyl ether
26	EPA	U.S. Environmental Protection Agency
27	GD	gestation day
28	GFR	glomerular filtration rate
29	G6PD	glucose-6-phosphate dehydrogenase
30	GSH	glutathione
31	Hb	hemoglobin
32	Hct	hematocrit
33	HEC	human equivalent concentration
34	HED	human equivalent dose

1	HH	hereditary hemochromatosis
2	Нр	haptoglobin
3	i.p.	intraperitoneal
4	i.v.	intravenous
5	IRIS	Integrated Risk Information System
6	KLH	keyhole limpet hemocyanin
7	LOAEL	lowest-observed-adverse-effect level
8	MAA	2-methoxyacetic acid
9	MCH	mean corpuscular hemoglobin
10	MCHC	mean corpuscular hemoglobin concentration
11	MCV	mean cell volume
12	ME	2-methoxyethanol
13	MOA	mode of action
14	NK	natural killer
15	NOAEL	no-observed-adverse-effect level
16	NTP	National Toxicology Program
17	NZW	New Zealand white
18	8-OHdG	8-hydroxydeoxyguanosine
19	OR	osmotic resistance
20	OXA	oxazolone
21	PBPK	physiologically based pharmacokinetic
22	PFC	plaque-forming cell
23	POD	point of departure
24	RBC	red blood cell
25	RfC	reference concentration
26	RfD	reference dose
27	ROS	reactive oxygen species
28	S.C.	subcutaneous
29	SCE	sister chromatid exchange
30	SD	standard deviation
31	$t_{\frac{1}{2}}$	half-life
32	TNFα	tumor necrosis factor-alpha
33	TNP-LPS	trinitrophenyl-lipopolysaccharide
34	UF	uncertainty factor
35	V_d	volume of distribution
36	WBC	white blood cell

х

Foreword

1	The purpose of this Toxicological Review is to provide scientific support and rationale
2	for the hazard and dose-response assessment in IRIS pertaining to chronic exposure to ethylene
3	glycol monobutyl ether (EGBE). It is not intended to be a comprehensive treatise on the
4	chemical or toxicological nature of EGBE.
5	The intent of Section 6, Major Conclusions in the Characterization of Hazard and Dose
6	Response, is to present the major conclusions reached in the derivation of the reference dose,
7	reference concentration and cancer assessment, where applicable and to characterize the overall
8	confidence in the quantitative and qualitative aspects of hazard and dose response by addressing
9	the quality of data and related uncertainties. The discussion is intended to convey the limitations
10	of the assessment and to aid and guide the risk assessor in the ensuing steps of the risk
11	assessment process.
12	For other general information about this assessment or other questions relating to IRIS,
13	the reader is referred to EPA's IRIS Hotline at (202) 566-1676 (phone), (202) 566-1749 (fax), or

14 <u>hotline.iris@epa.gov</u> (email address).

Authors, Contributors, and Reviewers

Chemical Managers/Authors

Angela Howard, Ph.D. National Center for Environmental Assessment U.S. Environmental Protection Agency Research Triangle Park, NC

Internal EPA Reviewers

Ila Cote, Ph.D., DABT National Center for Environmental Assessment U.S. Environmental Protection Agency Research Triangle Park, NC

Jennifer Jinot, Ph.D. National Center for Environmental Assessment U.S. Environmental Protection Agency Washington, DC

Jane Caldwell, Ph.D. National Center for Environmental Assessment U.S. Environmental Protection Agency Washington, DC

John Whalan National Center for Environmental Assessment U.S. Environmental Protection Agency Washington, DC Jeffrey Gift, Ph.D. National Center for Environmental Assessment U.S. Environmental Protection Agency Research Triangle Park, NC

Lynn Flowers, Ph.D., DABT National Center for Environmental Assessment U.S. Environmental Protection Agency Washington, DC

Gary Foureman, Ph.D. National Center for Environmental Assessment U.S. Environmental Protection Agency Research Triangle Park, NC

John Vandenberg, Ph.D. National Center for Environmental Assessment U.S. Environmental Protection Agency Research Triangle Park, NC

1. Introduction

1 This document presents background information and justification for the Integrated Risk 2 Information System (IRIS) Summary of the hazard and dose-response assessment of ethylene 3 glycol monobutyl ether (EGBE). IRIS Summaries may include oral reference dose (RfD) and 4 inhalation reference concentration (RfC) values for chronic and other exposure durations, and a 5 carcinogenicity assessment.

6 The RfD and RfC, if derived, provide quantitative information for use in risk assessments 7 for health effects known or assumed to be produced through a nonlinear, presumed threshold, 8 mode of action (MOA). The RfD, expressed in units of mg/kg-day, is defined as an estimate 9 (with uncertainty spanning perhaps an order of magnitude) of daily exposure to the human 10 population, including sensitive subgroups, that is likely to be without an appreciable risk of deleterious effects during a lifetime. The inhalation RfC, expressed in units of mg/m^3 , is 11 analogous to the oral RfD, but provides a continuous inhalation exposure estimate. The 12 13 inhalation RfC considers toxic effects for both the respiratory system (portal of entry) and effects 14 peripheral to the respiratory system (extrarespiratory or systemic effects). Reference values are 15 generally derived for chronic exposure (up to a lifetime), but may also be derived for acute (≤ 24 16 hours), short-term (>24 hours up to 30 days), and subchronic (>30 days up to 10% of lifetime) 17 exposure durations. All values are derived based on the assumption of continuous exposure 18 throughout the duration specified. Unless specified otherwise, the RfD and RfC are derived for 19 chronic exposure duration. 20 The carcinogenicity assessment provides information on the carcinogenic hazard 21 potential of the substance in question and quantitative estimates of risk from oral and inhalation 22 exposure may be derived. The information includes a weight-of-evidence judgment of the 23 likelihood that the agent is a human carcinogen and the conditions under which the carcinogenic 24 effects may be expressed. Quantitative risk estimates may be derived from the application of a 25 low-dose extrapolation procedure. If derived, the oral slope factor is an upper bound on the 26 estimate of risk per mg/kg-day of oral exposure. Similarly, an inhalation unit risk is an upper bound on the estimate of risk per $\mu g/m^3$ air breathed. 27

- Development of these hazard identification and dose-response assessments for EGBE has
 followed the general guidelines for risk assessment as set forth by the National Research Council
 (1983). EPA Guidelines and Risk Assessment Forum Technical Panel Reports that may have
- 31 been used in the development of this assessment include the following: *Guidelines for the Health*
- 32 Risk Assessment of Chemical Mixtures (U.S. EPA, 1986a), Guidelines for Mutagenicity Risk
- 33 Assessment (U.S. EPA, 1986b), Recommendations for and Documentation of Biological Values

1

34 for Use in Risk Assessment (U.S. EPA, 1988), Guidelines for Developmental Toxicity Risk

April 2008

DRAFT-DO NOT CITE OR QUOTE

- 1 Assessment (U.S. EPA, 1991), Interim Policy for Particle Size and Limit Concentration Issues in
- 2 Inhalation Toxicity (U.S. EPA, 1994a), Methods for Derivation of Inhalation Reference
- 3 Concentrations and Application of Inhalation Dosimetry (U.S. EPA, 1994b), Use of the
- 4 Benchmark Dose Approach in Health Risk Assessment (U.S. EPA, 1995), Guidelines for
- 5 Reproductive Toxicity Risk Assessment (U.S. EPA, 1996), Guidelines for Neurotoxicity Risk
- 6 Assessment (U.S. EPA, 1998), Science Policy Council Handbook: Risk Characterization (U.S.
- 7 EPA, 2000a), Benchmark Dose Technical Guidance Document (U.S. EPA, 2000b),
- 8 Supplementary Guidance for Conducting Health Risk Assessment of Chemical Mixtures (U.S.
- 9 EPA, 2000c), A Review of the Reference Dose and Reference Concentration Processes (U.S.
- 10 EPA, 2002), Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), Supplemental
- 11 Guidance for Assessing Susceptibility from Early-Life Exposure to Carcinogens (U.S. EPA,
- 12 2005b), Science Policy Council Handbook: Peer Review (U.S. EPA, 2006a), and A Framework
- 13 for Assessing Health Risks of Environmental Exposures to Children (U.S. EPA, 2006b).
- 14 The literature search strategy employed for this compound was based on the Chemical
- 15 Abstracts Service Registry Number (CASRN) and at least one common name. Any pertinent
- 16 scientific information submitted by the public to the IRIS Submission Desk was also considered
- 17 in the development of this document. The relevant literature was reviewed through August 2007.

2. Chemical and Physical Information

EGBE is also known as 2-butoxyethanol. EGBE is widely used as a solvent in various 1 2 applications, such as in surface coatings, spray lacquer, quick-dry lacquers, enamels, varnishes, 3 varnish removers, latex paint, and metal cleaners and in commercially available cleaning 4 products. EGBE has been estimated to range in concentration from 1 to 30% (volume/volume) in 5 industrial and commercial products. The average concentration of EGBE in household products 6 in 1977 was 2.6%. EGBE is a high production volume chemical with an estimated 390 million 7 pounds produced in the United States in 1992 (National Toxicology Program [NTP], 2000). 8 Some relevant physical and chemical properties of EGBE are: 9

Empirical formula: Molecular weight: Vapor pressure:	111-76-2 C ₄ H ₉ -O-CH ₂ CH ₂ -OH 118.2 0.88 mm Hg at 25°C (about 1200 ppm) Miscible
Log Kow: Henry's law constant: Flash point:	

10 EGBE exists as a colorless liquid at ambient temperature and pressure. Its evaporation 11 rate relative to butyl acetate is 0.08; thus, it is considered a "slow evaporator." It is miscible in 13 water and partitions about equally between phases of octanol and water. Considering the 14 magnitude of the octanol:water partition coefficient ($\approx 7:1$), it is unlikely that EGBE 15 bioaccumulates. Based on the magnitude of the Henry's law constant, it is anticipated that 16 partitioning of EGBE between water and air greatly favors the water phase.

3. Toxicokinetics

3.1. Absorption and Distribution

1 EGBE is absorbed and rapidly distributed in humans following inhalation, ingestion, or 2 dermal exposure. Kumagai et al. (1999) examined 10 polar organic solvents, including EGBE, 3 during short-term inhalation by humans. Four healthy male research subjects inhaled 25 ppm 4 EGBE for 10 minutes; the mean uptake was 79.7% in the last 5 minutes of EGBE respiration. 5 Johanson and Boman (1991) attempted to define the relative importance of the skin to the 6 total absorption of EGBE vapors by humans by comparing mouth-only and body-only exposures. 7 Four research subjects were exposed to 50 ppm EGBE mouth-only for 2 hours, followed by 8 1 hour of no exposure, then 2 hours of 50 ppm body-only exposure (i.e., exposed in a chamber 9 while breathing fresh air via a respirator). Blood samples were collected periodically for analysis 10 of EGBE under the assumption that the finger-prick blood samples represented mixed arterial 11 blood. Since the areas under the curve (AUCs) for the concentration of EGBE in the subjects' 12 blood samples following body-only exposures were three- to fourfold greater than following 13 mouth-only exposure, the authors concluded that the skin accounted for approximately 75% of 14 the total uptake of EGBE in a whole-body exposure. 15 Corley et al. (1994) suggested that Johanson and Boman's (1991) conclusion of greater 16 absorption of EGBE vapor through the skin than from the respiratory tract was inconsistent with 17 the physiological differences (relative surface area, blood perfusion, barrier thickness) favoring 18 absorption of vapors through the lungs. They reanalyzed the kinetic data of Johanson and 19 Boman, assuming that the finger-prick blood samples represented venous blood draining the skin 20 prior to mixing systemically. These revised calculations resulted in dermal uptake contributing 21 no more than 22% of the total uptake of EGBE in a whole-body exposure at average 22 temperatures and humidities (skin permeability coefficient of 3 cm/hour), assuming no clothing 23 to hinder absorption. 24 To provide experimental validation of the skin's role in the uptake of EGBE vapors, 25 Corley et al. (1997) conducted a study in which human research subjects exposed one arm to 50 ppm ¹³C-EGBE for 2 hours. Catheters installed in the antecubital vein of the unexposed arm 26 27 served as the primary site for blood collection, which was analyzed for both EGBE and 28 2-butoxyacetic acid (BAA). Finger-prick blood samples were collected from the exposed arm at 29 the end of the 2-hour exposure. If Johanson and Boman's (1991) assumption that finger-prick 30 blood samples represented systemic arterial blood was correct, then the concentrations of EGBE 31 and BAA in the finger-prick blood samples taken from the exposed arm at the end of the 2-hour 32 exposure should have been comparable to the corresponding catheter sample taken from the

1 unexposed arm. This was not the case, since the concentration of EGBE averaged nearly 1,500-

2 fold higher in the finger-prick blood samples than in the samples collected from the unexposed

3 arm, confirming the potential for portal of entry to have a major effect when using the finger-

4 prick sampling technique.

3.2. Metabolism and Elimination

5 The metabolism of EGBE has been studied extensively in rodents, particularly in rats, 6 and the large body of literature on this subject has been thoroughly reviewed (Commonwealth of 7 Australia, 1996; European Centre for Ecotoxicology and Toxicology of Chemicals, 1994). 8 Proposed pathways for the metabolism of EGBE in rats and humans are presented in Figure 3-1. 9 The principal products from metabolic processes in rats or humans are butoxyacetaldehyde 10 (BAL) and its corresponding carboxylic acid, BAA, and ethylene glycol (EG). 11 The two main oxidative pathways of EGBE metabolism observed in rats are via alcohol 12 dehydrogenase (ADH) and O-dealkylation by a cytochrome P450 (CYP450) dealkylase 13 (CYP 2E1). Because BAA is excreted in the urine of both rats and humans following EGBE 14 exposure, it has been suggested that the production of BAA through the formation of 15 BAL by ADH would be applicable to both rats and humans (Corley et al, 1997; Medinsky et al., 16 1990). However, the other proposed metabolic pathways of EGBE may only be applicable to 17 rats, since the metabolites of these pathways (i.e., EG, EGBE glucuronide, and EGBE sulfate) have been observed in the urine of rats (Bartnik et al., 1987; Ghanayem et al., 1987a), but not in 18 19 humans (Corley et al., 1997). In addition, Corley et al. (1997) confirmed an observation of 20 Rettenmeier et al. (1993) that approximately two-thirds of the BAA formed by humans is 21 conjugated with glutamine and, to a lesser extent, glycine. The BAA-glutamine and BAA-22 glycine conjugation pathways have not been detected in the rat. 23 Carpenter et al. (1956) first identified BAA as the metabolite responsible for the 24 hemolytic toxicity of EGBE by incubating BAA with whole blood from a variety of species. 25 Blood from rats, mice, and rabbits was more rapidly hemolyzed than blood from humans, 26 monkeys, dogs, or guinea pigs when incubated in vitro at 37.5°C with a saline solution of 0.1% 27 of the sodium salt of BAA. These results correlated well with osmotic fragility studies using 28 blood from these same species following in vivo inhalation exposures to EGBE. In contrast, a 29 much higher concentration (2.5%) of EGBE was required to produce a similar degree of 30 hemolysis in vitro. Subsequent investigations have shown that hemolytic blood concentrations of 31 BAA can be produced following oral or dermal administration or inhalation of EGBE.




Figure 3-1. Proposed metabolic scheme of EGBE in rats and humans.

Source: Adapted from Medinsky et al. (1990) and Corley et al. (1997).

1 The uptake and metabolism of EGBE is essentially linear following a 6-hour inhalation

- 2 exposure of up to 438 ppm, a concentration that causes mortality in animals (Sabourin et al.,
- 3 1992a). BAA is the primary metabolite in rats following drinking water (Medinsky et al., 1990)
- 4 and inhalation (Dill et al., 1998) exposures. EGBE is eliminated primarily as BAA in urine.
- 5 Lesser amounts of the glucuronide and sulfate conjugates of EGBE have been observed in the
- 6 urine of rats (Bartnik et al., 1987; Ghanayem et al., 1987a) but not humans (Corley et al., 1997).
- 7 No significant differences in the urinary levels of BAA were found following administration of
- 8 equivalent doses of EGBE dermally or in drinking water (Shyr et al., 1993; Sabourin et al.,
- 9 1992b; Medinsky et al., 1990). Corley et al. (1997) reported that the elimination kinetics of
- 10 EGBE and BAA appear to be independent of the route of exposure. Elimination of EGBE and
- 11 BAA following repeated inhalation exposure appears to be dependent on species, gender, age,
- 12 time of exposure, and exposure concentration (NTP, 2000; Dill et al., 1998).

1 Percutaneous absorption of EGBE in rats is rapid and produces measured blood levels of 2 BAA sufficient to produce hemolysis (Bartnik et al., 1987). Metabolism, disposition, and pharmacokinetic studies in male F344 rats conducted by Corley et al. (1994) produced hemolytic 3 blood concentrations of BAA (0.5 mM) following a single oral dose of 126 mg/kg of ¹⁴C-labeled 4 5 EGBE. Using their physiologically based pharmacokinetic (PBPK) model, they predicted that 6 such hemolytic blood concentrations would also be produced in rats following a single 6-hour 7 EGBE inhalation exposure greater than 200 ppm. A report that evaluated the NTP (2000) 8 inhalation bioassay suggests that BAA blood concentrations in rats exceeded 0.5 mM 9 (approximately 67 µg BAA/g blood), following exposure to 62.5 ppm EGBE for both 1-day and 10 12-month exposure durations (Dill et al., 1998). 11 The metabolic basis for the hematotoxicity of EGBE was studied in male F344 rats by 12 using pyrazole and cyanamide as metabolic inhibitors of ADH and aldehyde dehydrogenase 13 (ALD), respectively (Ghanayem et al., 1987b). Male F344 rats, 9 to 13 weeks old, were 14 pretreated with pyrazole or cyanamide followed by administration of 500 mg/kg EGBE by gavage. The use of pyrazole protected rats from EGBE-induced hematotoxicity and resulted in a 15 16 10-fold lower ratio of BAA to conjugated EGBE excreted in urine. Cyanamide treatment 17 significantly reduced the hematotoxic response in a manner similar to that of pyrazole; it also 18 resulted in a high mortality rate in rats given cyanamide and EGBE. This effect was possibly due 19 to the increased levels of unmetabolized BAL; the effect was not observed in animals treated 20 with cyanamide or EGBE alone. Pyrazole completely blocked the increase in spleen weight to 21 body weight ratios seen in EGBE-treated animals. Gavage administration of either BAL or BAA 22 at equivalent molar doses to 125 mg/kg EGBE produced identical increased spleen to body 23 weight ratios and identical increases in free hemoglobin (Hb) levels in plasma. Pretreatment of 24 rats with cyanamide prior to administration of BAL provided significant protection against BAL-25 induced hematotoxicity. These studies confirm the central role of BAA in the hematotoxic 26 response elicited in rats. 27 Green et al. (2002) explored reasons that female mice develop marked hyperkeratosis in

28 the forestomach when given oral doses (1/day for 10 days) of either EGBE or BAA. Irritation 29 from the carboxylic acid BAA is hypothesized to cause cell damage followed by cell 30 proliferation and eventually the observed hyperkeratosis. Their studies examined the activity and 31 localization of ADH and ALD, the principal enzymes involved in the metabolism of EGBE in the 32 stomach tissues of mice and rats, the localization of these enzymes in a human stomach sample, 33 and whole body autoradiography of mice exposed to radiolabeled EGBE (see Section 4.4.1). 34 Tissue homogenates were prepared from female B6C3F1 mice (n = 30) and rats (n = 10; gender)35 and species not specified) and centrifuged at $41,000 \times g$, with the supernatants used to examine 36 the metabolism of EGBE by ADH and ALD. The stomachs were separated into fore and 37 glandular sections and used to measure the metabolism of EGBE to BAL and BAL to BAA by

- 1 ADH and ALD, respectively. A marked species difference in ALD activity was observed between
- 2 rats and mice:
- 3 Rats: $K_m = 0.29 \text{ mM}$
- 4 $V_{max} = 1.627$ nmol/minute per mg protein, forestomach, $K_m = 0.73$ mM
- 5 $V_{max} = 2.170$ nmol/minute per mg protein, glandular stomach
- 6 Mice: $K_m = 46.59 \text{ mM}$
- 7 $V_{max} = 17.094$ nmol/minute per mg protein, forestomach, $K_m = 87.01$ mM

8 $V_{max} = 13.986$ nmol/minute per mg protein, glandular stomach

 K_m values were up to one order of magnitude greater in mice compared to rats. Based upon the K_m and V_{max} values reported, while the mouse ALD enzyme has a lower affinity than the rat enzyme for EGBE, the mouse enzyme has a much greater capacity to metabolize EGBE to the intermediate without becoming saturated. The fact that EGBE is held in the forestomach, along with the information that rates for the ADH enzyme were of the same order of magnitude for rats and mice, suggests that mice are capable of generating more BAA in the forestomach than rats for the same dose and exposure duration.

16 Green et al. (2002) also examined the distribution of ALD and ADH in rat, mouse, and 17 human stomach tissue sample from a single individual, using histochemical staining. The 18 stratified squamous epithelium of the forestomach of both rats and mice contained the highest 19 staining intensity for ALD and ADH. These enzymes were found throughout the mucosa in the 20 human stomach tissue sample; the highest concentration was found in the mucus-producing cells 21 at the surface. Data indicates that the distribution of these enzymes in humans is more closely 22 comparable to that found in the rodent glandular stomach than in the rodent forestomach. This 23 finding, combined with the difference in ALD and ADH activity between mouse and rat 24 forestomach, suggests that humans are at much lower risk for the tissue irritation seen in the 25 mouse forestomach.

26 The effects of age, dose, and metabolic inhibitors on the toxicokinetics of EGBE were

- studied in male F344 rats (Ghanayem et al., 1990). Rats aged 3–4 months and 12–13 months
- were administered a single gavage dose of 31.2, 62.5, or 125 mg/kg EGBE. Pretreatments
- 29 included pyrazole, cyanamide, or probenecid, an inhibitor of renal anion transport. Toxicokinetic
- 30 parameters for EGBE, including AUC, maximum plasma concentration (C_{max}), and clearance
- 31 rate (Cl_s), were dose dependent; AUC and C_{max} increased and Cl_s decreased as dose levels
- 32 increased. Other measured parameters were unaffected by dose. Age had no effect on half-life
- 33 $(t_{1/2})$, volume of distribution (V_d), or C1_S of EGBE, but C_{max} and AUC increased with age. As
- 34 expected from previous studies, inhibition of EGBE metabolism by either pyrazole or cyanamide
- resulted in significantly increased $t_{\frac{1}{2}}$ and AUC, as well as decreased Cl_S. BAA toxicokinetics
- 36 were also altered by dose and age, as well as by administration of metabolic inhibitors.
- 37 Statistically significant, slight increases in C_{max} , AUC, and $t_{\frac{1}{2}}$ were seen at higher doses; these

8

38 results were more pronounced in older rats. Probenecid pretreatment at EGBE dose levels of 31.2

- 1 and 62.5 mg/kg produced no changes in the measured toxicokinetic parameters for EGBE.
- 2 Pretreatment produced two- to threefold increases in AUC, and two- to sixfold increases in $t_{\frac{1}{2}}$ for
- 3 BAA. These results indicate that renal organic acid transport is vital to renal elimination of BAA.
- 4 The increased C_{max} , AUC, and $t_{\frac{1}{2}}$ in older versus younger rats may be due to differences in
- 5 relative contributions of the two primary metabolic pathways previously discussed, or to
- 6 compromised renal clearance.
- 7 For humans, the elimination kinetics of EGBE and BAA appear to be independent of the
- 8 route of exposure. The $t_{\frac{1}{2}}$ in humans for the elimination of EGBE and BAA averaged 0.66 and
- 9 3.27 hours, respectively. For whole-body exposures under exercise conditions, the elimination t_{ν_2}
- 10 for EGBE and BAA were 0.66 and 4 hours, respectively (Johanson and Johnsson, 1991;
- 11 Johanson, 1986). For dermal exposure to neat liquids, the $t_{1/2}$ for elimination of EGBE and BAA
- were 1.3 and 3.1 hours, respectively (Johanson et al., 1988). For dermal exposure to vapors, the elimination $t_{\frac{1}{2}}$ for EGBE was 0.53–0.6 hour.
- 14 Haufroid et al. (1997) conducted a study on 31 male workers exposed to low levels of
- 15 EGBE in a beverage package production plant. The average airborne EGBE exposure
- 16 concentration was $2.91 \pm 1.30 \text{ mg/m}^3$ (0.59 \pm 0.27 ppm). Post-shift urine samples showed an
- 17 average BAA concentration of 10.4 mg/g creatinine. One exposed individual who exhibited a
- 18 very low urinary BAA excretion was found to possess a genetic polymorphism for CYP 2E1 that
- 19 produced increased oxidative activity. However, the researchers did not measure BAA
- 20 conjugated to glutamine, an alternative pathway for BAA excretion in humans. Further
- 21 investigations on the influence of genetic polymorphisms for CYP 2E1 on urinary BAA
- 22 excretion rate are needed before conclusions can be drawn.
- 23 Johanson and Johnsson (1991) analyzed venous blood samples collected at 0, 2, 4, and 24 6 hours from exposure from five healthy, male research subjects exposed to 20 ppm EGBE via 25 inhalation for 2 hours during light physical exercise on a bicycle ergometer. Blood samples were 26 analyzed for BAA concentrations. An average peak blood concentration of 45 µM BAA was 27 reached 2–4 hours after exposure. The range of concentration was from 36 to 60μ M. The 28 average $t_{\frac{1}{2}}$ for elimination of BAA from blood was 4.3 hour, with a range from 1.7 to 9.6 hours, 29 suggesting that blood levels of BAA would probably not increase following prolonged 30 occupational exposures to concentrations of EGBE vapor at or below existing occupational 31 exposure limits of 20–25 ppm. Thus, blood levels would not reach those shown to cause adverse 32 effects in vitro. The average renal clearance of BAA was 23–39 mL/minute, which was only 33 about one-third of the glomerular filtration rate (GFR). The authors suggested that the low 34 clearance of BAA relative to the GFR could have been related to the binding of BAA to proteins 35 in blood or to a low efficiency in renal tubular secretion. The low pKa of 3.5 estimated by the 36 researchers indicates that tubular reabsorption is unlikely, because more than 99% of the BAA in
- 37 normal human urine (pH \sim 6) is ionized. The V_d averaged 15 L (range 6.5–25 L) based on whole

1 blood measurements, and was approximately equal to the volume of extracellular water (13-

2 16 L), a further indication of binding of BAA to blood proteins.

3 Laitinen (1998) reported BAA levels in a study of eight silkscreen printers (gender not 4 specified) exposed to a mixture of EGBE and 2-butoxyethylacetate. Daily mean 8-hour air 5 concentrations ranged from 0.1 to 0.6 ppm during a 5-day period. Urine samples from these 6 workers contained 75 mg BAA/g creatinine immediately after the work shift, and 58 mg/g 7 creatinine the following morning, 14 to 16 hours post-shift. Laitinen et al. (1998) reported 8 similar post-shift urinary levels of 60 mg BAA/g creatinine in another group of 37 male and 15 9 female silkscreen workers exposed to 5 ppm EGBE and its acetate for one 8-hour workday. 10 Deisinger and Boatman (2004) determined the extent of the in vivo formation of BAL 11 and BAA from EGBE and their elimination kinetics from blood, liver, and forestomach of mice. 12 Male and female B6C3F1 mice (n = 4/gender/time point) were administered oral doses of 13 600 mg/kg EGBE dissolved in distilled water. At 5, 15, 45, and 90 minutes following the dose, 14 blood, liver, and forestomach tissues, along with forestomach contents, were collected and processed to determine EGBE, BAL, and BAA concentrations in the samples. High EGBE 15 16 concentrations were measured at all time points; maximum concentrations occurred 5 minutes 17 after dosing, with a mean of 123 mM in females and 129 mM in males. EGBE levels in blood

18 and liver were also at maximum concentrations at 5 minutes post-dosing, but at levels that were

19 roughly 50-fold lower than in the forestomach. BAA concentrations in all organs were

20 substantial in the 5-minute samples, and concentrations continued to increase until leveling off in

21 the 45- and 90-minute samples. Concentrations of BAA measured in the forestomach were lower

than concentrations in blood and liver tissues. Furthermore, BAA was found to be associated

23 with forestomach tissues, rather than forestomach contents. BAL levels were highest in the initial

samples, 5 minutes post-dose, then declined. Levels of BAL measured in the forestomach were

25 10-fold to 100-fold lower than the parent compound or carboxylic acid metabolite. No

26 differences between male and female mice were apparent in the parent compound or BAA organ

27 concentrations at comparable time points following dosing, but the BAL concentrations were up

to twofold greater at some time points in the liver and forestomach of female mice compared tomale mice.

30 Dill et al. (1998) reported on toxicokinetic findings collected from exposures carried out 31 in male and female F344 rats and male and female B6C3F1 mice as part of the 2-year EGBE 32 inhalation toxicity and carcinogenicity study conducted by the NTP (2000). Blood samples were 33 collected from some of these animals post- exposure (i.e., after the daily 6-hour exposure) after 34 1 day, 2 weeks, and 3, 6, 12, and 18 months of exposure to target EGBE concentrations of 0 and 35 31.2 ppm (rats only) and 62.5, 125, or 250 ppm (mice only) by whole-body inhalation and assayed for EGBE. Post-exposure time points varied from 10 to 720 minutes following 1 day. 36 37 2 weeks, and 3 and 6 months and varied from 10 to 2,880 minutes following 12 months. Post-38 exposure 16-hour urine samples were collected after 2 weeks and 3, 6, 12, and 18 months of

1 exposure and assayed for BAA. In addition, a separate set of aged mice were kept in the control 2 chamber and exposed to EGBE for 3 weeks when they were approximately 19 months old. Post-3 exposure blood samples were collected after 1 day and 3 weeks of exposure; 16-hour urine 4 samples were collected after 2 weeks of exposure. Overall, mice eliminated both EGBE and 5 BAA from blood faster than rats: for example after the 1-day exposure, $t_{1/2}$ for rats was less than 6 10 minutes, and $t_{\frac{1}{2}}$ for mice was less than 5 minutes. In contrast, the rate of BAA elimination 7 from blood decreased as the exposure concentration increased. As exposure continued, the rates 8 of elimination for both EGBE and BAA decreased in both species, resulting in longer residence 9 times in the blood. At 1 day post-exposure, $t_{\frac{1}{2}}$ in male rats was 9.4 minutes, and at 18 months 10 post-exposure t_{1/2} was 15.8 minutes. Female rats were significantly less efficient in clearing BAA 11 from their blood than males, possibly as a result of reduced renal clearance in female rats. The 12 aged mice were observed to eliminate BAA from blood >10 times slower than young mice after 13 1-day of exposure, but this difference was less obvious after 3 weeks of exposure. These findings 14 provide evidence that the elimination kinetics of EGBE and BAA following repeated inhalation 15 exposure to EGBE appears to be dependent on various factors, including species, gender, age, 16 time of exposure, and exposure concentration. 17 Using rate constants derived from mouse stomach fractions (Green et al., 2002) and 18 making several assumptions about the use of these enzyme activity data, Corley et al. (2005a) 19 estimated that 250 ppm EGBE would result in peak C_{max} concentrations of 7 µM EGBE, 0.5 µM 20 BAL, and 3,250 µM BAA in liver tissue of male mice at the end of a 6-hour inhalation exposure. 21 The model includes the metabolism of EGBE to BAL via ALD, and the subsequent metabolism 22 of BAL to BAA via ADH in both the liver and forestomach. The model predicts that the 23 concentrations of BAL in gastrointestinal tract tissues of male and female mice at 5 minutes 24 postdosing, the time of maximal concentration, would be 18 and 33 µM, respectively, following 25 oral gavage exposure to 600 mg/kg EGBE. This compares well with the levels of BAL actually 26 observed in forestomach tissue of male and female mice at 5 minutes post-dosing, 19 and 33 μ M, 27 respectively, following oral gavage exposure to EGBE at 600 mg/kg (Deisinger and Boatman,

28 2004).

4. Hazard Identification

4.1. Studies in Humans: Epidemiology, Case Reports, Clinical Controls

1 Carpenter et al. (1956) conducted three controlled inhalation studies. In the first study, a 2 group of two men and six rats were exposed simultaneously for 4 hours to an EGBE 3 concentration of 113 ppm in a 1,250-cubic foot room. Effects observed in humans included nasal 4 and ocular irritation, a metallic taste, and belching. Erythrocyte osmotic fragility did not change 5 for the men, yet rose appreciably for the rats. In a second study, a group of two men, one woman, 6 and three rats were exposed to 195 ppm EGBE for two 4-hour periods, separated by a 30-minute 7 recess, in a 6.5-cubic foot room. There was no change in the subjects' blood pressure, erythrocyte 8 fragility, or pulse rate. They experienced nose and throat irritation, followed by ocular irritation 9 and disturbed taste; one subject reported a headache. In the rats, an increase in erythrocyte 10 fragility values was noted. In the third study, two men and two women were exposed for 8-hours 11 to a 100 ppm EGBE concentration. No changes in blood pressure, erythrocyte fragility, or pulse 12 rate were observed. Again, nasal and throat irritation followed by ocular irritation and a 13 disturbing metallic taste were experienced. Two subjects reported headaches. 14 There are a number of case reports of acute ingestion of EGBE, consisting primarily of 15 accidental or intentional ingestion. Bauer et al. (1992) reported the effects of acute ingestion of 16 500 mL of window cleaner containing 9.1% EGBE and 2.5% ethanol by a 53-year-old alcoholic 17 male. He was comatose with metabolic acidosis, shock and noncardiogenic pulmonary edema 18 when brought to a hospital, approximately 10 hours after ingestion. He had increased heart rate, 19 decreased blood pressure, and transient polyuria and hypoxemia. Hypochromic anemia was 20 evident with an Hb concentration of 9.1 g/100 mL, a hematocrit (Hct) of 25%, and 21 thrombocytopenia. The patient recovered and was discharged after 15 days. 22 Gijsenbergh et al. (1989) reported that a 23-year-old woman weighing 64 kg ingested 23 approximately 25-30 g of EGBE (~400-500 mg/kg) and ethanol (~4:1 ratio) as a window 24 cleaner in an apparent suicide attempt. She was comatose when admitted to the hospital, 25 exhibiting dilated pupils, obstructive respiration, and metabolic acidosis, including depression of 26 blood Hb concentration and hematuria. The presence of EGBE in the blood and dialysis fluid 27 was confirmed. Treatment consisted of supportive therapy, forced diuresis, bicarbonate 28 administration, and hemodialysis. Her Hb concentration fell from 11.9 g Hb/100 mL upon 29 admission to 8.9 g Hb/100 mL. She was discharged after 8 days. 30 Gualideri et al. (2003, 1995) reported a case of a suicide attempt with an industrial-

31 strength window cleaner. The 18-year-old male weighed 71 kg; he consumed between 360 and

1 480 mL of a concentrated glass cleaner that contained 22% EGBE, a dose equivalent to 1.131– 2 1,509 mg/kg. He was admitted to the hospital with no abnormalities other than epigastric 3 discomfort within 3 hours post-ingestion. Approximately 10 hours post-admission, the patient 4 was noticeably lethargic, weak, and hyperventilating, symptoms consistent with the onset of 5 metabolic acidosis. BAA was measured; the highest serum concentration found was 6 4.86 mmol/L, collected approximately 16 hours post-ingestion. The patient was transferred to a 7 tertiary care hospital where hemodialysis was initiated at approximately 24 hours post-ingestion. 8 Ethanol therapy was started 30 minutes later. Treatment also consisted of intravenous (i.v.) doses 9 of 100 mg thiamine and 50 mg folic acid every 12 hours and 50 mg pyridoxine every 6 hours. 10 Following 4 hours of dialysis, the patient was alert and remained hemodynamically stable. Ten 11 days after discharge, the patient was readmitted following a second ingestion of 480 mL of the 12 same cleaner, a EGBE dose equivalent to 1,509 mg/kg. Treatment included ethanol therapy and hemodialvsis, and was initiated within a few hours of ingestion to control the metabolic acidosis. 13 14 Due to this early treatment, ethanol therapy had an impact on the disposition of EGBE and BAA. 15 As with the first episode, metabolic acidosis was manifested. This high-dose oral ingestion was 16 nearly 1.1–1.5 g EGBE/kg body weight. The highest serum BAA concentration was 17 2.07 mmol/L, collected 22 hours post-ingestion. No evidence of hemolysis or renal abnormalities 18 was detected. 19 A 50-year-old woman ingested approximately 250-500 mL of a window cleaner

20 containing 12% EGBE, representing ~30-60 mL, in an apparent suicide attempt (Rambourg-21 Schepens et al., 1988). She was diagnosed with metabolic acidosis, hypokalemia, a rise in serum 22 creatinine level, and a marked increase in urinary excretion of oxalate crystals. Moderate 23 hemoglobinuria appeared on the third day post-exposure, and a progressive erythropenia was 24 noted. In the absence of more complete hematologic details from this and other similar case 25 studies, it is not possible to determine whether these effects were due to hemolysis or other 26 factors related to the profound blood chemistry changes observed. The clinical status improved 27 gradually and the patient was discharged on the tenth day.

Burkhart and Donovan (1998) summarized the case of a 19-year-old male who ingested
20–30 ounces, or ~590–885 mL, of a product that contained 25–35% EGBE, an exposure

30 equivalent to ~177–265 mL, estimated at >3,000 mg/kg, along with 15–25% propylene glycol,

5-10% monoethanolamine, and 1-3% potassium hydroxide. On his arrival at the hospital 3.5

32 hours after ingestion, the patient was deeply comatose with severe hypotension. Hematuria

33 developed on the second day, with no evidence of renal or hepatic toxicity; however, pulmonary

34 toxicity consisting of severe aspiration pneumonia was present. The patient had a significant

35 recovery, despite severe neurologic deficits that were slow to resolve.

Osterhoudt (2002) reported on a 16-month-old girl who ingested an unknown amount of
cleaning solution containing EGBE (10–30%), monoethanolamine (5–10%), alkoxylated linear
alcohols (1–5%), ethylenediaminetetraacetic acid (1–5%), and potassium hydroxide (1–5%).

13

April 2008

DRAFT-DO NOT CITE OR QUOTE

Metabolic acidosis was manifest, and a single dose (15 mg/kg) of the ALD inhibitor fomepizole
 was administered. Within 2 hours, the metabolic acidosis was completely resolved, and there was
 no evidence of alkaline mucosal injury, hepatic or renal dysfunction, or hemolysis.

Dean and Krenzelok (1991) reported that 24 children, aged 7 months to 9 years, were
observed subsequent to oral ingestion of at least 5 mL of glass window cleaner containing EGBE
in the 0.5–9.9% range. Two children drank more than 15 mL, and were treated by gastric lavage.
No symptoms of EGBE poisoning, such as metabolic acidosis, and no hemolysis were observed
in any of the children.

9 Raymond et al. (1998) reported on seven clerical workers who were evaluated 8 months 10 after they entered a file room where the supervisor believed that EGBE had been applied 11 overnight to strip the floor. Exact details of the product used were unknown, but based on 12 containers found and exposure symptoms of noted intense eye and respiratory irritation, marked 13 dyspnea, nausea, and faintness, the authors suggested that they were exposed to EGBE 14 concentrations of 200-300 ppm. Of major concern were skin spots-cherry angiomas-that 15 appeared between 4 and 22 weeks after exposure in six of the seven workers. All workers 16 continued to experience recurrent eye and tracheobronchial irritation; four had a dry cough. 17 Workplace air sampling conducted by a certified industrial hygienist one week after the floor 18 stripping found no detectable EGBE, although traces (0.1-0.2 ppm) of formaldehyde were 19 identified. Five years after the exposure, four of the workers who could be contacted reported 20 that they continued to have outbreaks of new cherry angiomas. It should be noted that no other 21 studies linking EGBE exposure to outbreaks of cherry angiomas are available in the literature. 22 The authors included the observation that, since this report, they had seen three patients who they 23 believe were also exposed to EGBE vapor in an unrelated incident, and who did not develop any 24 skin spots. Cherry angiomas are the most common cutaneous vascular lesion; they are benign 25 and formed by a proliferation of dilated venules. The spots occur more frequently with increasing 26 age but can appear in younger individuals. There are reports in the literature of cherry angiomas 27 appearing following individual exposure to other chemicals, such as bromides (Cohen et al., 28 2001), glutaraldehyde (Raymond et al., 1998), and sulfur mustard gas (Firooz et al., 1999). 29 A cross section of 31 male workers, aged 22 to 45, employed for 1–6 years, who were 30 exposed to low levels of EGBE in a beverage packing production plant were monitored by 31 Haufroid et al. (1997). The effect of external EGBE exposure and internal BAA levels on 32 erythrocyte lineage were investigated: red blood cell (RBC) count, Hb, Hct, mean cell volume 33 (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration 34 (MCHC), haptoglobin (Hp), reticulocyte count, and osmotic resistance (OR), a measure of 35 osmotic fragility. Also studied were serum glutamic-oxaloacetic and glutamic-pyruvic transaminases and renal creatinine and urinary retinol binding protein parameters. The average 36 airborne concentration of EGBE was 2.91 mg/m³, or 0.6 ppm (standard deviation [SD] of ± 1.30 37 38 mg/m^3 or 0.27 ppm). In addition, there was coexposure to methyl ethyl ketone. Single

14

April 2008

DRAFT-DO NOT CITE OR QUOTE

1 determinations of BAA in post-shift urine samples were used to assess exposure to low levels of 2 EGBE. No differences were observed for RBC counts, Hb, MCV, MCH, Hp, reticulocyte count, 3 and OR between exposed and control workers. The only statistically significant change observed 4 in exposed workers when compared with a matched control group (n = 21) was a 3.3% decrease 5 in Hct (p = 0.03) and a 2.1% increase in MCHC (p = 0.02). The implications of these small 6 erythroid effects are unclear. Both values are within their corresponding normal clinical ranges 7 and, given that no statistically significant changes were observed in other erythroid parameters, 8 they do not appear to be related to the more severe adverse effects observed in laboratory 9 animals. Furthermore, no correlation was found between any of the nine erythroid parameters 10 measured and the parameters of internal exposure. No significant differences were observed in 11 hepatic and renal biomarkers. 12 Several human studies investigated the dermal absorption of EGBE. Jakasa et al. (2004) dermally exposed six male research subjects, ages 22–55, to 50%, 90%, or neat EGBE for 4 13 hours on the forearm over an area of 40 cm². The dermal absorption of EGBE from aqueous 14 15 solutions was markedly higher than from neat EGBE. In Jones et al. (2003), four research subjects were exposed via inhalation of 50 ppm EGBE for 2 hours on nine separate occasions, 16

17 with each occasion separated by 3 weeks, at varying temperatures and humidity levels. Results

18 show that "baseline" dermal contribution to total body absorption of EGBE vapor in

19 appropriately dressed workers was, on average, 11%. Higher temperature (30° C, mean 14%, p =

20 0.03) and greater humidity (65% relative humidity, mean 13%, p = 0.1) both increased dermal

absorption. The wearing of whole-body overalls did not attenuate absorption (mean 10%). By

22 combining several factors together in the industrial scenario, dermal absorption of vapors was

reported to be significantly increased to a mean value of 39% of the total absorbed dose.

4.2. Subchronic and Chronic Studies and Cancer Bioassays in Animals: Oral and Inhalation

4.2.1. Subchronic Studies

4.2.1.1. Oral

A number of subchronic studies by the oral gavage route of exposure have been conducted. Krasavage (1986) conducted a toxicity study using groups of 10 COBS CD (SD)BR adult male rats treated by gavage with 222, 443, or 885 mg/kg-day undiluted EGBE 5 days/week for 6 weeks. Endpoints evaluated throughout the study included body weight, food consumption, clinical signs, and survival. Hematology and serum clinical chemistry parameters were determined after the last treatment. Dose-related changes were observed in the RBC counts of all treatment groups, including statistically significant decreases in RBC count and Hb

31 concentration, and a statistically significant increase in MCH. Statistically significant

1 hematological changes occurring at 443 and 885 mg/kg-day were increased MCV and decreased 2 MCHC. The increased MCV at higher doses is likely due to both an increase in MCV and in the 3 number of larger reticulocytes in the circulation following the erythropoietic response (NTP, 4 2000). Based on decreased RBC count and trends in Hb and other hematological endpoints, the 5 lowest-observed-adverse-effect level (LOAEL) was determined to be 222 mg/kg-day, the lowest 6 dose tested. A no-observed-adverse-effect level (NOAEL) was not identified. 7 Nagano et al. (1979) performed a toxicity study in male JCL/ICR mice (five/group) using 8 gavage doses of 0, 357, 714, or 1430 mg/kg-day EGBE 5 days/week for 5 weeks. Parameters 9 evaluated at the end of the study were hematology (RBC and white blood cell [WBC] counts, 10 MCV, and Hb), absolute and relative weights of testes, and testicular histology. Mean RBC 11 counts were significantly lower than the control values in the 357 and 714 mg/kg-day groups, but 12 WBC counts were not affected. All animals in the 1,430 mg/kg-day group died before 13 examinations were performed: mortality was not observed in the lower dose groups, and no 14 differences in testes weights or histology were found. The LOAEL for this study, based on the 15 reduced RBC count, was 357 mg/kg-day. A NOAEL was not determined. 16 Siesky et al. (2002) investigated whether subchronic exposure to EGBE in F344 male 17 rats, 8–10 weeks old, and B6C3F1 male mice, 8–10 weeks old, produced an increase in oxidative 18 damage and deoxyribonucleic acid (DNA) synthesis in endothelial cells and hepatocytes in the 19 mouse liver, the putative cancer targets. Mice (60/group) were treated via gavage with doses of 0, 20 225, 450, and 900 mg/kg-day and rats (20/group) with 0, 225, and 450 mg/kg-day for 90 days. A 21 dose-related increase in hemolysis was observed in both rats and mice. An increase in the 22 percentage of iron-stained Kupffer cells was observed following 450 and 900 mg/kg in mice and 23 225 and 450 mg/kg in rats. An increase in oxidative damage, as measured by 8-24 hydroxydeoxyguanosine (8-OHdG) levels, was seen in mouse livers at 450 and 900 mg/kg-day 25 after 7 or 90 days, while no increase was seen in rat livers at any dose or time point examined. 26 Vitamin E levels were reduced by all doses of EGBE in the mouse and rat liver (statistically 27 significant at 7 and 90 days in both mice and rats); however, the basal level of vitamin E was 28 \sim 2.5-fold higher in rat than in mouse liver. The LOAEL for this study was 450 mg/kg-day in 29 mice and 225 mg/kg-day in rats, based on the percentage of iron-stained Kupffer cells. The 30 NOAEL was 225 mg/kg-day in mice, and a NOAEL was not determined in rats. 31 NTP (1993) performed a 13-week toxicity study in F344 rats and B6C3F1 mice, where 32 groups of 10 animals/gender/species received EGBE in drinking water at doses of 0, 750, 1500, 33 3000, 4500, and 6000 ppm in rats and 0, 750, 1,500, 3,000, 4,500, and 6,000 ppm in mice. The 34 corresponding doses in mg/kg-day, based on measured drinking water consumption were: 0, 69, 35 129, 281, 367, or 452 mg/kg-day in male rats; 0, 82, 151, 304, 363, or 470 mg/kg-day in female rats; 0, 118, 223, 553, 676, or 694 mg/kg-day in male mice; and 0, 185, 370, 676, 861, or 36 37 1,306 mg/kg-day in female mice. Due to a dose-related decrease in water consumption in the 2-38 week studies, the test chemical was administered at a constant concentration (ppm) in the 13-

1 week studies rather than on a mg/kg body weight basis. Hematology was performed on rats but 2 not on mice. Complete histological exams were performed on all control animals and all animals 3 in the highest dose group. Vaginal cytology and sperm indices were evaluated in rats and mice 4 from the control and three highest dose groups. Hematologic changes in both genders persisting 5 until or developing by 13 weeks included dose-related indications of mild-to-moderate anemia. 6 Portions of the hematologic results from the NTP 13-week rat drinking-water study are presented 7 in Table 4-1. The various results shown in this table are indicative of the various degrees of 8 hemolysis caused by exposure to increasing concentrations of EGBE. Overall, the dose-related 9 increase in MCV is indicative of erythrocyte swelling that would be expected to precede cell 10 lysis and an increase in the number of reticulocytes. Deficits in RBCs as a result of lysis manifest 11 through clear dose-related decreases in the measures of both RBC count and Hb concentration. 12 Hct would be expected to decrease but did not. The increases noted both in reticulocytes (young 13 RBCs) and, at higher doses, in nucleated erythrocytes (immature and prematurely released blood 14 cells) are homeostatic responses that would be anticipated to occur as the lysed blood cells are 15 being replaced. More specifically, male rats evaluated at 13 weeks showed significantly reduced 16 RBC counts at \geq 281 mg/kg-day and reduced Hb concentration, reduced platelets, and increased 17 bone marrow cellularity at \geq 367 mg/kg-day. These data also suggest that female rats are more 18 sensitive to the effects from EGBE, since several statistically significant effects occurred at the 19 750-ppm concentration, the lowest level tested in females; males did not show statistically 20 significant effects until two dose levels higher, 3,000 ppm. In addition, the degree to which these 21 various measures were affected was somewhat greater in females than males, (indicated as 22 percent control in the tables), particularly at the three highest exposure concentrations.

Statistically significant hematologic effects in female rats at week 13 included reduced RBC counts and Hb concentrations at \geq 82 mg/kg-day and increased reticulocytes, decreased platelets, and increased bone marrow cellularity at approximately 304 mg/kg-day, all being indicative of hemolysis. There were no histopathological changes in the testes or epididymis at \geq 129 mg/kg-day.

28 Table 4-2 shows that liver lesions, including cytoplasmic alterations, hepatocellular 29 degeneration, and pigmentation were observed in the mid- and high-dose groups (129, 281, 367, 30 and 452 mg/kg-day for males and 151, 304, 363, and 470 mg/kg-day for females; statistics not 31 reported).). As with the hematologic effects, these effects appeared to be more severe in females 32 than in males. Cytoplasmic alterations of liver hepatocytes, consisting of hepatocytes staining 33 more eosinophilic and lacking the basophilic granularity of the cytoplasm present in hepatocytes 34 from control animals, were observed in the lowest-dose groups tested (69 mg/kg-day for males 35 and 82 mg/kg-day for females). The lack of cytoplasmic granularity or "ground-glass" 36 appearance of the hepatocytes suggests that this response was not due to enzyme induction 37 (Greaves, 2000). The cytoplasmic alterations were judged to increase in severity in both genders, 38 but especially in females; as the doses increased with the severity in the two highest dose groups

April 2008

17 DRAFT-DO NOT CITE OR QUOTE

		750 ppm	1,500 ppm	3,000 ppm	4,500 ppm	6,000 ppm
Endpoint [*]	Control	(69 mg/kg-day)	(129 mg/kg-day)	(281 mg/kg-day)	(367 mg/kg-day)	(452 mg/kg-day)
Hct (%)					**	
Males	44.8 ± 0.8	$45.0 \pm 0.6 (100)$	44.7 ± 0.4 (99)	44.1 ± 0.7 (98)	$42.3 \pm 0.6^{**}$ (94)	43.4 ± 0.4 (97)
Females	44.8 ± 0.6	$43.2 \pm 0.8 \ (96)$	$42.8 \pm 0.7 (95)$	43.6 ± 0.7 (97)	44.4 ± 0.7 (99)	46.1 ± 0.7 (103)
Hb (g/dL)					ato ato ato	1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1
Males	15.0 ± 0.2	$15.2 \pm 0.1 (101)$	14.9 ± 0.1 (99)	14.6 ± 0.1 (97)	$14.0 \pm 0.1_{***}^{***}$ (93)	$13.7 \pm 0.2^{***}_{***}$ (91)
Females	14.9 ± 0.2	$14.4 \pm 0.2^{**}$ (97)	$13.9 \pm 0.2^{\$}$ (93)	$14.2 \pm 0.2^{\$}$ (95)	$14.0 \pm 0.2^{***}$ (94)	$13.4 \pm 0.2^{***}$ (90)
Erythrocytes (106/µL)						
Males	8.64 ± 0.15	$8.74 \pm 0.10(101)$	$8.54 \pm 0.09(99)$	$8.11 \pm 0.12^{**}_{***}$ (94)	$7.48 \pm 0.12^{***}$ (86) $6.80 \pm 0.11^{***}$ (83)	$7.18 \pm 0.12^{***} (83) \\ 6.58 \pm 0.14^{***} (81)$
Females	8.15 ± 0.09	$7.59 \pm 0.15^{***} \ (93)$	$7.09 \pm 0.14^{***}$ (87)	$7.00 \pm 0.12^{***}$ (86)	$6.80 \pm 0.11^{***}$ (83)	$6.58 \pm 0.14^{***}$ (81)
Reticulocytes (106/µL)						
Males	0.14 ± 0.03	0.24 ± 0.06	0.15 ± 0.02	0.18 ± 0.02	0.22 ± 0.05	$0.46 \pm 0.07^{***}_{***}$
Females	0.12 ± 0.02	0.17 ± 0.03	0.19 ± 0.03	$0.28 \pm 0.03^{***}$	$0.28 \pm 0.05^{***}$	$0.27 \pm 0.05^{***}$
Nucleated erythrocytes (103/µL)						
Males	0.00 ± 0.00	0.00 ± 0.00	0.01 ± 0.01	0.01 ± 0.01	0.00 ± 0.00	$0.04 \pm 0.02^{***}_{***}$
Females	0.01 ± 0.01	0.03 ± 0.02	0.02 ± 0.01	0.05 ± 0.02	$0.10 \pm 0.03^{**}$	$0.16 \pm 0.04^{***}$
MCV (fL)						
Males	52.0 ± 0.4	$51.5 \pm 0.3(99)$	52.3 ± 0.4 (100)	$54.4 \pm 0.3^{***}_{***}$ (105)	$56.7 \pm 0.5_{***}^{***}$ (109)	$60.6 \pm 1.1_{***}^{***}$ (116)
Females	54.8 ± 0.3	$57.0 \pm 0.4^{***}$ (104)	$60.5 \pm 0.4^{***}$ (110)	$62.4 \pm 0.6^{***}$ (114)	$65.3 \pm 0.6^{***}$ (119)	$70.1 \pm 0.9^{***}$ (128)
MCH (pg)					***	
Males	17.4 ± 0.2	17.4 ± 0.1	17.5 ± 0.2	$18.0 \pm 0.2^{**}_{***}$	$18.7 \pm 0.3^{***}_{***}$	$19.1 \pm 0.3^{***}_{***}$
Females	18.3 ± 0.2	18.9 ± 0.2	19.7 ± 0.2	$20.2 \pm 0.3^{***}$	$20.6 \pm 0.2^{***}$	$20.4 \pm 0.1^{***}$
Hemosiderin (incidence)						
Males	0/10	0/10	0/10	0/10	0/10	7/10
Females	0/10	0/10	2/10	10/10	10/10	10/10

Table 4-1. Hematology and hemosiderin data from the 13-week drinking-water exposure to EGBE in F344 rats.

*Values listed are mean \pm standard error at various EGBE concentrations in ppm for the 13-week time point. Percent of control values in parentheses. **Statistically significant difference, $p \le 0.05$. *** Statistically significant difference, $p \le 0.01$.

Table 4-2. Incidence*	and severity of selected histopathological lesions from the 13-week drinking water exposure to EGBE in F344
rats.	

	Control	750 ppm (69 mg/kg-d)	1500 ppm (129 mg/kg-d)	3000 ppm (281 mg/kg-d)	4500 ppm (367 mg/kg-d)	6000 ppm (452 mg/kg-d)
Rat						
Ν	10	10	10	10	10	10
Liver cytoplasmic alterations (NR)						
Males	0	4 (1.0)	8 (1.0)	7 (1.1)	10 (2.0)	10 (1.8)
Females	0	5 (1.4)	9 (2.0)	10 (2.2)	10 (3.0)	10 (3.0)
Hepatocellular degeneration (NR)						
Males	0	0	0	8 (1.0)	8 (1.0)	8 (1.0)
Females	0	0	0	10 (1.3)	10 (1.3)	10 (1.1)
Kupffer cell pigmentation (NR)						
Males	0	0	0	0	0	7 (1.0)
Females	0	0	2 (1.0)	10 (1.2)	10 (1.9)	10 (1.9)
Mouse						
Ν	10	10	10	10	10	10
Relative kidney weight (right) (mg organ wt/g body wt)						
Females (only)	6.33 ± 0.10	$7.69 \pm 0.14^{***}$	$8.06 \pm 0.29^{***}$	$7.47 \pm 0.19^{***}$	$7.55 \pm 0.18^{***}$	$8.21 \pm 0.26^{***}$
Necropsy body weight (g) §						
Females (only)	31.1 ± 0.7	31.8 ± 0.8	30.9 ± 1.5	$28.0 \pm 0.7^{**}$	$28.4 \pm 0.5^{**}$	$27.8 \pm 0.9^{***}$

*Incidences represent the number of animals with lesions. Average severity (in parentheses) is based on the number of animals with lesions. 1 =minimal, 2 =mild, 3 =moderate, 4 =marked.

$$p \le 0.05$$

p = 0.01NR = Statistics not reported

\$ mean \pm standard error

Source: NTP (1993)

1 being judged as "moderate." Liver pigmentation, colored brown to green and staining strongly 2 positive for iron (indicative of hemosiderin accumulation), was noted in the cytoplasm of 3 Kupffer cells in both genders of rats. In females, liver pigmentation was noted in 0/104 controls and 0/10 at 82 mg/kg-day, 2/10 with a severity grade of 1 (minimal) at 151 mg/kg-day, and 10/10 in the three highest dose levels; the severities increased from a numerical grade of 1.2 5 6 in the 304 mg/kg-day group to 1.9 in both upper two dose groups. In males, the hemosiderin 7 pigmentation was noted in animals exposed to the highest dose only (452 mg/kg-day) at an 8 incidence of 7/10 and a severity rating of 1 (minimal). No hepatic pigmentation was reported in 9 the mice exposed for 13 weeks. The hematological (decreased RBC count and Hb) and hepatic 10 changes were dose-related; 69-82 mg/kg-day was considered a LOAEL. A NOAEL was not 11 identified.

12 Female mice showed statistically significant reductions in body weight gain starting at 13 3000 ppm, and statistically significant increases in relative kidney weight at all doses. Changes at 14 the higher doses followed the reductions in body weight at those dose levels, while the increases 15 at lower doses (750 and 1500 ppm) were due to increased absolute kidney weights at those 16 doses. Body weight reduction followed the decreased water consumption data. No 17 histopathologic changes were noted at any dose level, even though relative kidney weights 18 showed a statistically significantly increase at 750 and 1500 ppm in the absence of reduction in 19 body weight gain. 20

Keith et al. (1996) administered EGBE at 120 mg/kg-day for 120 days by gavage to
transgenic FVB/N mice (25 mice/gender/group) carrying the v-Ha-ras oncogene and observed
the animals for an additional 120 days. EGBE did not induce increases in tumors at any site.

4.2.1.2. Inhalation

23 Wistar-derived rats (23 animals/group, gender not specified) were exposed to 0, 135, or 24 320 ppm EGBE for 7 hours/day, 5 days/week for 5 weeks (Werner et al., 1943a). Hematologic 25 endpoints — RBC, WBC, differential, and reticulocyte counts and Hb concentration — were 26 evaluated. Exposure to 320 ppm EGBE resulted in an increased percentage of circulating 27 immature granulocytes, a decreased Hb concentration and RBC count, and an increased 28 reticulocyte count. These hematologic changes were not severe; they were reversed 3 weeks after 29 discontinuing exposure. No effect on the WBC count was observed. In another study, Werner 30 et al. (1943b) exposed groups of two dogs of unspecified strain to subchronic inhalation doses of 31 0 or 415 ppm EGBE for 7 hours/day, 5 days/week for 12 weeks. Necropsies were performed 32 5 weeks post-exposure; hematologic parameters were examined before, during, and after the 33 exposure. No statistical analysis was presented. The authors concluded that exposure of dogs to 34 EGBE vapors resulted in decreased Hb concentration and RBC count with increased 35 hypochromia, polychromatophilia, and microcytosis. These hematologic effects were not severe; 36 they were reversed 5 weeks after the end of exposure.

1 Carpenter et al. (1956) studied the hemolytic effects of EGBE vapor inhalation in rats, 2 mice, dogs, and monkeys, in addition to humans. An unspecified strain of rats (15/gender/group) 3 was exposed via inhalation to 54, 107, 203, 314, or 432 ppm EGBE 7 hours/day, 5 days/week for 4 6 weeks. Erythrocyte osmotic fragility was observed in rats immediately after a single 7-hour 5 exposure to 107 ppm or higher. Osmotic fragility in females exceeded that for males. In almost 6 all cases, these high fragility values returned to normal after the rats rested overnight. In the same 7 study, the authors exposed groups of 10 male C3H mice to 100, 200, or 400 ppm EGBE 7 8 hours/day for 30, 60, or 90 days. An increase in erythrocyte osmotic fragility occurred at all 9 concentrations and was consistent throughout the exposures. In all instances, erythrocyte osmotic 10 fragility was normal after a 17-hour rest period. The LOAELs for these rat and mouse studies 11 were 54 and 100 ppm, respectively. No NOAELs were reported. The authors reported slight 12 increases in erythrocyte osmotic fragility for a male and a female dog (basenji hybrids) exposed 13 to 200 ppm EGBE for 31 days (7 hours/day). RBC counts and Hb concentrations were slightly 14 decreased in the female. Erythrocyte permeability, as determined by radioiodine uptake, was 15 increased in both genders, but was not statistically different when compared with control values. 16 A female dog succumbed after 8 days of inhalation exposure to 385 ppm of EGBE (7 hours/day). 17 Symptoms included loss of weight, transitory increases in erythrocyte osmotic fragility, nasal and 18 ocular infection, weakness, apathy, anorexia, and increased WBC count. Necropsy of this animal 19 revealed severe congestion and hemorrhage of the lungs and congestion of the liver and both 20 kidneys. In addition, a severe subcapsular hemorrhage was found in one adrenal gland. A male 21 dog survived after 28 days of inhalation exposure to 385 ppm of EGBE for 7 hours/day. Effects 22 in the male were similar to the female, but developed more slowly. At autopsy, congestion of the 23 kidneys was not observed. In studies on male and female monkeys, occasional rises in 24 erythrocyte osmotic fragility were reported that were more frequent in the female than in the 25 male following 90-day inhalation exposure to 100 ppm of EGBE. 26 A 90-day subchronic inhalation study was performed using F344 rats (16/gender/group) 27 exposed to EGBE for 6 hours/day, 5 days/week at concentrations of 0, 5, 25, and 77 ppm (Dodd 28 et al., 1983). After 31 completed exposures (6 weeks), the 77 ppm female rats had slight but 29 statistically significant decreases in RBC counts (13% below control value) and Hb 30 concentrations, accompanied by an 11% increase above the control value in MCH. The 77 ppm 31 males exhibited slight (5%) but statistically significant decreases in RBC counts and Hb 32 concentration that were accompanied by increases in MCH. At the end of the 90-day study 33 (66 exposures), the hematologic effects seen in the 77 ppm exposed animals had either lessened

34 or returned to the ranges of control values and were no longer statistically significant. The 35 NOAEL was determined to be 25 ppm, and the LOAEL was 77 ppm.

In the subchronic portion of the inhalation NTP (2000) study, F344 rats and B6C3F1 36 37 mice (10/gender) were exposed to EGBE concentrations of 0, 31, 62.5, 125, 250, and 500 ppm 38

(0, 150, 302, 604, 1,208, and 2,416 mg/m³) for 6 hours/day, 5 days/week for 14 weeks.

21

April 2008

DRAFT-DO NOT CITE OR OUOTE

1 Hematologic and hemosiderin staining results are presented in Table 4-3 and Table 4-4. These 2 results are indicative of the various degrees of hemolysis caused by exposure to increasing 3 concentrations of EGBE. Both rat genders exhibited clinical signs at the three highest doses, 4 consistent with the hemolytic effects of EGBE, including: (1) deficits in RBCs as a result of lysis 5 manifestation through the clear dose-related decrease in Hct, a finding consistent with decreases 6 noted for both RBC count and Hb concentrations; and (2) increases in both reticulocytes and 7 nucleated erythrocytes at higher doses, homeostatic responses that would be anticipated to occur 8 as the lysed blood cells are being replaced. Female rats may be somewhat more sensitive: several 9 statistically significant effects occur at the 31 ppm level in females, as opposed to a single 10 parameter for males. In addition, the degree to which these various measures are affected is 11 somewhat greater in females than males, indicated as percent control, particularly at the three 12 highest concentrations. Hematologic evaluation showed mild-to-moderate regenerative anemia at 13 all concentrations in females and at the three highest concentrations in males. Exposure-related 14 trends were noted for reticulocyte count, RBC count, MCV, Hb concentration, and Hct. Liver-to-15 body-weight ratios increased significantly in males at the two highest concentrations and in females at the highest concentration. Histopathologic effects at concentrations in excess of 16 17 62.5 ppm for male rats and 31 ppm for females consisted of excessive splenic congestion in the 18 form of extramedullary hematopoiesis, hemosiderin accumulation in Kupffer cells, liver necrosis, 19 centrilobular hepatocellular degeneration, renal tubular degeneration, intracytoplasmic Hb and 20 hemosiderin deposition, and bone marrow hyperplasia. In addition, five moribund female rats 21 were sacrificed from the highest concentrations, and one from the 250 ppm group. The LOAEL 22 for hematological alterations was 31 ppm for female rats and 62.5 ppm for male rats. The 31 ppm 23 exposure level was considered a NOAEL for male rats. 24 The mice exposed via the inhalation route exhibited clinical signs consistent with the 25 hemolytic effects of EGBE at the two highest concentrations for both genders (NTP, 2000). 26 Hematologic evaluation indicated a moderate regenerative anemia (marked by decreased RBC 27 counts, increased reticulocyte counts, and increased MCV) with an increase in platelets at the 28 three highest concentrations in both genders. Histopathological effects consisted of excessive 29 extramedullary splenic hematopoiesis, renal tubular degeneration, hemosiderin deposition in the 30 spleen and kidney and accumulation in Kupffer cells, and testicular degeneration. Forestomach 31 necrosis, ulceration, inflammation, and epithelial hyperplasia were observed at concentrations 32 greater than 31 ppm for females and 62.5 ppm for males. In addition, four females and 33 four males either died or were sacrificed moribund at the highest concentration. The NOAEL for 34 male and female mice was 31 ppm and the LOAEL in mice was 62.5 ppm, based on 35 histopathological changes in the forestomach.

Endpoint [*]	Control	31 ppm (150 mg/m ³)	62.5 ppm (302 mg/m ³)	125 ppm (604 mg/m ³)	250 ppm (1,208 mg/m ³)	500 ppm (2,416 mg/m ³)
Hct (%)						
Males	46.8 ± 0.5	45.8 ± 0.6 (98)	47.0 ± 0.4 (100)	$44.5 \pm 0.5^{***}_{***}$ (95)	$41.1 \pm 0.3^{***}_{***}$ (88)	$37.3 \pm 0.4^{***}_{***}$ (80)
Females	48.5 ± 0.5	$46.0 \pm 0.5^{***} \ (95)$	$45.2 \pm 0.5^{***} \ (93)$	$42.9 \pm 0.4^{***}$ (88)	$40.0 \pm 0.3^{***}$ (82)	$36.2 \pm 0.6^{***}$ (75)
Hb (g/dL)						
Males	15.5 ± 0.1	$14.8 \pm 0.3(95)$	$15.4 \pm 0.1(99)$	$14.5 \pm 0.2^{***}_{***}$ (94)	$13.1 \pm 0.1_{***}^{***}$ (85)	$11.7 \pm 0.1_{***}^{***}$ (75)
Females	15.6 ± 0.1	$15.0 \pm 0.1^{***}$ (96)	$14.6 \pm 0.1^{***}$ (94)	$13.6 \pm 0.1^{***}$ (87)	$12.5 \pm 0.1^{***}$ (80)	$10.5 \pm 0.3^{***}$ (67)
Erythrocytes $(10^6/\mu L)$						
Males	9.05 ± 0.08	$8.71 \pm 0.14^{**}_{***}(96)$	$8.91 \pm 0.06(98)$	$8.01 \pm 0.08^{***}_{***}$ 89)	$7.10 \pm 0.07_{***}^{***}$ (78)	$5.97 \pm 0.05^{***}_{***}(66)$
Females	8.48 ± 0.05	8.08 ± 0.07 ^{***} (95)	$7.70 \pm 0.08^{***}$ (91)	$6.91 \pm 0.05^{***}$ (81)	$6.07 \pm 0.04^{***}$ (72)	$4.77 \pm 0.15^{***}(56)$
Reticulocytes $(10^6/\mu L)$						
Males	0.16 ± 0.02	0.17 ± 0.03	0.15 ± 0.02	$0.30 \pm 0.04^{***}$	$0.48 \pm 0.06^{***}_{***}$	$0.68 \pm 0.07^{***}_{***}$
Females	0.13 ± 0.02	0.10 ± 0.01	0.16 ± 0.02	$0.26 \pm 0.04^{**}$	$0.34 \pm 0.04^{***}$	$0.40 \pm 0.11^{***}$
Nucleated erythro. $(10^3/\mu L)$						
Males	0.04 ± 0.02	0.05 ± 0.01	0.04 ± 0.03	0.11 ± 0.03	$0.17 \pm 0.04^{***}_{***}$	$0.20 \pm 0.06^{**}$
Females	0.04 ± 0.02	0.05 ± 0.02	$0.12 \pm 0.03^{**}$	0.18 ± 0.07	$0.61 \pm 0.24^{***}$	$0.73 \pm 0.27^{***}$
MCV (fL)						
Males	50.4 ± 0.3	$50.2 \pm 0.2 (100)$	$50.7 \pm 0.2 (100)$	$53.1 \pm 0.2^{***}_{***}$ (105)	$53.8 \pm 0.3^{***}$ (107) $61.6 \pm 0.2^{***}$ (112)	$58.5 \pm 0.3^{***}_{***}(117)$
Females	55.1 ± 0.3	$55.3 \pm 0.2 (100)$	56 .4 ± 0.2 (102)	$58.7 \pm 0.2^{***}$ (107)	$61.6 \pm 0.2^{***}$ (112)	$66.8 \pm 0.9^{***}$ (121)
MCH (pg)						
Males	17.1 ± 0.1	17.0 ± 0.1	17.3 ± 0.1	$18.1 \pm 0.1^{***}_{***}$	$18.4 \pm 0.1^{***}_{***}$	$19.5 \pm 0.1_{***}^{***}$
Females	18.4 ± 0.1	18.6 ± 0.2	$19.0 \pm 0.0^{***}$	$19.6 \pm 0.1^{***}$	$20.6 \pm 0.1^{***}$	$22.0 \pm 0.1^{***}$
Hemosiderin (incidence)						
Males	0/10	0/10	0/10	7/10	10/10	10/10
Females	0/10	0/10	10/10	10/10	9/9	5/5

Table 4-3. Hematology and hemosiderin data from a 14-week inhalation study of EGBE in F344 rats.

*Values listed are mean \pm standard error (percent of control). **Statistically significant difference, $p \le 0.05$. ***Statistically significant difference, $p \le 0.01$.

Source: NTP (1993).

Endpoint [*]	Control	31 ppm (150 mg/m ³)	62.5 ppm (302 mg/m ³)	125 ppm (604 mg/m ³)	250 ppm (1,208 mg/m ³)	500 ppm (2,416 mg/m ³)
Hct (%) Males Females	47.3 ± 1.0 46.2 ± 0.3	$48.3 \pm 0.4 (102) 45.9 \pm 0.3 (99)$	$47.6 \pm 0.5 (101) 45.8 \pm 0.3 (99)$	$46.6 \pm 0.4 (99) 45.1 \pm 0.2^{***} (98)$	$\begin{array}{c} 44.2 \pm 0.4^{***} \ (93) \\ 42.3 \pm 0.4^{***} \ (92) \end{array}$	$36.3 \pm 1.4^{***} (77) 37.8 \pm 1.0^{***} (82)$
Hb (g/dL) Males Females	15.7 ± 0.4 15.7 ± 0.1	$16.0 \pm 0.1 (102) \\ 15.4 \pm 0.1^{**} (98)$	$15.9 \pm 0.1 (101) \\ 15.4 \pm 0.1^{**} (98)$	$15.4 \pm 0.1^{***} (98) 14.8 \pm 0.1^{***} (94)$	$14.4 \pm 0.1^{***} (92) \\ 13.7 \pm 0.1^{***} (87)$	$11.4 \pm 0.4^{***} (73) \\ 11.6 \pm 0.1^{***} (74)$
Erythrocytes (10 ⁶ /µL) Males Females	9.71 ± 0.22 9.72 ± 0.05	$10.04 \pm 0.08 (103) \\ 9.55 \pm 0.06^{**} (98)$	$9.77 \pm 0.1 (101)$ $9.51 \pm 0.06^{**} (98)$	$9.47 \pm 0.06^{**} (98) 9.18 \pm 0.05^{***} (94)$	$\begin{array}{c} 8.90 \pm 0.07^{***} \ (92) \\ 8.57 \pm 0.06^{***} \ (88) \end{array}$	$7.21 \pm 0.23^{***} (74) 7.35 \pm 0.07^{***} (76)$
Reticulocytes (10 ⁶ /µL) Males Females	0.21 ± 0.03 0.18 ± 0.02	0.22 ± 0.03 0.21 ± 0.03	$0.21 \pm 0.02 \\ 0.19 \pm 0.02$	$\begin{array}{c} 0.32 \pm 0.03^{**} \\ 0.29 \pm 0.02^{***} \end{array}$	$\begin{array}{c} 0.45 \pm 0.04^{***} \\ 0.47 \pm 0.04^{***} \end{array}$	$\begin{array}{c} 0.79 \pm 0.20^{***} \\ 1.17 \pm 0.28^{***} \end{array}$
MCV (fL) Males Females	49.1 ± 0.4 48.3 ± 0.3	$48.5 \pm 0.3 (99) 48.8 \pm 0.2 (101)$	$49.0 \pm 0.4 (100) 48.8 \pm 0.2 (101)$	$49.7 \pm 0.4 (101) 49.5 \pm 0.5 (102)$	$49.8 \pm 0.4 (101) 49.0 \pm 0.3 (101)$	$48.3 \pm 0.9 (98) 48.8 \pm 1.0 (101)$
MCH (pg) Males Females	16.2 ± 0.1 16.1 ± 0.1	$16.0 \pm 0.1 (99)$ $16.0 \pm 0.1 (99)$	$16.2 \pm 0.1 (100) \\ 16.2 \pm 0.1 (101)$	$16.2 \pm 0.0 (100) \\ 16.1 \pm 0.1 (100)$	$16.2 \pm 0.1 (100) 16.0 \pm 0.0 (99)$	$\begin{array}{c} 15.8 \pm 0.2 \ (98) \\ 15.8 \pm 0.1 \ (98) \end{array}$
Hemosiderin (incidence) Males Females	0/10 0/10	0/10 0/10	0/10 0/10	0/10 0/10	0/10 10/10	6/6 6/6

Table 4-4. Hematology and hemosiderin data from a 14-week inhalation study of EGBE in B6C3F1 mice.

*Values listed are mean \pm standard error (percent of control). **Statistically significant difference, $p \le 0.05$. ***Statistically significant difference, $p \le 0.01$.

Source: NTP (1993)

4.2.2. Chronic Studies and Cancer Bioassays

4.2.2.1. Inhalation

1 NTP (2000) also completed a two-species, 2-year inhalation study on EGBE in both 2 genders of rats and mice. In this chronic study, animals were exposed to EGBE 6 hours/day, 3 5 days/week at concentrations of 0, 31, 62.5, and 125 ppm $(0, 150, 302, \text{and } 604 \text{ mg/m}^3)$ for groups of 50 F344/N rats and 0, 62.5, 125, and 250 ppm (0, 302, 604, and 1,208 mg/m³) for 4 5 groups of 50 B6C3F1 mice. The researchers stated that the highest exposure was selected to 6 produce a 10–15% depression in hematologic indices, and survival was significantly decreased 7 in male mice at 125 and 250 ppm (54.0% and 53.1%, respectively). They reported that no effect 8 on survival was observed in rats, but survival was statistically significantly decreased in male 9 mice exposed to 125 or 250 ppm, compared with chamber controls (NTP, 2000). Although 10 statistics were not reported for mean body weights, the rats exposed to 31 and 62.5 ppm had 11 similar mean body weights to the control rats. Mean body weights of the exposed mice were 12 generally less than for controls, with females experiencing greater and earlier reductions. From 13 week 17 to the end of the study, the mean body weights of 125 ppm female rats were generally 14 less than those of controls. Non-neoplastic effects in rats included hyaline degeneration of the 15 olfactory epithelium in males (13/48, 21/49, 23/49, 40/50) and females (13/50, 18/48, 28/50, 16 40/49) and Kupffer cell pigmentation in the livers of males (23/50, 30/50, 34/50, 42/50) and 17 females (15/50, 19/50, 36/50, 47/50) (Table 4-5). The severity of the olfactory lesion was not 18 affected by exposure. The Kupffer cell pigmentation is a result of hemosiderin accumulation and 19 is a recognized secondary effect of the hemolytic activity of EGBE (NTP, 2000). 20 Non-neoplastic, statistically significant effects in mice included forestomach ulcers and 21 epithelial hyperplasia, hematopoietic cell proliferation and hemosiderin pigmentation in the 22 spleen, Kupffer cell pigmentation in the livers, and bone marrow hyperplasia (males only). 23 Hyaline degeneration of the olfactory epithelium (females only) was increased relative to 24 chamber controls, but was not statistically significant. As in the rats, the Kupffer cell 25 pigmentation was considered a secondary effect of the hemolytic activity of EGBE. Bone 26 marrow hyperplasia, hematopoietic cell proliferation and hemosiderin pigmentation in the spleen were also attributed to the primary hemolytic effect; it was followed by regenerative hyperplasia 27 28 of the hematopoietic tissue. The forestomach lesions did not appear to be related to the hemolytic 29 effect of EGBE. Incidences of ulcer were significantly increased in all exposed female groups, 30 as well as males exposed to 125 ppm. Incidences of epithelial hyperplasia, usually focal, were 31 significantly increased in all exposed groups of males and females. The hyperplasia was often 32 associated with ulceration, particularly in the females, and consisted of thickness of the stratified 33 squamous epithelium and sometimes the keratinized layer of the forestomach.

	Control	31 ppm	62.5 ppm	125 ppm	250 ppm
Rat					
Kupffer cell pigmentation, hemosiderin in the liver Male Female	23/50 15/50	30/50 19/50	34/50 [*] 36/50 [*]	42/50 [*] 47/50 [*]	NT NT
Hyaline degeneration of the olfactory epithelium Male Female	13/48 13/50	21/49 [*] 18/48	23/49 [*] 28/50 [*]	40/50 [*] 40/49 [*]	NT NT
Mouse					
Kupffer cell pigmentation, hemosiderin in the liver Male Female	0/50 0/50	NT NT	0/50 5/50*	8/49 ^{**} 25/49 ^{**}	30/49 ^{**} 44/50 ^{**}
Hematopoietic cell proliferation in the spleen					
Male Female	12/50 24/50	NT NT	11/50 29/50	26/48 ^{**} 32/49	42/50 ^{**} 35/50 [*]
Hemosiderin in the spleen					
Male Female	0/50 39/50	NT NT	6/50 [*] 44/50	45/48 ^{**} 46/49 ^{**}	44/49 ^{**} 48/50 ^{**}
Forestomach ulcers					
Male Female	1/50 1/50	NT NT	2/50 7/50 [*]	9/49 ^{**} 13/49 ^{**}	3/48 22/50 ^{**}
Forestomach epithelial hyperplasia					
Male Female	1/50 6/50	NT NT	7/50 [*] 27/50 ^{**}	16/49 ^{**} 42/49 ^{**}	21/48 ^{**} 44/50 ^{**}
Hyaline degeneration of the olfactory epithelium Females (only)					
	6/50	NT	14/50	11/49	12/50
Bone marrow hyperplasia Males (only)	0/50	NT	1/50	9/49*	5/50*

Table 4-5. Selected Female and Male Rat and Mouse Non-neoplastic effects from the 2-year **Chronic EGBE Inhalation Study**

*Statistically significant difference, $p \le 0.05$. **Statistically significant difference, $p \le 0.01$.

NT = not tested

Source: NTP (2000)

1

Ulceration consisted of a defect in the forestomach wall that penetrated the full thickness of the epithelium and frequently contained accumulations of inflammatory cells and debris.

2 3

Using the same exposure levels described above, additional groups of rats

4 (27/gender/exposure group) and mice (30/gender/exposure group) in the 2-year study were

5 examined at 3, 6, and 12 months (8–10 animals/time point) for hematologic effects (NTP, 2000).

6 Nine each male and female rats were exposed to 31 ppm EGBE, specifically to evaluate

7 hematology at 3 months, and to receive a total evaluation at 6 months. Animals were

8 continuously exposed, as described above, until their sacrifice at 3, 6, or 12 months. As in the 14-

- 1 week study, inhalation of EGBE by both species resulted in the development of exposure-related
- 2 hemolytic effects, inducing a responsive anemia. In rats, the anemia was persistent and did not
- 3 progress or ameliorate in severity from 3 months to the final blood collection at 12 months.
- 4 Statistically significant (p < 0.05) decreases in automated and manual Hct values, Hb
- 5 concentrations, and RBC counts occurred at 3, 6, and a 12 months in the 125 ppm female mice
- 6 and the 250 pm male and female mice. Statistically significant decreases in these same
- 7 endpoints were also observed in 62.5 ppm females at 6 months and in 125 ppm males at 6 and 12
- 8 months (decreased in Hct were observed only at 3 and 6 months). MCV was increased in female
- 9 mice at the highest duration (12 months) and exposure (250 ppm) levels. Reticulocyte counts
- 10 were increased significantly in the 125 ppm females at 3 and 6 months and in the 125 ppm males
- 11 at 6 months of exposure. Table 4-6 shows the responses available for a representative measure
- 12 of the hematologic effects from EGBE exposure. Hct levels for male and female rats and mice
- 13 measured after 3 months or 12 months are presented.

Control 31.2 ppm 62.5 ppm 125 ppm 250 ppm Female rats* $43.3 \pm 0.5^{***}$ (93) $42.2 \pm 0.5^{***}$ (91) 46.5 ± 0.5 46.1 ± 0.5 (95) _ 3 months 42.3 ± 0.4 *** (93) 45.4 ± 0.2 $45.3 \pm 0.3 (100)$ _ 12 months Male rats* 44.9 ± 0.2 $46.9 \pm 0.5 (104)$ 44.8 ± 0.4 (100) $42.9 \pm 0.5^{**}$ (95) _ 3 months 47.8 ± 0.4 $45.9 \pm 0.8 * * (96)$ $42.9 \pm 1.2^{***}$ (90) 12 months Female mice* $46.2 \pm 0.5^{***}$ (94) 49.3 ± 0.5 48.9 ± 0.4 (99) $43.7 \pm 0.5^{***}$ (89) _ 3 months 46.9 ± 0.4 46.3 ± 0.4 (99) 43.8 ± 0.4 *** (93) $41.8 \pm 0.3^{***}$ (89) _ 12 months Male mice* $46.0 \pm 0.4^{**}$ (97) $43.7 \pm 0.2^{***}$ (92) 47.5 ± 0.3 $47.3 \pm 0.5 (100)$ _ 3 months $48.7 \pm 1.9^{**}$ (102) $42.1 \pm 0.4^{***}$ (88) 47.9 ± 0.4 46.4 ± 1.0 (97) 12 months

 Table 4-6. Comparison of Female and Male Rat and Mouse Hct (Manual) Values from 3and 12-month Inhalation Exposures to EGBE.

*These results are from a serial sacrifice conducted as a part of the 2-year chronic inhalation study. Values listed are mean \pm standard error (percent of control).

– data were not available.

**Statistically significant difference, $p \le 0.05$.

*** Statistically significant difference, $p \le 0.01$.

Source: NTP (2000)

14

In vitro studies by Ghanayem (1989) have shown that the hemolysis caused by the EGBE

- 15 metabolite BAA is preceded by erythrocyte swelling. If the observed increase in MCV is in
- 16 response to cell swelling, it could be a preliminary indicator of the hemolytic effect. Other
- 17 researchers, however, have attributed the increased MCV at all exposures and the increased
- 18 MCH at higher exposures to the erythropoietic response subsequent to hemolysis and the
- 19 corresponding increase in the number of larger reticulocytes in circulation (cited in NTP, 2000).
- 20Reticulocyte counts were significantly increased in female rats at 62.5 ppm (6 and 12 months)April 200827DRAFT-DO NOT CITE OR QUOTE

and in male rats at 125 ppm (3 and 6 months). Since a statistically significant increase in reticulocyte count was not observed at any time point in males or females exposed to 31 ppm or in males exposed to 62.5 ppm, it appears that reticulocyte count alone cannot account for the increase in MCV. The observed increases in MCV may be a combined result of both erythrocyte swelling prior to, and an increased number of reticulocytes subsequent to, hemolysis; the former would be more influential at lower exposure levels, and the latter would have more relative

7 impact at higher levels.

8 Similar effects indicating anemia were also observed in mice, where females were the 9 more sensitive. As in rats, the anemia response was observed at slightly higher doses, but was 10 persistent and did not progress or ameliorate in severity from 3 months to the final blood 11 collection at 12 months. Table 4-6 shows the manual hematocrit values in male and female rats 12 and mice at 3 months and 12 months. Statistically significant (p < 0.05) decreases in automated 13 and manual Hct values and Hb and RBC counts occurred at 3, 6, and 12 months in the 125 ppm 14 females and the 250 ppm males and females. Statistically significant decreases in these endpoints 15 were also observed in 62.5 ppm females exposed for 6 months and in 125 ppm males exposed for 16 6 and 12 months (decreases in Hct were observed only at 3 and 6 months). No changes were 17 observed in the MCV of mice, except for an increase in female mice at the highest duration (12 18 months) and exposure (250 ppm) levels. Reticulocyte counts were increased significantly in the 19 125 ppm females at 3 and 6 months and in 125 ppm males at 6 months of exposure.

At the end of the 2-year chronic bioassay (NTP, 2000), neoplastic effects were observed in female rats and in male and female mice. In female rats, the combined incidence of benign and/or malignant pheochromocytoma of the adrenal medulla was 3/50, 4/50, 1/49, and 8/49. The incidence in the high-dose group (16%) does not represent a statistically significant increase over the chamber control group (6%), but it exceeded the historical control ($6.4 \pm 3.5\%$; range 2– 13%) for this effect.

26 The low survival rate in male mice exposed to 125 and 250 ppm EGBE may have been 27 due to carcinogenic effects in the liver. A high rate of hepatocellular carcinomas was found in 28 these exposure groups (10/50 [control], 11/50, 16/50, 21/50); the increase at the high-exposure 29 level was statistically significant (p < 0.01). When hepatocellular adenomas and carcinomas are 30 combined, no significant increase was observed in any exposure group. However, the incidence 31 of hemangiosarcomas in males exposed to 250 ppm (8%) was significantly increased (p = 0.046) 32 relative to chamber controls (0/50, 1/50, 2/49, 4/49), and exceeded the range of historical 33 controls (14/968; $1.5 \pm 1.5\%$; range 0–4%). No organisms consistent with *Helicobacter* 34 hepaticus were found in the 14 mice evaluated (NTP, 2000). The researchers concluded from this 35 that *H. hepaticus* was not a factor in the development of liver neoplasms. No significant 36 increases in benign or malignant hepatocellular tumors or hemangiosarcomas were noted in the 37 female mice, and the incidence of hepatocellular adenomas actually decreased significantly (p < p

April 2008

- 1 0.05) in relation to the control chamber group (16/50, 8/50, 7/49, 8/49). However, in light of the
- 2 high survival rate of the exposed female mice relative to the control animals (29/50, 31/50,
- 3 33/50, 36/50), the high exposure of 250 ppm may not have provided the maximum tolerated
 dose.
- 5 Forestomach squamous cell papillomas and carcinomas, combined, were significantly 6 increased (trend test = 0.003) in female mice relative to the chamber controls (0/50, 1/50, 2/50, 7 6/50). The incidence of these tumor types (12%) at the highest exposure level was statistically 8 significant and exceeded the range for the occurrence of these tumors in historical controls 9 $(0.9 \pm 1.1\%)$; range 0–3%). The first incidence of these tumors appeared in the group exposed to 10 250 ppm at 582 days, compared with 731 days at 62.5 and 125 ppm. This indicates a decreased 11 latency period in the highest exposure group. While the incidence of these types of forestomach 12 tumors was not significantly increased over controls in male mice (1/50, 1/50, 2/50, 2/50), the 13 incidence of squamous cell papillomas (4%) in the two highest exposure groups exceeded the 14 range for historical controls $(0.5 \pm 0.9\%)$; range 0–2%). The increased incidences of forestomach
- 15 neoplasms in males, as in females, occurred in groups with ulceration and hyperplasia.

16 Section 4.6 has a discussion of the cancer data from this study. With respect to the

17 noncancer findings, a NOAEL could not be determined, and a LOAEL of 62.5 ppm was

18 determined in mice for hemosiderin deposition. In rats, a NOAEL could not be determined and a

19 LOAEL of 31 ppm was determined for hemosiderin deposition.

4.3. Reproductive and Developmental Studies: Oral and Inhalation

20 Due to the known reproductive toxicity, such as effects to male testes and sperm, of two other glycol ethers, ethylene glycol methyl ether (EGME; 2-methoxyethanol) and ethylene glycol 21 22 ethyl ether (EGEE; 2-ethoxyethanol), the reproductive toxicity of EGBE was studied in a variety 23 of oral studies (NTP, 1993; Exon et al., 1991; Heindel et al., 1990; Foster et al., 1987; Grant 24 et al., 1985; Nagano et al., 1984, 1979) and inhalation studies (NTP, 2000; Dodd et al., 1983) using rats, mice, and rabbits. Several developmental studies have addressed EGBE toxicity from 25 26 conception to sexual maturity, including toxicity to the embryo and fetus, following oral (Sleet 27 et al., 1989; Wier et al., 1987), inhalation (Nelson et al., 1984; Tyl et al., 1984), and dermal 28 (Hardin et al., 1984) exposures in rats, mice, and rabbits. In many instances, LOAELs and 29 NOAELs were reported for both parental and developmental effects; therefore, the 30 developmental studies can also be used to assess systemic toxicity as well as developmental 31 toxicity. 32 EGBE did not cause adverse effects in the reproductive organs, including testes, in any 33 study. In a two-generation reproductive toxicity study, fertility was reduced in mice only at very

- 34 high, maternally toxic, doses (>1000 mg/kg). Maternal toxicity, related to the hematologic effects
- 35of EGBE, and relatively minor developmental effects, have been reported in developmental
April 200829DRAFT-DO NOT CITE OR QUOTE

studies and are discussed below. No teratogenic effects were noted in any of the studies. It can be concluded from these studies that EGBE is not significantly toxic to the reproductive organs of adult males or females, or to the developing fetuses of laboratory animals.

4 As discussed in Section 4.2, Nagano et al. (1979) performed a toxicity study in male 5 JCL/ICR mice (five/group), using gavage doses of 0, 357, 714, or 1,430 mg/kg-day EGBE 6 5 days/week for 5 weeks. A LOAEL of 357 mg/kg-day based on reduced RBC count was 7 identified, but no changes in testes weight or histology were observed. In another study, Nagano 8 et al. (1984) used the same dosing regimen up to 2,000 mg/kg-day to test EGBE and other glycol 9 ethers. Testicular atrophy was observed for EGEE and EGME, but not for EGBE. 10 Grant et al. (1985) exposed male F344 rats (six/group) to gavage doses of 0, 500, or 11 1,000 mg/kg-day EGBE and EGME for 4 days. Severe testicular atrophy was observed in rats 12 fed 500 mg/kg-day EGME, but no significant effect was noted in rats fed up to 1,000 mg/kg-day

13 EGBE.

14 Krasavage (1986) conducted a toxicity study using groups of 10 COBS CD(SD)BR adult 15 male rats treated by gavage with 222, 443, or 885 mg/kg-day undiluted EGBE 5 days/week for 16 6 weeks. They found no effects on testicular weight and no histopathological lesions in the testes, 17 seminal vesicles, epididymides, or prostate gland at any exposure level.

Foster et al. (1987) fed Alpk/AP (Wistar-derived) male rats single gavage doses of 0, 174, 434, or 868 mg/kg BAA. Occasional significant decreases in the weight of the prostate gland and seminal vesicles were observed, but the decreases were not time- or dose-related. No treatmentrelated lesions were noted following histologic examination of the testes, epididymides, or prostate. BAA did not produce any changes in testicular cell populations when introduced in vitro at 5 mM. Simultaneous testing of the acids of EGME and EGEE resulted in significant spermatocyte cell loss and damage in vivo and in vitro.

25 Subchronic reproductive studies were conducted using male and female Swiss CD-1 26 mice. Heindel et al. (1990) exposed them to EGBE in drinking water at doses of 0, 700, 1,300, 27 and 2,000 mg/kg-day for 7 days premating; subsequently, they exposed the mice for 98 days 28 while cohoused as breeding pairs. The higher two-dose levels resulted in mortality: 13/20 died 29 during the study in the 2,000 mg/kg-day group and 6/20 died in the 1,300 mg/kg-day dose group, 30 as compared with 1 each in the 700 mg/kg-day group and the control group. Statistically 31 significant toxic effects seen in the 1,300 and 2,000 mg/kg-day dose groups with adult mice 32 included decreased body weight gain, increased kidney and liver weights, and dose-related 33 decreases in water consumption. Statistically significant developmental effects observed in the 34 1,300 and 2,000 mg/kg-day dose groups included decreased pup weight and fewer and smaller 35 litters produced per pair. A significant reduction (5%) in live pup weight was also observed in the 36 700 mg/kg-day dose group. No adverse effect on fertility was observed in the 700 mg/kg-day 37 dose group.

April 2008

1 At the completion of the 98-day continuous breeding phase, F_0 breeding pairs were 2 separated and housed individually, while exposure to EGBE continued. When the last litter was 3 weaned, a 1-week crossover mating trial was performed to determine effects by gender. F₀ males 4 and females from the 1,300 mg/kg-day dose group were mated with male and female control 5 animals. The exposed mice had significantly lower body weights and increased relative kidney 6 weights, but reproductive organ weights, sperm motility and morphology, and estrous cycle 7 length and frequency did not differ from control mice. In the only histopathological examination 8 carried out on treated females, no kidney lesions were observed. The proportion of successful 9 copulation was equivalent in all groups, and no developmental effects were observed in any 10 offspring. However, the number of fertile females was significantly reduced in the group where 11 treated females were mated with control males, suggesting that fertility effects were primarily 12 due to effects on the female mice.

A final phase of this study assessed the fertility and reproductive effects of EGBE in firstgeneration (F₁) pups. There were insufficient numbers of offspring to assess the two highest dose groups, and no adverse effect on fertility was noted when offspring of the low, 700 mg/kg-day dose group were mated. Thus, the researchers concluded that the 700 and 1,300 mg/kg-day dose levels are considered to be NOAEL and LOAEL values, respectively, for both maternal and reproductive effects. A minimal LOAEL for developmental effects was 700 mg/kg-day, where a very slight decrease in pup weight was observed.

A study by Exon et al. (1991), also discussed in Section 4.4.5, looked at reproductive parameters in male rats. Groups of six Sprague-Dawley rats were exposed to EGBE in drinking water at doses of 0, 180, or 506 mg/kg-day (males) for 21 days. While testicular atrophy and necrosis and a reduced number of spermatogenic cells were observed in males exposed to EGME, no adverse effects on fertility parameters were seen in males at any of the tested doses of EGBE.

26 NTP (1993) evaluated the effects of EGBE on the reproductive systems of male and 27 female B6C3F1 mice (five/gender/group) following 2-week drinking water exposure to doses of 28 93, 148, 210, 370, or 627 mg/kg-day for males and 150, 237, 406, 673, or 1364 mg/kg-day for 29 females. No deaths were reported, and there were no effects on body weight. Thymus weights 30 were decreased in the highest male dose group. There were no treatment-related gross lesions in 31 any of the reproductive organs and histopathological examinations were not performed. NTP 32 (1993) also exposed male and female F344 rats (five/gender/group) to EGBE for 2 weeks in 33 drinking water. Male rats received doses of 73, 108, 174, 242, or 346 mg/kg-day, and females 34 received 77, 102, 152, 203, or 265 mg/kg-day. No treatment-related deaths occurred during the 35 study, and no changes in body weight were observed in male rats that could be related to 36 treatment. However, female rats had lower weight gain in the highest dose group. Water

- consumption was lowest in the highest dose group in both genders, and no treatment-related
 gross lesions of reproductive organs were reported.
- Dodd et al. (1983) (also discussed in Section 4.2) performed a 90-day subchronic
 inhalation study on F344 rats. Male and female rats (16/gender/group) were exposed to EGBE
 for 6 hours/day, 5 days/week at concentrations of 0, 5, 25, and 77 ppm. They reported no changes
 in testicular weight or in the pathology of the epididymides or testes of male rats at any exposure
 level; reproductive organs of the female rats were not examined histologically.
- 8 NTP (2000) performed chronic and subchronic inhalation studies of EGBE in F344 rats 9 and B6C3F1 mice in which reproductive organs were examined. In the subchronic portion of the NTP (2000) studies, rats and mice (10/gender/group) were exposed to concentrations of 0, 31, 10 11 62.5, 125, 250, and 500 ppm of EGBE 6 hours/day, 5 days/week for 14 weeks. Testicular 12 degeneration was reported in 2/4 mice from the 500 ppm group that died or were killed moribund. No other effects were noted in the reproductive organs of rats or mice. Exposure 13 14 concentrations were 0, 31, 62.5, and 125 ppm for groups of 50 F344/N rats and 0, 62.5, 125, and 15 250 ppm for groups of 50 B6C3F1 mice. No effects were noted in the reproductive organs of
- 16 either species, but the researchers reported that survival was significantly decreased in male mice
- 17 at 125 and 250 ppm (54.0 and 53.1%, respectively).
- 18 Prenatal and postnatal developmental toxicity tests were conducted in CD-1 mice by Wier 19 et al. (1987). Animals received 0, 350, 650, 1,000, 1,500, or 2,000 mg/kg-day via gavage on 20 gestational days (GDs) 8–14. Maternal toxicity included mortality of 3/6 animals in the 21 1,000 mg/kg-day group and 6/6 in the 2,000 mg/kg-day group. Treatment-related clinical 22 observations were lethargy, abnormal breathing, and green or red vaginal discharge (the latter at \geq 1500 mg/kg-day). Based on clinical signs in the prenatal study, the LOAEL for maternal effects 23 24 was 350 mg/kg-day. The LOAEL for developmental toxicity was determined to be 1,000 mg/kg-25 day, based on a statistically significant increase in the number of resorptions and a reduced 26 number of viable fetuses. The corresponding NOAEL for prenatal effects was 650 mg/kg-day. In 27 the postnatal study, reproductive effects were evaluated in offspring of CD-1 mice administered 28 EGBE via gavage at 0, 650, or 1,000 mg/kg-day on GDs 8–14. Maternal body weight was 29 lowered at 1,000 mg/kg-day. Survival and body weight gain of offspring were unaffected by 30 treatment. No adverse reproductive or developmental effects were observed. In a simultaneous 31 study with EGEE, developmental toxicity was noted at doses below maternal toxicity levels.
- Developmental toxicity was noted at doses below maternal toxicity levels. Developmental toxicity was investigated following the administration of EGBE in distilled water by gavage to groups of 28–35 pregnant F344 rats at doses of 0, 30, 100, or 200 mg/kg-day on GDs 9–11, or doses of 0, 30, 100, or 300 mg/kg-day on GDs 11–13 (Sleet et al., 1989). GDs 9–13 were are the most critical periods of fetal cardiovascular development. Food and water measurements, body and organ weights, clinical signs, hematologic analyses of
- 37 dams, amount of corpora lutea, uterine contents, and number of dead and live fetuses were

1 monitored. Maternal effects of EGBE given in either dosing sequence included marked, dose-

2 related reductions in body weight and/or weight gain, increases in kidney and spleen weights,

3 severe hematotoxicity as evidenced by a decrease in HCT, Hb, and RBC counts;, and an increase

4 in reticulocytes at doses \geq 100 mg/kg-day. No indications of developmental toxicity were

5 observed at the two lower doses. Viability of embryos was reduced by EGBE treatment at the

6 200 mg/kg-day dose (GDs 9–11), but not at 300 mg/kg-day (GDs 9–13). A decreased platelet

7 count was noted in the fetuses at 300 mg/kg-day (GDs 9–13). Cardiovascular or other types of

8 malformations were not found at any dose. The LOAEL for maternal toxicity was 100 mg/kg-

9 day, based on signs of hematotoxicity, with a NOAEL established at 30 mg/kg-day. The LOAEL

for developmental toxicity was 200 mg/kg-day, based on decreased viability of embryos, with a
 NOAEL for this endpoint at 100 mg/kg-day.

12 Sprague-Dawley rats (15/group) were exposed to 0, 150, or 200 ppm EGBE via 13 inhalation for 7 hours/day on GDs 7–15 (Nelson et al., 1984). Rats exposed to 200 ppm showed 14 some evidence of hematuria on the first day of exposure; no adverse effects were noted 15 thereafter, not in offspring. The LOAEL was 200 ppm for slight maternal toxicity; a NOAEL was 16 identified at 150 ppm. The NOAEL for developmental toxicity was 200 ppm. Simultaneous 17 testing revealed that 50 ppm exposures to EGME were toxic at all levels of embryonic and fetal

18 development.

19 Pregnant F344 rats (36/group) and New Zealand white (NZW) rabbits (24/group) were 20 exposed to 0, 25, 50, 100, or 200 ppm EGBE via inhalation for 6 hours/day on GDs 6–15 for rats 21 or days 6–18 for rabbits (Tyl et al., 1984). Fetuses were weighed and evaluated for viability, 22 body weight, and morphological development, including external, visceral, and skeletal 23 malformations. In rats, fetotoxicity was observed at 100 and 200 ppm in the form of retarded 24 skeletal ossification of vertebral arches or centra, sternebrae, or phalanges. Maternal toxicity was 25 also evident at 100 and 200 ppm by increased incidence of hematuria, reduced RBC count, 26 decreased weight gain, and reduced food consumption. For both maternal and developmental 27 toxicity in the rat, the NOAEL and LOAEL values were 50 and 100 ppm, respectively. In rabbits, 28 fetal skeletal ossification of sternebrae and rudimentary ribs was delayed at 200 ppm. Maternal 29 toxicity was also evident at 200 ppm as an increased incidence of clinical signs, reduced gravid 30 uterine weight, and decreased weight gain. For both maternal and developmental effects in the rabbit, the NOAEL and LOAEL values were 100 and 200 ppm, respectively. 31

32 Reproductive toxicity tests were performed on female Sprague-Dawley rats (N not

33 specified) via dermal administration during GDs 6–15, four times per day at 1800 and

34 5400 mg/kg-day (Hardin et al., 1984). In the highest dose group, 10/11 rats died between days 3

35 and 7 of treatment. Signs associated with treatment included red-stained urine, ataxia, inactivity,

36 rough coats, and necrosis of the tail tip. At the lower dose, body weight was slightly reduced, yet

37 there was no evidence of embryo- or fetotoxicity, gross malformations or variations,.

4.4. Other Studies

4.4.1. Acute and Short-Term Exposure Studies

Ghanayem et al. (1987c) conducted acute toxicity studies designed to assess the effect of 1 age on toxicity by comparing effects in treated young (4–5 weeks old) and adult rats (9–13 2 3 weeks, 5–6 months, and/or 16 months old). The researchers exposed male F344 rats (six/group) 4 using single gavage doses of EGBE in water (99% purity) of 0, 32, 63, 125, 250, 250, or 500 5 mg/kg-day. Evaluations included total RBC and WBC counts, urine Hb concentration, organ 6 weights, and histology of the liver, spleen, bladder, kidney, and testes. Focal necrosis of the liver 7 was observed in adult rats exposed at a dose of 250 or 500 mg/kg. Hematologic effects were 8 found to be dose- and age-dependent; older rats being more sensitive than younger rats. 9 Significant decreases in RBC counts, Hct, and Hb and increases in free plasma Hb occurred at 10 125 mg/kg-day in both young and adult rats, with the younger rats exhibiting significantly less pronounced responses. The incidence of hemoglobinuria was also dose and age dependent. 11 12 Concentrations of free Hb in urine also were significantly higher in older rats than in younger 13 rats at all doses. These researchers suggested that the metabolic basis of the age-dependent 14 toxicity of EGBE may be due to a reduced ability by older rats to metabolize the toxic metabolite 15 BAA to CO₂ and a diminished ability to excrete BAA in the urine. Based on increased Hb 16 concentrations in the urine and associated hemolytic effects at higher doses, the LOAEL for this 17 study was determined to be 32 mg/kg-day for both young and adult rats. A NOAEL was not 18 identified. 19 Ghanayem and Sullivan (1993) performed acute oral toxicity studies in male F344 rats (N 20 not specified), using single gavage doses of 250 mg/kg-day EGBE in tap water. MCV and Hct 21 values increased immediately after treatment and decreased with time following exposure. 22 Hemolysis and decreases in Hb concentrations and RBC counts were reported. 23 Grant et al. (1985) gavaged groups of 24 male F344 rats with EGBE (purity 99.9%) in 24 water at doses of 0, 500, or 1,000 mg/kg-day for 4 days. Six rats per dose were examined at 1, 4, 8, and 22 days after the last dose. The animals were evaluated for changes in body weight, 25 26 hematology, organ weight, and histology. Hematology evaluations showed marked dose-related 27 effects on circulating RBCs and WBCs. Changes at 500 and 1,000 mg/kg-day on postdosing day 28 1 included significant dose-related decreases in Hb concentration and total WBC and lymphocyte 29 counts and increases in MCV, reticulocyte counts, and MCH. Hct was also reduced at

30 1,000 mg/kg-day. Most of the RBC changes subsequently returned to normal, although MCV and

- 31 MCH remained increased at day 22. Body weight gain was sufficiently reduced throughout the
- 32 posttreatment period at 1,000 mg/kg-day. Changes in relative organ weights were evident on
- 33 posttreatment day 1, including increased liver and spleen weights at 500 and 1,000 mg/kg-day
- 34 and increased kidney and reduced thymus weights at 1,000 mg/kg-day. These changes returned

to normal by posttreatment day 22, except for liver and spleen weights that were at 1,000 mg/kgday, somewhat increased levels (~5 and ~20%, respectively). The authors determined that EGBE appears to be relatively inactive as a bone marrow toxicant due to the observed proliferative

- 4 response and the lack of hemorrhage at any time in the bone marrow of EGBE treated animals.
- 5 Based on hemolytic anemia with associated reticulocytosis and increased hematopoiesis, a
- 6 LOAEL was established at 500 mg/kg-day, the lowest dose tested. A NOAEL was not identified.

Ghanayem et al. (1992) administered EGBE to male F344 rats (six/group) via gavage for
12 days at dose levels of 0 and 125 mg/kg-day. These investigators identified effects of EGBE
exposure similar to those identified above. Significant hemolysis occurred, becoming more
pronounced up to the third day of dosing. Gradual recovery was observed up to day 12. MCV,
ATP concentration, reticulocyte counts, and relative spleen-to-body weight ratios increased up to
the sixth day of dosing and declined thereafter. Liver-to-body-weight ratios were slightly lowered
on days 3 and 6 and slightly increased on day 12.

14 Several studies investigated EGBE-induced effects on specific organs and cells. Four 15 male and four female F344 rats were exposed to two, three, or four daily doses of EGBE at 250 mg/kg-day. Ezov et al. (2002) investigated hemolytic anemia and disseminated thrombosis 16 17 in rats by investigating the organs for hemolysis and histopathologic evidence of disseminated 18 thrombosis. Significant morphological changes in erythrocytes were noted in both genders of 19 rats, while disseminated thrombosis and infarction were seen mainly in females and consisted of 20 tissue necrosis in the brain, liver, bones, eyes, lungs, and heart. Renal tubular necrosis associated 21 with Hb casts was seen in both genders. Koshkaryev et al. (2003) measured changes in 22 adherence, aggregability, and deformability of RBCs. EGBE exposure did not affect RBC 23 aggregability, and its effect on deformability was inconclusive; however, the exposure clearly 24 enhanced RBC adherence to endothelial cells, with adherence highest at day 2, the first day 25 examined, after which it decreased sharply with time. Shabat et al. (2004) studied bone marrow 26 injury and reported extensive vascular thrombosis resulting in necrosis of bone marrow cells, 27 bone-lining cells, and cortical and trabecular osteocytes. The authors concluded that, in EGBE-28 treated rats, interactions of several factors may generate a thrombotic crisis, such as the release 29 of procoagulant factors from destroyed erythrocytes; they further concluded that disturbed blood 30 flow may result from alterations in the rheology of erythrocytes, including self-aggregation, 31 deformation, and adherence to the endothelium of the blood vessel wall. Redlich et al. (2004) 32 investigated the dental effects from EGBE-induced hemolysis and thrombosis. Odontoblastic 33 necrosis in the dental pulp of incisors and molars and muscle-cell damage in the tongue were 34 observed; the most severe changes occurred in females. These effects were probably the result of 35 ischemic events in the blood vessels supplying these tissues, rather than a direct cytotoxic effect 36 of EGBE.

1 Corlev et al. (1999) conducted a series of studies in B6C3F1 mice investigating aspects 2 of EGBE toxicity, including the occurrence of forestomach lesions in both oral and inhalation 3 exposure routes, the dose-response of forestomach irritation, and the occurrence of forestomach 4 lesions as a consequence of systemic-only exposure. To determine the extent that activities 5 during inhalation exposures (e.g., grooming) could contribute to observed forestomach lesions, 6 groups of female mice were exposed for 6 hours to target concentrations of 250 ppm EGBE via 7 whole-body (n = 20) and nose-only (n = 20) exposures and concentrations on the fur that were 8 available for oral consumption via grooming measured. For whole-body exposures, 9 9.2 ± 2.9 mg/kg was available compared with 7.5 ± 2.3 mg/kg for the nose-only exposures. Little 10 difference was detected in the internal dose of EGBE from whole-body versus nose-only 11 exposures, as measured by the analysis of EGBE and in BAA detected in blood and urine 12 postexposure. To inform the dose response of toxicity in the forestomach tissues in mice, neat 13 EGBE was administered to male and female mice (five/gender/dose) via gavage (no vehicle) for 14 1 week at doses of 100, 400, or 800 mg/kg-day. The dose in the 100 mg/kg-day group was 15 increased to 1,200 mg/kg-day after 2 days. Severe hemolysis and mortality were seen, and the 16 2-week study was terminated after only four doses. Forestomach lesions consisting of focal areas 17 of irritation and epithelial hyperplasia were seen at all exposure levels in this study. Next, the 18 researchers administered saline solutions of EGBE to groups of three mice by either 19 intraperitoneal (i.p.) or subcutaneous (s.c.) injection at 400 or 600 mg/kg-day for 3 consecutive 20 days or 0 and 400 mg/kg-day for 5 consecutive days. Focal irritation in the forestomach, similar 21 to that seen in gavage and inhalation studies, was seen in the three mice administered EGBE by 22 i.p. injection at 600 mg/kg for 3 days, while 1/3 mice at 400 mg/kg i.p. and at 400 and 600 mg/kg s.c. for 3 days also had forestomach lesions, minimal effects. At 400 mg/kg (5-day study), 23 24 1/6 mice (i.p.) and 2/6 mice (s.c.) also had minimal lesions. From these results, it can be 25 concluded that: (1) the contribution to forestomach exposure from grooming activities, etc., 26 during whole-body inhalation exposures is incidental; (2) the exposure of forestomach lesions to 27 EGBE is similar from gavage and inhalation exposures; and (3) forestomach tissues show a 28 similar irritative response whether EGBE exposure is systemic or portal of entry. 29 In another series of studies, male and female B6C3F1 mice (16/gender/group) were 30 exposed by oral gavage to 0, 400, 800, or 1200 mg/kg-day of neat EGBE for 2 days (Poet et al., 31 2003). A high level of mortality was seen; the dose was reduced by half and the dosing 32 discontinued when survival did not improve after two additional doses. Lesions, including 33 epithelial hyperplasia and inflammation of the forestomach, were seen at the higher dose levels 34 in both males and females, and minimal-to-mild forestomach epithelial hyperplasias were seen in 35 the lower-dose groups, as well as in both genders. In a study similar to that performed by Corley et al. (1999), female mice were exposed, either by whole-body or nose-only inhalation, to a 36 37 single 6-hour exposure of 250 ppm EGBE; the concentrations on the fur available for oral

consumption via grooming were measured. An average of 205–69 µg of EGBE was detected on
 the fur of the mice exposed whole-body, while an average of 170–52 µg was detected on the fur

3 of the mice exposed nose-only (Poet et al., 2003).

4 Green et al. (2002) conducted a series of experiments to examine the effects and 5 distribution of EGBE in vivo. First, female B6C3F1 mice (five/group) were given a single, daily 6 gavage dose of either EGBE or BAA (0, 50, 150, or 500 mg/kg) for 10 days. Eighteen hours after 7 the last dose, animals were sacrificed to look at cell proliferation in the forestomach and 8 glandular stomach. The only dose-dependent finding was a thickening of the keratinized layers 9 or hyperkeratosis of the forestomach (statistics not reported). A NOAEL of 150 mg/kg EGBE 10 and 50 mg/kg BAA was observed. No effects were seen in the glandular stomachs at any dose 11 levels. In the next set of studies, female B6C3F1 mice (n = 12) were exposed whole-body to 250 ppm 2- butoxy[1-¹⁴C]ethanol (specific activity 0.365 mCi/mmol) for 6 hours. Following the 12 exposure, animals were given free access to food and water; they were terminated (four per time 13 14 point) at 5 minutes and 24 and 48 hours after exposure and whole body autoradiography was 15 performed. Female B6C3F1 mice (n = 12) were given a single i.v. injection of 10 mg/kg 2-16 butoxy[1-¹⁴C]ethanol (850 μ Ci/kg). The animals were then given free access to food and water 17 and terminated (four per time point) at 4, 24, and 48 hours after dosing, and whole body 18 autoradiograms were prepared. These studies showed that whether EGBE was delivered by 19 inhalation or by i.v., radiolabeled EGBE was found in the buccal cavity, esophagus, and stomach. 20 This suggests that EGBE somehow enters the stomach via the buccal cavity and esophagus 21 following inhalation exposure.

Administration of a 2,000 mg/kg oral dose of EGBE to guinea pigs caused complete mortality of females and 60% mortality of males (Shepard, 1994a, b), but a dose of 1,000 mg/kg caused only a 20% mortality of either gender. Clinical signs and gross necropsy indicated toxicity was due to irritation of the stomach. There was no evidence of hemolytic toxicity.

26 Gingell et al. (1998) performed acute oral and inhalation toxicity studies in the guinea 27 pig. A dose of 2,000 mg/kg EGBE was administered by gavage to five male and five females. 28 After excessive mortality (3/5 males, 5/5 females) was observed at this dose, reduced doses of 29 500 and 1000 mg/kg were administered. No animals died at 500 mg/kg, and 1/5 males and 1/5 30 females died at 1,000 mg/kg. The acute oral median lethal dose for both genders was 1,414 31 mg/kg (95% confidence interval [CI] = 1020-1961 mg/kg). Clinical signs in the guinea pigs 32 included slight-to-severe weakness, salivation and staining of face or abdomen hair, and 33 respiratory difficulties in a few males. No evidence of RBC toxicity or hemolysis was observed. 34 In the inhalation study, male and female guinea pigs were exposed for 1 hour to 633 ppm and 35 691 ppm, respectively. No mortality, clinical signs of toxicity, or exposure-related pathological signs were noted. Thus, the median lethal concentration for a 1-hour exposure for guinea pigs 36 37 was >633 ppm in males and >691 ppm in females.

4.4.2. Dermal Exposure Studies

1 EGBE appears to be readily absorbed after contact with animal skin. Rats and rabbits 2 exhibit varying degrees of hematotoxicity following dermal application of EGBE (Allen, 1993a, 3 b, c, d; Bartnik et al., 1987; Tyler, 1984). Bartnik et al. (1987) performed acute dermal toxicity 4 tests using Wistar rats (six/gender/group). A single application of 200, 260, 320, 375, or 5 500 mg/kg EGBE was placed on the dorsal shaved skin of rats and covered with a glass capsule. 6 Hemolytic and/or hemoglobinuria effects were observed at 500 mg/kg EGBE within 6 hours of 7 application. No effects were observed at 200 mg/kg. 8 Repeated occluded application of EGBE either neat or as a dilute aqueous solution to 9 NZW rabbits (five/gender/group) of 18, 90, 180, or 360 mg/kg (6 hours/day, nine consecutive 10 applications) produced hemoglobinuria in males at 360 mg/kg and in females at 180 or 11 360 mg/kg (Tyler, 1984). Only female rabbits showed decreased RBC counts, decreased Hb and 12 MCHC, and increased MCH concentrations at the highest treatment level. Recovery was noted 13 after 14 days. In a separate 13-week study, occluded dermal administration of EGBE to NZW 14 rabbits (10/gender/group) at exposure levels of 10, 50, or 150 mg/kg 6 hours/day, 5 days/week, 15 produced no observable hematological effects (Tyler, 1984). 16 Occlusion or semi-occlusion of the site of EGBE administration was also a determining 17 factor. For example, some studies have shown no clinical signs of hematotoxicity in Sprague-18 Dawley rats (five/gender/group) administered EGBE dermally at 2,000 mg/kg (24-hour 19 exposure) either semi-occluded or occluded (Allen, 1993a, b). However, clinical signs of 20 systemic toxicity were noted following the occluded exposure. In similar studies in NZW rabbits 21 (five/gender/group), red-stained urine was reported at semi-occluded doses of 2,000 mg/kg 22 EGBE, along with other clinical signs of systemic toxicity (Allen, 1993c, d). Similar effects 23 occurred at occluded doses of 500, 707, and 1,000 mg/kg in this species; deaths occurred at the 24 500 and 1,000 mg/kg exposures. Thus, hematotoxicity varied from nonexistent to severe. In

25 guinea pigs, dermal administration of EGBE at 2,000 mg/kg produced no deaths, clinical signs of 26 toxicity, or treatment-related signs of organ toxicity (Gingell et al., 1998; Shepard, 1994b).

27 In an assessment of immune parameters, female BALB/c mice (five/group) were 28 topically exposed to EGBE at 100, 500, 1,000, and 1,500 mg/kg-day for 4 consecutive days 29 (Singh et al., 2001). A statistically significant increase in spleen-to-body-weight ratio, and a 29% increase in splenic cellularity was observed at 1,500 mg/kg. Splenic proliferative responses to the 30 31 T-cell mitogen, concanavalin-A (con-A), were significantly decreased by 32% at 500 mg/kg-day 32 and 35% at 1,000 mg/kg-day. Allogeneic antigen-driven lymphoproliferative responses in the 33 mixed lymphocyte response were significantly reduced by 55% at 500 mg/kg-day and 56% at 34 1,000 mg/kg-day. However, natural killer (NK) cell activity, cytotoxic T-lymphocyte activity, and 35 the T-dependent plaque-forming cell (PFC) response were not significantly affected by EGBE

38

36 exposure. A dose of 100 mg/kg-day was a NOAEL.

April 2008

1 Singh et al. (2002) exposed female BALB/c mice (five/group) via gavage to 50, 150, or 2 400 mg/kg EGBE, or topically on the ear to 0.25, 1.0, 4.0, or 16.0 mg EGBE. The researchers 3 measured the oxazolone (OXA)-induced contact hypersensitivity response (CHR). Mice that 4 received the gavage doses of EGBE for 10 consecutive days did not exhibit a significantly 5 altered OXA-induced CHR as measured by ear swelling 24 hours post-challenge. In contrast, 6 topical exposure to EGBE significantly suppressed the OXA-induced CHR at a dose of 4.0 mg 7 EGBE/ear, but not at any other dose. 8 The studies indicate that while the dermal route of exposure can be expected to contribute 9 to overall exposure, the concentrations at which effects occur in animals are higher than those

10 found following oral and inhalation exposure. In humans, toxicokinetic studies have shown that

11 dermal absorption of EGBE vapors do contribute to the total body burden, showing the

12 importance of the dermal route is of exposure.

4.4.3. Ocular Exposure Studies

13 EGBE has been found to be an irritant when instilled in rabbit (Jacobs and Marten, 1989; 14 Kennah et al., 1989). Kennah et al. (1989) performed the Draize eye irritation test in rabbits. The 15 percent EGBE concentration and corresponding scores by the Texaco single-digit toxicity 16 classification system were 100%-66, 70%-49, 30%-39, 20%-2, and 10%-1. In an 17 assessment that measured corneal thickness, the highest concentration was classified as severely 18 irritating, the 70% concentration was moderately irritating, and the others were mildly irritating. 19 Jacobs and Marten (1989) conducted ocular tests on NZW rabbits (n = 6) to determine the effects 20 of EGBE (100 µL, 99% pure) on eye irritation. The undiluted chemical was dropped onto the 21 lower lid of one eye; the other eye served as a control. The eyes were examined and graded for 22 ocular reactions at 4, 24, 48, 72, 96, and 168 hours post-instillation. The authors determined that 23 EGBE should be classified as an irritant based on the mean erythema scores and percent corneal 24 thickening.

4.4.4. Genotoxicity

Although weakly genotoxic responses have been obtained in two laboratories (Elias et al., 1996; Hoflack et al., 1995), EGBE is not expected to be mutagenic or clastogenic based on the available data (summarized in Table 4-7). The NTP reported negative responses for mutagenicity when EGBE was tested in *Salmonella typhimurium* strains TA97, TA98, TA100, TA1535, and TA1537 at up to 10 mg/plate with and without metabolic activation (Zeiger et al., 1992). However, Hoflack et al. (1995) reported that at 38 µmol/plate (4.5 mg/plate), EGBE induced a weak mutagenic response in salmonella tester strain TA97a in the absence of S9 mix (Hoflack

32 et al., 1995). The work of Hoflack and colleagues was repeated by Gollapudi et al. (1996), and

- 33 EGBE was found to be negative in these tester strains when evaluated at 0.5, 1.0, 2.5, 5.0, 8.5,
- 34 and 10 mg/plate in the presence and absence of Aroclor-induced rat liver S9 mix. Thus, the weak

April 2008

positive result reported in salmonella TA97a by Hoflack et al. (1995) is unconfirmed. A plausible
explanation put forth by Gollapudi et al. (1996) is that, given the sensitivity of the Ames test,
perhaps the weak positive result reported by Hoflack et al. (1995) is attributed to an impurity in
their test material.

Elias et al. (1996) reported that EGBE did not induce chromosomal aberrations in
Chinese hamster V79 fibroblast cells but that EGBE, at treatment concentrations of ≥8.5 mM,
weakly induced SCEs and micronuclei and potentiated the clastogenicity induced by methyl
methanesulfonate. Elias et al. (1996) also reported that EGBE weakly induced aneuploidy
(numerical chromosomal anomalies) in V79 cells; however, this response was found at very high
concentrations (16.8 mM EGBE).

11 When tested at doses nearing toxicity, EGBE and its metabolite BAL were not mutagenic 12 in an in vitro gene mutation assay using Chinese hamster ovary (CHO) cells (CHO-AS52) 13 (Chiewchanwit and Au, 1995). In contrast, Elias et al. (1996) reported that both EGBE and BAL 14 weakly induced gene mutations in Chinese hamster V79 cells only at high treatment 15 concentrations (\geq 7.5 mg/mL). It should be noted that Chiewchanwit and Au (1995) reported 16 high cytotoxicity at 38.1 mM EGBE (4.5 mg/mL). The gene mutation data presented by Elias et 17 al. (1996) is in graphic form only with mean values and no SDs presented. The presence or 18 absence of cytotoxicity was not reported. BAL was also tested for induction of DNA damage in 19 the mouse endothelial cell line, SVEC4-10, using the comet assay. BAL failed to produce a 20 statistically significant increase in DNA strand breaks at any of the concentrations or time points 21 examined (Klaunig and Kamendulis, 2005, 2004; Reed et al., 2003). Other lines of evidence 22 indicate that direct interaction of BAL with the DNA molecules does not play a significant role 23 in the carcinogenic activity of EGBE. First, BAL causes cytotoxicity at levels associated with 24 chromosome effects, and cytotoxicity itself can have effects that result in chromosome damage, 25 such as reduction in the repair of sister chromatid exchanges (SCEs). Second, acetaldehyde is 26 recognized as "weakly mutagenic" and structural comparisons of the aldehyde metabolites of 27 glycol ethers shows that longer-chain aldehydes such as BAL are less mutagenic (Chiewchanwit 28 and Au, 1995). Third, if BAL were a stable mutagenic metabolite in any of the in vitro assays 29 exposed to EGBE, one would expect them to give positive results; however, the results were 30 generally negative. Elias et al. (1996) suggested that the V79 cells possess neither ALD nor ADH. The relevance of these studies, or of any systems that lack these enzymes, is of limited 31 32 value in elucidating the MOA of toxicity in biological systems that possess these enzymes.

Type of test, test species	Dose*	Result	Reference	
	In vitro tests: I	GBE	1	
Reverse mutation, <i>S. typhimurium</i> , TA97, TA98, TA100, TA1535, TA1537	10 mg/plate	Negative (w/ and w/o metabolic activation)	Zeiger et al. (1992) (work done for NTP)	
Reverse mutation, <i>S. typhimurium</i> his–TA 98, TA 100, TA 102	115 μmol/plate (14.0 mg/plate)	Negative (w/and w/o metabolic activation)	Hoflack et al. (1995)	
Reverse mutation, <i>S. typhimurium</i> his- TA97a	38 µmol/plate (4.5 mg/plate)	Weakly positive (w/o metabolic activation)	Hoflack et al. (1995)	
Reverse mutation, <i>S. typhimurium</i> his- TA97a, TA 100; <i>Escherichia coli</i> WP2uvrA	10 mg/plate	Negative (w/and w/o metabolic activation)	Gollapudi et al. (1996)	
Sister chromatid exchanges (SCEs), micronuclei (MNs) and aneuploidy (AP) in V79 cells	10–100 mM (SCE) 8.46 mM (MN) 16.8 mM (AP)	Weakly positive (w/o metabolic activation)	Elias et al. (1996)**	
Potentiation of clastogenicity induced by methyl methanesulfonate	8.5 mM	Positive (w/o metabolic activation)	Elias et al. (1996)**	
Chromosomal aberrations, V79 cells and human lymphocytes	Not available	Negative (w/o metabolic activation)	Elias et al. (1996)**	
Gene mutation, Chinese hamster ovary cells	38.1 mM ^{***} (4.5 mg/mL)	Negative (w/o metabolic activation)	Chiewchanwit and Au (1995)	
DNA damage, SVEC4-10 mouse endothelial cells	10 mM	Negative	Klaunig and Kamendulis (2005)	
	In vitro tests:	BAL		
Reverse mutation, S. typhimurium his-TA 97a, TA 98, TA 100 and TA 102	43 µmol/plate (5.0 mg/plate)	Negative (w/and w/o metabolic activation)	Hoflack et al. (1995)	
Chromosomal aberrations, V79 cells and human lymphocytes	0.1-1 mM;cytotoxicity not reported	Positive (w/o metabolic activation)	Elias et al. (1996)**	
DNA damage, SVEC4-10 mouse endothelial cells	1 mM	Negative	Klaunig and Kamendulis (2005)	
	In vitro tests:	BAA		
Reverse mutation, S. typhimurium his-TA 97a, TA 98, TA 100 and TA 102	8 μmol/plate (0.9 mg/plate)	Negative (w/ and w/o metabolic activation); dose limited by toxicity	Hoflack et al. (1995)	
SCEs and CAs, V79 cells	0.8 mM	Negative (w/o metabolic activation)	Elias et al. (1996)**	
Aneuploidy, V79 cells	0.38 mM	Weakly positive (w/o metabolic activation)	Elias et al. (1996)**	
MN assay, V79 cells	10 mM	Positive (w/o metabolic activation	Elias et al. (1996)**	
DNA damage, SVEC4-10 mouse endothelial cells	10 mM	Negative	Klaunig and Kamendulis (2005)	
	In vivo tests: E	GBE		
MNs, bone marrow erythrocytes of male mice or rats	550 mg/kg-day, mice 450 mg/kg-day, rats	Negative Negative	NTP (1996)	
DNA adducts FVB/N mice Sprague-Dawley rats	120 mg/kg-day; mice and rats	No changes in DNA methylation	Keith et al. (1996)	

Table 4-7. Summary of genotoxicity studies on EGBE, BAL, and BAA.

*Doses are either the lowest effective dose or the highest ineffective dose. **All in vitro assays were performed without the addition of an exogenous metabolic activation system. ***The authors found that this dose was cytotoxic.

41

April 2008

1 BAA has been found negative for reverse mutations in S. typhimurium his⁻ with and 2 without metabolic activation (Hoflack et al., 1995). Concentrations of up to 8 µmol/plate were 3 tested, and dose was limited by toxicity. BAA (up to 10 mM) was also found negative for 4 induction of DNA damage in SVEC4-10 mouse endothelial cells (Klaunig and Kamendulis, 5 2005) and in an SCE assay in V79 cells (Elias et al., 1996). BAA was weakly positive for 6 aneuploidy in V79 cells at 0.38 mM and positive for micronuclei induction in the same cell line 7 at 10 mM, as reported by Elias et al. (1996). As noted above, the data means are presented in 8 graphic form without SDs and cannot be critically evaluated; no cytotoxicity data are reported. 9 EGBE did not increase the incidence of micronuclei in the bone marrow cells of male 10 mice or rats (NTP, 1996). Animals were given three i.p. injections of EGBE 24 hours apart and 11 sacrificed 24 hours after the last injection; rats were dosed at 0, 7, 14, 28, 56, 112.5, 225, or 12 450 mg/kg and mice were dosed at 0, 17, 34, 69, 137.5, 275, or 550 mg/kg (NTP, 1996). There 13 was high mortality (2/5 mice survived) in mice injected with 1,000 mg/kg doses of EGBE. Keith 14 et al. (1996) treated Sprague-Dawley rats and transgenic FVB/N mice carrying the v-Ha-ras 15 oncogene with a single oral dose of 120 mg/kg EGBE; there was no increase in DNA adducts in 16 the brain, liver, kidney, testes, or spleen of the rats, and no changes in DNA methylation patterns 17 in either species.

In conclusion, EGBE has been tested in conventional genotoxicity tests for its potential to induce gene mutations in systems and cytogenetic damage both in vitro and in vivo. Available data do not support a mutagenic or clastogenic mechanism for EGBE. Two laboratories (Elias et al., 1996; Hoflack et al., 1995) reported weak genotoxicity responses in vitro at toxic doses. These results, however, are questionable given limited published information. Elliott and Ashby (1997) reviewed the results of the available genotoxicity studies on EGBE and concluded that the data indicate that EGBE has no significant genotoxic activity.

4.4.5. Immunotoxicity

April 2008

25 Based on the results of the Exon et al. (1991) study, it appears that the immune system is 26 not a sensitive target of EGBE. Groups of six Sprague-Dawley rats were exposed to EGBE in 27 drinking water at doses of 0, 180, or 506 mg/kg-day (males) or 0, 204, or 444 mg/kg-day 28 (females) for 21 days. All rats were injected s.c. with heat-aggregated aqueous keyhole limpet 29 hemocyanin (KLH), a T-cell dependent antigen, on days 7 and 13 following the start of dosing. 30 Endpoints evaluated on day 21 included body weight, absolute and relative organ weights 31 (spleen, thymus, liver, kidney, testis), and histology of thymus, liver, kidney, and testis. Splenic 32 histology was not assessed, because this tissue was used as a source of cells for immune function 33 assays. Immune function assays included NK cell cytotoxicity, antibody response to a T- cell 34 dependent antigen as determined by measurement of KLH-specific serum immunoglobulin G 35 levels, delayed-type hypersensitivity reaction, interleukin-2 and interferon production, and spleen 36 cell counts. Terminal body weights were somewhat lower than controls in all exposed groups,

42

2 dose-related changes in organ weights or histology were observed. NK cell cytotoxic responses 3 were significantly enhanced in males at 180 mg/kg-day and females at 204 mg/kg-day. At the 4 highest dose tested in males and females, the NK cell cytotoxic response was increased above 5 control, but this finding was not statistically significant. A decreased NK cell cytotoxic response 6 is an indication of compromised nonspecific immune system integrity. Given that this study 7 showed an increased response and no dose-response relationship, these findings are not 8 considered to be an indication of an adverse response. No significant alterations in other immune 9 parameters were noted. 10 Smialowicz et al. (1992a) reported on results of experiments that examined the primary

and the decreases were statistically significant in all groups except the 180 mg/kg-day males. No

11 antibody response to a T-cell independent antigen (trinitrophenyl-lipopolysaccharide [TNP-LPS]) 12 measured with a PFC assay to determine the immunotoxic potential of a variety of glycol ethers. 13 This author had previously reported that the shorter-chain glycol ether 2-methoxyethanol (ME) 14 and its principal metabolite 2-methoxyacetic acid (MAA) suppressed the antibody response to 15 TNP-LPS as measured by the PFC assay in F344 rats but not CD-1 mice (Smialowicz et al., 16 1992b). Having established the sensitivity of F344 rats to suppression of the antibody response to 17 the T-cell independent antigen TNP-LPS by ME and MAA, the authors examined other glycol 18 ethers, including 2-butoxyethanol, in the same dose range, for their ability to suppress the 19 antibody response to TNP-LPS by using the same PFC assay. Male F344 rats were immunized 20 with a single i.v. injection of 0.5 mL of 40 µg/mL TNP-LPS, then dosed (six/dose group) by 21 gavage with 50–400 mg/kg-day of various glycol ethers, including EGBE (0, 50, 100, 200, 400 22 mg/kg-day) for 2 days. All rats exposed to 400 mg /kg-day EGBE died, and the 200 mg/kg-day 23 EGBE dose resulted in one dead and one moribund rat. This finding was not unexpected, as the 24 hematotoxicity of EGBE in older rats has been reported in the literature (Ghanayem et al., 1987c; 25 Tyler, 1984; Carpenter et al., 1956). EGBE did not suppress the primary antibody response to 26 TNP-LPS in the PFC assay.

27 In an assessment of immune parameters, female BALB/c mice (five/group) were 28 topically exposed to EGBE at 100, 500, 1,000, and 1,500 mg/kg-day for 4 consecutive days 29 (Singh et al., 2001). A statistically significant increase in spleen-to-body-weight ratio was 30 observed at 1,500 mg/kg, and splenic cellularity was increased by 29% at this dose. Splenic 31 proliferative responses to the T-cell mitogen, con-A, were significantly decreased by 32% at 32 500 mg/kg-day and 35% at 1,000 mg/kg-day. Allogeneic antigen-driven lymphoproliferative 33 responses in the mixed lymphocyte response were significantly reduced by 55% at 500 mg/kg-34 day and 56% at 1,000 mg/kg-day. However, NK cell activity, cytotoxic T-lymphocyte activity, 35 and the T-dependent PFC response were not significantly affected by EGBE exposure. For those 36 immune parameters measured, 100 mg/kg-day was a NOAEL.

1

Singh et al. (2002) exposed female BALB/c mice (five/group) via gavage to 50, 150, or
 400 mg/kg EGBE or topically to 0.25, 1.0, 4.0, or 16.0 mg EGBE on the ear and measured the
 OXA-induced CHR. Mice that received the gavage doses of EGBE for 10 consecutive days did
 not exhibit a significantly altered OXA-induced CHR as measured by ear swelling 24 hours
 postchallenge. In contrast, topical exposure to EGBE significantly suppressed the OXA-induced
 CHR at a dose of 4.0 mg EGBE/ear, but not at any other dose.

4.4.6. Other In Vitro Studies

7 Ghanayem (1989) compared the metabolic and cellular basis of EGBE-induced 8 hemolysis of rat and human erythrocytes in vitro. EGBE is not metabolized when incubated with 9 blood from male F344 rats and causes no hemolysis or metabolic alterations at concentrations of 10 up to 10 mM. A concentration of 20 mM EGBE was required to produce significant hemolysis of 11 rat blood. This may be due to a nonspecific effect occurring at a concentration that is not 12 physiologically relevant. In contrast, incubation of rat blood with BAL or BAA at concentrations 13 of 0.5, 1.0, or 2.0 mM caused a time- and concentration-dependent increase in cell swelling (i.e., 14 increased Hct) followed by hemolysis. This response was more pronounced for BAA, with 15 nearly complete hemolysis observed after 4-hour incubation at 2.0 mM. BAL produced only 16 slight hemolysis under the same conditions. The addition of ADH (with nicotine adenine 17 dinucleotide cofactor) to rat blood followed by BAL produced a potentiation of the hemolytic 18 effects. Addition of cyanamide, an ADH inhibitor, significantly decreased the effects with or 19 without added ADH. Both BAL and BAA caused a time- and concentration-dependent decrease 20 in blood ATP concentrations, although this effect may be secondary to the swelling and lysis 21 observed. Addition of exogenous ATP failed to reverse the hemolytic effects. Neither EGBE nor 22 its metabolites, BAL and BAA, caused any detectable changes in the concentrations of 23 glutathione (GSH) or glucose-6-phosphate dehydrogenase (G6PD) in rat erythrocytes. Blood 24 from male and female human volunteers was unaffected by 4-hour incubations with BAA at 25 concentrations of up to 4.0 mM. At 8 mM, slight but significant hemolysis of human blood was 26 observed: blood from female volunteers showed a slightly greater sensitivity. These studies show 27 that the erythrocyte membrane is the likely target for BAA, that humans of both genders are 28 relatively insensitive to the hemolytic effects of BAA, as compared with rats. 29 Udden (2000) compared effects on RBC morphology in male F344 rats (five/group) 30 dosed with 125 or 250 mg/kg EGBE via gavage with the effects of incubation of rat erythrocytes 31 in vitro with BAA (1 or 2 mM). In vivo exposure resulted in stomatoacytosis and spherocytosis 32 in blood smears and cup-shaped cells and spherocytosis in fixed samples. In vitro incubation 33 resulted in erythrocytes with cup shapes and spherocytosis in the fixed samples. Since in vivo

34 and in vitro exposure caused similar changes in RBC morphology in rats, this study provides

35 additional evidence for the role of BAA in causing the hemolytic effects from EGBE exposure

36 in rats.

April 2008

1 Udden (2002) performed in vitro comparisons of sub-hemolytic and hemolytic effects in 2 rat and human RBCs in response to exposure of high BAA, using samples from hospitalized 3 adults, hospitalized children, and well adults. Erythrocyte parameters measured included 4 deformability, size distribution, density, MCV, count, osmotic fragility, and hemolysis. Exposure 5 for 4 hours resulted in loss of deformability, although at concentrations 150-fold different; the 6 first significant alterations noted in cells exposed was at 0.05 mM BAA in rats and at 7.5 mM 7 BAA in humans. Significant increases in MCV after a 4-hour exposure to BAA were noted at 8 0.05 mM in rats and at 10.0 mM in humans, a 200-fold difference. A similar differential in 9 concentration range was noted in osmotic fragility. Testing of erythrocytes for changes in MCV 10 and percent hemolysis from in vitro exposure to either 0 or 10 mM BAA showed no differences 11 among the well adults or the hospitalized children. The percent hemolysis seen in the average 12 response of the hospitalized adults to 10 mM BAA was significantly increased, from 0.54-13 0.69%. Significant increases in MCV were noted for all three of these groups, including the well 14 adults. The mechanisms underlying erythrocyte damage and the resistance of human cells to 15 these effects remain unknown. It should be noted, however, that although the sub-hemolytic 16 responses were similar for human and rat erythrocytes, other aspects of the erythrocytes, 17 including morphology and cell density, were altered in the rats but not in human cells. These 18 differences between species suggest that the mechanisms underlying the observed pre-hemolytic 19 effects may be different between rats and humans.

20 The possibility exists that certain human subpopulations, including the aged and those 21 predisposed to hemolytic disorders, might be at increased risk from EGBE exposure. Udden 22 (1995, 1994) investigated this possibility using blood from the elderly (mean age 71.9; range 64– 23 79 years; five men and four women), from seven patients with sickle cell disease, and from four 24 subjects with hereditary spherocytosis, three of whom were studied post-splenectomy and one 25 studied pre-splenectomy. Using a sensitive assay for erythrocyte deformability (Udden, 1994; 26 Udden and Patton, 1994), it was shown that blood from all of these potentially sensitive groups 27 was unaffected by incubations of up to 4 hours with 2.0 mM BAA.

28 Udden and Patton (2005) examined the role of osmolarity and cation composition of the 29 cell suspension buffers in the mechanism of BAA-induced hemolysis of rat RBCs. Adding 30 sucrose to the cell suspension media or replacing external sodium with potassium protected rat 31 RBCs from BAA-induced hemolysis. The authors also observed that adding as little as 0.05 mM 32 CaCl₂ to the buffer delayed the time course of the hemolytic response, while adding MgCl₂ had 33 no effect. Use of the calcium-activated potassium channel inhibitor charybdotoxin blocked the 34 protective effect of calcium. From this, the authors suggest that BAA causes sodium and calcium 35 to enter the cell. While calcium initially has a protective effect via a loss of potassium through 36 the calcium-activated potassium channel, compensating for the osmotic effect of increased cell

- 1 sodium, calcium may subsequently have other deleterious effects through activation of proteases
- 2 and other calcium-activated processes.
- 3 Corthals et al. (2006) tested EGBE, BAL, and BAA in the comet assay to determine their 4 ability to induce DNA damage in SVEC4-10 mouse endothelial cells. EGBE (up to 10 mM), 5 BAL (up to 1 mM), and BAA (up to 10 mM) did not produce significant increases in DNA 6 damage relative to controls at any of the time points examined (2, 4, and 24 hours). The 7 researchers next tested the effect of hemolyzed mouse RBC lysate and ferrous sulfate in the same 8 system and found that the hemolyzed RBCs produced a statistically significant increase in DNA damage at the highest concentration tested (10×10^6 hemolyzed RBCs) for 4 hours. No other 9 time points were significant. Ferrous sulfate produced statistically significant increases in DNA 10 11 damage at the highest time point and the lowest concentration tested (24 hours, 0.1 µM) and at 12 all time points (2, 4, and 24 hours) in the mid- and high doses that were tested (0.5 μ M and 1.0 13 μM). The next experiment examined the ability of EGBE, BAA, ferrous sulfate, and hemolyzed 14 RBCs to stimulate tumor necrosis factor-alpha (TNF α) release from cultured mouse macrophages (RAW 264.7 cells). Hemolyzed RBCs (10×10^6 cells) resulted in a statistically 15 significant increase (p < 0.05) in TNF α release following a 4-hour treatment. Treatment with 16 17 EGBE, BAA, or ferrous sulfate did not result in increased TNFα release. Finally, the authors 18 report that macrophages activated with hemolyzed RBCs (10×10^6) for 4 hours were able to 19 increase DNA synthesis in mouse endothelial cells through co-culturing for 24 hours. These 20 macrophages, were not, however, able to increase endothelial cell DNA damage (after 4- or 24-21 hour treatment) as measured by the comet assay. The authors did find that LPS activated 22 macrophages after a 4-hour treatment produced statistically significant increases (p < 0.05) in 23 endothelial cell DNA damage, as measured by the comet assay.

4.5. Synthesis and Evaluation of Major Noncancer Effects and Mode of Action: Oral and Inhalation

24 Intravascular hemolysis is the primary response elicited in sensitive species following inhalation, oral, or dermal administration of EGBE. The carboxylic acid metabolite of EGBE, 25 26 BAA, has been shown to be the causative agent in this hemolysis. Hemolysis can be induced in 27 vivo following administration of EGBE or in vitro following addition of BAA to either whole 28 blood or washed erythrocytes. In vitro tests have shown that BAA produces a concentration- and 29 time-dependent swelling of rat erythrocytes, and changes in the normal erythrocyte morphology 30 from the typical discocyte form to a spherocyte form prior to lysis. This response appears to be 31 mediated by the erythrocyte membrane and results in an increase in osmotic fragility and a loss 32 of deformability of the erythrocyte, thereby leading to hemolysis. Older erythrocytes are

1 apparently more sensitive to the hemolytic effects of BAA than are younger cells or newly

2 formed reticulocytes.

3 The primary response of hemolysis is indicated via dose-related clinical observations of 4 decreases in Hct, Hb concentration, and RBC count in the blood of laboratory animals exposed 5 to EGBE. The hemolysis-related events of macrocytosis and increased MCV were also observed 6 in the rat, considered to be a sensitive species, and are attributed at least partly to the increased 7 number of larger reticulocytes in the circulation following the erythropoietic compensatory 8 response (NTP, 2000). These alterations were persistent throughout the chronic animal exposures 9 but do not appear to progress with extended exposure (from 3 months to 1 year for rats). These 10 changes persist despite functioning, compensatory, homeostatic mechanisms.

11 Liver effects were noted in the NTP (2000) reports of subchronic and chronic inhalation 12 studies in rats and mice and in the subchronic drinking water study in rats. These included 13 statistically significant increases in the iron-staining hepatic pigmentation attributed to 14 hemosiderin, the storage protein for insoluble iron, believed to be derived from the Hb released 15 during hemolysis. Nyska et al. (2004) examined the possible association between chemically induced hemosiderin deposition and hemangiosarcomas in the liver of mice from 130 NTP 16 17 bioassays, and found a highly significant association between liver hemangiosarcoma and 18 apparent Kupffer cell pigmentation. The cause for the hemosiderin deposition in all cases was the 19 erythrocyte hemolytic effect of the compounds. However, in an NTP (1993) subchronic drinking 20 water study, hepatocellular cytoplasmic changes were observed in male rats at an exposure level 21 (750 ppm) below the level at which hematological changes were recorded (1,500 ppm). This 22 finding raises the possibility of a direct, primary hepatic toxicity due to either EGBE or an EGBE 23 metabolite. Similar liver effects observed in female rats at the 750 ppm exposure level were 24 accompanied by hematological effects.

25 In the same NTP (1993) report, no liver lesions were reported in mice exposed to 26 drinking water containing up to 6,000 ppm EGBE. The lesions reported in rats consisted of 27 cytoplasmic alterations, hepatocellular degeneration, and pigmentation. The cytoplasmic 28 alterations, the only lesion observed at the 750 ppm exposure level (corresponding to a 29 consumption of roughly 55 mg/kg-day EGBE for adult male rats), were described as hepatocytes 30 staining more eosinophilic and lacking the amphophilic-to-basophilic granularity of the cytoplasm present in hepatocytes from control animals. Greaves (2000) suggested that the lack of 31 32 cytoplasmic granularity or ground-glass appearance of the hepatocytes is an indication that the 33 response does not involve enzyme induction. The hepatocellular degeneration and pigmentation 34 observed at the higher exposure levels in both genders was centrilobular, which is consistent with 35 the Kupffer cell pigmentation and hemosiderin deposition reported in the NTP (2000) inhalation 36 studies. This information, along with the observation that all other rat and mouse oral and 37 inhalation studies of EGBE report hemolysis at or below exposure levels that result in liver

April 2008

effects, suggests that at least these cytoplasmic hepatocellular changes in male rats reported in
the NTP (1993) drinking water study may reflect adaptation to a subclinical level of hemolysis.
However, focal necrosis of the liver observed in male rats following gavage administration of
250 and 500 mg/kg EGBE (Ghanayem et al., 1987b) was judged to be inconsistent with typical
anoxic centrilobular necrosis associated with anemia (Edmonson and Peters, 1985). The effects
observed in the Ghanayem et al. (1987b) study may be associated with the high bolus exposures
employed.

8 The liver alterations documented throughout these studies suggest a defined progression 9 of pathological events with increasing doses of EGBE with increasing levels of hemolysis. In 10 particular, hepatic hemosiderin deposition in the liver is a dose-related sequela of the hemolytic 11 activity caused by EGBE exposure. This deposition was noted to follow a clear dose-response 12 relationship as well as to increase in severity in the chronic rat and mouse NTP studies; it shows 13 a statistically significantly increase relative to the chamber controls. Although some hemosiderin 14 deposition in the spleen and liver may be expected with increasing age, the extent of hemosiderin 15 deposits noted by NTP in the livers of EGBE exposed animals is not normal. For these reasons, 16 hemosiderin deposition in the liver has been considered a pathological finding (Muller et al., 17 2006). The following issues relate to the relevance of these hemolytic and hepatic effects to

18 humans and to the MOA of EGBE.

19 The weight of evidence from a variety of studies in animals and humans suggests that 20 certain species are more susceptible to the hemolytic effects of EGBE. It appears that humans are 21 less sensitive to the hemolytic effects of EGBE than rats and mice. On one end of the sensitivity 22 range is the guinea pig, which displays no hemolytic effects from EGBE at exposure levels as 23 high as an oral dose of 1,000 mg/kg or a dermal dose of 2,000 mg/kg. The rat, converselywhich 24 displays increased osmotic fragility of erythrocytes at single-inhalation exposures below 25 100 ppm and single oral exposures below 100 mg/kg EGBE. No hemolysis was been observed in 26 controlled laboratory acute inhalation exposures of human volunteers at up to 195 ppm EGBE. 27 Some reversible hemolytic effects have been described in addition to more debilitating effects in 28 humans who consumed single oral doses of 400–1500 mg/kg EGBE in cleaning formulations 29 (see Section 4.1). Effects in humans from chronic exposure to EGBE have not been studied. 30 With respect to gender sensitivity, it has been consistently noted (Ezov et al., 2002; NTP, 31 2000, 1993; Dodd et al., 1983; Carpenter et al., 1956) that female rats are more sensitive to 32 EGBE-induced hemolysis than males. This gender difference is consistent with toxicokinetic 33 data for male and female rats reported by the NTP (2000) 2-year study. Female rats eliminated 34 BAA, the toxic metabolite of EGBE, more slowly from the blood, resulting in a larger AUC for 35 the blood concentration of BAA versus time. This may be a result of the reduced renal excretion observed in female versus male rats. NTP (2000) also reported that, like female rats, female mice 36 37 tended to have greater blood concentrations of BAA at any given time than males. This may

April 2008

explain the slight increase in incidence and severity of the anemic response found in female, as
 compared to male, mice. However, unlike female rats, female mice excrete slightly more BAA

- than male mice; no significant difference between female and male mice has been noted in the overall rate of elimination or the $t_{\frac{1}{2}}$ of BAA.
- 5 Some studies (Ghanayem et al., 1990, 1987c) were designed to assess the effect of age on 6 the toxicokinetics and hemolytic effects in young and adult rats treated with single EGBE gavage 7 exposures. Both blood retention (Ghanayem et al., 1990) and hematologic effects (Ghanayem 8 et al., 1987c) were found to be dose- and age-dependent with older rats retained more of the 9 EGBE metabolite BAA in their blood and were more sensitive than younger rats. The increased 10 blood retention of BAA (as measured by increased C_{max} , AUC, and $t_{\frac{1}{2}}$) in older rats versus 11 younger rats may be due to metabolic differences or compromised renal clearance. The 12 researchers suggested that the pharmacokinetic basis of the age-dependent toxicity of EGBE may 13 be due to a reduced ability by older rats to metabolize the toxic metabolite BAA to CO₂, and a 14 diminished ability to excrete BAA in the urine. No comparable studies exist for an analysis of 15 liver effects.

16 While older rats appear to be more severely affected by acute doses of EGBE, continuous 17 exposures appear to impart a certain level of tolerance to rats and mice over time. Apparent 18 tolerance to EGBE-induced hemolysis in rats and mice has been seen in subchronic (Krasavage, 19 1986; Grant et al., 1985) and chronic (NTP, 2000) studies. Ghanayem et al. (1992, 1990) 20 investigated this effect in the male F344 rat. Daily gavage administration of EGBE at 125 mg/kg 21 for 12 days resulted initially in hemolytic anemia, which was more pronounced following the 22 third day, but the animals recovered gradually to near pretreatment levels by day 12. 23 Additionally, rats treated for 3 days at 125 mg/kg followed by a 7-day recovery period were 24 significantly less sensitive to subsequent treatment with EGBE at either 125 or 250 mg/kg, as 25 were rats that were bled and subsequently treated. Ghanayem et al. (1992, 1990) proposed that 26 the tolerance to hemolysis following repetitive dosing is not due to changes in EGBE 27 metabolism, but to the replacement of older and more susceptible erythrocytes with younger, less 28 susceptible cells. However, chronic studies in rats and mice (NTP, 2000) have shown that any 29 increased resistance imparted by these immature erythrocytes diminishes with age. Rats and 30 mice chronically exposed to EGBE experienced anemia that persisted with no apparent progression or amelioration of severity for 9 months, up to the final blood collection at 12 31 32 months of age. Apparently, there is a balance in these rodents between the release of 33 reticulocytes to the circulation and the aging process, so that the level of susceptible cells and 34 severity of anemia remains relatively constant.

A number of secondary effects resulting from the hemolytic toxicity of EGBE have been reported in studies with rats, mice, and rabbits. In the rat, the organs generally affected include most prominently the liver (see discussions above) but also the kidneys, spleen, bone marrow,

April 2008

1 and, to a lesser extent, the thymus (Shabat et al., 2004; NTP, 1993; Exon et al., 1991; Grant et al., 2 1985). Typically, increased liver and kidney weights are observed with corresponding decreases 3 in body weights at doses that produce a hematotoxic response. Accompanying this are 4 hepatocellular degeneration, hemosiderin deposition in the liver, and congested spleens. Renal 5 damage is often reported, accompanied by hemosiderin accumulation, renal tubular 6 degeneration, and intracytoplasmic Hb. Often these effects are more pronounced in females. 7 Hematopoiesis in bone marrow and spleen, increased cellularity of bone marrow, and splenic 8 congestion are all secondary to the hematotoxicity of EGBE and develop as a compensatory 9 response to hemolysis. In addition, intact erythrocytes have been observed histopathologically in spleens from EGBE-treated rats, but not in spleens from control animals. This suggests an 10 11 increased rate of removal of damaged erythrocytes in EGBE-treated rats (Ghanayem et al., 12 1987c). Mild lymphopenia and neutrophilia were observed at hemolytic doses of EGBE 13 (Ghanayem et al., 1987c) and were reported to be consistent with a "stress" leukogram produced 14 by the release of endogenous corticosteroids (Wintrobe, 1981a). Neutrophilia, commonly 15 associated with acute hemolysis or hemorrhage (Wintrobe, 1981b), was also observed. 16 In conclusion, humans are significantly less sensitive to the hemolytic toxicity of EGBE 17 than are typical laboratory species such as mice, rats, or rabbits, although human erythrocytes do 18 appear capable of responding similarly to the causative EGBE metabolites, albeit at much higher 19 exposures. This marked species difference in sensitivity has been demonstrated in several 20 laboratory studies and through the use of in vitro studies using either whole blood or washed 21 erythrocytes. Based on the results of in vitro testing, blood concentrations of the hemolytically 22 active metabolite BAA must reach levels in human blood in excess of 7.5 mM for prehemolytic 23 changes to occur. Comparable effects in rat blood occur at in vitro concentrations approximately 24 150-fold lower. In addition, blood from potentially sensitive individuals, including the elderly or 25 those with congenital hemolytic disorders, does not show an increased hemolytic response when 26 incubated with up to 2 mM BAA for 4 hours. Based on simulations from PBPK modeling, 6-hour 27 whole-body exposure of humans to saturated atmospheres of EGBE will result in maximum 28 blood concentrations of BAA below those needed to produce hemolysis (Corley et al., 2005a). 29 Most of the liver alterations documented throughout the EGBE exposure database are 30 related directly to hemolysis. Prominent among these alterations is hemosiderin deposition, a 31 pathological finding whose occurrence is related to hemolysis (Muller et al., 2006). Humans also 32 experience hemosiderin deposition in the liver, principally in hepatocytes, as a consequence of 33 excessive hemolysis, such as with thalassemia, a hereditary form of hemolytic anemia (Iancu 34 et al., 1976). Hemosiderin deposition in the liver is a pathological response that follows the 35 precursor hematologic effects, which, as a group, do not appear to progress with changes in 36 duration of exposure from subchronic to chronic.

4.6. Evaluation of Carcinogenicity

4.6.1. Summary of Overall Weight of Evidence

Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), EGBE is 1 deemed "not likely to be carcinogenic to humans" at expected environmental concentrations, 2 3 based on laboratory animal evidence, mode-of-action information, and limited human study 4 information. The available data indicate that carcinogenic effects from EGBE are not likely to 5 occur in humans in the absence of the critical noncancer effects, including hepatic hemosiderin 6 staining and irritant effects at the portal of entry and are not likely to be carcinogenic to humans 7 exposed at levels at or below the RfC and RfD values established in this assessment. Carpenter 8 et al. (see Section 4.1) reported that no changes in erythrocyte osmotic fragility were found in human subjects exposed to up to 195 ppm (942 mg/m³; \sim 600 times the RfC) for two 4-hour 9 periods separated by a 30-minute break. At oral doses of 400-500 mg/kg with a one-time bolus 10 11 dose (see Section 4.1), hematuria has been noted in two human case reports. This dose is 3000 to 12 3500 times the RfD and would need to be sustained for a significant period of time to produce 13 hemosiderin deposition. This is unlikely to occur because the primary response of humans to 14 high oral doses of EGBE, as shown in the case studies in Section 4.1, is metabolic acidosis, 15 which, if not treated, can lead to shock and eventually death. No information is available on the 16 carcinogenic effects of EGBE via the oral or inhalation route in humans. A 2-year inhalation 17 bioassay with mice and rats (NTP, 2000) reported tumors of the liver in male mice, forestomach 18 tumors in female mice, and tumors of the adrenal medulla in female rats. Non-neoplastic effects 19 in rats included hyaline degeneration of the olfactory epithelium and Kupffer cell pigmentation. 20 Non-neoplastic effects in mice included forestomach ulcers and epithelial hyperplasia, 21 hematopoietic cell proliferation, Kupffer cell pigmentation, hyaline degeneration of the olfactory 22 epithelium (females only), and bone marrow hyperplasia (males only). 23 EGBE has been tested in conventional genotoxicity tests for its potential to induce gene 24 mutations in vitro and cytogenetic in both in vitro and in vivo, and the available data do not 25 support a mutagenic or clastogenic mechanism for EGBE. Two laboratories (Elias et al., 1996; 26 Hoflack et al., 1995) did report weak genotoxicity responses in vitro at high treatment

- 27 concentrations, but results were not replicated in five other labs reporting negative results.
- The hypothesized MOA for the tumors observed following EGBE treatment involves exposure to high doses for prolonged periods of time. This MOA is described in the sections that follow. The weight of evidence indicates that EGBE is not likely to be carcinogenic to humans at
- 31 expected environmental concentrations.

4.6.2. Synthesis of Human, Animal, and Other Supporting Evidence

NTP (2000) conducted a 2-year inhalation study on EGBE in both genders of F344/N rats
 and B6C3F1 mice. Rats (50/gender/group) were exposed to concentrations of 0, 31, 62.5, and

51

April 2008

1 125 ppm (0, 150, 302, and 604 mg/m³) and mice (50/gender/group) were exposed to 2 concentrations of 0, 62.5, 125, and 250 pm (0, 302, 604, and 1,208 mg/m³). The NTP report stated that the highest exposure was selected to produce a 10–15% depression in hematologic 3 4 indices and survival was significantly decreased in male mice at 125 and 250 ppm (54.0 and 5 53.1%, respectively). While the NTP researchers report that no effect on survival was observed 6 in rats, the female rats appeared to show a trend toward decreased survival that may have been 7 attributable to the hematological effects. Mean body weights of rats exposed to 31 and 62.5 ppm 8 were similar to those of control animals. Mean body weights of the exposed mice were generally 9 less than for controls, with females experiencing greater and earlier reductions. From week 17 to 10 the end of the study, the mean body weights of 125 ppm female rats were generally less than 11 those of controls.

At the end of the 2-year chronic bioassay (NTP, 2000), neoplastic effects were observed in female rats and in male and female mice. In female rats, the combined incidence of benign and/or malignant pheochromocytoma of the adrenal medulla was 3/50, 4/50, 1/49, and 8/49. The incidence in the high-dose group (16%) did not represent a statistically significant increase over the chamber control group (6%), but it exceeded the historical control (6.4–3.5%; range 2–13%) for this effect.

18 The low survival rate in male mice exposed to 125 and 250 ppm EGBE may have been 19 due to carcinogenic effects in the liver. A high rate of hepatocellular carcinomas was found in 20 these exposure groups (10/50 [control], 11/50, 16/50, 21/50); the increase at the high-exposure 21 level was statistically significant (p < 0.01). However, when hepatocellular adenomas and 22 carcinomas were combined, no significant increase was observed in any exposure group. The 23 incidence of hemangiosarcomas in males exposed to 250 ppm (8%) was also significantly 24 increased (p = 0.046) relative to chamber controls (0/50, 1/50, 2/49, 4/49) and exceeded the 25 range of historical controls (14/968; $1.5 \pm 1.5\%$; range 0–4%). No significant increases in benign 26 or malignant hepatocellular tumors or hemangiosarcomas were noted in the female mice, and the 27 incidence of hepatocellular adenomas actually decreased significantly (p < 0.05) in relation to the 28 control chamber group (16/50, 8/50, 7/49, 8/49). It should be noted that in light of the high 29 survival rate of the exposed female mice relative to controls (29/50, 31/50, 33/50, 36/50), the 30 high exposure of 250 ppm may not have provided the maximum tolerated dose. 31 Forestomach squamous cell papillomas and carcinomas, combined), were significantly 32 increased (trend test = 0.003) in female mice relative to the chamber control group (0/50, 1/50, 33 2/50, 6/50). The incidence of these tumor types (12%) at the highest exposure level was also

34 statistically significant and exceeded the range for the occurrence of these tumors in historical

35 controls $(0.9 \pm 1.1\%)$; range 0–3%). The first incidence of these tumors appeared in the group

36 exposed to 250 ppm at 582 days, as compared to 731 days at 62.5 and 125 ppm, indicating a

37 decreased latency period in the highest exposure group. While the incidence of these types of

April 2008

1 forestomach tumors was not significantly increased over controls in male mice (1/50, 1/50, 2/50,

2 2/50), the incidence of squamous cell papillomas (4%) in the two highest exposure groups

3 exceeded the range for historical controls $(0.5 \pm 0.9\%)$; range 0–2%). The increased incidence of

4 forestomach neoplasms in males, as in females, occurred in groups with ulceration and

5 hyperplasia.

6 The NTP (2000) study concluded that there was no evidence showing carcinogenic 7 activity in male F344/N rats, and equivocal evidence of carcinogenic activity in female F344/N 8 rats, based on increased combined incidences of benign (mainly) and malignant 9 pheochromocytoma of the adrenal medulla. The researchers reported some evidence of 10 carcinogenic activity in male B6C3F1 mice based on increased incidences of hemangiosarcoma

11 of the liver and an increase in the incidence of hepatocellular carcinoma, as well as some

12 evidence of carcinogenic activity in female B6C3F1 mice based on increased incidence of

13 forestomach squamous cell papilloma (mainly) or carcinoma.

14 With respect to the pheochromocytomas reported in female rats, while the data showed a

15 positive trend (p = 0.044) and the high-dose tumor frequencies (16%) were above the upper

16 range of historical controls (13%), the tumor incidence data were not statistically significant.

17 Further, the NTP (2000) report noted that pheochromocytomas can be difficult to distinguish

18 from non-neoplastic adrenal medullary hyperplasia. The presence of mild-to-moderate

19 compression of the adjacent tissue is a primary criterion used to distinguish pheochromocytomas

20 from medullary hyperplasia; most tumors observed were small and not substantially larger than

21 the more severe grades of adrenal medullary hyperplasia. Interpretation of these tumors should

22 be done cautiously. Given the marginal dose response, lack of tumor evidence in any other organ

23 system of the rats, and reported difficulties in distinguishing pheochromocytomas from non-

24 neoplastic adrenal medullary hyperplasia, this tumor type was not given significant weight in the

25 qualitative or quantitative assessment of EGBE cancer potential.

4.6.3. Mode of Action Information

4.6.3.1. Hypothesized Mode of Action for Liver Tumor Development in Male Mice

The hypothesized MOA for EGBE-induced liver tumors in male mice is believed to 26 27 involve iron accumulation and subsequent oxidative stress due to the hemolytic effects of a 28 metabolite of EGBE. Male mice developed hepatocellular carcinomas and hemangiosarcomas in 29 the liver that appeared to be exposure-related. The incidence of hemangiosarcomas was 30 statistically significant and increased over both concurrent and historical control groups. The 31 hepatocellular carcinomas were within the range of historical controls for male mice, but are also 32 considered in this discussion because the dose-response trend is significant and because a similar 33 MOA has been suggested for this tumor (Klaunig and Kamendulis, 2005). The incidences in the 34 high dose group of these two types of tumors were only slightly higher than the upper end of the

April 2008

1	range for h	storical controls. Furthermore, these two tumor types were not increased in other
2	organs (e.g	, bone, bone marrow) and were not noted in either rats or female mice. The
3	hypothesize	d MOA involves the hemolysis of RBCs, the accumulation of hemosiderin, and
4	subsequent	oxidative stress that leads to neoplasia in the two cell types believed to be the origin
5	for these tw	o tumors: hepatocytes for hepatocellular carcinoma and endothelial cells for
6	hemangiosa	rcomas. Only the male mice developed these tumor types, and this is hypothesized to
7	be due to the	eir susceptibility to oxidative stress. Mice are known to be more susceptible to
8	oxidative st	ress than rats because of their lower antioxidant capacity (Siesky et al., 2002;
9	Bachowski	et al., 1997). The available studies suggest that iron accumulation from the hemolytic
10	effects of E	GBE produces liver oxidative damage that is more severe in mice and increased DNA
11	synthesis ir	both endothelial cells and hepatocytes that may be unique to mice (Corthals et al.,
12	2006; Siesk	y et al., 2002). From this and reported differences in antioxidant capacity ¹ and
13	background	rates of these tumors ² between male and female mice, it can be hypothesized that
14	events lead	ng to oxidative stress contribute to the transformation of male mouse endothelial
15	cells to hen	angiosarcomas and hepatocytes to hepatocellular carcinomas. A series of events that
16	may lead to	the formation of liver tumors follows.
17		
18		Step Event
19		
20	(1)	EGBE is metabolized to BAL, which is subsequently oxidized to BAA.
21	(2)	BAA causes RBC swelling and hemolysis and an increase in Hb levels.
22	(3)	Excess Hb from damaged RBCs is taken up by phagocytic (Kupffer) cells of the
23		spleen and liver and stored as hemosiderin.
24	(4)	Oxidative damage and increased synthesis of endothelial and hepatocyte DNA are
25		initiated by one or more of the following events:
26		(a) Generation of reactive oxygen species (ROS) from Hb-derived iron within
27		Kupffer cells and perhaps from within hepatocytes and sinusoidal endothelial
28		cells
29		(b) Activation of Kupffer cells to produce cytokines/growth factors that suppress
30		apoptosis and promote cell proliferation
31	(5)	ROS results in oxidative DNA damage to hepatocytes and endothelial cells.
32	(6)	ROS modulates hepatocyte and endothelial cell gene expression.

¹While the reason for the sex difference in liver tumor susceptibility between male and female mice is not clear, it has been shown that estrogens can be protective through their antioxidant capacities and through their modulation of the activities of other antioxidants (Nyska et al., 2004).

²NTP has observed liver hemangiosarcomas in 105/4183 (2.51%) male versus just 35/4177 (0.84%) female historical controls (Klaunig and Kamendulis, 2005; NTP, 2000). In addition, other chemicals reported by NTP to cause both early onset hemosiderin buildup and liver tumors have also exhibited this male specificity (U.S. EPA, 2005c).

- (7) ROS stimulates hepatocyte and endothelial cell proliferation.
 - (8) ROS promotes initiation of hepatocyte and endothelial cells.
 - (9) ROS promotes neoplasm formation.

1 2

3

4

5 The first two steps, the metabolism of EGBE to BAA and the association of BAA with 6 hemolytic effects, have been clearly established in many studies, both in vitro and in vivo, with 7 sensitivities ranging from extreme sensitivity as in rats, mice, rabbits and dogs, to moderate to 8 extreme insensitivity seen in monkeys, guinea pigs, and humans (see Section 3). The third step 9 has been seen in both genders of rats and mice exposed to EGBE in multiple studies that 10 observed hemosiderin within Kupffer cells and hepatocytes after RBC breakdown (Siesky et al., 11 2002; NTP, 2000; Kamendulis et al., 1999; Ghanayem and Sullivan, 1993; Ghanayem et al., 1987a, b; Krasavage, 1986). A number of studies (Siesky et al., 2002; Park et al., 2002; 12 13 Kamendulis et al., 1999) provide support for Step 4a by showing that in vivo exposure to EGBE 14 increases 8-OHdG levels (an indicator of oxidative damage) in mice, but not rats, and decreases 15 vitamin E levels in rats and mice. Using rat and mouse hepatocytes, Park et al. (2002) showed 16 that FeSO₄ produced dose-related changes in these same indicators in mouse hepatocytes, but not 17 in rat hepatocytes, and that treatment with EGBE or BAA did not produce changes in these 18 oxidative stress parameters. Additionally, Nyska et al. (2004) analyzed 130 2-year 19 carcinogenicity studies of B6C3F1 mice from NTP bioassays and concluded that a significantly 20 increased risk of inducing hepatic hemangiosarcomas in male B6C3F1 mice exists in studies 21 with compounds that caused increased tissue burdens of ROS. Klaunig and Kamendulis (2005) 22 and Corthals et al. (2006) provided support for Step 4b, by showing that the activation of Kupffer 23 cells, either through RBC hemolytic components and/or iron accumulation in the Kupffer cells, 24 results in the production of cytokines such as $TNF\alpha$. The comet assay has been used to assess 25 DNA damage to endothelial cells from ROS (Step 5) (Klaunig and Kamendulis, 2005, 2004; 26 Reed et al., 2003). While Step 6 has not been shown directly for endothelial cells or hepatocytes 27 exposed to EGBE, induction of oxidative damage has been shown to modify gene expression in 28 mammalian cells. In addition, ROS production can stimulate cell proliferation and the inhibition 29 of apoptosis (Klaunig and Kamendulis, 2005; Nyska et al., 2004). Siesky et al. (2002) observed 30 increased DNA synthesis in endothelial cells and hepatocytes in vivo in mice but not in rats at 31 doses that produced hemangiosarcomas in the mouse liver (NTP, 2000) (Step 7). Steps 8 and 9 32 are consistent with the lack of direct genotoxicity of EGBE (see Section 4.4.4) and the high rate 33 of spontaneous endothelial neoplasms in the male mouse liver relative to the rat (Klaunig and 34 Kamendulis, 2005). The observation of decreased antioxidant capacity and increased 8-OHdG 35 levels in male mice also lends supports to the proposed steps of initiation and promotion of 36 neoplasms by ROS (Klaunig et al., 1998).

4.6.3.1.1. Temporal association and species specificity

1 Key steps in the proposed MOA (i.e., hemolysis, hepatic hemosiderin buildup, and 2 oxidative damage) have all been observed in subchronic or shorter-duration rat and mouse 3 studies of EGBE (Siesky et al., 2002; NTP, 2000; Kamendulis et al., 1999) well in advance of 4 tumor formation. Differences between rats and mice with respect to these responses may help to 5 explain the relative sensitivity of male mice to the formation of liver tumors following EGBE 6 exposure. In mice, Siesky et al. (2002) observed a dose-dependent increase in levels of liver 7 oxidative stress indicators at exposure days 7 and 90, increased endothelial cell DNA synthesis at 8 exposure days 7 and 14, and increased hepatocyte DNA synthesis at 90 days. No increase in ROS 9 or the DNA synthesis of either cell type was observed in rats at any time point.

4.6.3.1.2. Dose-response relationships

10 Six chemicals have been determined by the NTP to cause hemosiderin buildup in the 11 livers of mice. As shown in Table 4-8, male mice exposed to chemicals that caused a significant 12 hemosiderin buildup in Kupffer cells within 13 weeks of exposure also showed an increased 13 incidence of hemangiosarcomas and hepatocellular carcinomas following chronic exposure. The 14 dose responses for endpoints describing possible precursor effects, splenic hematopoietic cell 15 proliferation, and liver hemosiderin accumulation appear to be dose-related and coincident to the 16 formation of tumors. Dose-responses for several hemolytic effects were also observed in rats, but 17 liver tumors were not increased in rats at any dose. However, the high dose used in the rat study was only half that of the high dose used in the mouse study, leaving the possibility that similar 18 19 responses could have been observed in rats if higher doses of EGBE were tolerated by this 20 species. 21 Of these six chemicals, liver hemangiosarcomas were observed with the only four 22 chemicals that induced hemosiderin buildup by week 13, but not with the other two chemicals

- for which hemosiderin buildup was not observed until the end of the 2-year study (U.S. EPA,
- 24 2005c; Gift, 2005). Two of the four chemicals that induced early liver hemosiderin accumulation
- and increased hemangiosarcoma incidence, EGBE and p-chloroaniline hydrochloride, also
- 26 induced an increase in hepatocellular carcinomas. Early buildup of hemosiderin combined with
- 27 early increases in endothelial cell and hepatocyte DNA synthesis would result in a longer
- exposure of cells to oxidative damage via iron-generated radicals (Step 4). This would be
- 29 consistent with a mechanism involving a continuing cycle of damage and repair and
- 30 accumulation of DNA mutations (Steps 5 and 6). In addition to an earlier onset of hemosiderin
- 31 buildup, mice also show evidence of a more sustained hemolytic response to EGBE than rats.³

³Mice experienced an increase in liver and splenic hematopoietic cell proliferation throughout the 2-year NTP (2000) study, while rats tended to compensate for the effects of EGBE after a few months. This increased April 2008 56 DRAFT-DO NOT CITE OR QUOTE

Table 4-8. Incidence of liver hemangiosarcomas and hepatocellular carcinomas in studies of NTP chemicals that caused increased hemosiderin in Kupffer cells in male mice.

Chemical (NTP TR #)	Hemosiderin	\mathbf{SC}^*	Hemangiosarcoma	Hepatocarcinoma	Type ^{***}
2-Butoxyethanol (EGBE) (TR-484)	0/50, 0/50, 8/49 ^{°°} , 30/49 ^{°°}	yes	0/50, 1/50, 2/49, 4/49§	10/50, 11/50, 16/49, 21/49 ^{°°}	Ι
p-Chloroaniline hydrochloride (TR-351)	$0/50, 0/49, 0/50, 50/50^{\pm}$	yes	2/50, 2/49, 1/50, 6/50	3/50, 7/49, 11/50 [§] , 17/50 [□]	G
p- Nitroaniline (TR-418)	1/50, 1/50, 8/50 [§] , 50/50 ^{°°}	yes	0/50, 1/50, 2/50, 4/50	10/50, 12/50, 13/50, 6/50	G
Pentachloroanisole (TR-414)	1/50, 50/50 ^{°°} , 50/50 ^{**,¤}	yes	2/50, 8/50, 10/50 [§]	9/50, 16/50, 12/50	G
C.I. Pigment Red 3 $(TR-407)^{\pm}$	0/50, 5/50, 30/50, 41/50	no	0/50, 1/50, 1/50, 0/50	5/50, 10/50, 8/50, 4/50	F
o-Nitroanisole (TR-416)	0/50, 0/50, 3/50, 16/50 ^{°°}	no	2/50, 2/50, 1/50, 0/50	7/50, 12/50, 11/50, 7/50	F

* Chemicals that caused hemosiderin accumulation in Kupffer cells following subchronic (SC) exposure are identified with a "yes" in this column.

^{**} The authors of this study could not identify the source of the Kupffer cell pigmentation. They speculate that it may consist of porphyrins known to be produced from exposure to chlorinated hydrocarbons, but the possibility that it may have consisted of hemosiderin could not be discounted.

*** I = inhalation, G = gavage, F = feedp < 0.05

$${}^{9}p \le 0.03$$

 $\tilde{p} \le 0.01$ [±]Statistics not reported

4.6.3.1.3. Biological plausibility and coherence of the database

1 Oxidative damage plays an important role in the pathogenesis of several diseases, 2 including cancer and cardiovascular disease (Djordjevic, 2004; Lesgards et al., 2002; Klaunig 3 et al., 1998). In support of the proposed hypothesis, increased ROS are known to accompany the 4 release of large amounts of iron from hemolysis (Ziouzenkova et al., 1999). If EGBE causes 5 oxidative stress via hemolysis, then the production of protein and DNA damage would be 6 expected, including the production of 8-OHdG, accompanied by a decrease in antioxidant levels, 7 such as Vitamin E (Houglum et al., 1997; Yamaguchi et al., 1996; Wang et al., 1995). These 8 effects were verified by both Kamendulis et al. (1999) and Siesky et al. (2002), who measured a 9 dose-dependent increase in levels of ROS indicators, including 8-OHdG and malondialdehyde, 10 and a decrease in vitamin E levels in the livers of mice, but not in rats, after acute and subchronic 11 exposure to EGBE. The fact that mice are more susceptible than rats to ROS from EGBE 12 exposure is consistent with the proposed MOA, and is a reasonable explanation for why

- 13 hemangiosarcomas are not observed in rats following chronic EGBE exposure, despite the fact
- 14 that rats are at least as sensitive as mice to the hemolytic effects of EGBE.

tolerance in rats is evidenced by a lack of induction of splenic hematopoiesis at the end of the 2-year NTP (2000) study.

1 Iron, which is known to accumulate in cells of rodent livers following EGBE exposure, 2 can produce hydroxyl radicals in combination with oxidative by-products via the Fenton reaction 3 (Kamendulis et al., 1999). The damaging effects of iron overload to liver sinusoidal cells have 4 been shown in rats following a single i.p. injection of 200 mg iron/kg (Junge et al., 2001). In addition, endothelial cells appear to be relatively sensitive to oxidative stress (Spolarics, 1999; 5 6 DeLeve, 1998). Liver hemangiosarcomas develop from the endothelial cell component of the 7 vascular sinusoidal cells of the liver (Frith and Ward, 1979). 8 In vivo studies have indicated that pretreatment of rats with an ALD inhibitor, pyrazole, 9 prior to a single 125 mg EGBE/kg gavage exposure protected against hemolysis (Ghanayem et al., 1987b), presumably by blocking the production of both BAL and BAA. Pretreatment of 10 11 rats with an ADH inhibitor, cyanamide, prior to a single 125 mg EGBE/kg gavage exposure, 12 reduced hemolytic responses, but increased RBC swelling, increased mortality, decreased BAA 13 formation and excretion in the urine, and increased the urinary excretion of EGBE conjugates 14 with glucuronide and sulfate (Ghanayem et al., 1987b). This hematotoxicity in the presence of cyanamide may be due to BAL, but residual BAA may also be a factor. EGBE + cyanamide 15 16 decreased BAA concentrations in rats; however, some BAA was formed and the BAA t_{1/2} was 17 increased Ghanayem et al. (1990), and, when Ghanayem et al. (1987b) administered a gavage 18 dose of 125 mg BAL/kg + cyanamide to rats, the researchers observed almost no hemolytic 19 activity. Furthermore, gavage administration to rats of 125 mg EGBE/kg and the molar 20 equivalent of BAL and BAA resulted in no significant difference between the hemolytic effects 21 of the three chemicals between 2 and 24 hours postexposure (Ghanayem et al., 1987b). These 22 data suggest that EGBE's hemolytic activity (without coexposures) is due to BAA and that the 23 metabolism of EGBE and BAL to BAA takes place rapidly and completely.

4.6.3.1.4. Relevance of the hypothesized MOA to humans

The occurrence of liver tumors in mice exposed to EGBE is hypothesized to occur
through an MOA that requires first a dosage of EGBE that is high enough to cause sustained
hemolysis of RBCs and, second, leads to sufficient buildup of hemosiderin in the Kupffer cells of
the liver to produce ROS and subsequent neoplasm formation.
Several studies have examined the susceptibility of RBCs to BAA-induced hemolysis,
and have found a range in sensitivity from the sensitive (rats, mice, rabbits, and dogs) to the less
sensitive (monkeys, guinea pigs, and humans). Human volunteers experienced no hemolysis

- 31 from controlled laboratory acute inhalation exposures (up to 195 ppm), a dosage which caused
- 32 significant erythrocyte fragility in rats (Carpenter et al., 1956). Only mild hemolytic effects have
- been observed in humans acutely exposed to oral doses of EGBE (400–1500 mg/kg), doses that
- have been shown to cause marked hemolytic effects in rats (Ghanayem et al., 1987c; Grant et al.,
- 35 1985). RBCs from populations that were potentially more sensitive to hemolysis in general—the

- 1 elderly, and individuals with sickle cell anemia and hereditary spherocytosis—were tested in
- 2 vitro and not found to exhibit hemolysis after exposure to concentrations 40-fold higher, the
- 3 highest tested in the study, as opposed to those shown to induce hemolysis in rat RBCs (Udden,
- 4 1994; Udden and Patton, 1994). In an in vitro study of RBCs from hospitalized children and
- 5 adults, concentrations of up to 150-fold higher than those used in rat studies, the highest tested in
- 6 the study, did not produce hemolysis (Udden, 2002). The resistance of human RBCs to the initial
- 7 event of hemolysis makes it unlikely that they would experience the subsequent effects of
- 8 increased hemosiderin deposition through this pathway, and consequently would not be at
- 9 increased risk of tumor development through this MOA.

4.6.3.1.5. Other possible MOAs for liver tumor development in male mice

10 Although certain key events in EGBE's MOA for the development of liver tumors in 11 male mice are fairly well-described and plausible, some alternative considerations (also 12 supported by scientific literature) may be involved. ROS can potentially be derived from two 13 sources: iron overloading in the liver (through Fenton and Haber-Weiss reactions) and Kupffer 14 cell activation. Via either source, oxygen radicals can induce oxidative damage to DNA and 15 lipids as documented in the liver following EGBE treatment (Siesky et al., 2002). The activation 16 of Kupffer cells, through phagocytosis of RBC hemolytic components or iron in the Kupffer cell, results in the production of cytokines, possibly including vascular endothelial growth factor that 17 18 may elicit a growth response on endothelial cells (Corthals et al., 2006). In addition to the 19 production of oxidative DNA damage, ROS, whether derived from Kupffer cell activation or 20 other biological processes, can alter gene expression (e.g., MAP kinase/AP-1 and NF κ B), 21 resulting in stimulation of cell proliferation and/or inhibition of apoptosis (Klaunig and 22 Kamendulis, 2004).

Another recognized mechanism for the development of chemically-induced liver
 hemangiosarcomas involves direct interaction with DNA. This MOA is recognized for vinyl

- chloride and thorotrast, two agents that are known to induce hemangiosarcomas in humans. The
- 26 EGBE metabolite BAL is considered to have the greatest potential to interact with DNA, since it
- has been shown to cause in vitro SCE at concentrations ranging from 0.2 to 1 mM (Elliot and
- Ashby, 1997). However, high ADH activity in the liver, as in the forestomach, is expected to
- 29 result in very short residence time and low C_{max} liver tissue concentrations of BAL. Corley et al.
- 30 (2005b) extended their 1994 model (Appendix A) to include the metabolism of EGBE to BAL
- 31 via ALD and the subsequent metabolism of BAL to BAA via ADH in both the liver and
- 32 forestomach. As shown in Figure 4-2, using rate constants derived from mouse stomach fractions
- 33 (Green et al., 2002) and making several assumptions about the use of these enzyme activity data,
- Corley et al. (2005a) estimated that 250 ppm EGBE (the highest concentration used in the NTP

- 1 [2000] study) would result in peak C_{max} concentrations of 7 μ M EGBE, 0.5 μ M BAL, and 3,250
- 2μ M BAA in liver tissue of male mice at the end of a 6-hour exposure period.

60




Figure 4-2. Simulated concentrations of EGBE, BAL, and BAA in liver tissues of female mice exposed via inhalation for 6 hours to 250 ppm EGBE.

BE = EGBE.

Source: Adapted from Corley et al. (2005b).

1 Thus, the Corley et al. (2005b) PBPK model suggests that the high cytotoxic 2 concentrations of BAL that showed some evidence of clastogenicity may not be relevant to the 3 target organ where lower concentrations of BAL would exist in the presence of metabolizing 4 enzymes. A recent gavage study performed by Deisinger and Boatman (2004) provided support 5 for the Corley et al. (2005b) model and the predicted low levels of the BAL metabolite in liver tissue.⁴ In addition, as discussed in Section 4.4.4, evidence from in vivo and in vitro genotoxicity 6 7 assays does not suggest that BAL would have any significant genotoxicity in vivo.⁵ 8 Furthermore, the MOA for hemangiosarcoma induction by genotoxins such as vinyl chloride and 9 thorotrast involves the initiation of hepatocellular and sinusoidal cell hyperplasia and sinusoidal 10 compression, leading to the development of fibrous septa, generally in the periportal area, out of which eventually develop multiple areas of angiosarcomas (Foster, 2000). EGBE exposure does 11 12 not generate this same pattern of effects prior to the development of cancer in mice.

⁴The Corley et al. (2005b) model predicts that the concentrations of BAL in liver tissues of male and female mice would be 17 and 29 μ M, respectively, following oral gavage exposure to 600 mg/kg EGBE. The levels of BAL actually observed in the liver tissue of male and female mice, following oral gavage exposure to EGBE at 600 mg/kg, 3 and 4 μ M, respectively, were even lower than the predicted values (Deisinger and Boatman, 2004).

⁵ The exposure concentrations that would be necessary to cause these effects in humans, if attainable at all, are likely to be much higher than the RfC and RfD.

4.6.3.2. Hypothesized Mode of Action for Forestomach Tumor Development in Female Mice

1	A significant increase over controls (experimental and historical) of papillomas and one					
2	carcinoma of the forestomach (6/50; 12%) was reported by NTP (2000) in female mice exposed					
3	for 2 years to 250 ppm EGBE by inhalation. An increase was also seen in squamous cell					
4	papillomas in male mice, although this did not reach the level of statistical significance.					
5	Significant increases in forestomach papillomas and carcinomas were not observed in rats of					
6	either gender. The study also showed statistically significant, dose-dependent increases in					
7	hyperplasia for both male and female mice, and for ulceration in female mice. Male mice showed					
8	significant increases in ulceration at the 125 ppm exposure. The process of irritation, hyperplasia,					
9	and ulceration is thought to be a part of the cell injury and regeneration process elicited by					
10	irritant chemicals such as EGBE, and the study authors hypothesized that the neoplasia may					
11	occur due to an increase in the cell replication associated with regeneration.					
12	A hypothesized series of events that may lead to the formation of forestomach tumors is					
13	as follows:					
14	Step Event					
15						
16	(1) Deposition of EGBE/BAA in the stomach and forestomach via consumption or					
17	reingestion of EGBE laden mucus, salivary excretions, and fur material					
18	(2) Retention of EGBE/BAA in food particles of the forestomach long after being					
19	cleared from other organs					
20	(3) Metabolism of EGBE to BAL, which is rapidly metabolized to BAA systemically					
21	and in the forestomach					
22	(4) Irritation of target cells by BAA leading to hyperplasia and ulceration					
23	(5) Continued injury by BAA and degeneration leading to high cell proliferation and					
24	turnover					
25	(6) High levels of cell proliferation and turnover leading to clonal growth of					
26	spontaneously initiated forestomach cells.					
27	There are a number of studies that have demonstrated Steps 1 and 2 (i.e., the deposition					
28	and retention of EGBE and BAA in the forestomach). Studies have shown this occurs following					
29	whole-body exposure (Poet et al., 2002; Green et al., 2002), nose-only inhalation (Poet et al.,					
30	2002), i.v. exposure (Poet et al., 2002; Green et al., 2002; Bennette, 2001), i.p. exposure (Poet					
31	et al., 2002; Corley et al., 1999), s.c. exposure (Corley et al., 1999), and gavage exposures (Poet					
32	et al., 2002; Green et al., 2002; Ghanayem et al., 1987a, b). It is of note that following i.v. and					
33	inhalation exposures in mice, EGBE metabolites rapidly accumulate in salivary secretions and					
34	are swallowed (Green et al., 2002; Bennette, 2001), leading to the collection and retention of the					
35	chemical(s) in the forestomach. The same process is likely to occur through other systemic					

1 exposures. The metabolism of EGBE to BAA (Step 3) has been shown in both in vitro and in 2 vivo tests with rats, mice, rabbits, guinea pigs, dogs, monkeys, and humans, (see Section 3) and 3 is further supported by the EGBE PBPK model developed by Corley et al. (2005b). Step 4, the 4 irritation of target cells, has been seen in both genders of B6C3F1 mice, (Poet et al., 2003; Green 5 et al., 2002; NTP, 2000), with irritation and a compensatory proliferative response reported 6 following exposure to EGBE. Female mice were shown to have more extensive and severe 7 forestomach lesions than male mice and were observed in the NTP (2000) study to have 8 statistically significant increases in forestomach tumors. This suggests the importance of the 9 continued damage and high cell proliferation (Step 5) that is associated with tumor formation. 10 Green et al. (2002) found that the number of cells in S-phase (an indication of cell turnover) 11 increased in a dose-dependent fashion after exposure to EGBE and BAA, even though none of 12 the changes were statistically significant due to the high turnover for the control group. Step 6, 13 high levels of cell proliferation and turnover, leads to clonal growth of spontaneously initiated 14 cells and is supported by the continuum of effects observed in the mice (Green et al., 2002; NTP, 15 2000) and the effects seen with other irritant compounds (Kroes and Wester, 1986). 16 Green et al. (2002) also provided relevant information regarding Step 3 through 17 examination of the activity and localization of ALD and ADH in the stomach tissues of mice. 18 rats, and a human sample. Whole body autoradiography of mice that had been exposed to 19 radiolabeled EGBE was also performed. Histochemical staining of stomach tissues from the 20 rodent species showed the dehydrogenase enzymes to be heavily concentrated in the stratified 21 squamous epithelium of the forestomach of both rats and mice, whereas their distribution in the 22 glandular stomach was more diffuse. By comparison, histochemical analysis of a human stomach 23 tissue sample showed both enzymes to be present and evenly distributed throughout the 24 epithelial cells of the entire stomach mucosa. A marked species difference in ALD activity in the forestomach was observed between rats ($K_m = 0.29 \text{ mM}$; $V_{max} = 1.627 \text{ nmol/minute per mg}$ 25 protein) and mice ($K_m = 46.59 \text{ mM}$; $V_{max} = 17.094 \text{ nmol/minute per mg protein}$) with K_m values 26 27 up to one order of magnitude greater in mice compared to rats. These differences indicate that 28 mice forestomach tissues would have the capacity to metabolize appreciably larger amounts of 29 EGBE to BAL, and subsequently to BAA, than would the rat forestomach. Whole body 30 autoradiography of mice exposed to EGBE clearly demonstrated selective accumulation in the 31 forestomach, which would provide substrate for these enzymes. Collectively, these data 32 demonstrate several points regarding the observed forestomach toxicity in mice following 33 exposure to EGBE, including: (1) the accumulation of EGBE in the target tissue, the 34 forestomach, of mice; (2) a high degree of localization in the forestomach (as compared to the 35 glandular stomach) tissues of both rats and mice of the enzymes that metabolize EGBE to the 36 corresponding carboxylic acid; and (3) kinetic differences in these enzymes consistent with mice 37 being capable of metabolizing more EGBE to BAA than rats. The data also suggest that human

April 2008

63 DRAFT-DO NOT CITE OR QUOTE

1 stomach tissues do not have a high localization of the EGBE metabolizing enzymes; the diffuse

- 2 distribution of these enzymes in the human stomach sample examined is more similar to the
- 3 distribution seen in the glandular portions of the rodent species examined. These observations
- 4 suggest that human stomach tissues would be less capable of accumulating and localizing BAA
- 5 than rat tissues and, thus, would be less likely to be exposed to the irritating effects of BAA.

4.6.3.2.1. Temporal association

6 All of the steps in the proposed MOA have been observed to occur in female mice prior 7 to tumor formation. NTP (2000) reported that female mice experienced epithelial hyperplasia 8 (1/10, 5/10, 9/10, and 10/10) after just 13 weeks of exposure at the same exposure levels used in 9 the chronic study, 0, 62.5, 125, and 250 ppm. The reported incidence of a forestomach papilloma 10 or carcinoma in female mice was 731, 731, and 582 days in the 62.5, 125, and 250 ppm exposure 11 groups, respectively. This is consistent with the findings of Ghanayem et al. (1994, 1993, 1986), 12 who investigated the temporal relationship between the induction of this type of forestomach 13 lesion by another nonmutagenic irritant, ethyl acrylate (EA), and the development of squamous 14 cell papillomas and carcinomas. These researchers observed cell proliferation/hyperplasia in the 15 forestomach of all rats that received EA by gavage (200 mg/kg, 5 days/week) for 6 or 12 months. 16 All these potentially precancerous forestomach lesions regressed in animals treated with EA for 6 months and allowed 2 or 15 months of recovery, and no forestomach neoplasms were observed. 17 18 Although EA, an unsaturated aldehyde, is not a metabolite of EGBE, it is an analog of BAL and

a much more potent carcinogen than either EGBE or BAL (Gold et al., 1993).

20 For EGBE, the high incidence of forestomach hyperplasia, the relatively lower incidence 21 of papillomas, and the late occurrence of a single carcinoma in the high, 250-ppm, exposure 22 group, are suggestive of a temporal relationship and tumor progression following EGBE 23 exposure to female mice. Male mice may show the beginnings of tumorigenic effects as the incidence of papillomas increases, but such findings have not been statistically significant 24 25 compared to concurrent or historical controls. No hyperplasia and no tumors were observed in 26 inhalation studies of rats (NTP, 2000) or in drinking water studies of mice (NTP, 1993), 27 supporting the need for these steps prior to tumor formation.

4.6.3.2.2. Dose-response relationships

- 28 The incidence of epithelial hyperplasia (6/50, 27/50, 42/49, 44/50) and ulceration (1/50,
- 29 7/50, 13/49, 22/50) in EGBE-exposed female mice were dose-related and significantly increased
- 30 over both concurrent and historical controls at lower dose levels than the forestomach tumors.
- 31 The hyperplasia was often associated with ulceration, particularly in the female mice.
- 32 Forestomach tumors observed by NTP (2000) (incidence 0/50, 1/50, 2/50, 6/50) increased over
- 33 control animals only at exposure levels above those that caused significant hyperplasia. The

April 2008

1 increased incidence of the forestomach neoplasms occurred in groups with ulceration and

2 hyperplasia, suggesting a dose-dependent relationship between the non-neoplastic and the

3 neoplastic lesions.

4.6.3.2.3. Biological plausibility and coherence of the database

4 Both mutagenic and nonmutagenic chemicals have been shown to induce forestomach tumors in rodents (NTP, 2000; Ghanayem et al., 1994, 1993, 1986; Kroes and Wester, 1986). 5 6 Some nonmutagenic substances that cause such tumors appear to require long-term contact with 7 the forestomach epithelium, leading to irritation, cell proliferation, and neoplasia. The 8 overstimulation of repair processes and enhancement of growth-promoting factors are believed 9 to be involved (Harrison, 1992). Promotion and other activities associated with the stimulation of 10 cell proliferation have been observed for many of these compounds (Ghanayem et al., 1994; 11 Clayson et al., 1991). High concentrations of EGBE and its BAA metabolite sequestered in the 12 forestomach are assumed to cause chronic irritation and the more serious damage observed in the 13 forestomach lining of female mice. The incidence of ulcers was significantly increased in all 14 exposed groups of females. NTP (2000) suggests that EGBE exposure-induced irritation caused 15 inflammatory and hyperplastic effects in the forestomach and that the neoplasias (papillomas and 16 one carcinoma) were associated with a continuation of the injury/degeneration process.

17 Other substances that induce forestomach hyperplasia in male and female mice following 18 inhalation exposure include acetonitrile, 1,3-butadiene, and chloroprene (U.S. EPA, 2005c). Both 19 propionic and butyric acid have been shown to induce proliferative responses in forestomach 20 epithelium after only 7 days, and long-term propionic acid exposure has produced papillomas in 21 the rat forestomach (Kroes and Wester, 1986). Since high levels of EGBE and BAA have been 22 observed in the stomachs of mice following i.v., i.p., oral gavage, and inhalation exposures, it is 23 apparent that the chemical partitions to the forestomach via multiple routes, including grooming 24 of fur, systemic blood circulation, ingestion of salivary excretions and respiratory tract mucus, 25 and possibly repartitioning of the stomach contents (Poet et al., 2003; Green et al., 2002). 26 Because the forestomach functions as a storage organ, there is a reduced requirement for 27 vascularization. The planar capillary network within the epithelial layers of the rodent 28 forestomach contrasts strongly with the thick mucosal network of capillaries in the glandular 29 stomach of rodents (Browning et al., 1983). The cells of the forestomach epithelium, especially 30 the more superficial squamous cells, are separated from capillaries by substantial diffusion 31 distances (Bueld and Netter, 1993; Browning et al., 1983). In addition, the glandular stomach 32 contains a complex mucosal protection and buffering system necessary to withstand the high 33 acidity of the digestion process. As a result, irritant substances that concentrate in the 34 forestomach may produce hyperplasia in the forestomach, but not in the glandular stomach or 35 other gastrointestinal tissue (Kroes and Wester, 1986).

65

April 2008

4.6.3.2.4. Relevance of the hypothesized MOA to humans

1	Wh	ile this proposed MOA is thought to be of qualitative relevance to humans, the EGBE
2	exposure co	oncentrations that would be necessary to cause hyperplastic effects and tumors in
3	humans, if	attainable at all, are likely to be much higher than the concentrations necessary to
4	cause fores	tomach effects in mice for several reasons:
5	(1)	The mouse forestomach serves a food storage function and the slow rate of emptying
6		provides a sink for EGBE where it is metabolized to BAA and remains in contact
7		with squamous epithelium long after EGBE has been cleared from the rest of the
8		body. While the human esophagus is histologically similar to the murine
9		forestomach, the contact time with food and other ingested substances is short,
10		because this organ does not have a storage function. Thus, the risk for esophageal
11		tumors is low (Kroes and Wester, 1986). The human stomach also has a faster rate of
12		emptying than the rodent forestomach, and is further protected from irritant
13		compounds by a mucous layer that is not present in the rodent forestomach.
14	(2)	The localization of the enzymes needed for acid production in the human stomach
15		tissue is not the same as it is in the target, the rodent forestomach (Green et al.,
16		2002).
17	(3)	A margin of exposure analysis (see Appendix C) indicates that the exposure
18		concentrations necessary to cause hyperplastic effects in humans would be much
19		higher than the existing RfD and RfC for EGBE.

4.6.3.2.5. Other possible MOAs for forestomach tumor development in female mice

20 Though the evidence favors the hypothesis that BAA is the principal toxic metabolite of 21 EGBE, roles for BAL (Ghanayem et al., 1987b) and butyric acid (Harrison et al., 1991) have 22 been suggested. It is not likely that butyric acid plays a significant role in the toxicity of EGBE, 23 particularly at environmentally relevant concentrations. High concentrations of butyric acid have 24 caused ulceration and other preneoplastic lesions in mice (Harrison et al., 1991). However, low 25 concentrations of butyric acid do not appear to be harmful, since it naturally occurs in the diet 26 through the fermentation of fiber and starch and as a significant portion (up to 10 mol%) of total 27 bovine milk fatty acid (Smith and German, 1995). 28 Another possible alternative MOA could exist if EGBE or one of its metabolites were to

Another possible alternative MOA could exist if EGBE or one of its metabolites were to have the capability of damaging a cell through direct interaction with its DNA. As has been

30 discussed in Section 4.4.4, there is no clear evidence that EGBE or BAA is genotoxic. BAL, a

31 short-lived metabolite of EGBE, has been found to be clastogenic in in vitro assays without

32 enzyme activation at concentrations ranging from 0.2–1 mM (Elliot and Ashby, 1997). However,

66

33 as has been discussed, in vivo and in vitro genotoxicity assays do not suggest that BAL would

34 have any significant genotoxicity in vivo. In addition, chemicals for which

April 2008

DRAFT-DO NOT CITE OR QUOTE

1 mutagenesis/genotoxic effects play a significant role generally induce more tumors at earlier 2 time points than near the end of the conducted bioassays due to their ability to both initiate and 3 promote tumor pathogenesis. The mutagenic compound ethylene dibromide, for instance, was 4 reported to induce forestomach tumors in all dose groups 168-280 days from the start of 5 exposure (U.S. EPA, 2004). EGBE is consistent with other forestomach carcinogens that are not 6 mutagenic, such as EA, in that observed tumors generally did not progress to carcinoma and 7 were not observed until well into the study (i.e., after long periods of forestomach cell damage 8 and repair). The first reported incidence of forestomach papilloma or carcinoma in female mice 9 was 731, 731, and 582 days in the 62.5, 125, and 250 ppm EGBE exposure groups, respectively 10 (NTP, 2000).

11 It does not appear that EGBE, BAL, or BAA preferentially bind to stomach tissue 12 macromolecules (Poet et al., 2003; Green et al., 2002). Poet et al. (2003) found that high levels 13 of EGBE concentrate in the food content of the forestomach following i.p. exposure (Poet et al., 14 2003), indicating that the observed sequestering of EGBE in the forestomach is related to its 15 retention in the food that remains there, not to preferential binding to proteins within 16 forestomach tissue.

4.6.3.3. Conclusions About the Hypothesized Modes of Action

Inhalation exposure of B6C3F1 mice to EGBE gave rise to tumors in the liver and
forestomach. The liver tumors, hemangiosarcomas and hepatocellular carcinomas occurred in
males only and were significantly elevated over controls with a positive trend test for the
hemangiosarcomas. The forestomach tumors occurred in females only, had a positive trend test
result, and were significantly increased over controls only at the highest dose.

22 The MOAs that have been developed for these tumors reflect the evidence for the nonmutagenic nature of EGBE and its metabolites. For the liver tumors, the hypothesized key 23 24 steps of the MOA are metabolism of EGBE to BAA, hemolysis of RBCs with release of Hb and 25 hepatic hemosiderin accumulation, followed by oxidative stress, modulation of gene expression, 26 cell proliferation, promotion and neoplasm, leading to the formation of liver tumors. For the 27 forestomach tumors the hypothesized steps are metabolism to BAA, followed by tissue irritation and subsequent cytotoxicity, compensatory proliferation, and the induction of forestomach 28 29 tumors. No other viable MOAs have been identified that adequately explain the existing 30 laboratory animal and human observations.

Both of these MOAs have some degree of qualitative significance for humans since the
 principal biological components supporting them are all present and the processes can occur in
 humans. Collectively, however, the evidence presented in this assessment for these MOAs
 suggests that both MOAs have only limited quantitative significance to humans, principally due
 to kinetic/dynamic differences from the rodents. In the case of the liver tumors, in vitro data
 suggest there is a 40- to 150-fold difference in the dose that produces hemolytic changes in the
 April 2008

1 RBCs of humans as compared to rodents. This difference is supported by the Carpenter et al.

- 2 (1956) study, in which no changes in erythrocyte fragility were measured in humans at the
- 3 highest tested concentration, 195 ppm, but increased erythrocyte fragility was measured in
- 4 coexposed rats. Further, PBPK model simulations performed by Corely et al. (2005a) predict that
- 5 given the vapor pressure of EGBE, the maximum blood level of BAA that can be obtained from
- 6 inhalation exposure would be lower than the predicted concentrations from bolus exposures that
- 7 have not resulted in hemolytic effects, and lower than concentrations that have been shown to
- 8 produce an effect on human RBCs in vitro (Udden, 2002). In the case of the forestomach tumors,
- 9 the primary difference between mice and humans is in the degree of kinetics in the metabolizing
- 10 enzymes involved in the production and clearance of BAA. Thus, the hypothesized key events in
- 11 the MOAs for the animal tumors (liver and forestomach) are not likely to occur in humans,
- 12 especially at low doses.
- 13 Based on the preceding analysis, EGBE is deemed not likely to be carcinogenic to
- 14 humans at expected environmental concentrations, when examining it on its physical-chemical
- 15 properties, toxicokinetic and dynamic factors, and MOA information.

4.7. Susceptible Populations

16 The hemolytic effect of EGBE is presumed to be caused by its primary metabolite, BAA, 17 interacting with the RBC membrane. Potentially susceptible subpopulations would include 18 individuals with enhanced metabolism or decreased excretion of BAA. As discussed in Section 19 4.7.1, older rats have reduced ability to metabolize the toxic metabolite BAA to CO_2 and a 20 diminished ability to excrete BAA in the urine (Ghanayem et al., 1990, 1987c). However, the 21 relevance of this finding to the possible susceptibility of elderly humans is uncertain; as 22 discussed in Section 3, humans may have conjugation pathways for the excretion of BAA, such 23 as BAA-glutamine and BAA-glycine, that are not present in rats. 24 It would also be expected that individuals whose RBC membranes are more susceptible

25 to the lysis caused by BAA would be more sensitive to effects from EGBE exposure. However, 26 RBCs from normal, aged, sickle-cell anemia, and hereditary spherocytosis patients were no more 27 sensitive to the hemolytic effects of BAA than RBCs from healthy volunteers when tested in 28 vitro (Udden, 1994). As work in this area continues, further information on the metabolic or 29 structural differences that result in the lower sensitivity of human RBCs compared to rat RBCs 30 may eventually identify characteristics in humans that may indicate increased susceptibility. For 31 instance, it is unknown if a genetic predisposition to hemolytic anemia from other causes, such 32 as G6PD deficiency, would lead to increased susceptibility to EGBE-induced hemolysis. G6PD 33 deficiency appears in approximately 400 variants, thus describing a genetically heterogeneous 34 disorder. The label has been applied to all types of moderate to severe enzyme deficiency with 35 intermittent, induced hemolytic episodes with chronic hemolytic anemia. To date, complete April 2008 68 DRAFT-DO NOT CITE OR QUOTE

1 deficiency of this enzyme has not been identified. The clinical result is the reduced ability to 2 produce nicotinamide adenine dinucleotide phosphate, an enzyme required for reactions of 3 various biosynthetic pathways, as well as for the stability of catalase and the maintenance of 4 GSH levels. Catalase and glutathione peroxidase are the primary enzymes in the detoxification of 5 hydrogen peroxide. Thus, cells are dependent on G6PD for this pathway; without it, they are 6 vulnerable to oxidative damage. RBCs are sensitive to this loss of enzyme: they rely on this 7 system for their antioxidant defenses. Other human risk factors for anemia include ingestion of 8 certain therapeutic drugs, infections, family history, diet, and systemic illnesses (Berliner et al., 9 1999).

10 Individuals with hereditary hemochromatosis (HH) represent a population potentially 11 susceptible to increased release of iron from any source. It is reported that 5/1,000 persons of 12 northern European descent are homozygous for the gene or genes that cause hemochromatosis, although it is unknown what proportion of this population will go on to develop the HH 13 14 phenotype (Pietrangelo, 2004). Individuals with this disorder are not able to reduce their 15 absorption of iron in response to increasing iron levels in the body. Iron stores in the body 16 continue to increase. The iron stores normally start out as ferritin, then eventually as aggregates 17 of a breakdown product of ferritin called hemosiderin. HH is a condition characterized by 18 excessive iron deposition in the form of hemosiderin, found in the liver, heart, skin, joints, 19 pancreas, and other endocrine organs. It is unknown whether individuals with this condition 20 would be susceptible to the effects of EGBE exposure. There is no indication in the literature, 21 however, that RBCs in individuals with HH are more fragile, and is therefore unlikely that HH 22 would increase the risk of hemolysis or additional hemosiderin deposition from EGBE exposure. 23 Studies have shown differences in the localization of iron between HH patients and rodents. In 24 HH patients, iron appears to accumulate preferentially in the parenchymal cells of the liver, early 25 on as ferritin and later as hemosiderin, due to increased iron absorption from the duodenum; late 26 in the disease, iron storage is seen in Kupffer cells and reticular endothelial cells of the bone 27 marrow (Knutson and Wessling-Resnick, 2003; Valberg et al., 1975). In contrast, EGBE-induced 28 toxicity in mice and rats results in initial and preferential accumulation of hemosiderin in 29 Kupffer by phagocytosing senescent RBCs (NTP, 2000). While it is clear that macrophages and 30 other cells can in fact contain hemosiderin, the relative level compared to hepatocytes is much 31 less; staining in these cells is typically seen in late stages of the disease (Kwittken and Tartow, 32 1966). The human course of developing hepatocellular carcinomas as a consequence of HH is 33 also guite different compared to the development in the mouse model of hemangiosarcoma. 34 Human cases of HH-induced hepatocellular carcinoma are typically observed in the presence of cirrhosis of the liver, another long-term process that reflects the chronic nature of the disease 35 progression in humans (Harrison and Bacon, 2005). Hemangiosarcomas, the tumor type of 36 37 concern in the male mice, have not been associated with HH in the literature.

April 2008

DRAFT-DO NOT CITE OR QUOTE

69

4.7.1. Possible Childhood Susceptibility

1 A number of factors may differentially affect children's responses to toxicants. The only 2 human toxicity information available on the toxicity of EGBE to children is from the case study 3 by Dean and Krenzelok (1991). They observed 24 children, age 7 months to 9 years, after oral 4 ingestion of at least 5 mL of glass window cleaner containing EGBE in the 0.5–9.9% range 5 (potentially 25–1500 mg EGBE exposures). Two children who had taken greater than 15 mL did 6 well after gastric emptying or lavage and observation in the hospital. The remainder were 7 watched at home after receiving diluting oral fluids. No symptoms of EGBE poisoning or 8 hemolysis were observed. While the effects reported in adult poisonings have been more severe 9 than those reported in these children, the adults tended to consume larger volumes and different 10 concentrations of EGBE, making it extremely difficult to assess the correlation of toxic effects 11 with age sensitivity.

12 As discussed above, there are numerous risk factors for anemia that might predispose an 13 individual to, or compound the adverse effects of, EGBE-induced hemolysis. It is generally 14 recognized, however, that children do not share the same risk factors for anemia as adults for a 15 number of reasons, including: (1) a higher rate of RBC turnover; (2) lower incidence of 16 neoplastic disease in childhood as either a direct or indirect cause of anemia (<7,000 of the 17 1,000,000 new cases of cancer each year in the U.S. occur in individuals <15 years of age); (3) 18 the fact that iron deficiency is almost always secondary to nutritional factors in children; (4) the 19 relative rarity of alcoholism and its related liver disease; (5) a much lower incidence of anemia 20 associated with thyroid disease; and (6) a rarity of cardiovascular disease other than congenital 21 heart diseases, with the result that valve replacement, malignant hypertension, and the use of 22 certain drugs are not usually a factor (Berliner et al., 1999; Hord and Lukens, 1999). 23 Anemia in children is usually associated with an abnormality of the hematopoietic system

24 (Berliner et al., 1999; Hord and Lukens, 1999). Studies of the osmotic fragility and deformability 25 of RBCs exposed to BAA, the toxic metabolite of EGBE (Udden, 1994), suggest that certain 26 patients with abnormal hematopoietic systems, such as sickle-cell anemia or hereditary 27 spherocytosis, are not more sensitive to the hemolytic effects of EGBE than normal adults. Other 28 studies suggest that the RBCs of children may be pharmacodynamically less sensitive to 29 hemolysis than those of adults. RBCs of neonates and children up to 6 months of age differ from 30 normal adult RBCs in that they are larger and have higher levels of Hb F versus adult Hb A 31 (Lewis, 1970). Frei et al. (1963) showed that the larger calf erythrocytes containing Hb F were 32 osmotically more resistant than smaller, adult erythrocytes containing Hb A and suggested that, 33 as fetal erythrocytes are replaced by postnatal erythrocytes, the total population of RBCs 34 becomes more susceptible to lysis. 35 The effect of age on EGBE-induced hematotoxicity was studied in male F344 rats by

36 Ghanayem et al. (1990, 1987c). These studies also demonstrated the time course for the onset

April 2008

1 and resolution of the hematological and histopathologic changes accompanying hemolysis. Adult

- 2 male F344 rats were significantly more sensitive to the hemolytic effects of EGBE than were
- 3 young (4–5 week) male rats following administration of a single gavage dose of EGBE.
- 4 Concurrent metabolism studies found increased blood retention of EGBE metabolite BAA (as
- 5 measured by increased C_{max} , AUC, and t_{4}) in young rats and that these rats eliminated a
- 6 significantly greater proportion of the administered EGBE dose as exhaled CO₂ or as urinary
- 7 metabolites. The rats also excreted a greater proportion of the EGBE conjugates, glucuronide and
- 8 sulfate, in the urine. These researchers suggested that a reduced ability by older rats to
- 9 metabolize the toxic metabolite BAA to CO2 along with a diminished ability to excrete BAA in
- 10 the urine may explain the age-dependent toxicity of EGBE.
- 11 NTP (2000) also found that young mice eliminated BAA 10 times faster than aged mice 12 following a 1-day exposure to EGBE. This difference was not as apparent after 3 weeks of exposure, suggesting that factors other than age may be involved (Dill et al., 1998). 13
- 14 Available in vitro information suggests that children are no more and are possibly less
- 15 sensitive to the hemolytic effects of BAA than adults. Udden (2002) compared the in vitro
- 16 responses of erythrocytes (percent hemolysis and MCV alterations) obtained from hospitalized
- adults (n = 29 to 40) and hospitalized children (n = 25 to 46) to 0 or 10 mM BAA for 4 hours. 17
- BAA (10 mM) produced comparable significant increases in MCV in both adults (from 87.1 to 18
- $89.2 \text{ }\mu\text{m}^3$; 2%) and children ($92.8-95.2 \text{ }\mu\text{m}^3$; 3%). In the case of hemolysis in response to BAA, 19
- 20 the response was noted as being significantly increased for hospitalized adults (0.54–0.69%;
- 21 28%) but not for hospitalized children (0.68%–0.75%; 10%).
- 22 Relatively minor developmental effects due to maternal toxicity related to hematologic 23 effects of EGBE exposure were found in studies using rats, mice, and rabbits dosed orally, by 24 inhalation, or dermally (NTP, 1993; Heindel et al., 1990; Sleet et al., 1989; Wier et al., 1987; 25 Hardin et al., 1984; Tyl et al., 1984). No teratogenicity was noted in any studies. It can be 26 concluded that EGBE is not significantly toxic to developing fetuses of laboratory animals.

4.7.2. Possible Gender Differences

27 Gender differences have been noted in a number of animal and human studies: females 28 were more susceptible to effects from EGBE exposure. In the NTP (1993) 2-week drinking water 29 studies with EGBE, the absolute and relative thymus weights in female F344 rats at the highest 30 exposure level (265 mg/kg-day) were slightly reduced. In the 13-week studies, male rats in the 31 highest three dose groups and females in all dose groups suffered mild (males) to moderate 32 (females) anemia. In addition, females, but not males, displayed significantly increased urea 33 nitrogen creatine. 34 Gender differences have also been noted in some studies that observed the hemotoxic

35 effects of dermal administration of EGBE. Repeated application of EGBE either neat or as a 36 dilute aqueous solution (occluded) to male or female NZW rabbits at exposure levels of 18, 90,

71

April 2008

DRAFT-DO NOT CITE OR QUOTE

1 180, or 360 mg/kg (6 hours/day, nine applications) produced hemoglobinuria in males at

2 360 mg/kg and females at 180 or 360 mg/kg (Tyler, 1984). Only female rabbits showed

decreased RBC counts, Hb concentrations, and MCHC along with increased MCH at the highest
treatment level. Recovery was noted following a 14-day observation period.

5 A number of secondary effects resulting from the hemolytic toxicity of EGBE, such as 6 effects on the rat liver, kidneys, spleen, bone marrow, and, to a lesser extent, the thymus, were 7 more pronounced in females. In the NTP drinking water studies (1993), liver lesions in females, 8 but not males, included cytoplasmic alterations, hepatocellular degeneration, and pigmentation. 9 These effects were most pronounced in the three highest dose groups.

Carpenter et al. (1956) reported female rats to be more sensitive than males to the hemolytic effects of EGBE. In dogs, slight increases in erythrocyte osmotic fragility in both the male and female basenji hybrids were seen, but RBC counts and Hb concentrations were slightly decreased in the female. Overall, the effects were seen in both genders, but appeared to develop more slowly in the males. In monkeys, occasional rises in erythrocyte osmotic fragility were recorded during the exposure period more frequently in the female than in the male.

16 In the process of studying and comparing the metabolic and cellular basis of EGBE-

17 induced hemolysis of rat erythrocytes in vitro with human erythrocytes, Ghanayem (1989)

18 observed that the blood from male and female human volunteers was unaffected by 4-hour

19 incubations with BAA at concentrations of up to 4.0 mM. At 8 mM, only slight but significant

20 hemolysis of human blood was observed, with blood from females showing a slightly greater

21 sensitivity.

22 The NTP 2-year inhalation bioassay (NTP, 2000; Dill et al., 1998) also reported evidence 23 of gender specificity in mice and rats, particularly with respect to the elimination of BAA in rats. 24 Female rats eliminated BAA more slowly from the blood, as indicated by a smaller elimination 25 rate constant, longer elimination $t_{\frac{1}{2}}$, and larger AUC. In addition, the maximum blood 26 concentrations (C_{max}) of BAA were greater for females at each concentration and time point. It 27 has been suggested because a smaller amount of BAA was excreted in the urine of female rats, 28 higher blood concentrations of BAA accumulated in the females (Dill et al., 1998). Mouse data 29 from the NTP (2000) study also suggest a slightly increased hematologic effect among female 30 mice; however, while female mice tended to have higher blood concentrations of BAA, they

31 excreted more BAA in urine than male mice.

5. Dose-Response Assessments

5.1. Inhalation Reference Concentration (RfC)

1 In general, the RfC is an estimate, with uncertainty spanning perhaps an order of 2 magnitude, of a daily exposure to the human population—including susceptible subgroups—that 3 is likely to be without an appreciable risk of adverse health effects over a lifetime. It is derived 4 from a lower confidence limit on the benchmark dose (BMDL), a NOAEL, a LOAEL, or another suitable point of departure (POD), with uncertainty/variability factors applied to reflect 5 6 limitations of the data used. The RfC is expressed in terms of mg/m³ of exposure to an agent and 7 is derived by a methodology similar to the RfD. Ideally, studies with the greatest duration of 8 exposure and conducted via the inhalation route of exposure give the most confidence for 9 derivation of an RfC.

5.1.1. Choice of Principal Study and Critical Effect, with Rationale and Justification

10 There are no studies reported in which humans have been exposed subchronically or 11 chronically to EGBE by the inhalation route of exposure. The animal studies considered for 12 selection as principal studies include the 14-week and 2-year inhalation studies by NTP (2000) in 13 rats and mice, the developmental toxicity study by Tyl et al. (1984) in rats and rabbits, the 14 developmental toxicity study by Nelson et al. (1984) in rats, and the subchronic study by Dodd et 15 al. (1983) in rats. The NTP (2000) study was selected as the principal study because it was 16 conducted in two species and provides data for different durations and for more dose groups than 17 the other studies. The developmental toxicity studies identified effects at doses higher than the 18 doses associated with the critical effects identified in the NTP (2000) study and were not used for 19 quantitative purposes. While the subchronic study by Dodd et al. (1983) was a well-conducted 20 one, the NTP (2000) study contained more dose groups, more animals per group, and a longer 21 duration of exposure. Thus, Dodd et al. (1983) was not used for quantitative purposes. Two 22 endpoints from the NTP (2000) study-the hemolytic endpoint from the 14-week inhalation 23 study and the hemosiderin deposition endpoint from the 2-year inhalation study—were used for 24 the critical effect. The hemolytic endpoints in the 1999 EGBE toxicological review were used to 25 derive the reference values (see Section 5.1.5), but were not used to derive the values in this 26 updated assessment. New mode of action information published since the 1999 EGBE 27 toxicological review is included in this document, and this information supports the hemosiderin

- 1 deposition endpoint as an important, key event in the proposed MOA. A comparison of the
- 2 NOAELs and LOAELs for the candidate studies are summarized in Table 5-1.

	Species		No./dose		Effect lev	els (ppm)
Reference	(strain)	Gender	group	Duration/effect	NOAEL	LOAEL
NTP (2000)	Rat (F344)	М	9–10	14 week, hematologic	31	62.5
			50	2 year, hematologic, hemosiderin	_	31
		F	9–10	14 week, hematologic	-	31
			50	2 year, hematologic, hemosiderin	_	31
NTP (2000)	P (2000) Mouse M 9–10 2 year, histopathology of the forestomach		_	62.5		
			50	2 year, hematologic, hemosiderin	62.5	125
		F	9–10	2 year, histopathology of the forestomach	_	62.5
			50	2 year, hematologic, hemosiderin	_	62.5
Tyl et al. (1984)	Rat (F344)	F	30-31	GD 6-15, hematologic	50 ppm	100 ppm
Nelson et al. (1984)	Rat (Sprague- Dawley)	F	15	GD 7-15, hematologic	150 ppm	200 ppm
Dodd et al. (1983)	Rat (F344)	M, F	10	13 week, hematologic	25 ppm	77 ppm

Table 5-1. Results of candidate studies

3 The primary effects of EGBE exposure, hematological effects, were observed in both 4 species and genders tested. Female rats (NTP, 2000) appeared to be most sensitive among 5 animals studied. A mild-to-moderate regenerative anemia was observed in females exposed to all 6 concentrations, with a LOAEL of 31 ppm identified for hematological effects in male and female 7 rats and no NOAEL. Exposure-related trends were noted for reticulocyte count, RBC count, 8 MCV, Hb concentration, and Hct. The hematological endpoints were considered for the 9 derivation of the RfC; however, they presented a number of difficulties. It was not clear which of 10 the hematological endpoints (changes in RBC count, reticulocyte count, MCV, Hb concentration, 11 and Hct) observed in EGBE-exposed animals should be used to derive an RfC. In the case of 12 benchmark dose (BMD) analysis, the proper benchmark response (BMR) level for the BMD 13 derivation was unclear. In addition, while these hematologic effects were observed in both the

- 1 subchronic and chronic studies and persisted with exposure duration, they did not progress in
- 2 severity in the subchronic-to-chronic study (see Table 4-3, Table 4-6, and Table 5-2). Further,
- 3 better model fits were obtained from the BMD analysis of the subchronic study, which used two
- 4 more exposure concentrations than the chronic study. For these reasons, the hematologic
- 5 responses from the 14-week subchronic study were chosen for use in the BMD analyses of this
- 6 endpoint (see Section 5.1.2.2.1). Selection of the most appropriate hematologic endpoints for use
- 7 in the BMD analysis also required consideration of EGBE's MOA for hemolysis.

Effect/time [*]	Control	31 ppm	62.5 ppm	125 ppm	250 ppm	500 ppm
Female rat						
Hemosiderin 14 week 2 year	0/10 15/50	0/10 19/50	10/10 [§] 36/50 [¤]	10/10 ^{*§} 47/50 ^{°°}	9/9 [§] NT	5/5 [§] NT
RBC count [#] 14 week 1 year	8.48±0.05 7.81±0.05	8.08±0.07§ (95) NT	7.70±0.08§ (91) 7.42±0.06§ (95)	6.91±0.05§ (82) 6.75±0.05§ (86)	6.07±0.04§ (72) NT	4.77±0.15§ (56) NT
Male rat						
Hemosiderin 14 week 2 year	0/10 23/50	0/10 30/50	0/10 34/50 ^{°°}	7/10 [§] 42/50 [□]	10/10 [§] NT	10/10 [§] NT
RBC count [#] 14 week 1 year	9.05±0.08 8.88±0.08	8.71±0.14 ^{°°} (96) NT	8.91±0.06 (94) 8.39±0.15 [§] (94)	8.01±0.08 [§] (89) 7.43±0.20 [§] (84)	7.10±0.07 [§] (78) NT	5.97±0.05 [§] (66) NT
Female mous	е		•		•	
Hemosiderin 14 week 2 year	0/10 0/50	0/10 NT	0/10 5/50 ^{°°}	0/10 25/49 [§]	10/10 [§] 44/50 [§]	6/6 [§] NT
RBC count [#] 14 week 1 year	9.72±0.05 9.32±0.09	9.55±0.06° (98) NT	9.51±0.06 [□] (98) 9.14±0.08 (98)	9.18±0.05 [§] (94) 8.50±0.12 [§] (91)	8.57±0.06 [§] (88) 8.08±0.09 [§] (87)	7.35±0.07 [§] (76) NT
Male mouse						
Hemosiderin 14 week 2 year	0/10 0/50	0/10 NT	0/10 0/50	0/10 8/49 [§]	0/10 30/49 [§]	6/6 [§] NT
RBC count [#] 14 week 1 year	9.71±0.22 9.58±0.07	10.04±0.08 (103) NT	9.77±0.10 (101) 9.73±0.49 (102)	9.47±0.06 ^{°°} (98) 9.36±0.32 ^{°°} (98)	8.90±0.07 [§] (92) 8.33±0.10 [§] (87)	7.21±0.23 [§] (74) NT

75

Table 5-2. Female and male rat and mouse liver hemosiderin staining incidence and RBC
from subchronic and chronic EGBE inhalation studies.

*Mean \pm standard error; percent of control in parentheses.

#RBC count as 106/ μ L.

 $\ensuremath{\texttt{Z}}\xspace$ Statistically significant difference, $p \leq 0.05.$

 $Statistically significant difference, p <math display="inline">\leq$ 0.01; NT = not tested.

Source: NTP (2000).

April 2008

1 The suggested MOA of EGBE hemolysis is based on data indicating that BAA, an 2 oxidative metabolite of EGBE, the first hypothesized event in the MOA, is likely to be the 3 causative agent in hemolysis (Ghanayem et al., 1990, 1987b; Carpenter et al., 1956). The second 4 event in the MOA is erythrocyte swelling, and cell lysis, which is believed to be preceded by an 5 increase in the osmotic fragility and a loss of deformability of the erythrocyte (Udden, 1995b, 6 1994; Udden and Patton, 1994; Ghanayem, 1989). This results in decreased values for RBC 7 count, Hb, and Hct and in response, an increase in the production of immature RBCs 8 (reticulocytes) by the bone marrow.

9 Although changes in reticulocyte and nucleated erythrocyte counts sometimes represent 10 the largest measurable differences between exposed animals and unexposed control animals, this 11 parameter is highly variable and does not always exhibit a clear dose-dependent trend (NTP, 12 2000, 1993). While these endpoints can be indirect markers of RBC lysis, they are governed by 13 multiple feedback control processes that can be both very sensitive and variable. Therefore, a 14 change in reticulocyte or nucleated erythrocyte count is not considered a suitable endpoint for 15 deriving the RfC or RfD.

16 Until more is known about the molecular interaction between BAA and specific cellular 17 molecules, it is reasonable to assume that changes in MCV and RBC count are measurements of 18 precursor events in response to both oral and inhalation EGBE exposure. Therefore, dose-19 response information on MCV and RBC count are key endpoints used in the BMD analyses, and 20 were considered for derivation of the RfC and RfD for EGBE.

21 While the toxicokinetic data suggest that MCV should theoretically be the earlier 22 indicator of hemolytic effects from EGBE exposure, recent studies suggest that the relationship 23 between the rate of MCV increase and RBC count decrease may not be consistent across 24 exposure protocols. In the gavage studies of Ghanayem et al. (1987c) and the inhalation studies 25 of NTP (2000), Hct, a measure of RBC volume relative to blood volume, tended to decrease 26 along with RBC count and Hb at all exposure levels for which a hematologic effect was 27 observed. However, Hct did not change as RBC count and Hb decreased, following drinking 28 water exposures (NTP, 1993). Thus, the loss of erythrocytes in the drinking water studies 29 (reduced RBC count) was apparently offset by a concurrent increase in the size of the individual 30 cells (increased MCV). This was not the case in the gavage and inhalation studies. For these 31 reasons, greater weight is given to reduced RBC count, as opposed to increased MCV. 32 While the hemolytic effects appeared to be among the earliest effects from EGBE 33 exposure, the hemosiderin deposition endpoint was selected as the critical effect. This effect was 34 found to occur in both species and genders of animals tested, with rats being the more sensitive 35 species; the effect also occurred in the 14-week subchronic NTP inhalation study. The suggested

36 MOA of EGBE-induced liver effects is based on the observation that the hemolytic effects led to

April 2008

76 DRAFT-DO NOT CITE OR QUOTE

1 compensatory erythropoiesis and significant increases in blood degradation products, including

- 2 an increased accumulation of hemosiderin in the liver Kupffer cells of EGBE-exposed animals.
- 3 The hemosiderin accumulation seen in the Kupffer cells was found to increase in severity with
- 4 increasing dose and exposure duration (Table 5-2), unlike the hemolytic endpoints, such as
- 5 decreased Hct, which did not progress from 3 to 12 months (Table 4-6). Thus, hemosiderin
- 6 deposition in Kupffer cells in the rat liver is believed to be a sequela to the hematologic effects.
- 7 Because of the progression of this effect with chronic exposure, hemosiderin is deemed to be the
- 8 most sensitive effect. A NOAEL was not identified, while a LOAEL of 31 ppm was identified in
- 9 both male and female rats.
- 10 The 2-year chronic inhalation study by the NTP (2000) observed forestomach ulcers in
- 11 female mice at all exposure levels, but this effect has not been observed in any other species,
- 12 including mice exposed orally to EGBE (NTP, 1993). Though the incidence of this lesion
- 13 increased with exposure, severity of the lesion did not increase with increasing dose. While this
- 14 effect was not considered a critical effect for the derivation of an RfC, Appendix C contains the
- 15 BMD analysis for this endpoint for comparison purposes.

5.1.2. Methods of Analysis, Including Models (PBPK, BMD, etc.)

- 16 PODs for the RfC derivation in terms of the human equivalent concentrations (HECs)
- 17 have been calculated via the application of PBPK modeling and the use of internal dose metrics
- 18 published by Dill et al. (1988) to obtain NOAEL and BMCL estimates.

5.1.2.1. Derivation of the POD Using PBPK Modeling and the NOAEL/LOAEL Method

- 19 The lowest NOAEL/LOAEL observed in any subchronic or chronic study of EGBE is the 20 31 ppm LOAEL for hematologic effects observed in the NTP study (2000) in rats. In order to 21 estimate a corresponding human equivalent exposure, an internal dose metric associated with this 22 exposure level is estimated and a PBPK model is used to estimate the human exposure level that 23 would result in that internal dose.
- Initially, it was important to determine what estimate of internal dose (i.e., dose metric) could serve as the most appropriate metric for the effects under consideration. PBPK models of Lee et al. (1998) and Corley et al. (1994, 1997) are capable of calculating several measures of dose for both EGBE and BAA, including:
- 28 C_{max}C The peak concentration of EGBE or BAA in the blood during the exposure
 29 period;
- AUCC Area under the curve (AUC), represents the cumulative product of concentration
 and time for EGBE and BAA in the blood.
- 32 Dill et al. (1998) published measured AUC, but not C_{max}, blood concentrations of EGBE
 33 and its principal metabolite BAA at various exposure durations in both genders of B6C3F1 mice

and F344 rats exposed to the same concentrations used in the NTP (2000) chronic studies. Cmax 1 2 values would need to be derived from a PBPK model. Two pieces of information were used to 3 select C_{max} for BAA in the blood as the more appropriate dose metric for the main hemolytic endpoint associated with this LOAEL. First, as discussed in Section 4.5, there is convincing 4 5 evidence to indicate that an oxidative metabolite, BAA, is the causative agent for EGBE-induced 6 hemolysis (Carpenter et al., 1956; Ghanayem et al., 1987b, 1990). With this in mind, dose 7 metrics for BAA in blood appear to be more appropriate than those for EGBE in blood, since 8 they are more closely linked mechanistically to the toxic response. Second, EGBE-induced 9 hemolysis appears to be dependent upon the dose rate. Ghanayem et al. (1987c) found that 10 gavage doses to F344 male rats of 125 mg/kg EGBE resulted in hemolytic effects including 11 reduced RBC count, Hb, and Hct, as well as kidney pathology (Hb casts and intracytoplasmic 12 Hb). However, it should be noted that hemolytic effects were not reported at a similar acute 13 drinking water dose of 140 mg/kg (Medinsky et al., 1990). While a drop in RBC count and Hb 14 (9% and 7%, respectively) was noted in F344 male rats after 1 week of drinking water exposure 15 to 129 mg/kg-day EGBE, dose-related kidney pathology was not observed in these rats, even 16 after 13 weeks of drinking water exposure up to 452 mg/kg-day EGBE (NTP, 1993). Finally, as 17 is discussed in Section 5.1.1, hematological endpoints indicative of hemolysis do not progress 18 with increased inhalation duration. Corley et al. (1994) also suggested that C_{max} is a more 19 appropriate dose metric for the hemolytic effects of EGBE than AUC. 20 The PBPK models developed for EGBE are briefly summarized in Table 5-3. Johanson 21 (1986) and Shyr et al. (1993) do not address BAA distribution, and are only parameterized for 22 humans and rats, respectively. The model described by Lee et al. (1998) is the most appropriate 23 model for the estimation of rat and mouse internal doses following inhalation exposure. That 24 model is used here to estimate the C_{max} of BAA in blood following inhalation exposure to female rats, the more sensitive gender.⁶ The human PBPK model of Corley et al. (1994, 1997) was then 25

26 used to obtain estimates of human inhalation exposure concentrations associated with the female

27 rat BAA blood concentrations.⁷ Established EPA (2006c) methods and procedures were used to

28 review, select and apply these chosen PBPK models.⁸

⁶ The Lee et al. (1998) model was chosen in this case because it is an extension of the Corley et al. (1994, 1997) model that includes added parameters for female rats.

⁷ The basic components of the Corley model are summarized in Appendix A.

⁸ EPA notes that the review of the PBPK models was conducted prior to their use in the 1999 EGBE toxicological review.

Model	Species	Routes of exposure	Comments
Johanson (1986)	Human	Inhalation	BAA not addressed
Shyr et al. (1993)	Rat	Inhalation, oral, dermal	BAA excretion
Corley et al. (1997, 1994)	Rat and human	Inhalation, oral, dermal	BAA distribution and excretion; male rats only
Lee et al. (1998)	Rat and mouse	Inhalation	BAA distribution and excretion; males and females

Table 5-3. Summary of PBPK models.

1	A five-step procedure was used to calculate the LOAEL HEC:
2	
3	Step 1: Calculate the internal dose surrogate (Cmax for BAA in blood) corresponding to
4	female rat LOAEL (Lee et al., 1998) by using the actual experimental exposure
5	regimen (6 hours/day, 5 days/week) in model simulations.
6	Female rat LOAEL = 31 ppm
7	$C_{max} BAA = 41 \ \mu M$
8	
9	Step 2: Verify that steady state was achieved (e.g., no change in BAA C _{max} as a result of
10	prolonging the exposure regimen).
11	There were no changes in the C_{max} of BAA in blood during any 24-hour simulation
12	period, using a 6 hour/day, 5 days/week exposure regimen at the female rat LOAEL,
13	indicating that steady state was achieved.
14	
15	Step 3: Simulate the internal dose surrogate by calculating the Cmax for BAA in blood
16	for humans continuously exposed (24 hours/day, 7 days/week) to varying
17	concentrations of EGBE (Corley et al., 1997, 1994).

Concentration of EGBE	C _{max} BAA in blood
in air (ppm)	(µM)
1	2.6
5	13.0
10	26.1
20	52.9
50	137.1
100	295.0

18 Step 4: Calculate the LOAEL_{HEC} of EGBE for continuous human exposure in air that 19 resulted in the same internal dose (C_{max} of BAA) in blood calculated for the anim

resulted in the same internal dose (C_{max} of BAA) in blood calculated for the animal study in step 1.

79

21 Female rat C_{max} BAA = 41 μ M

April 2008

20

1	HEC continuous exposure = 18 ppm (calculated by regression of internal dose
2	versus the concentration of EGBE in air from step 3).
3	
4	Step 5: Convert the EGBE exposure units from ppm to mg/m3
5	$LOAEL_{HEC}$ (mg/m ³) = conversion factor × $LOAEL_{HEC}$ (ppm)
6	$= 4.84 \text{ (mg/m}^{3}) \div \text{(ppm)} \times 18 \text{ ppm}$
7	= 4.84 (mg/m ³) \div (ppm) × 18 ppm = 88 mg/m ³
8	

5.1.2.2. Derivation of the POD Using PBPK Modeling and BMD Modeling Methods

9 It is recognized that the NOAEL/LOAEL designations listed in Table 5-1 do not

10 necessarily indicate the slope of the concentration-response curve, an important factor in

11 benchmark concentration (BMC) analysis, used to assess inhalation studies in the same manner

12 as BMDs are used to assess oral studies (U.S. EPA, 2000, 1995b). For this reason, BMC analyses

13 were performed on selected hemolytic endpoints from the subchronic study and on the

14 hemosiderin staining endpoint from the chronic study in male and female rats (NTP, 2000).

5.1.2.2.1. BMD approach applied to hematological data.

15 For the purposes of deriving an RfC for EGBE from hemolytic endpoints, both MCV and 16 RBC count response data were evaluated in female rats from the 14-week subchronic NTP 17 (2000) study (see Section 5.1.1). The current BMD technical guidelines (U.S. EPA, 2000) 18 suggest the use of 1 SD from the control mean for the BMR level for continuous data in the 19 absence of additional information, such as a minimal level of change in the endpoint that is 20 generally considered to be biologically significant. Because the hemolytic endpoints are 21 continuous measurements that have a relatively small historical variance in rats, and because 22 low-dose responses for these endpoints were generally near or within 5% of the control mean, 23 the BMCL₀₅ was considered to be an appropriate POD for derivation of the RfC (U.S. EPA, 24 2000, 1995b). The steepest concentration-response curves (and the lowest BMCL₀₅ estimate) 25 were obtained for decreased RBC count in female rats, and a 5% change was found to be 26 statistically significant. Higher levels of response (e.g., $\geq 10\%$ reductions) are in the exposure 27 range where other more severe responses related to anemia occur, such as MCV increases and 28 increased reticulocyte counts. Lower levels of response, for instance, 1 SD from the control 29 mean, an approximate 2% reduction for these data, are relatively distant from the observable data 30 and other responses related to anemia (see Appendix B for the 1 SD data). C_{max} for BAA in 31 arterial blood of rats was determined by using the PBPK model of Lee et al. (1998). Dermal 32 exposure to EGBE vapor was not considered in the predicted blood levels, because the estimated 33 relative contribution of the skin to the total uptake of unclothed humans exposed to 25 ppm

80

April 2008

DRAFT-DO NOT CITE OR QUOTE

- 1 EGBE for 8 hours ranged from only 4.6 to 27.5%, depending on temperature, humidity, and
- 2 exercise level (Corley et al., 1997). Thus, dermal uptake is predicted to contribute less than 10%,
- 3 even if 50% of an individual's skin is exposed. The results of this modeling effort are
- 4 summarized in Table 5-4.

Table 5-4. Model estimates of BAA blood levels in female rats following inhalation exposures.

Exposure		
concentration (ppm)	Female rat body weight (g)	BAA in arterial blood C_{max} in female rats (μM)
31	216	40.4
61.5	211	85.9
125	214	189.5
250	210	451.3
500	201	1143.3

Source: Lee et al. (1998).

5 All BMD analyses were performed using models in EPA BMD software (BMDS),

6 version 1.4.1 (U.S. EPA, 2000). Graphical figures and text output files for selected BMC

7 analyses are provided in Appendix B. The fit statistics and BMC information derived from the

8 continuous models available in the BMD software as applied to the female rat RBC count data

9 versus C_{max} BAA are shown in Table 5-5. All models were fit using restrictions and option

10 settings suggested in the EPA BMD technical guidance document (U.S. EPA, 2000). The best

11 model fit to these data, from visual inspection and comparison of Akaike Information Criterion

12 (AIC) values, was obtained using the Hill model. The BMCL₀₅ was determined to be $37.2 \,\mu$ M,

13 using the 95% lower confidence limit of the dose-response curve expressed in terms of the C_{max}

14 for BAA in blood. The Corley et al. (1997) PBPK model was used to back-calculate an HEC of

15 17 ppm (81.4 mg/m³), assuming continuous exposure (24 hours/day).

Table 5-5. Comparison of BMC/BMCL values for female rat RBC count data from a 14week subchronic inhalation study, using modeled blood Cmax (3 months) of the EGBE metabolite BAA as a common dose metric.

Model	BMC ₀₅ (µM)	BMCL ₀₅ (µM)	p Value	AIC*	Scaled residual ^{**}
2nd degree polynomial	60.8414	54.5902	< 0.0001	-90.947514	0.15
Power	74.5253	68.2041	< 0.0001	-52.341720	0.218
Hill***	42.2297	37.1792	0.1669	-109.272293	0.168

*AIC = -2L + 2P, where L is the log-likelihood at the maximum likelihood estimates for the parameters and P is the number of model degrees of freedom (usually the number of parameters estimated).

**Chi-square residual (measure of how model predicted response deviates from the actual data) for the dose group closest to the BMC scaled by an estimate of its SD. Provides a comparative measure of model fit near the BMC. Residuals that exceed 2.0 in absolute value should cause questioning model fit in this region.

***Model choice based on adequate p value (>0.1), visual inspection, low AIC and low (absolute) scaled residual. .

5.1.2.2.2. BMD approach applied to hemosiderin staining data.

1 For the purposes of deriving an RfC for EGBE, hemosiderin staining data were evaluated 2 in male and female rats from the 2-year chronic study by NTP (2000). The current BMD 3 technical guidelines (U.S. EPA, 2000) suggest the use of 10% extra risk as a BMR level for 4 quantal data as this is at or near the limit of sensitivity in most cancer bioassays and in some 5 noncancer bioassays as well. Because the hemosiderin staining endpoint was observed in control animals and a 10% increase in incidence was within the observable range of the data, 10% extra 6 7 risk was considered an appropriate BMR and a $BMCL_{10}$ an appropriate POD for derivation of 8 the RfC (U.S. EPA, 2000, 1995b). All BMD assessments in this review were performed using 9 EPA BMDS version 1.4.1. Graphical figures and text output files for selected BMC analyses are 10 provided in Appendix B.

11 The AUC was selected as the appropriate dose metric due to the nature of the endpoint,

12 hemosiderin deposition. This endpoint increased in severity with increased duration (subchronic

13 to chronic) and is believed to be the result of the cumulative exposure to EGBE as opposed to a

14 peak event. Table 5-6 reports AUC BAA blood concentrations measured at 12 months⁹ published

by Dill et al. (1998) in both genders of B6C3F1 mice and F344 rats exposed to the same

16 concentrations used in the NTP (2000) chronic studies of these test animals.

Table 5-6. AUC BAA blood concentrations measured at 12 months in both sexesB6C3F1 mice and F344 rats.

Exposure Concentration (nnm)	Gender		$AUC_{BAA} (\mu mol-h/L)^*$	
Exposure Concentration (ppm)	Genuer	n	mean	SE
Rats				
31.2	Male	7	358.3	16.6
	Female	5	638.8	18.7
62.5	Male	6	973.0	86.2
	Female	9	1128.9	50.9
125	Male	9	2225.6	71.1
	Female	12	3461.8	154.8
Mice				
62.5	Male	10	1206.6	205.6
	Female	12	1863.6	112.4
125	Male	9	2819.8	685.1
	Female	6	5451.6	508.9
250	Male	10	17951.5	1770.4
	Female	11	18297.1	609.7

^{*}Authors reported AUC values in terms of μ g-min/g, which were converted to units consistent with the PBPK model of μ mol-h/L by dividing by 60 min/h and 132.16 g/mol and multiplying by 1060 g/L.

Source: Dill et al. (1998).

82

⁹ Dill et al. (1998) also reported 18 month data, but due to the smaller number of animals and higher variability in this data the 12 month data were used for the purposes of this analysis.

1 The fit statistics and BMC information derived from the dichotomous models available in 2 the BMD software as applied to the male and female rat hemosiderin staining data versus AUC 3 BAA are shown in Table 5-7. All models were fit using restrictions and option settings suggested 4 in the EPA BMD technical guidance document (U.S. EPA, 2000). The best model fit to these 5 data, as determined by visual inspection, examination of low dose model fit (i.e., scaled residual 6 for the dose group closest to the BMD) and comparison of overall fit (i.e., AIC values), was 7 obtained using a multistage model (1st degree) for the male response data and a Log-Logistic 8 model for the female response data. The male rat BMC10 was 196 µmol-hour/L and the 9 BMCL10 was determined to be 133 µmol-hour/L, using the 95% lower confidence limit of the 10 dose-response curve expressed in terms of the AUC for BAA in blood. The BMC₁₀ and BMCL₁₀ 11 values for the female rat were determined to be 425 and 244 µmol-h/L, respectively. Assuming 12 continuous exposure (24 h/day), the Corley et al. (1997) PBPK model was used to back-calculate human equivalent concentrations of 3.4 ppm (16 mg/m³) from the male rat data and 4.9 ppm (24) 13 14 mg/m^3) from the female rat data, 15 Likewise, the fit statistics and BMC information for male and female mouse hemosiderin 16 staining data versus AUC BAA are shown in Table 5-8. All models were fit using restrictions and 17 option settings suggested in the EPA BMD technical guidance document (EPA, 2000). The best 18 model fit to these data, as determined by visual inspection, examination of low dose model fit 19 (i.e., scaled residual for the dose group closest to the BMD) and comparison of overall fit (i.e., 20 AIC values), was obtained using a log-probit model for both the male and female response data. 21 The male mouse BMC₁₀ was 3077 µmol-h/L and the BMCL₁₀ was determined to be 2448 µmol-22 h/L using the 95% lower confidence limit of the dose-response curve expressed in terms of the 23 AUC for BAA in blood. The BMC₁₀ and BMCL₁₀ values for the female mouse were determined to be 1735 and 1322 µmol-h/L, respectively. Assuming continuous exposure (24 h/day), the 24 25 Corley et al. (1997) PBPK model was used to back-calculate human equivalent concentrations of 26 36 ppm (174 mg/m³) from the male mouse data and 20 ppm ($97mg/m^3$) from the female mouse

data.

Table 5-7. Comparison of BMC/BMCL values for male and female rat liver hemosiderin staining data from inhalation chronic study using measured blood AUC (12 months) of the EGBE metabolite BAA as a common dose metric.

Model	BMC ₁₀ (µmol-h/L)	BMCL ₁₀ (µmol-h/L)	p value	AIC*	Scaled Residual ^{**}			
Male Rats								
Multistage-1st degree***	196.252	133.141	0.8680	247.234	0.441			
Gamma***	196.253	133.141	0.8680	247.234	0.441			
Logistic	259.296	192.773	0.7692	247.476	0.526			
Log-Logistic	166.376	69.3279	0.5623	249.283	0.313			
Probit	271.525	205.882	0.7450	247.54	0.517			
Log-Probit	368.336	241.992	0.6309	247.876	0.765			
Weibull***	196.253	133.141	0.8680	247.234	0.441			
		Female Rats						
Multistage-1st degree	122.166	214.555	0.0698	218.868	-1.945			
Gamma	316.635	134.02	0.0554	219.229	-1.238			
Logistic	273.693	221.689	0.0993	218.188	-1.294			
Log-Logistic ^{***}	424.527	243.69	0.1533	217.526	-0.896			
Probit	291.017	241.206	0.0683	218.985	-1.260			
Log-Probit	427.728	248.683	0.1238	217.884	-0.965			
Weibull	266.515	130.801	0.0454	219.58	-1.377			

* AIC = Akaike Information Criteria = -2L + 2P, where L is the log-likelihood at the maximum likelihood estimates for the parameters, and p is the number of model degrees of freedom (usually the number of parameters estimated) ** Chi-square residual (measure of how model predicted response deviates from the actual data) for the dose group closest to the BMC scaled by an estimate of its standard deviation. Provides a comparative measure of model fit near the BMC. Residuals that exceed 2.0 in absolute value should cause one to question model fit in this region.

*** Model choice based on adequate p value (> 0.1), visual inspection, low AIC and low (absolute) scaled residual. The Multistage (1st degree) is referred to as the chosen model for male rats, though equivalent fit was obtained by the restricted Gamma and Weibull models.

	BMC ₁₀	BMCL ₁₀			
Model	(µmol-h/L)	(µmol-h/L)	p value	AIC*	Scaled Residual ^{**}
Male Mice			•		
Multistage-1st	2100.07	1613.9	0.3067	117.571	-1.766
degree					
Gamma	2725.35	1702.27	0.1452	118.559	1.358
Logistic	6605.45	5333.72	0.0022	127.326	2.789
Log-Logistic	2616.51	1628.48	0.1882	118.02	1.193
Probit	5917.06	4825.09	0.0031	126.405	2.734
Log-Probit ^{***}	3076.8	2448.3	0.1290	116.614	1.946
Weibull	2689.76	1687.09	0.1445	118.712	-1.448
Female Mice			•		
Multistage-1st	946.491	769.879	0.3680	142.669	-1.583
degree					
Gamma	1402.92	818.367	0.3420	143.288	-0.817
Logistic	2897.15	2341.03	0.0002	162.338	-0.942
Log-Logistic	1705.75	1121.43	0.8223	141.501	-0.343
Probit	2860.03	2364.52	0.0002	161.681	-0.829
Log-Probit ^{***}	1734.53	1322.06	0.8237	141.498	-0.315
Weibull	1282.82	804.234	0.2958	143.631	-0.988

Table 5-8. Comparison of BMC/BMCL values for male and female mouse liverhemosiderin staining data from inhalation chronic study using measured blood AUC (12months) of the EGBE metabolite BAA as a common dose metric

* AIC = Akaike Information Criteria = -2L + 2P, where L is the log-likelihood at the maximum likelihood estimates for the parameters, and p is the number of model degrees of freedom (usually the number of parameters estimated) ** Chi-square residual (measure of how model predicted response deviates from the actual data) for the dose group closest to the BMC scaled by an estimate of its standard deviation. Provides a comparative measure of model fit near the BMC. Residuals that exceed 2.0 in absolute value should cause one to question model fit in this region. *** Model choice based on adequate p value (> 0.1), visual inspection, low AIC and low (absolute) scaled residual. The Log-Probit model provides a slightly better fitthan other models for both genders.

5.1.2.3. Selection of the POD

Consideration of the available data has led to the selection of the two-year inhalation

2 study (NTP, 2000) and increased hemosiderin staining in the liver of male F344 rats as the

3 principal study and critical effect for deriving the chronic RfC for EGBE. This is a high-quality

4 study and when coupled with information on the mode of action, EPA concluded this is a

- 5 precursor to an adverse effect and is appropriate for use in deriving the RfC. A BMCL10 of 133
- 6 μmol-h/L for hemosiderin staining in liver of male rats chronically exposed to EGBE (NTP,
- 7 2000) was used as the point of departure to calculate the RfC. A human PBPK model (Corley et
- 8 al., 1997) was used to back-calculate to a human equivalent concentration of 16 mg/m3 (3.4
- 9 ppm) for the BMCLHEC. A total uncertainty factor (UF) of 10 was applied to the BMCLHEC:10
- 10 for consideration of intraspecies variation (UF_H: human variability) to obtain an RfC of 1.6
- 11 mg/m^3 . The rationale for the application of these UFs is provided in Section 5.1.3. The final

1

- 1 calculation of an RfC derived from the NOAEL/LOAEL and BMC modeling approaches are
- 2 presented in Table 5-9.

Table 5-9. Summary of the application of UFs for RfC derivations using NOAEL/LOAEL and BMC modeling approaches for male rat liver hemosiderin staining.

	Approach*				
Factor ^{**}	LOAEL	BMCL ₁₀			
UF _H	10	10			
UFA	1	1			
UFs	1	1			
UFL	3	1			
UF _D	1	1			
UF (total)	30	10			
$POD/UFs = RfC (mg/m^3)$	88/30 = 2.9	16/10 = 1.6			

*PODs—LOAEL_{HEC} = 88 mg/m³ based on hematological effects in male and female rats; $BMCL_{10HEC} = 16 \text{ mg/m}^3$ based on hemosiderin staining in male rats.

^{**}The rationale for the selection of these UFs is discussed in Section 5.1.3. UF_H—intrahuman variability, UF_A—interspecies variation, UF_S—subchronic to chronic extrapolation, UF_L—LOAEL to NOAEL extrapolation, UF_D—database insufficiencies.

Source: NTP (2000).

5.1.3. RfC Derivation, Including Application of Uncertainty Factors (UFs)

3 UFs are applied to account for recognized uncertainties in extrapolation from 4 experimental conditions to the assumed human scenario (e.g., chronic exposure over a lifetime when subchronic studies are used for deriving a toxicity value). The application of UFs may 5 include the use of a partial UF of $10^{1/2}$ (3.2) based on the assumption that the actual values for 6 7 the UFs are log-normally distributed. Application of these factors in the assessments is such that, 8 when a single partial UF is applied, the factor is rounded to 3-for instance, the total factor for 9 individual UFs of 3 and 10 would be 30 (3×10). When two partial UFs are evoked, however, 10 they are not rounded, such that a UF of 3, 3, and 10 would result in a total uncertainty of 100 (actually $10^{1/2} \times 10^{1/2} \times 10^{1}$) (U.S. EPA, 2002). UFs applied for this RfC assessment and the 11 12 justification for their use are as follows. 13 A value of 10 was selected to account for variation in sensitivity within the human 14 population (UF_H). Potentially susceptible subpopulations include individuals with enhanced 15 metabolism or decreased excretion of BAA and individuals whose RBC membranes are more 16 susceptible to the lysis caused by BAA, the precursor step to developing hemosiderin staining in the liver. A UF of 10 was used to account for the uncertainty associated with the variability of the 17 18 human response to the effects of EGBE. Human in vitro studies suggest that the elderly and 19 patients with fragile RBCs would not be more sensitive to the hemolytic effects of EGBE than

86

April 2008

1 normal adults. Laboratory animal studies suggest that older animals are more sensitive than

- 2 neonates, and that females are more sensitive than males (see Section 4.7). However, actual
- 3 human responses to EGBE have not been observed under a broad enough range of exposure
- 4 conditions, such as repeat/long-term exposures, and potentially sensitive subjects, such as
- 5 individuals predisposed to hemolytic anemia or infants, to warrant the reduction of the UF_H
- 6 below the default value of 10. While developmental studies do not reveal increased susceptibility
- 7 in infants, none of the developmental studies examined fetal or infant blood for signs of effects
- 8 from prenatal exposure to EGBE.
- 9 A UF of 1 was used to account for interspecies variation (UF_A) for toxicodynamic and
- 10 toxicokinetic differences between animals and humans. Traditionally, these components are 11 individually represented by partial UFs of 3 for a total UF of 10 in the absence of chemical-
- 12 specific information; thus, application of a full UF of 10 would depend on two areas of
- 13 uncertainty (i.e., toxicokinetic and toxicodynamic uncertainties). In this assessment, the
- 14 toxicokinetic uncertainty is addressed by the determination of an HEC, using a combination of
- 15 measured internal blood levels in the test animals and PBPK modeling. In vivo (Carpenter et al.,
- 16 1956) and in vitro (Udden, 2002; Udden and Patton, 1994; Ghanayem and Sullivan, 1993) results
- indicate that, toxicodynamically, humans may be less sensitive than rats to the hematologicaleffects of EGBE.
- 19 A UF to account for extrapolation from subchronic to chronic exposure (UF_S) was not 20 needed because the RfC was derived from a chronic study.
- A UF for LOAEL-to-NOAEL extrapolation was not used because the current approach is to address this factor as one of the considerations in selecting a BMR for BMD modeling. In this case, a BMR of a 10% change in hemosiderin staining was selected under an assumption that it represents a biologically significant change.
- 25 A value of 1 was used for the database UF (UF_D). Chronic and subchronic studies are
- available for two species (rats and mice), and several reproductive and developmental studies,
- 27 including a two-generation reproductive toxicity study. There are limited studies available
- 28 looking at humans following short-term inhalation exposure
- The combined PBPK and BMC modeling method using hemosiderin as an endpoint was used to derive the RfC. In addition, MOA information was used to inform the choice of the critical effect. The total UF is 10. Thus the RfC, is $16 \text{ mg/m}^3 \div 10 = 1.6 \text{ mg/m}^3$.

5.1.4. RfC Comparison Information

For comparison purposes, Figure 5-3 presents the POD, applied UFs, and derived
 reference values, including the RfC, for the effect endpoints discussed. BMC modeling was done
 using EPA BMDS version 1.4.1 (U.S. EPA, 2000), and results are provided in Appendices B and

- 1 C. This comparison is intended to provide information on alternative endpoints associated with
- 2 EGBE exposure. The selected RfC value is circled; BMC analyses are provided in Appendices C
- 3 and D.




Figure 5-3. Points of departure for selected endpoints with corresponding applied UFs and derived RfC.

4 Figure 5-3 shows PODs and comparison reference values (including the RfC) that could 5 be derived from the various endpoints, to allow a comparison with the chosen critical effect and 6 the resultant RfC for the critical effect. Hemolytic effects and effects related to hemolysis (i.e., 7 hemosiderin deposition) are the most sensitive endpoints for identification of a NOAEL or a 8 BMCL in the subchronic and chronic studies available; these endpoints have been considered as 9 the critical endpoint for derivation of the RfC. The BMCL05 for RBC count changes in female 10 rats was 37.2 µM, using Cmax at 3 months, and was converted to an inhalation HEC 11 (BMCLHEC) of 81.4 mg/m3 using the EPA model. Though adequate model fit per EPA BMD 12 technical guidance (U.S. EPA, 2000) could not be obtained for the NTP (2000) 3-month male rat RBC response (see Appendix B), this BMCL result (BMCL₀₅ of 37.2 µM converted to a 13

April 2008

1 BMCL_{HEC} of 81.4 mg/m³) is provided for comparison purposes. For the hemosiderin endpoint,

- 2 both male and female data from the chronic study were considered. The $BMCL_{10}$ for
- 3 hemosiderin staining in male rats was 133 μ M-h/L using the AUC for BAA in arterial blood at
- 4 12 months and was converted to a BMCL_{HEC} of 16 mg/m³ using the Corley et al (1994; 1997)
- 5 human PBPK model. The BMCL₁₀ for hemosiderin staining in female rats was 244 μ M-h/L
- 6 using the AUC for BAA in arterial blood at 12 months and was converted to a BMCL_{HEC} of
- 7 24 mg/m³ using the Corley et al (1994; 1997) human PBPK model.

5.1.5. Previous Inhalation Assessment

- 8 The previous IRIS assessment for EGBE was entered into the database on December 31,
- 9 1999; it contains an inhalation RfC of 13 mg/m³. The RfC was based on the BMC₀₅ HEC of
- 10 380 mg/m³ for changes in RBC count in female F344 rats following a 14-week inhalation
- 11 exposure (NTP, 1998). A total UF of 30 was used to account for human variability and
- 12 extrapolation from an adverse effect level.

5.2. Oral Reference Dose (RfD)

- 13 In general, the RfD is an estimate, with uncertainty spanning perhaps an order of
- 14 magnitude, of a daily exposure to the human population—including susceptible subgroups—that
- 15 is likely to be without an appreciable risk of adverse health effects over a lifetime. It is derived
- 16 from a statistical BMDL, a NOAEL, a LOAEL, or another suitable POD, with
- 17 uncertainty/variability factors applied to reflect limitations of the data used. The RfD is
- 18 expressed in terms of mg/kg-day of exposure to an agent and is derived by a similar
- 19 methodology to the RfC. Ideally, studies with the greatest duration of exposure and conducted
- 20 via the oral route of exposure give the most confidence for derivation of an RfD. The database of
- 21 oral studies for EGBE is more limited than the database of inhalation studies. For this reason, a
- 22 PBPK model for EGBE has been applied to the inhalation data for derivation of an RfD.

5.2.1. Choice of Principal Study and Critical Effect, with Rationale and Justification

- 23 No studies have been reported in which humans have been exposed subchronically or
- 24 chronically to EGBE by the oral route of exposure, and thus would be suitable for derivation of
- an oral RfD. No chronic oral laboratory animal studies are currently available for EGBE. The
- 26 results of the only two available subchronic 91-day drinking water studies in rats and mice (NTP,
- 27 1993) are summarized in Table 5-10.

	Species				Effect levels (mg/kg-day)	
Reference	(strain)	Gender	Animals/dose	Effect	NOAEL	LOAEL
NTP (1993)	Rat	М	10	Hepatocellular changes	_	54.9*
	(F344)	F	10	Hematological	_	58.6*
NTP (1993)			10	Body weight	223	553**
(B6C3F1)		F	10	Body weight	370	676**

Table 5-10. Subchronic 91-day drinking water studies in rats and mice

*Doses were calculated using water consumption rates and body weights measured during the last week of exposure and, therefore, differ slightly from those reported by the authors and presented in Section 4.2. **The LOAEL in mice was based on reduced body weight and body weight gain.

1 Based on a comparison of NOAELs and LOAELs for hematological and liver effects, rats 2 are clearly more sensitive to the noncancer effects of EGBE than mice. As discussed in Section 3 4.2, hematologic and hepatocellular changes were noted in both rat genders. In females, both 4 hematologic and hepatocellular changes were noted at the low-dose level (58.6 mg/kg-day, using 5 water consumption rates and body weights measured during the last week of exposure). Only 6 hepatocellular cytoplasmic changes were observed in low-dose male rats (54.9 mg/kg-day, using 7 water consumption rates and body weights measured during the last week of exposure). 8 In the female rat study (NTP, 1993), groups of 10 F344 rats were exposed to 0, 82, 151, 9 304, 363, and 470 mg/kg-day EGBE via drinking water for 13 weeks. Body and organ weights 10 were measured, and clinical, hematological, gross, and histopathologic examinations were 11 conducted. Decreases in body weight were observed in female rats exposed to the two highest 12 dose levels. Hematologic changes were observed at all dose levels after 13 weeks and were 13 indicative of mild-to-moderate anemia. These changes included reduced RBC count, Hb, and 14 Hct, as well as increased reticulocyte count and MCV. Liver hemosiderin pigmentation was 15 noted in the cytoplasm of Kupffer cells in both genders. In females it was noted in 0/10 controls 16 in 82 mg/kg-day treated animals, 2/10 with a severity grade of 1 (minimal) at 151 mg/kg-day, and 10/10 in the three highest dose levels, with the severities noted as increasing from a 17 18 numerical grade of 1.2 in the 304 mg/kg-day group to 1.9 in both of the upper two dose groups. 19 In males the pigmentation was noted in animals exposed to the highest dose only (452 mg/kg-20 day) at an incidence of 7/10 and a severity rating of 1 (minimal). No hepatic pigmentation was 21 reported in the mice exposed for 13 weeks. 22 Hematological effects leading to RBC lysis-organ accumulation of iron in the form of 23 hemosiderin accumulation—appear to be the most sensitive of the effects caused by EGBE in

24 laboratory animals. Less clear, however, is whether one of the hematological endpoints (changes

25 in RBC count, reticulocyte count, MCV, HCT, and Hb) or incidence of hemosiderin pigmentation

observed in EGBE-exposed animals is the most appropriate basis for an RfC/RfD (see Section
 5.1.1).

3 A BMD analysis has also been performed on the hemosiderin pigmentation endpoint 4 observed in the NTP (2000) chronic EGBE inhalation study (Section 5.1.2.2.2), and PBPK 5 models have been applied to extrapolate this BMD to a human equivalent oral exposure (Section 6 5.2.2.2.2). As discussed, hematological endpoints indicative of hemolysis do not progress with 7 increasing duration of inhalation exposure, whereas the incidence of hemosiderin pigmentation 8 did progress considerably with chronic exposure (Table 5-2). Furthermore, not enough is known 9 about the mechanism of action of EGBE to make a biologically-informed determination 10 regarding which hematological endpoints-changes in RBC count, reticulocyte count, MCV, 11 Hct, and Hb—observed in EGBE-exposed animals should be used to derive an RfC and, in the 12 case of BMD analysis, what a proper BMR level should be for the BMD derivation. Finally, 13 hematologic effects signified by changes in RBC count, reticulocyte count, MCV, HCT, and Hb 14 are considered precursor effects to the pathological finding of hemosiderin deposition (Section 15 4.5). For these reasons, and because the hemolytic effects of EGBE appear to be consistent 16 between oral and inhalation routes of exposure, an RfD has been derived via the application of a 17 PBPK model to perform a route-to-route extrapolation from the incidence of hemosiderin 18 pigmentation observed in the NTP (2000) chronic inhalation study of EGBE. BMD/NOAEL 19 analyses of hematologic endpoints and hemosiderin pigmentation observed in the oral NTP 20 (1993) subchronic study are provided below for comparison purposes. 21 Another issue that needs to be addressed with respect to the NTP (1993) study is the lack 22 of reported forestomach lesions at even the highest drinking water doses administered in this 23 study relative to the considerable incidence of forestomach hyperplasia and ulceration observed 24 at all exposure levels in the NTP (2000) subchronic and chronic inhalation studies of mice. This 25 is difficult to explain, considering the lowest dose in the subchronic drinking water study is predicted to result in similar, if not higher, Cmax blood levels of the EGBE metabolite BAA (the 26 27 presumed irritant), compared to the lowest exposure concentration in the NTP (2000) subchronic 28 inhalation study. There is no clear explanation. It has been suggested that oral non-bolus dosing 29 of EGBE does not result in high enough local concentrations of EGBE and BAA (Poet et al., 30 2003). Studies with other forestomach carcinogens that are not mutagenic have demonstrated that 31 forestomach effects are dependent not only on the dose but also on the chemical concentration in 32 the dosing solution (Ghanayem et al., 1985), and other effects of EGBE appear to be highly 33 dependent on the concentration attained (Ghanayem et al., 2001, 2000; Long et al., 2000; Nyska 34 et al., 1999). In addition, first-pass liver metabolism of orally administered EGBE may affect the 35 extent to which EGBE reaches the forestomach via the route that has been proposed following 36 i.v. injection, distribution to salivary glands followed by the swallowing of EGBE-laden saliva

April 2008

91 DRAFT-DO NOT CITE OR QUOTE

1 (Poet et al., 2003; Green et al., 2002). In any case, since forestomach irritation was not reported

2 in rats or mice in the NTP (1993) drinking water study, this is not considered a sensitive

3 endpoint, and route-to-route extrapolation of this endpoint from inhalation data is not considered

4 appropriate for use in the RfD derivation.

5.2.2. Methods of Analysis, Including Models (PBPK, BMD, etc.)

5 PODs for the RfD derivation in terms of the human equivalent doses (HEDs) have been 6 calculated via the application of PBPK modeling to NOAEL and BMDL estimates.

Of the available PBPK models (Table 5-3), the Corley et al. (1997, 1994) model is 7 8 considered the most complete and appropriate for use in the derivation of the oral RfD, because 9 it has been experimentally validated for the most sensitive species (rats) and humans, covers both 10 oral and inhalation routes of exposure, and addresses both the distribution and excretion of the 11 toxic metabolite, BAA, following oral EGBE exposure. This model is summarized in Appendix 12 A. As in the case of the RfC (see Section 5.1.2.1), C_{max} is considered a more appropriate dose 13 metric than AUC for the hematological effects. The PBPK model of Corley et al. (1997, 1994) 14 was used to obtain estimates of human C_{max} concentrations from the female rat drinking water 15 study data.

16 The four steps involved in using the Corley et al. (1997, 1994) PBPK model as modified

by Corley et al. (1997) to calculate the HED corresponding to the LOAEL identified in the

18 animal study (LOAEL_{HED}) were to (1) calculate the internal dose surrogate (C_{max} BAA in blood)

19 corresponding to the female rat LOAEL, assuming that the drinking water was consumed only

20 during a 12-hour awake cycle on a 7 day/week schedule in model simulations; (2) verify that

21 steady state was achieved (e.g., no change in BAA C_{max} as a result of prolonging the exposure

22 regimen); (3) simulate the internal dose surrogate (C_{max} BAA in blood) for humans consuming

23 EGBE in drinking water, assuming that a 70-kg human consumes an average of 2 L of water

during a 12-hour awake cycle; and (4) calculate the HED (mg/kg-day) for the amount of EGBE

25 consumed in 2 L of water that resulted in the same internal dose (C_{max} BAA) simulated for the

animal in step 1 as shown below.

5.2.2.1. Derivation of POD Using PBPK Model and NOAEL/LOAEL Method

```
27Step 1: Calculate the C_{max} for BAA in blood corresponding to female rat LOAEL.28Female rat LOAEL = 59 mg/kg-day (calculated for final week of 13-week study to29correspond with the final hematological determination) C_{max} BAA = 103 \muM30Step 2: Verify steady state.31There were no changes in the C_{max} of BAA in blood during any 24-hour simulation32period using a 12 hour/day, 7 day/week drinking water exposure regimen at the33female rat LOAEL, indicating that steady state was achieved.
```

1	Step 3: Calculate the C _{max} for BAA in blood for humans continuously exposed to varying
2	concentrations of EGBE.
3	Table 5-11 shows modeled estimates of BAA in blood of humans exposed continuously
4	to varying concentrations of EGBE in water (Corley et al., 1997, 1994). Drinking water volume
5	is 2.1. some some dage some 12. har some in andres

5 is 2 L consumed over 12 hours in a day.

EGBE concentration (ppm) in water	Calculated dose of EGBE from drinking water (mg/kg-day)	C _{max} BAA in blood (µM)
24	0.7	9
48	1.4	18
94	2.7	36
188	5.4	73
375	10.7	147
750	21.4	299

Table 5-11. Modeled estimates of BAA in human blood exposed to EGBE in water.

6	Step 4: Calculate the LOAEL HED for a 70-kg human consuming EGBE in 2 L of
7	drinking water/day that results in the same internal dose of EGBE (C_{max} of BAA in
8	blood) calculated for the animal study in step 1.
9	Female rat C_{max} for BAA in blood at LOAEL = 103 μ M
10	$LOAEL_{HED}$ continuous exposure = 7.6 mg/kg-day (calculated by
11	regression of the internal dose versus the dose of EGBE from step 3)
12	The LOAEL _{HED} calculated using the PBPK model is likely a high estimate of the HED,
13	since the model is based on male rat kinetic data, and female rats have been observed to have
14	slightly higher concentrations of BAA in blood than male rats at similar exposure levels. In other
15	words, use of male rat kinetic data results in estimates of the BAA concentrations in human
16	blood associated with an effect (LOAEL _{HED}) that are lower than if female rat kinetic data had
17	been used. In addition, the internal dose surrogate, C_{max} for BAA in blood, is highly dependent
18	on the rate of water ingestion. Since drinking-water exposures are highly complex and variable, a
19	simplifying assumption was used in all simulations that the entire dose of EGBE in drinking
20	water was consumed over a 12-hour period each day corresponding to the awake cycle for both
21	rats and humans. This assumption resulted in higher C_{max} blood concentrations of BAA in both
22	rats and humans than would have been calculated using the original Corley et al. (1994) structure
23	that assumed that drinking-water uptake occurred over a 24 hour/day dosing period.

5.2.2.2. Derivation of POD Using PBPK and BMD Methods

5.2.2.2.1. BMD approach applied to hematological data.

Although a lower LOAEL was reported in male rats, this value gives no indication of the relative slopes of the dose-response curves for males and females. Because this is an important factor for BMD analyses (U.S. EPA, 2000, 1995b), a comparison of the MCV and RBC count results for both male and female rats was performed and demonstrated that female rats are more sensitive to the effects of EGBE than are males. Therefore, dose-response information on these hematological effects in female rats was selected as the basis for the oral RfD BMD analyses discussed below.

8 As was discussed in Section 5.2.1, MCV and RBC count are continuous response

9 measurements of precursor events associated with EGBE exposure and are considered the most

10 appropriate hematologic endpoints for use in a BMD analysis. C_{max} is considered the more

11 appropriate dose metric for use in evaluating the chosen hemolytic endpoints. C_{max} for BAA in

12 arterial blood, as was determined using the PBPK model of Corley et al. (1994) as modified by

13 Corley et al. (1997) (see Section 5.2.2.1). The results of this modeling effort are summarized in

14 Table 5-12.

Table 5-12. Model estimates of BAA blood levels in female rats following oral exposures.

EGBE concentration	Water EGBE intake	Female body	BAA in blood		
in water (ppm)	(L/day)	weight (g)	Dose (mg/kg-day)	C_{max} (μM)	
750	0.0147	188	59	103	
1500	0.0155	185	125	253	
3000	0.0125	180	208	495	
4500	0.0101	164	277	738	
6000	0.0101	150	404	1355	

Source: Corley et al. (1997, 1994).

15 A BMD analysis was performed using EPA BMDS version 1.4.1. As can be seen from the

16 results in Table 5-13, RBC count was the more sensitive of the two hematological endpoints

17 assessed. All models were fit using restrictions and option settings suggested in the EPA BMD

18 technical guidance document (U.S. EPA, 2000) except for the choice of BMR.

Table 5-13. Comparison of female rat RBC count and MCV BMD/BMDL values from an oral subchronic study using modeled blood Cmax (3 months) of the EGBE metabolite BAA as a common dose metric.

Model	$BMD_{05}\left(\mu M ight)$	$BMDL_{05}\left(\mu M\right)$	p Value	AIC*	Scaled residual ^{**}			
<i>RBC</i> count								
1st degree polynomial	393.105	325.835	< 0.0001	-26.323	-2.35			
Power	393.105	325.835	< 0.0001	-26.323	-2.35			
Hill ^{***}	62.3999	36.2595	0.7038	-48.884	0.204			
MCV								
1st degree polynomial	229.179	200.063	< 0.0001	141.85	3.12			
Power	229.179	200.063	< 0.0001	141.85	3.12			
Hill ^{***}	126.844	104.244	0.1757	120.96	-0.315			

 $^*AIC = -2L + 2P$, where L is the log-likelihood at the maximum likelihood estimates for the parameters and P is the number of model degrees of freedom (number of parameters estimated).

**Chi-square residual (measure of how model predicted response deviates from the actual data) for the dose group closest to the BMD scaled by an estimate of its SD provides a comparative measure of model fit near the BMD. Residuals that exceed 2.0 in absolute value should cause questioning of model fit in this region.

** Model choice based on adequate p value (>0.1), visual inspection, low AIC, and low (absolute) scaled residual.

Source: NTP (1993).

1

For continuous response data, the current BMD technical guidelines (U.S. EPA, 2000)

2 suggest the use of 1 SD for the BMR level in the absence of additional information, such as a

3 minimal level of change in the endpoint that is generally considered to be biologically

4 significant. Because the chosen hemolytic endpoints are continuous measurements that have a

5 relatively small historical variance in rats and because low-dose responses for these endpoints

6 were generally near or within 5% of the control mean, the BMDL₀₅ was considered to be a more

7 appropriate POD for derivation of the RfD (U.S. EPA, 2000, 1995b). Higher levels of response

8 (e.g., $\geq 10\%$ reduction) are in the exposure range where other more severe responses related to

9 anemia occur (e.g., RBC decreases, increased reticulocyte counts). Lower levels of response

10 (e.g., 1 SD, approximately a 3% reduction for these data) are relatively distant from the

11 observable data and other responses related to anemia (1 SD data have been provided in

12 Appendix B).

13 The best model fit to the RBC count and MCV data (from visual inspection and

14 comparison of AIC values and scaled residuals near the BMD) was obtained using a Hill model

15 (see Table 5-13). A graphical plot and textual description of the results of the Hill model

16 assessment of RBC count responses in female rats (NTP, 2000) versus corresponding PBPK

17 estimates of C_{max} for BAA in female rat blood are provided in Appendix B.

18 The BMD₀₅ was 62μ M and the BMDL₀₅ was determined to be 36μ M using the 95%

- 19 lower confidence limit of the dose-response curve expressed in terms of the C_{max} for BAA in
- 20 blood. The Corley et al. (1997, 1994) PBPK model was used to back-calculate an HED

(BMDL_{HED}) of 3 mg/kg-day, assuming that rats and humans receive their entire dose of EGBE
 from drinking water over a 12-hour period each day.

5.2.2.2.2. BMD approach applied to hemosiderin endpoint.

3 Due to the limited oral database, EPA believes that a route-to-route extrapolation will 4 increase the confidence in the determination of the RfD POD. Inhalation studies considered for 5 derivation of the RfC are used to supplement the oral database using the route-to-route 6 extrapolation as described below.

5.2.2.3. Route-to-Route Extrapolation from Inhalation Data

7 A route-to-route extrapolation was performed on the data used in the derivation of the 8 RfC from the NTP (2000) chronic inhalation study because of the lack of a chronic oral study for 9 EGBE. As with the species-to-species extrapolation used in the development of the RfC, the dose 10 metric used for species-to-species (rat to human) and route-to-route (inhalation to oral) is the 11 AUC of BAA at 12 months in arterial blood. This dose metric was used for dose-response 12 modeling of chronic inhalation data (Section 5.1.2.2.2) to derive the POD of 133 μ mol-h/L, 13 expressed as a BMDL. The BMDL was then back-calculated using the human PBPK model 14 (Corley et al. 1997; 1994) to obtain an equivalent human oral drinking water dose (BMDL_{HED}) of 15 1.4 mg/kg-day. As for the HED estimations in Sections 5.2.2.1 and 5.2.2.2.1, a simplifying 16 assumption was used that the entire dose of drinking water EGBE was consumed over a 12-hour 17 period each day.

5.2.2.4. Selection of the POD

18 The BMCL chosen for the RfC is used to determine the POD for the RfD. This value is

19 based on a more comprehensive chronic data set and is below the range of estimates from

- 20 available oral data of shorter duration of exposure. Hemosiderin deposition in male rat liver is
- 21 the critical effect chosen for derivation of the RfC. New mode of action information (see Section
- 4.6.3.1) supports the hemosiderin deposition endpoint as an important key event in the proposed
- 23 MOA. The BMCL for the RfC (AUC of 133 μ M-H/L BAA in arterial blood at 12 months) is
- converted using the Corley et al. (1994, 1997) model to an oral human equivalent dose
- 25 (BMDL_{HED}) of 1.4 mg/kg-day. This extrapolated oral value is consistent with and slightly lower
- 26 than the LOAEL_{HED} of 7.6 mg/kg-day and the BMDL_{HED} of 3 mg/kg-day estimated from the
- subchronic oral (NTP, 1993) study. The final calculation of an RfD derived from the
- 28 NOAEL/LOAEL and BMC modeling approaches is presented in Table 5-14.

	Approach*		
Factor ^{**}	LOAEL (NTP, 1993)	$BMDL_{10}$ male rat liver hemosiderin staining (NTP, 2000)	
UF _H	10	10	
UFA	1	1	
UFs	1	1	
UFL	3	1	
UF _D	1	1	
UF (total)	30	10	
POD/UFs = RfD (mg/kg-day)	7.6/30 = 0.3	1.4/10 = 0.14	

Table 5-14. Summary of the application of UFs for RfD derivations using NOAEL/LOAEL and BMD modeling approaches.

^{*}The rationale for the selection of these UFs is discussed in Section 5.1.3 below.

**PODs—LOAEL_{HED} = 7.6 mg/kg-day based on hematological effects from the oral study; the BMDL_{10HED} = 1.4 mg/kg-day, and the approach is based on a route-to-route extrapolation from inhalation data (see Section 5.2.2.3).

5.2.3. RfD Derivation, Including Application of Uncertainty Factors (UFs)

UFs are applied to account for recognized uncertainties in extrapolation from 1 2 experimental conditions to the assumed human scenario (e.g., chronic exposure over a lifetime when subchronic studies are used for deriving a toxicity value). The application of UFs may 3 include the use of a partial UF of $10^{1/2}$ (3.2) based on the assumption that the actual values for 4 5 the UFs are log-normally distributed. Application of these factors in the assessment is such that, 6 when a single partial UF is applied, the factor is rounded to 3 (e.g., the total factor for individual 7 UFs of 3 and 10 would be $30 [3 \times 10]$). When two partial UFs are evoked, however, they are not 8 rounded, such that a UF of 3, 3, and 10 would result in a total uncertainty of 100 (actually $10^{1/2} \times 10^{1/2} \times 10^{1}$). UFs applied for this RfD assessment and the justification for their use follow. 9 A value of 10 was selected to account for variation in sensitivity within the human 10 11 population (UF_H). Potentially susceptible subpopulations include individuals with enhanced 12 metabolism or decreased excretion of BAA, and individuals whose RBC membranes are more 13 susceptible to the lysis caused by BAA. A UF of 10 was used to account for the uncertainty 14 associated with the variability of the human response to the effects of EGBE. Human in vitro 15 studies suggest that the elderly and patients with fragile RBCs would not be more sensitive to the hemolytic effects of EGBE than normal adults, and laboratory animal (rats, calves, and mice) 16 17 studies suggest that older animals are more sensitive than neonates, and that females are more 18 sensitive than males (see Section 4.7). However, actual human responses to EGBE have not been 19 observed in a broad enough range of exposure conditions (e.g., repeat/long-term exposures) and 20 potentially sensitive subjects (e.g., individuals predisposed to hemolytic anemia, infants) to 21 warrant the reduction of the UF_H below the default value of 10. While developmental studies do 22 not reveal increased susceptibility in infants, none of the developmental studies examined fetal or 23 infant blood for signs of effects from prenatal exposure to EGBE.

1 A UF of 1 was used to account for interspecies variation (UF_A) for toxicodynamic and 2 toxicokinetic differences between animals and humans. Traditionally, these components are 3 individually represented by partial UFs of 3 for a total UF of 10 in the absence of chemical-4 specific information; thus, application of a full UF of 10 would depend on two areas of 5 uncertainty: toxicokinetic and toxicodynamic. In this assessment, the toxicokinetic uncertainty is 6 addressed by the determination of an HEC using PBPK modeling. There is in vivo (Carpenter 7 et al., 1956) and in vitro (Udden, 2002; Udden and Patton, 1994; Ghanayem and Sullivan, 1993) 8 information indicating that, toxicodynamically, humans may be less sensitive than rats to the 9 hematological effects of EGBE. Thus, a value of 1 was used to account for toxicodynamic 10 differences between rats and humans.

11 A UF to account for extrapolating from subchronic to chronic exposure (UF_S) was not 12 needed because the RfC was derived from a chronic study.

A UF for LOAEL-to-NOAEL extrapolation was not used because the current approach is to address this factor as one of the considerations in selecting a BMR for BMD modeling. In this case, a BMR of a 10% change in hemosiderin staining was selected under an assumption that it represents a biologically significant change.

17 A value of 1 was used for the database UF_D. While no chronic oral studies or adequate 18 human data are available for EGBE, PBPK models allow for deriving a BMDL from the chronic 19 inhalation study using measured internal dose metrics and then extrapolating it back to an 20 equivalent human oral dose. A comparison of NOAELs and BMDLs from the subchronic oral 21 and chronic inhalation studies using a common internal dose metric (AUC BAA) shows that 22 effects occur at approximately the same internal dose following inhalation and oral exposures 23 adding confidence to the application of the chosen PBPK model (Corley et al., 1997, 1994) to 24 derive an oral RfD from the NTP (2000) chronic inhalation study. Thus, the total UF is 10. The 25 RfD is 1.4 mg/kg-day \div 10 = 0.1 mg/kg-day.

5.2.4. Previous Oral Assessment

The previous IRIS assessment for EGBE was entered into the database on December 30, 1999 and contains an oral RfD of 0.5 mg/kg-day. The RfD was based on the BMD₀₅ HED of 5.1 mg/kg-day for changes in MCV in female F344 rats following a 91-day drinking-water exposure (NTP, 1993). A total UF of 10 was used to account for human variability. This assessment was conducted prior to the adoption of the current BMD technical guidance document (U.S. EPA, 2000c).

5.3. Uncertainties in the Derivation of the Inhalation Reference Concentration (RfC) and Oral Reference Dose (RfD)

The following is a more extensive discussion of uncertainties associated with the RfC and
 RfD for EGBE beyond the quantitative discussion in Sections 5.1.2, 5.1.3, 5.2.2, and 5.2.3. A
 summary of these uncertainties, along with uncertainties specific to the Section 5.4 cancer

4 analysis, is presented in Table 5-15.

5.3.1. Choice of endpoint

5 The impact of endpoint selection on the derivation of the RfC and RfD was discussed in 6 Sections 5.1.2.4 and 5.2.2.4. Comparison RfC values were also calculated (see Section 5.1.4) and 7 are intended to provide information on alternative health effects associated with EGBE exposure. 8 The comparison RfCs ranged from 1–18 mg/m³, depending on whether irritation (forestomach), 9 hematologic effects, or hemosiderin deposition data were used to derive the POD, with the latter 10 endpoint representing the lower end of the RfC range.

5.3.2. Choice of dose metric

11 The AUC for BAA in arterial blood was selected as the appropriate measure of dose due 12 to evidence for a causal association between BAA and hemolysis, between hemolysis and the 13 accumulation of hemosiderin in the liver, and between hemosiderin accumulation in the liver and 14 increased incidence of liver hemangiosarcoma. AUC is considered to be a more appropriate response measure because hemosiderin pigmentation increases in incidence and severity with 15 increased duration (subchronic to chronic), and is believed to be the result of the cumulative 16 17 exposure to EGBE/BAA as opposed to a peak exposure. The corresponding aldehyde of BAA, 18 BAL, was also considered as a choice for an internal dose measure. As discussed in Section 4.6, 19 BAL is the EGBE metabolite considered to have the greatest potential to interact directly with 20 DNA. However, high ADH activity in the liver and forestomach is expected to result in very 21 short residence time and in very low tissue concentrations of BAL; this scenario has been 22 demonstrated in simulations using the Corley et al. (2005b) PBPK model. Also, the Corley et al. 23 (2005b) PBPK model along with the gavage study of Deisinger and Boatman (2004) suggest that 24 the conditions of in vitro assays showing BAL to be clastogenic (e.g., no metabolic activation; 25 high cytotoxic concentrations of BAL) are considered to be of little relevance to the expected 26 target organ (liver) environment (e.g., high metabolic activity; low concentrations of BAL). Use 27 of an alternate measure of internal dose, for instance, a parent compound or C_{max}, would be more 28 difficult to justify based on available empirical information. However, for comparative purposes, a BMD analysis was done on the critical endpoint to determine the impact that choosing C_{max} of 29 30 BAA in blood rather than AUC of BAA in blood would have had on the $BMCL_{10}(HEC)$ 31 derivation. If C_{max} had been used as the dose measure, the BMCL₁₀(HEC) value would have been 1 39 mg/m³, approximately 2.4-fold higher than the 16 mg/m³ BMCL₁₀(HEC) value derived using

2 AUC as the dose measure.

5.3.3. Use of BMC approach

Utilization of the BMC approach has advantages over other approaches to dose-response analysis, such as, the NOAEL/LOAEL approach. These advantages include the capacity of the BMC approach to accommodate study sample size and reflect this in providing confidence bounds to the lower limit on dose. As shown in Tables 5-9 and 5-14, use of the BMC approach on the incidence of chronic hemosiderin deposition resulted in RfC and RfD values about threefold lower than RfC and RfD values that would have been derived via the NOAEL/LOAEL approach.

5.3.4. Choice of model for BMCL derivations

BMCL₁₀ estimates used in the derivation of the RfC, which formed the basis for both the noncancer and cancer quantitative assessments, spanned a twofold range (60–124 μ mol-hour/L) for female rats and threefold range (40–126 μ mol-hour/L) for male rats. All of the models fit reasonably well (*p* values above 0.1). Hence, this range of results can be considered a reflection,

14 in part, of model uncertainty.

5.3.5. Choice of animal to human extrapolation method

15 A PBPK model (Corley et al., 1997) was used to extrapolate animal to human concentration. An AUC blood level of BAA associated with a 10% increase in male mice with 16 hemosiderin pigmentation of 69.6 µmol-hour/L was estimated using the mouse PBPK model; the 17 18 human PBPK model was used to convert back to a human equivalent exposure concentration, or a BMCL₁₀(HEC), of 12 mg/m³. If no PBPK models were available, the BMCL₁₀(HEC) would 19 have been derived by dividing the BMCL₁₀ for external exposure concentration of 75 mg/m³ by 20 21 the threefold pharmacokinetic portion of the animal to human default adjustment factor (U.S. 22 EPA, 1994), resulting in a BMCL₁₀(HEC) of 25 mg/m³. This default value would have been 23 twofold higher than the value derived using the PBPK model.

5.3.6. Route-to-route extrapolation

24 To estimate an oral dose POD for chronic hemosiderin deposition, a route-to-route 25 extrapolation was performed on the inhalation exposure POD used to derive the RfC using a 26 PBPK model and assuming, as is discussed above, that the metric most closely associated with 27 the effects seen is the AUC measure in blood of BAA. One way of characterizing the uncertainty 28 associated with this approach is to compare dose levels (BMCL values) using this metric for 29 hemolytic effects-assumed to be associated with chronic hemosiderin deposition-derived from 30 (1) an existing oral subchronic NTP (1993) study; or (2) from a model estimating this metric from an existing inhalation subchronic NTP (2000, 1998) study. This analysis was performed 31

- 1 (see Section 5.2.2.3) and shows that the values derived using the second procedure were
- 2 consistently lower than using the former (i.e., were more potent by a factor of up to fourfold).
- 3 Thus, estimates using this procedure for route-to-route extrapolation would uniformly
- 4 overestimate the toxicity value and would result in lower RfD estimates.

5.3.7. Statistical uncertainty at the POD

5 Parameter uncertainty can be assessed through CIs. Each description of parameter

6 uncertainty assumes that the underlying model and associated assumptions are valid. For the

7 linear multistage model applied to the male mouse hemosiderin data, there is a reasonably small

8 degree of uncertainty at the 10% excess incidence level (the POD for derivation of the RfC),

9 with the 95%, single-sided lower confidence limit (BMCL) being about 30% below the

10 maximum likelihood estimate of the BMC.

5.3.8. Choice of bioassay

11 The NTP (2000) inhalation study was used for development of the RfC and RfD. This 12 was a well-designed study, conducted in both genders in two species with an adequate number of 13 animals per dose group and with examination of appropriate toxicological endpoints in both 14 genders of rats and mice. Alternative comparable bioassays were unavailable.

5.3.9. Choice of species/gender

The RfC was based on the incidence of liver hemosiderin pigmentation in male rats, the species and gender most sensitive to this effect (NTP, 2000). This event also occurs in female rats and in mice, and is thought to be a precursor to the observed increase in liver tumors in male mice.

¹⁰ If the RfC had been based on increased incidence of liver hemosiderin in another species/gender, such as male mice, a higher RfC value would have been derived. Similarly, the RfC would also have been higher had it been based on forestomach irritation, an effect less sensitive than hemosiderin deposition but considered to be a precursor event leading to the increase in incidence of forestomach squamous cell papillomas and one high-dose carcinoma observed by NTP (2000) in female mice.

5.3.10. Human relevance of noncancer responses observed in mice

- The effects of hemosiderin deposition and forestomach irritation may both have qualitative relevance to humans. However, for reasons discussed in Section 4.5, the exposure concentrations that would be necessary to cause these effects in humans, if attainable at all, are likely to be much higher than the RfC/RfD and well above concentrations necessary to cause
- 29 these effects in mice.

¹⁰ Increased liver hemangiosarcomas were not observed in the NTP (2000) chronic study of rats or female mice. Possible reasons for this species and gender specificity are discussed in Section 4.6 and 4.7.2, respectively.

5.3.11. Human population variability

The extent of interindividual variability associated with EGBE metabolism is not well 1 2 characterized in humans. As is discussed in Section 4.7, the hemolytic effect of EGBE is 3 presumed to be caused by the interaction of its primary metabolite, BAA, with the RBC 4 membrane. Potentially susceptible subpopulations or life stages would include individuals with 5 enhanced metabolism or decreased excretion of BAA. In addition, individuals whose RBC 6 membranes are more susceptible to the lysis caused by BAA could be more sensitive to EGBE. 7 However, RBCs from normal, aged, sickle-cell anemia, and hereditary spherocytosis patients 8 were no more sensitive to the hemolytic effects of BAA than RBCs from healthy volunteers 9 (Udden, 1994). As is discussed further in Section 4.7, some potentially susceptible 10 subpopulations or life stages have not been tested, and, when combined with the lack of 11 understanding about EGBE's mechanism of hemolytic action, this represents a considerable 12 source of uncertainty and forms the principal basis for the 10-fold UF applied to derive the RfD 13 and RfC values.

5.4. Cancer Assessment

14 In accordance with the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), 15 the method used to characterize and quantify cancer risk from a chemical depends on what is 16 known about the MOA of carcinogenicity and the shape of the cancer dose-response curve for 17 that chemical. An assumption of linearity is appropriate when evidence supports an MOA of 18 gene mutation due to DNA reactivity or supports an MOA that is anticipated to be linear. The 19 linear approach is used as a default option if the MOA of carcinogenicity is not understood. The 20 nonlinear approach "can be used for cases with sufficient data to ascertain the mode of action and to conclude that it is not linear at low doses..." (U.S. EPA, 2005). Alternatively, the MOA 21 22 may theoretically have a threshold, that is, the carcinogenicity may be a secondary effect of 23 toxicity that is itself a threshold phenomenon.

24 In the case of EGBE, the MOA of carcinogenicity for hepatic hemangiosarcoma, 25 hepatocellular adenoma and carcinoma, and forestomach tumor formation in animals is 26 reasonably well understood. A reference concentration and reference dose approach has been 27 used for EGBE because "When adequate data on mode of action provide sufficient evidence to 28 support a nonlinear mode of action for the general population and/or any subpopulations of 29 concern, a different approach — a reference dose/reference concentration that assumes that 30 nonlinearity – is used." (U.S. EPA, 2005). It is recognized, however, that while this approach fits 31 this case, other nonlinear approaches may be appropriate in other settings. Available data indicate 32 that EGBE is not likely to be mutagenic and that it is not expected to produce rodent tumors via a 33 mutagenic MOA. Rather, there is evidence that carcinogenic responses observed in animals are

1 associated with erythrocyte hemolysis, leading to oxidative damage and increased hepatocyte 2 and endothelial cell proliferation and initiation for the liver tumors, and associated with the 3 formation of BAA, an acidic metabolite, that leads to regenerative hyperplasia in response to 4 irritation for the forestomach tumors. Because cytolethality occurs only at exposure levels above 5 some critical dose, a nonlinear (threshold) approach is considered to be the most appropriate 6 method for characterizing the cancer risk from EGBE.

7 As discussed in Sections 4.2 and 4.6, there are currently no human studies addressing the 8 potential carcinogenicity of EGBE. A 2-year inhalation bioassay in mice and rats (NTP, 2000) 9 reported some evidence of carcinogenic activity in male B6C3F1 mice based on increased incidences of hemangiosarcoma of the liver and an increase in the incidence of hepatocellular 10 11 carcinoma, as well as some evidence of carcinogenic activity in female B6C3F1 mice, based on 12 increased incidences of forestomach squamous cell papilloma or carcinoma (mainly papilloma). 13 The study also reported no evidence of carcinogenic activity in male F344/N rats and equivocal 14 evidence of carcinogenic activity in female F344/N rats based on increased combined incidences 15 of benign and malignant pheochromocytoma (mainly benign) of the adrenal medulla. The 16 hypothesized MOA for the induction of hepatic hemangiosarcomas and hepatocellular 17 carcinomas reported in male mice exposed to EGBE may comprise a sequence of events that are 18 dose-dependent. First, EGBE is metabolized to the carboxylic acid, which then hemolyses RBCs. 19 This event leads to the release of excess iron that in turn could result in iron-induced formation 20 of ROS and subsequent oxidative damage to target tissues within the liver. Induction of cell 21 proliferation and neoplasm formation follows. This sequence of events is considered necessary 22 for the formation of the observed neoplasms. Strategies intended to control or omit any of these 23 key events, including the initial hemolytic event, would interrupt the process and prevent 24 formation of neoplasms. For these reasons, formation of neoplasms in humans would likely be 25 prevented by establishing levels of EGBE exposure in the dose range that does not result in the 26 initial hemolytic events and subsequent ROS-mediated cellular damage. Thus, for the assessment 27 of human cancer risk associated with the formation of hemangiosarcomas and hepatocellular 28 adenomas and carcinomas in animals, the RfD and RfC derived in Sections 5.1 and 5.2 should be 29 considered protective, as the carcinogenicity may be a secondary effect of toxicity that is itself a threshold phenomenon. 30 31 Available data suggest that the MOA for the induction of forestomach tumors reported in

Available data suggest that the MOA for the induction of forestomach tumors reported in female mice exposed to EGBE is dependent on the initial formation of the irritating metabolite BAA. This acidic metabolite produces chronic cytotoxicity, which results in compensatory epithelial cell regeneration. Chronic cell proliferation in preneoplastic cells is in turn associated with the formation of forestomach papillomas and carcinomas. In addition, the available data indicate that BAA may be preferentially formed in the forestomach due to the presence of levels of ADH that are higher than those found in the human stomach or esophagus. BMD modeling of

April 2008

103 DRAFT-DO NOT CITE OR QUOTE

1 the dose response for epithelial hyperplasia in female mice forestomachs was performed as a

- 2 comparison to reference values derived for precursor effects in the liver as discussed above and
- 3 is presented in Appendix C. The analysis in Appendix C shows that, had hyperplastic effects in
- 4 female mice been used as a POD, the resultant RfD and RfC values would have been much
- 5 higher than the RfD and RfC values derived in Sections 5.1 and 5.2 using hemosiderin

6 deposition as the critical effect for EGBE exposure. Thus, the analysis indicates that the RfD and

7 RfC based on liver effects would also be protective of forestomach toxicity. The exposure

8 concentrations that would be necessary to cause these effects in humans, if attainable at all, are

9 likely to be much higher than the RfC and RfD.

10 Female rats reported a marginally significant trend for pheochromocytomas, and the high 11 dose frequencies reported in the rats were only slightly different from the upper range of 12 historical controls (see Section 4.6). In addition, the histopathologic data indicated there was 13 difficulty distinguishing pheochromocytomas from non-neoplastic adrenal medullary 14 hyperplasia. Thus, these lesions are interpreted with caution as tumors. Given the marginal dose 15 response, lack of tumor evidence in any other organ system of the rats, and reported difficulties in distinguishing pheochromocytomas from non-neoplastic adrenal medullary hyperplasia, this 16 17 tumor was not given significant weight in the qualitative or quantitative assessment of EGBE 18 cancer potential.

5.4.1. Uncertainties in Cancer Risk Assessment

19 The cancer assessment of EGBE is based largely on the premise that key events in the 20 MOAs proposed for mice (forestomach irritation and hemolysis leading to increased hemosiderin 21 deposition) are not likely to occur in humans at concentrations at or below the RfC and RfD 22 values. Uncertainties in the RfC and RfD derivations are addressed in part in Sections 5.1.2, 23 5.1.3, 5.2.2, 5.2.3, and 5.3. This section will discuss additional uncertainties relative to the 24 human relevance of cancer responses observed in mice and the extrapolation method employed 25 for the estimation of low-dose cancer risk. All of these uncertainties are summarized in Table 26 5-15.

Consideration	Potential impact [*]	Decision	Justification [*]
Choice of low- dose extrapolation method	A linear low-dose extrapolation would likely drive the risk estimation when combined with site- specific exposure data	Nonlinear approach; RfC and RfD are considered protective of the key events leading to cancer.	Proposed key events in the two MOAs (forestomach irritation and hemolysis leading to ↑ liver hemosiderin) are not likely to occur in humans at the RfC or RfD.
Choice of endpoint	Use of forestomach endpoint could \uparrow RfC by up to 18-fold (see Section 5.3).	RfC is based on the most sensitive endpoint, increased liver hemosiderin.	Chosen endpoint is considered most relevant due to forestomach toxicokinetic and exposure issues.
Choice of dose metric	Alternatives could \uparrow or \downarrow RfC/RfD (e.g., use of C _{max} BAA increases RfC by two to threefold).	AUC for BAA in arterial blood.	Evidence for a causal association between the proposed key steps of BAA and hemolysis leading to ↑ liver hemosiderin and ↑ liver tumors. AUC chosen because hemosiderin ↑ with cumulative exposure to EGBE/BAA.
POD derivation method	RfC/RfD threefold lower than for NOAEL.	BMD method used.	Advantages include capacity to account for sample size and to provide confidence bounds on dose
Choice of model for BMCL derivation	Alternative models could \uparrow RfC up to threefold (see Section 5.3).	Multistage (1st degree) model chosen.	The best-fitting model was chosen based on EPA (2000) BMD technical guidance.
Choice of animal to human extrapolation method	Alternatives could \uparrow or \downarrow RfC/RfD (e.g., default would \uparrow RfC by twofold) (see Section 5.3).	A PBPK model was used to extrapolate animal to human concentrations.	Use of a PBPK model reduces uncertainty associated with the animal to human extrapolation. AUC blood levels of BAA are an appropriate dose metric, and a peer-reviewed and verified PBPK model exists that estimates this metric.
Statistical uncertainty at POD	POD would be ~40% higher if BMD were used.	BMDL used per EPA BMD guidance (U.S. EPA, 2000).	Limited size of bioassay results in sampling variability; lower bound is 95% CI on administered exposure.
Choice of bioassay	Alternatives could \uparrow or \downarrow RfC/RfD.	NTP (2000) study.	Alternative bioassays were inadequate.
Choice of species/ gender	RfC would be ↑ if based on another species/gender.	RfC is based on the most sensitive endpoint, increased liver hemosiderin, in the most sensitive species and gender, male rats.	experience an increase in liver tumors from EGBE exposure. If one relies on the MOA, however, liver hemosiderin increase in male rats is the appropriate key event and species to utilize for the RfC. Female mice exhibit forestomach papilloma but at higher doses.
Human relevance of rodent tumor data	If MOAs for tumors from EGBE were deemed not relevant, cancer descriptor would be "suggestive of human carcinogenic potential."	MOAs for liver and forestomach tumors are used.	Although EGBE has some evidence for liver tumors in male mice and forestomach tumors in female mice, the MOAs describe rationales as to why humans are unlikely to experience appreciable risk at environmental concentrations.
Human population variability	Low-dose toxicity ↑ to an unknown extent.	10-fold UF applied to derive the RfD and RfC values.	10-fold UF is applied principally because of limited data on human variability or potential susceptible subpopulations.

 Table 5-15. Summary of uncertainty in the EGBE noncancer and cancer risk assessments.

* \uparrow = increase; \downarrow = decrease.

5.1.1.1. Choice of low-dose extrapolation method

1 The MOA is a consideration in estimating risks. A linear low-dose extrapolation approach 2 was not considered to be optimal for the estimation of human carcinogenic risk associated with 3 EGBE exposure because of the physicochemical properties of EGBE, toxicokinetic limitations, 4 specific MOAs articulated earlier, and limitations in data to parameterize appropriate models. It 5 should be noted that the demonstration that a chemical is not mutagenic is insufficient, alone, to 6 postulate a nonlinear dose response. Key events in the MOAs proposed for mice (forestomach 7 irritation and hemolysis leading to increased hemosiderin deposition) are not likely to occur in 8 humans at concentrations at or below the RfC and RfD values. This assumes that the proposed 9 MOAs in mice are reasonably correct. If, for instance, hemosiderin accumulation in the mouse 10 liver is not the result of increased hemolysis but of EGBE interaction with other cell types, a 11 more direct, linear MOA for the observed increase in male mouse hemangiosarcomas might be 12 hypothesized. In order to illustrate the predicted cancer risk under such a scenario, the cancer 13 risks associated with the tumor types that were increased following EGBE exposure were 14 calculated using the default approach of low-dose linear extrapolation outlined in the cancer 15 guidelines (U.S. EPA, 2005). The results of this linear analysis are presented in Table 5-16. 16 For illustrative purposes, an estimate of the increased cancer risk at the RfC (1.6 mg/m^3) 17 was calculated using the inhalation unit risk, for hepatocellular tumors in male mice, that was 18 derived using a default linear low-dose extrapolation approach. The estimated increased cancer risk at the RfC in this comparison exercise would be 1.6 mg/m³ x 4.8 x $10^{-4} = 7.6 \times 10^{-4}$. This 19 20 value is only for illustrative purposes and indicates the differences in the two approaches. It 21 should not be misconstrued as an estimate of the cancer risk at the RfC since the default linear 22 approach is not recommended.

 Table 5-16. Illustrative potency estimates for tumors in mice, using a linear analysis approach.

	BMDL _{10HEC} (mg/m ³)*	Slope factor 0.1/BMDL _{10HEC} (risk/mg-m ³)
Hepatocellular carcinoma (males)	208	4.8×10^{-4}
Hemangiosarcomas (males)	575	1.7×10^{-4}
Papilloma or carcinoma of the forestomach (females)	544	1.8×10^{-4}

^{*}BMDL_{10HEC} values were calculated using AUC as the dose metric.

5.4.1.2. Human relevance of cancer responses observed in mice

23 The hypothesized MOAs for EGBE-induced liver tumors observed in male mice and

EGBE-induced forestomach tumors observed in female mice may both have qualitative

1 relevance to humans. However, for reasons discussed in Section 4.6, the exposure concentrations

2 that would be necessary to cause these effects in humans, if attainable at all, are likely to be

3 much higher than the RfC and RfD.

5.5. Potential Impact of Select Uncertainties on the RfC

In this assessment, the RfC forms the basis for the RfD. The range of possible results associated with some of the areas of uncertainty in the RfC derivation can be estimated (see Sections 5.3 and 5.4). Figure 5-4 graphically illustrates the change in the RfC that would result had particular choices, other than those presented in this assessment, been made (see summary in Table 5-15). These specific areas were presented in this illustration because there are data available that could be used to quantify their contribution to the uncertainty in the noncancer and cancer assessments.

11 The area of uncertainty that has the potential to have the greatest impact on the EGBE 12 assessment is that which is associated with the approach used to extrapolate human cancer risk 13 from the available rodent studies, that is, if human cancer risk had been estimated from a linear 14 extrapolation of responses observed in rodent studies. Figure 5-4 provides a graphic of the areas 15 of uncertainty, described in Table 5-15, for which there is quantitative information and impact on the RfC can be estimated. The "Cancer Approach" value in Figure 5-4 represents the difference 16 in the dose that was selected for the RfC and the dose that would represent a 10^{-5} increased 17 cancer risk if a default linear low-dose extrapolation approach were to be used. In this instance, 18 the comparison indicates that the dose associated with a 10^{-6} cancer risk, estimated via the linear 19 20 dose-response method, using the inhalation unit risk for hepatocellular tumors in male mice as 21 indicated in Table 5-16, is 56-fold lower than the RfC. Note that the default linear approach is 22 not recommended. 23 These discussions and illustrative tools should not be viewed as a comprehensive analysis 24

of all possible uncertainty considerations; rather, they exemplify what are believed to be
 important areas of uncertainties for which data are available. This characterization is presented in

26 an effort to make apparent the limitations of the assessment and to aid and guide the risk assessor

20 an error to make apparent the minitations of the assessment and to and and guide the fisk as

27 in the ensuing steps of the risk assessment process.




Figure 5-4. Potential impact of select uncertainties on the RfC for EGBE.

^{*}Illustrates the dose that would represent a 10^{-6} increased cancer risk if a default linear low-dose extrapolation approach were used. This dose is expressed as X-fold change in the RfC.

6. Major Conclusions in the Characterization of Hazard and Dose Response

6.1. Human Hazard Potential

EGBE is a clear, miscible solvent used in formulating cleaning products and protective
 coatings. It is metabolized primarily to the carboxylic acid, BAA, the proximate toxicant, in both
 humans and animals. BAA and its conjugates are readily excreted in the urine.

Hemosiderin deposition in the liver of male rats, as a consequence of hemolysis, is
identified as the critical endpoint of concern in toxicological studies on EGBE. Toxicologically,
this effect increases with both exposure concentration and duration, is not compensated for (as
with hemolysis), and is considered to be a clearly pathological finding. Mechanistically, this
effect is at the interface between noncancer and cancer effects from exposure to EGBE.

9 Observations regarding the potential relevance of EGBE toxicity to humans include the 10 insensitivity of human RBCs to the hemolytic effects of EGBE and its metabolite, BAA. While it 11 is established that humans can experience hemosiderin deposition in the liver as a consequence 12 of excessive hemolysis (Iancu et al., 1976), the relative insensitivity of human blood to the 13 effects of EGBE have been demonstrated in numerous in vitro studies through the use of either 14 whole blood or washed erythrocytes (e.g., Udden, 2002; Ghanayem and Sullivan, 1993). Humans 15 appear significantly less sensitive to the hemolytic toxicity of EGBE than are typical laboratory species, such as mice, rats, or rabbits, with reports from analyses of isolated RBCs demonstrating 16 17 that human RBCs are 40- to 150-fold less sensitive than rat RBCs (Udden, 2002). These 18 observations are inclusive of human RBCs from individuals with hereditary spherocytosis and 19 sickle cell anemia, conditions characterized by RBC sensitivity to hemolysis. Available in vivo 20 information with human exposure supports this species disparity in sensitivity to the hemolytic 21 effects of EGBE. Male rats in one study (NTP, 1993) experienced mild liver effects at a drinking-22 water dose lower than that which caused observable hemolytic effects. Available human toxicity 23 data show that the primary effects after acute oral ingestion of large doses of EGBE (most often 24 combined with other solvents) are reversible metabolic acidosis from the production of BAA and 25 some hematological changes. Occupational exposure to low levels of EGBE did not cause 26 adverse changes in hepatic, renal, or hematologic parameters (Haufroid et al., 1997). 27 Due to the known reproductive toxicity (i.e., toxicity to male testes and sperm) of two

other glycol ethers, EGME and EGEE, the reproductive toxicity of EGBE has been studied in a
variety of well-conducted oral studies (NTP, 1993; Exon et al., 1991; Heindel et al., 1990; Foster
et al., 1987; Grant et al., 1985; Nagano et al., 1984, 1979) and inhalation studies (NTP, 2000;

several developmental studies have addressed EGBE's toxicity from conception to sexual
maturity, including toxicity to the embryo and fetus, following oral exposures (Sleet et al., 1989;
Wier et al., 1987), inhalation exposures (Nelson et al., 1984; Tyl et al., 1984), and dermal
exposures (Hardin et al., 1984) to rats, mice, and rabbits. EGBE did not cause adverse effects in
any reproductive organ, including testes, in any study. In a two-generation reproductive toxicity
study, fertility was reduced in mice only at very high maternally toxic doses (>1000 mg/kg).
Maternal toxicity related to the hematologic effects of EGBE and relatively minor developmental

Nachreiner, 1994; Doe, 1984; Dodd et al., 1983) using rats, mice, and rabbits. In addition,

9 effects have been reported in developmental studies. No teratogenic effects were noted in any of

the studies. It can be concluded from these studies that EGBE is not significantly toxic to the reproductive organs (male or female) of either parents or to the developing fetuses of laboratory animals.

13 No reliable human epidemiological studies are available that address the potential 14 carcinogenicity of EGBE. The NTP (2000) performed a 2-year inhalation bioassay with rats and mice and found no evidence of carcinogenic activity in male F344/N rats and equivocal evidence 15 of carcinogenic activity in female F344/N rats, based on increased combined incidences of 16 17 benign and malignant pheochromocytoma (mainly benign) of the adrenal medulla. The 18 researchers reported some evidence of carcinogenic activity in male B6C3F1 mice, based on an 19 increased incidence of hemangiosarcoma of the liver and an increase in the incidence of 20 hepatocellular carcinoma that may have been exposure related. They also reported some 21 evidence of carcinogenic activity in female B6C3F1 mice, based on an increased incidence of 22 forestomach squamous cell papilloma or carcinoma (mainly papilloma). Based on its physical-23 chemical properties, toxicokinetic and dynamic factors, and MOA information, under existing 24 EPA guidelines (U.S. EPA, 2005), EGBE is judged not likely to be carcinogenic to humans at 25 expected environmental concentrations (see Section 4.6). The MOAs presented for the animal 26 tumors indicate that both high doses and sustained periods of exposure are necessary for the 27 carcinogenic response. The available human exposure/response information indicates that these 28 conditions are unlikely to occur because the primary response of humans to high oral doses of 29 EGBE, as shown in the case studies in Section 4.1 is metabolic acidosis, which, if not treated, 30 can lead to shock and eventually death. Further, based on simulations from PBPK modeling, the 31 maximum blood concentrations of BAA that could be produced in humans following exposure to 32 a saturated atmosphere of EGBE would be below those needed to produce hemolysis (Corley et 33 al., 2005a). Evidence from the only human inhalation exposure study available showed that, 34 while nasal and ocular irritation were reported in research subjects exposed to up to 195 ppm, no 35 changes in erythrocyte fragility were observed (Carpenter et al., 1956). For a more complete 36 discussion of the carcinogenic potential of EGBE, see Section 4.6.

1

6.2. Dose Response

The quantitative estimates of human risk from lifetime exposure to EGBE are based on
 animal experiments, as no relevant human data exist.

For derivation of the RfC, the most sensitive endpoint for dose-response assessment is the effect of inhalation exposure on hemosiderin staining in Kupffer cells, as reported in the study by NTP (2000). The RfC based on this endpoint is 1.6 mg/m^3 . This concentration is based on the human equivalent BMCL₁₀ of 16 mg/m^3 , which was back-calculated from rat data using the BMD and PBPK approach and the application of a tenfold UF.

8 The overall confidence in the RfC assessment is medium to high. Higher confidence is 9 placed in the RfC values derived from internal dose measures (PBPK method and combined 10 PBPK/BMC method) because pharmacokinetic differences between rats and humans were 11 accounted for using PBPK models (Lee et al., 1998; Corley et al., 1997, 1994) and actual measurements of internal blood concentrations in test aniumals of interest (Dill et al., 1998). 12 13 Higher confidence is placed on the NTP (2000) study; because it was a chronic study, it 14 employed both male and female rats and mice, it had a wide range of exposure levels, and 15 animals were observed twice daily. Medium-to-high confidence is placed on the database, 16 because data are available for a variety of animal species, including humans. While the database 17 lacks long-term human studies, the available short-term human controlled studies and case 18 reports as well as laboratory animal and in vitro studies provide evidence to suggest that, with 19 respect to the hemolytic effects of EGBE, long-term human exposures would be no more adverse 20 than long-term rat exposures. Confidence is not high, because the potential for effects in humans 21 from repeat, long-term exposures has not been investigated.

22 In the derivation of the RfC, a tenfold UF was applied, which was intended to account for 23 intrahuman variability. A value of 10 was selected to account for variation in sensitivity within 24 the human population (UF_H). Potentially susceptible subpopulations include individuals with 25 enhanced metabolism or decreased excretion of BAA and individuals whose RBC membranes 26 are more susceptible to the lysis caused by BAA. A UF of 10 was retained to account for the 27 uncertainty associated with the variability of the human response to the effects of EGBE. Human 28 responses to EGBE have not been observed in a broad enough range of exposure conditions (e.g., 29 repeat/long-term exposures) and potentially sensitive subjects (e.g., individuals predisposed to 30 hemolytic anemia, infants) to warrant the reduction of the UF_H below the default value of 10. 31 For derivation of the RfD, the BMD PBPK approach, along with the same internal dose 32 metric used in the derivation of the RfC, was used. As with the RfC, the RfD was based on 33 hepatic hemosiderin deposition data. The RfD based on this endpoint is 0.1 mg/kg-day. This 34 value was obtained by using a route-route extrapolation from the RfC, and dividing the estimated 35 human equivalent by a UF of 10. The HED was estimated using the AUC values for BAA in 36 blood as the dose metric, and calculating a BMDL₁₀ of 133 µM-hour/L BAA in arterial blood at April 2008 111 DRAFT-DO NOT CITE OR QUOTE

12 months. The PBPK model was then used to back-calculate an HED, assuming that rats and
 humans received their entire dose of EGBE from drinking water over a 12-hour period each day.

3 The overall confidence in the RfD assessment is medium to high. The RfD value has 4 been calculated for EGBE using a route-to-route extrapolation from the inhalation PBPK/BMC 5 method used to derive the RfC. A higher confidence is placed in the RfD values derived from this 6 combined method, since pharmacokinetic differences between rats and humans were accounted 7 for using a validated PBPK model (Corley et al., 1997 1994). High confidence is placed on the 8 NTP (2000) study because it was a chronic study, it employed both male and female rats and 9 mice, it had a wide range of exposure levels, and animals were observed twice daily. Medium-to-10 high confidence is placed on the database, because data are available for a variety of animal 11 species, including humans. While the database lacks long-term human studies, the available 12 short-term human controlled studies and case reports and laboratory animal and in vitro studies 13 provide ample evidence to suggest that, with respect to the hemolytic effects of EGBE, long-term 14 human exposures would be no more adverse than long-term rat exposures. Confidence is not 15 high, because the potential for effects in humans from repeat, long-term exposures has not been investigated. 16

17 A value of 10 was selected to account for variation in sensitivity within the human 18 population (UF_H). Potentially susceptible subpopulations include individuals with enhanced 19 metabolism or decreased excretion of BAA and individuals whose RBC membranes are more 20 susceptible to the BAA-induced hemolysis, the principal precursor event to the critical effect of 21 hemosiderin deposition in the liver. A UF of 10 was retained to account for the uncertainty 22 associated with the variability of the human response to the effects of EGBE. Human responses 23 to in vivo EGBE exposure have not been observed in a broad enough range of exposure 24 conditions (e.g., repeat or long-term exposures) and potentially sensitive subjects (e.g., 25 individuals predisposed to hemolytic anemia, infants) to warrant the reduction of the UF_H below 26 the default value of 10. For a more detailed discussion of the RfD UF, see Section 5.2.3. 27 Information regarding the reported liver and forestomach tumors observed in laboratory 28 animals exposed to EGBE indicates that the modes of action underlying these lesions are

29 nonmutagenic and include intermediate processes that have nonlinear dose-response

30 characteristics. Control or omission of these intermediate events would likely be sufficient to

31 prevent the occurrence of such tumors in humans, including potentially sensitive subpopulations

32 such as children.

¹¹ Application of nonlinear quantitative assessment methods indicate that the noncancer
 RfD (0.1 mg/kg/day) and RfC (1.6 mg/m³) values developed for EGBE are considered protective

¹¹These analyses are consistent with the nonlinear assessment approach described in the 2005 cancer guidelines (U.S. EPA, 2005).

- 1 of these key events and would serve to prevent the occurrence of carcinogenic effects in humans.
- 2 The exposure concentrations that would be necessary to cause these effects in humans, if
- 3 attainable at all, are likely to be much higher than the RfC and RfD.
- 4 The estimation of uncertainty in this analysis is based on the alternative approaches for
- 5 estimating the dose response that are discussed and shown in Sections 5.1.3 and 5.2.3 for the RfC
- 6 and RfD, respectively. These alternatives include using the NOAEL approach combined with the
- 7 measure of the internal dose estimated with the PBPK model and the BMC approach combined
- 8 with the same PBPK model. Table 5-9 and Table 5-14 show the uncertainty associated with each
- 9 of these approaches for the RfC and RfD, respectively. Other uncertainties associated with the
- 10 noncancer and cancer assessments presented in this toxicological review are summarized in
- 11 Table 5-15 and in Sections 5.4.1 and 5.5.

References

- Allen, DJ. (1993a) Ethylene glycol monobutyl ether: acute dermal toxicity (limit test) in the rat. Safepharm Laboratories, Ltd., Derby, United Kingdom, for Mitsubishi Petrochemical Co., Ltd., Tokyo, Japan; Project No. 13/540.
- Allen, DJ. (1993b) Ethylene glycol monobutyl ether: acute dermal toxicity (limit test) in the rat. Safepharm Laboratories, Ltd., Derby, United Kingdom, for Mitsubishi Petrochemical Co., Ltd., Tokyo, Japan; Project No. 13/542.
- Allen, DJ. (1993c) Ethylene glycol monobutyl ether: acute dermal toxicity test in the rabbit. Safepharm Laboratories, Ltd., Derby, United Kingdom, for Mitsubishi Petrochemical Co., Ltd., Tokyo, Japan; Project No. 13/605.
- Allen, DJ. (1993d) Ethylene glycol monobutyl ether: acute dermal toxicity test in the rabbit. Safepharm Laboratories, Ltd., Derby, United Kingdom, for Mitsubishi Petrochemical Co., Ltd., Tokyo, Japan; Project No. 13/606.
- Bachowski, S; Kolaga, KL; Xu, Y; et al. (1997) Role of oxidative stress in the mechanism of dieldrin=s hepatotoxicity. Ann Clin Lab Sci 27:196–209.
- Bartnik, FG; Reddy, AK; Klecak, G; et al. (1987) Percutaneous absorption, metabolism, and hemolytic activity of n-butoxyethanol. Fundam Appl Toxicol 8:59–70.
- Bauer, P; Weber, M; Mur, JM; et al. (1992) Transient non-cardiogenic pulmonary edema following massive ingestion of ethylene glycol butyl ether. Intensive Care Med 18:250–251.
- Bennette, D. (2001) The distribution of radioactivity in the female B6C3F1 mouse following a single intravenous injection of 2-butoxy[1-14c]ethanol. Central Toxicology Laboratory, Alderly Park, Macclesfield, Cheshire, United Kingdom; Report No. Ctl/r/1446.
- Berliner, N; Duffy, TP; Abelson, HT. (1999) Approach to adult and child with anemia. In: Hoffman, R; ed. Hematology: basic principles and practice. 2nd edition. New York, NY: Churchill Livingstone; pp. 468– 483.
- Browning, J; Gannon, BJ; O=Brien, P. (1983) The microvasculature and gastric luminal pH of the forestomach of the rat: a comparison with the glandular stomach. Int J Microcirc Clin Exp 2:109–118.
- Bueld, JE; Netter, KJ. (1993) Factors affecting the distribution of ingested propionic acid in the rat forestomach. Food Chem Toxicol 31:169–176.
- Burkhart, KK; Donovan, JW. (1998) Hemodialysis following butoxyethanol ingestion. Clin Tox 36:723–725.
- Carpenter, CP; Pozzani, UC; Wiel, CS; et al. (1956) The toxicity of butyl cellosolve solvent. AMA Arch Ind Health 14:114–131.
- Chiewchanwit T; Au, WW. (1995) Mutagenicity and cytotoxicity of 2-butoxyethanol and its metabolite, 2-butoxyacetaldehyde, in Chinese hamster ovary (CHO-AS52) cells. Mutat Res 334:341–346.
- Clayson, DB; Iverson, F; Nera, EA; et al. (1991) Early indicators of potential neoplasia produced in the rat forestomach by nongenotoxic agents: the importance of induced cellular proliferation. Mutat Res 248:321–331.
- Cohen AD; Cagnano E; Vardy DA. (2001) Cherry angiomas associated with exposure to bromides. Dermatology 202(1):52–53.

- Commonwealth of Australia. (1996) National Industrial Chemicals Notification and Assessment Scheme (NICNAS)—priority existing chemical no. 6—2-butoxyethanol in cleaning products. Australian Government Publishing Service, Canberra, Australia.
- Corley, RA; Bormett, GA; Ghanayem, BI. (1994) Physiologically-based pharmacokinetics of 2-butoxyethanol and its major metabolite, 2-butoxyacetic acid, in rats and humans. Toxicol Appl Pharmacol 129:61–79.
- Corley, RA; Markham, DA; Banks, C; et al. (1997) Physiologically-based pharmacokinetics and the dermal absorption of 2-butoxyethanol vapors by humans. Toxicol Appl Pharmacol 39:120–130.
- Corley, RA; Weitz, KK; Mast, TJ; et al. (1999) Final report: Short-term studies to evaluate the dosimetry and modes of action of 2-butoxyethanol in B6C3F1 mice, with cover letter dated 08/06/1999. Battelle Project No. 29753. Submitted under TSCA Section; EPA Document No. FYI-OTS-1099-1363; NTIS No. OTS0001363.
- Corley, RA; Grant, DM; Farris, E; et al. (2005a) Determination of age and gender differences in biochemical processes affecting the disposition of 2-butoxyethanol and its metabolites in mice and rats to improve PBPK modeling. Toxicol Lett 156:127–161.
- Corley, RA; Bartels, MJ; Carney, EW; et al. (2005b) Development of a physiologically based pharmacokinetic model for ethylene glycol and its metabolite, glycolic acid, in rats and humans. Toxicol Sci 85:476–490.
- Corthals, SM; Kamendulis, LM; Klaunig, JE. (2006) Mechanism of 2-butoxyethanol-induced hemangiosarcomas. Toxicol Sci 92(2):378–386.
- Dean, BS; Krenzelok, EP. (1991) Critical evaluation of pediatric ethylene glycol monobutyl ether poisonings. Vet Hum Toxicol 33:362.
- Deisinger, PJ; Boatman, RJ. (2004). In vivo metabolism and kinetics of ethylene glycol monobutyl ether and its metabolites, 2-butoxyacetaldehyde (BAL) and 2-butoxyacetic acid (BAA), as measured in blood, liver and forestomach homogenates from mice. Health and Environment Laboratories, Eastman Kodak Company, Rochester, NY for the American Chemistry Council, Arlington, VA.
- DeLeve, LD. (1998) Glutathione defense in non-parenchymal cells. Semin Liver Dis 18:403–413.
- Dill, JA; Lee, KM; Bates, DJ; et al. (1998) Toxicokinetics of inhaled 2-butoxyethanol and its major metabolite, 2-butoxyacetic acid, in F344 rats and B6C3F1 mice. Toxicol Appl Pharmacol 153:227–242.
- Djordjevic, VB. (2004) Free radicals in cell biology. Int Rev Cytol 237:57-89.
- Dodd, DE; Snelling, WM; Maronpot, RR; et al. (1983) Ethylene glycol monobutyl ether: acute, 9-day, and 90-day vapor inhalation studies in Fischer 344 rats. Toxicol Appl Pharmacol 68:405–414.
- Doe, JE. (1984) Further studies on the toxicology of the glycol ethers with emphasis on rapid screening and hazard assessment. Environ Health Perspect 57:199–206.
- ECETOC (European Centre for Ecotoxicology and Toxicology of Chemicals). (1994) Butoxyethanol criteria document. Special Report No. 7. Ecology and Toxicology Centre, European Chemical Industry, Brussels, Belgium.
- Edmonson, HA; Peters, RL. (1985) Liver. In: Kissane, JM; ed. Anderson=s pathology. St. Louis: Mosby; pp. 1096– 1213.
- Elias, Z; Daniere, MC; Marande, AM; et al. (1996) Genotoxic and/or epigenetic effects of some glycol ethers: results of different short-term tests. Occup Hyg 2:187–212.
- Elliott, BM; Ashby, J. (1997) Review of the genotoxicity of 2-butoxyethanol. Mutat Res 387:89–96.

- Exon, JH; Mather, GG; Bussiere, JL; et al. (1991) Effects of subchronic exposure of rats to 2-methoxyethanol or 2-butoxyethanol: thymic atrophy and immunotoxicity. Fundam Appl Toxicol 16:830–840.
- Ezov, N; Levin-Harrus, T; Mittelman, M; et al. (2002) A chemically induced rat model of hemolysis with disseminated thrombosis. Cardiovasc Toxicol 2:181–194.
- Feron, VJ; Hendriksen, CF; Speek, AJ; et al. (1981) Lifespan oral toxicity study of vinyl chloride in rats. Food Cosmet Toxicol 19(3):317–333.
- Firooz, A; Komeili A; Dowlati Y. (1999) Eruptive melanocytic nevi and cherry angiomas secondary to exposure to sulfur mustard gas. J Am Acad Dermatol 40(4):646–647.
- Foster, JR. (2000) EGBE (ethylene glycol butyl ether, EGBE): the proposed mode of action in the induction of hemangiosarcomas in male mouse liver and its significance for man. Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire, United Kingdom; Report no: Ctl/r/1465.
- Foster, PMD; Lloyd, SC; Blackburn, DM. (1987) Comparison of the in vivo and in vitro testicular effects produced by methoxy-, ethoxy-, and n-butoxy acetic acids in the rat. Toxicology 43:17–30.
- Frei, YF; Perk, K; Dannon, D. (1963) Correlation between osmotic resistance and fetal hemoglobin in bovine erythrocytes. Exp Cell Res 30:561.
- Frith, CH; Ward, JM. (1979) A morphologic classification of proliferative and neoplastic hepatic lesions in mice. J Environ Pathol Toxicol 3:329–351.
- Ghanayem, BI. (1989) Metabolic and cellular basis of 2-butoxyethanol-induced hemolytic anemia in rats and assessment of human risk in vitro. Biochem Pharmacol 38:1679–1684.
- Ghanayem, BI; Sullivan, CA. (1993) Assessment of the hemolytic activity of 2-butoxyethanol and its major metabolite, butoxyacetic acid, in various mammals including humans. Hum Exp Toxicol 12:305–311.
- Ghanayem, BI; Maronpot, RR; Matthews, HB. (1985) Ethyl acrylate-induced gastric toxicity. II. Structure-toxicity relationships and mechanism. Toxicol Appl Pharmacol 80:336–344.
- Ghanayem, BI; Maronpot, RR; Matthews, HB. (1986) Association of chemically-induced forestomach cell proliferation and carcinogenesis. Cancer Letters 32:271–278.
- Ghanayem, BI; Burka, LT; Sanders, JM; et al. (1987a) Metabolism and disposition of ethylene glycol monobutyl ether (2-butoxyethanol) in rats. J Pharmacol Exper Ther 15:478–484.
- Ghanayem, BI; Burka, LT; Matthews, HB. (1987b) Metabolic basis of ethylene glycol monobutyl ether (2-butoxyethanol) toxicity: role of alcohol and aldehyde dehydrogenases. J Pharmacol Exp Ther 242:222– 231.
- Ghanayem, BI; Blair, PC; Thompson, MB; et al. (1987c) Effect of age on the toxicity and metabolism of ethylene glycol monobutyl ether (2-butoxyethanol) in rats. Toxicol Appl Pharmacol 91:222–234.
- Ghanayem, BI; Sanders, JM; Clark, AM; et al. (1990) Effects of dose, age, inhibition of metabolism and elimination on the toxicokinetics of 2-butoxyethanol and its metabolites. J Pharmacol Exper Ther 253:136–143.
- Ghanayem, BI; Sanchez, JM; Matthew, HB. (1992) Development of tolerance to 2-butoxyethanol-induced hemolytic anemia and studies to elucidate the underlying mechanisms. Toxicol Appl Pharmacol 112:198–206.
- Ghanayem, BI; Sanchez, IM; Maronpot, RR; et al. (1993) Relationship between the time of sustained ethyl acrylate forestomach cell proliferation and carcinogenicity. Environ Health Perspect 101(Suppl. 5):277–280.

- Ghanayem, BI; Sanchez, IM; Matthews, HB; et al. (1994) Demonstration of a temporal relationship between ethyl acrylate induced forestomach hyperplasia and carcinogenesis. Toxicol Pathol 22:497–509.
- Ghanayem, BI; Ward, SM; Chanas, B; et al. (2000) Comparison of the acute hematotoxicity of 2-butoxyethanol in male and female F344 rats. Hum Exp Toxicol 19:185–192
- Ghanayem, BI; Long, P; Ward, SM; et al. (2001) Hemolytic anemia, thrombosis, and infarction in male and female F344 rats following gavage exposure to 2-butoxyethanol. Exp Toxicol Pathol 53:97–105.
- Gift, JS. (2005) U.S. EPA=s IRIS assessment of 2-butoxyethanol: the relationship of noncancer to cancer effects. Toxicol Lett 156:163B178.
- Gijsenbergh, FP; Jenco, M; Veulemans, H; et al. (1989) Acute butylglycol intoxication: a case report. Hum Toxicol 8:243–245.
- Gingell, R; Boatman, RJ; Lewis, S. (1998) Acute toxicity of ethylene glycol mono-n-butyl ether in the guinea pig. Food Chem Toxicol 36:825–829.
- Gold, LS; Manley, NB; Slone, TH; et al. (1993) The fifth plot of the carcinogenic potency database: results of animal bioassays published in the general literature through 1988 and by the National Toxicology Program through 1989. Environ Health Perspect 100:65–135.
- Gollapudi, BB; Barber, ED; Lawlor, TE; et al. (1996) Re-examination of the mutagenicity of ethylene glycol monobutyl ether to Salmonella tester strain TA97a. Mutat Res 370:61–64.
- Grant, D; Sulsh, S; Jones, HB; et al. (1985) Acute toxicity and recovery in the hemopoietic system of rats after treatment with ethylene glycol monomethyl and monobutyl ethers. Toxicol Appl Pharmacol 77:187–200.
- Greaves, P. (2000) Hepatocellular hypertrophy and hyperplasia. In: Histopathology of preclinical toxicity studies: interpretation and relevance in drug safety evaluation. 2nd edition. New York, NY: Elsevier; pp. 445–448.
- Green, T; Toghill, A; Lee, R; et al. (2002) The development of forestomach tumors in the mouse following exposure to 2-butoxyethanol by inhalation. Studies on the mode of action and relevance to humans. Toxicology 180:257–273.
- Gualideri, JF; Harris, CR; Corley, RA; et al. (1995) Multiple 2-butoxyethanol intoxications in the same patient: clinical findings, pharmacokinetics, and therapy. J Toxicol Clin Toxicol 33(5):550–551.
- Gualideri, JF; DeBoer, L; Harris, CR; et al. (2003). Repeated ingestion of 2-butoxyethanol: case report and literature review. J Toxicol Clin Toxicol 41:57–62.
- Hardin, BD; Goad, PT; Burg, JR. (1984) Developmental toxicity of four glycol ethers applied cutaneously to rats. Environ Health Perspect 57:69–74.
- Harrison, PTC. (1992) Propionic acid and the phenomenon of rodent forestomach tumorigenesis: a review. Food Chem Toxicol 30:333–340.
- Harrison, S; Bacon, B. (2005). Relation of hemochromatosis with hepatocellular carcinoma: epidemiology, natural history, pathophysiology, screening, treatment, and prevention. Med Clin N Am 89:391–409.
- Harrison, PTC; Grasso, P; Badescu, V. (1991) Early changes in the forestomach of rats, mice and hamsters exposed to dietary propionic and butyric acid. Food Chem Toxicol 29:367–371.
- Haufroid, V; Thirion, F; Mertens, P; et al. (1997) Biological monitoring of workers exposed to low levels of 2-butoxyethanol. Int Arch Occup Environ Health 70:232–236.

- Heindel, JJ; Gulati, DK; Russell, VS; et al. (1990) Assessment of ethylene glycol monobutyl and monophenyl ether reproductive toxicity using a continuous breeding protocol in Swiss CD-1 mice. Fundam Appl Toxicol 15:683–696.
- Hoflack, JC; Lambolez, L; Elias, Z; et al. (1995) Mutagenicity of ethylene glycol ethers and of their metabolites in Salomenella typhimurium his-. Mutat Res 341:281–287.
- Hord, JD; Lukens, JN. (1999) Anemia unique to infants and young children. In: Lee, RG; ed. Wintrobe's clinical hematology. Vol. 2. 10th edition. Baltimore, MD: Williams & Wilkins; pp. 1518–1537.
- Houglum, K; Ramm, GA; Crawford, DH; et al. (1997) Excess iron induces hepatic oxidative stress and transforming growth factor β1 in genetic hemochromatosis. Hepatology 26:605–610.
- Iancu, TC; Neustein, HB; Landing, BH. (1976). The liver in thalassaemia major: ultrastructural observations. Ciba Found Symp 51:293–316.
- Jacobs, GA; Marten, MA. (1989) An objective method for the evaluation of eye irritation in vivo. Food Chem Toxicol 27:255–258.
- Jakasa, I; Mohammadi, N; Kruse, J; et al. (2004) Percutaneous absorption of neat and aqueous solutions of 2-butoxyethanol in volunteers. Int Arch Occup Environ Health 77:79–84.
- Jepson, GW; Hoover, DK; Black, RK; et al. (1994) A partition coefficient determination method for nonvolatile chemicals in biological tissues. Toxicol Appl Pharmacol 22:519–524.
- Johanson, G. (1986) Physiologically-based pharmacokinetic modeling of inhaled 2-butoxyethanol in man. Toxicol Lett 34:23–31.
- Johanson, G; Boman, A. (1991) Percutaneous absorption of 2-butoxyethanol vapor in human subjects. Br J Ind Med 48:788–792.
- Johanson, G; Dynesius, B. (1988) Liquid/air partition coefficients of six commonly used glycol ethers. Br J Ind Med 45:561–564.
- Johanson, G; Johnsson, S. (1991) Gas chromatographic determination of butoxyacetic acid in human blood after exposure to 2-butoxyethanol. Arch Toxicol 65:433–435.
- Johanson, G; Boman, A; Dynesius, B. (1988) Percutaneous absorption of 2-butoxyethanol in man. Scan J Work Environ Health 14:101–109.
- Johanson, G; Wallen, M; Nordquist, MB. (1986) Elimination kinetics of 2-butoxyethanol in the perfused rat liverCdose dependence and effect of ethanol. Toxicol Appl Pharmacol 83:315–320.
- Jones, K; Cocker, J; Dodd, LJ; et al. (2003) Factors affecting the extent of dermal absorption of solvent vapors: a human volunteer study. Ann Occup Hyg 47:145–150.
- Junge, B; Carrion, Y; Bosco, C; et al. (2001) Effects of iron overload and lindane intoxication in relation to oxidative stress, Kupffer cell function, and liver injury in the rat. Toxicol Appl Pharmacol 170:23–28.
- Kamendulis, LM; Park, JJ; Klaunig, JE. (1999) Potential mechanisms of rodent liver toxicity by EGBE: oxidative stress studies. Indiana University, School of Medicine, Indianapolis, IN, final report for the Ethylene Glycol Ethers Panel, Chemical Manufacturers Association, Arlington, VA.
- Keith, G; Coulais, A; Edorh, A; et al. (1996) Ethylene glycol monobutyl ether has neither epigenetic nor genotoxic effects in acute treated rats and in sub-chronic v-Ha-ras transgenic mice. Occup Hyg 2:237–249.

- Kennah, HE, II; Hignet, S; Laux, PE; et al. (1989) An objective procedure for quantifying eye irritation based on changes of corneal thickness. Fundam Appl Toxicol 12:258–268.
- Klaunig, JE; Xu, Y; Isenberg, JS; et al. (1998) The role of oxidative stress in chemical carcinogenesis. Environ Health Perspect 106 Suppl 1:289–295.
- Klaunig, JE; Kamendulis, LM. (2004) Effect of 2-butoxyacetaldehyde on the induction of DNA damage (comet) in rodent endothelial cells. Final report to Ethylene Glycol Ethers Panel, American Chemistry Council, Arlington, VA; January 14, 2004.
- Klaunig, JE; Kamendulis, LM. (2005) Mode of action of butoxyethanol induced mouse liver hemangiosarcomas and hepatocellular carcinomas. Toxicol Lett 156:107–115.
- Knutson, M; Wessling-Resnick, M. (2003). Iron metabolism in the reticuloendothelial system. Critical Rev Biochem Mol Bio 38(1):61–88.
- Koshkaryev, A; Barshtein, G; Nyska, A; et al. (2003) 2-Butoxyethanol enhances the adherence of red blood cells. Arch Toxicol 77:465–469.
- Krasavage, WJ. (1986) Subchronic oral toxicity of ethylene glycol monobutyl ether in male rats. Fundam Appl Toxicol 6:349–355.
- Kroes, R; Wester, PW. (1986) Forestomach carcinogens: possible mechanisms of action. Food Chem Toxicol 24:1083–1089.
- Kumagai, S; Oda, H; Matsunaga, I; et al. (1999) Uptake of 10 polar organic solvents during short-term respiration. Toxicol Sci 48:255–263.
- Kwittken, J; Tartow, LR. (1966). Hemochromatosis and kupffer-cell sarcoma with unusual localization of iron. J Pathol Bacteriol 92(2):571–573.
- Laitinen, J. (1998) Correspondence between occupational exposure limit and biological action level values for alkoxyethanols and their acetates. Int Arch Occup Environ Health 71:117–124.
- Laitinen, J; Liesivuori, J; Savolainen, H. (1998) Urinary NAG and GAG as biomarkers of renal effects in exposure to 2-alkoxyalcohols and their acetates. J Occup Environ Med 40:595–600.
- Lee, KM; Dill, JA; Chou, BJ; et al. (1998) Physiologically based pharmacokinetic model for chronic inhalation of 2-butoxyethanol. Toxicol Appl Pharmacol 153:211–226.
- Lesgards, J-F; Durand, P; Lassarre, M; et al. (2002) Assessment of lifestyle effects on the overall antioxidant capacity of health subjects. Environ Health Perspect 110:479–486.
- Lewis, AE. (1970) Principles of hematology. New York, NY: Appleton-Century-Crofts.
- Long[,] PH; Maronpot, RR; Ghanayem, BI; et al. (2000) Dental pulp infarction in female rats following inhalation exposure to 2-butoxyethanol. Toxicol Pathol 28:246–252.
- Maltoni, C; Lefemine, G; Ciliberti, A; et al. (1981) Carcinogenicity bioassays of vinyl chloride monomer: a model of risk assessment on an experimental basis. Environ Health Perspect 41:3–29.
- Medinsky, MA; Singh, G; Bechtold, WE; et al. (1990) Disposition of three glycol ethers administered in drinking water to male F344/N rats. Toxicol Appl Pharmacol 102 :443–455.
- Muller, A; Jacobsen H; Healy E; et al. (2006) Hazard classification of chemicals inducing haemolytic anaemia: an EU regulatory perspective. Regul Toxicol Pharmacol 45(3):229–241.

- Nachreiner, DJ. (1994) Ethylene glycol butyl ether: acute vapor inhalation toxicity study in guinea pigs. Union Carbide Corporation and Bushy Run Research Center (BRRC), Export, PA, for the Chemical Manufacturers Association; Arlington, VA; Project ID 94N1392.
- Nagano, K; Nakayama, E; Koyano, M; et al. (1979) Testicular atrophy of mice induced by ethylene glycol mono alkyl ethers. Jpn J Ind Health 21:29–35.
- Nagano, K; Nakayama, E; Oobayashi, H; et al. (1984) Mouse testicular atrophy induced by ethylene glycol alkyl ethers in Japan. Environ Health Perspect 57:75–84.
- Nelson, BK; Setzer, JV; Brightwell, WS; et al. (1984) Comparative inhalation teratogenicity of four glycol ether solvents and an amino derivative in rats. Environ Health Perspect 57:261–271.
- NRC (National Research Council). (1983) Risk assessment in the federal government: managing the process. Washington, DC: National Academy Press.
- NTP (National Toxicology Program). (1993) Technical report on toxicity studies of ethylene glycol ethers 2-methoxyethanol, 2-ethoxyethanol, 2-butoxyethanol administered in drinking water to F344/N rats and B6C3F1 mice. Public Health Service, U.S. Department of Health and Human Services; NTP No. 26; NIH Publ. No. 93-3349. Available from the National Institute of Environmental Health Sciences, Research Triangle Park, NC.
- NTP (National Toxicology Program). (1996) Toxicology and carcinogenesis studies of acetonitrile (CAS No. 75-05-8) in F344/N rats and B6C3F1 mice (inhalation studies). Public Health Service, U.S. Department of Health and Human Services; NTP TR 447. Available from the National Institute of Environmental Health Sciences, Research Triangle Park, NC and online at http://ehp.niehs.nih.gov/ntp/docs/400-4xx-doc.html.
- NTP (National Toxicology Program). (1998) NTP technical report on the toxicology and carcinogenesis studies of 2-butoxyethanol (CAS No. 111-76-2) in F344/N rats and B6C3F1 mice (inhalation studies). Public Health Service, U.S. Department of Health and Human Services; NTP TR 484; NIH Draft Publ. No. 98-3974. Available from the National Institute of Environmental Health Sciences, Research Triangle Park, NC.
- NTP (National Toxicology Program). (2000) NTP technical report on the toxicology and carcinogenesis studies of 2-butoxyethanol (CAS No. 111-76-2) in F344/N rats and B6C3F1 mice (inhalation studies). Public Health Service, U.S. Department of Health and Human Services; NTP TR 484; NIH Publ. No. 00-3974. Available from the National Institute of Environmental Health Sciences, Research Triangle Park, NC and online at http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/tr484.pdf.
- Nyska, A; Maronpot, RR; Ghanayem, BI. (1999) Ocular thrombosis and retinal degeneration in female rats by 2-butoxyethanol. Human Exp Toxicol 18:577–582.
- Nyska, A; Haseman, JK; Kohen, R; et al. (2004) Association of liver hemangiosarcoma and secondary iron overload in B6C3F1 mice—the National Toxicology Program experience. Toxicol Pathol 32:222–228.
- Osterhoudt, KC. (2002) Fomepizole therapy for pediatric butoxyethanol intoxication. J Toxicol Clin Toxicol 40:929–930.
- Park, J; Kamendulis, LM; Klaunig, JE. (2002) Effects of 2-butoxyethanol on hepatic oxidative damage. Toxicol Lett 126:19–29.
- Pietrangelo, A. (2004) Hereditary hemochromatosis—a new look at an old disease. N Engl J Med 350:2383-2397.
- Poet, TS; Soelberg, JJ; Curry, TL; et al. (2002) In vivo kinetic studies with 2-butoxyethanol Part 1: Target tissue dosimetry. Battelle Memorial Institute, Columbus, OH, final report (draft) for the Ethylene Glycol Ethers Panel, American Chemistry Council, Arlington, VA; Battelle Project No. 4097f4.

- Poet, TS; Soelberg, JJ; Weitz, KK; et al. (2003) Mode of action and pharmacokinetic studies of 2-butoxyethanol in the mouse with an emphasis on forestomach dosimetry. Toxicol Sci 71:176–189.
- Rambourg-Schepens, MO; Buffet, M; Bertault, R; et al. (1988) Severe ethylene glycol butyl ether poisoning. Kinetics and metabolic pattern. Hum Toxicol 7:187–189.
- Raymond, LW; Williford, LS; Burke, WA. (1998). Eruptive cherry angiomas and irritant symptoms after one acute exposure to the glycol ether solvent 2-butoxyethanol. J Occup Environ Med 40:1059–1064.
- Redlich, M; Maly, A; Aframian, D; et al. (2004) Histopathologic changes in dental and oral soft tissues in 2-butoxyethanol-induced hemolysis and thrombosis in rats. J Oral Pathol Med 33:424–429.
- Reed, JM; Kamendulis, LM; Klaunig, JE. (2003) Examination of DNA damage in endothelial cells following treatment with 2-butoxyethanol using the single cell gel electrophoresis (Comet) assay. Toxicologist 72(S1):206.
- Rettenmeier, AW; Hennigs, R; Wodarz, R. (1993) Determination of butoxyacetic acid and N-butoxyacetylglutamine in urine of lacquerers exposed to 2-butoxyethanol. Int Arch Occup Environ Health 65:S151-S153.
- Russel, FGM; Wouterse, AC; van Ginneken, CAM. (1987) Physiologically-based pharmacokinetic model for the renal clearance of phenolsulfonphthalein and the interaction with probenecid and salicyluric acid in the dog. J Pharmacol Biopharm 15:349–368.
- Sabourin, PJ; Medinsky, MA; Birnbaum, LS; et al. (1992a) Effect of exposure concentration on the disposition of inhaled butoxyethanol by F344 rats. Toxicol Appl Pharmacol 114:232–238.
- Sabourin, PJ; Medinsky, MA; Thurmond, F; et al. (1992b) Effect of dose on the disposition of methoxyethanol, ethoxyethanol, and butoxyethanol administered dermally to male F344/N rats. Fundam Appl Toxicol 19:124–132; erratum, Fundam Appl Toxicol 20:508–510.
- Shabat, S; Nyska, A; Long, PH; et al. (2004) Osteonecrosis in a chemically induced rat model of human hemolytic disorders associated with thrombosisCa new model for avascular necrosis of bone. Calcif Tissue Int 74:220–228.
- Shepard, KP. (1994a) Ethylene glycol monobutyl ether: acute oral toxicity study in the guinea pig. Corporate Health and Environment Laboratories, Eastman Kodak Company, Rochester, NY, for the Chemical Manufacturers Association, Arlington, VA.
- Shepard, KP. (1994b) Ethylene glycol monobutyl ether: acute dermal toxicity study in the guinea pig. Corporate Health and Environment Laboratories, Eastman Kodak Company, Rochester, NY, for the Chemical Manufacturers Association, Arlington, VA.
- Shyr, LJ; Sabourin, PJ; Medinsky, MA; et al. (1993) Physiologically-based modeling of 2-butoxyethanol disposition in rats following different routes of exposure. Environ Res 63:202–218.
- Siesky, AM; Kamendulis, LM; Klaunig, JE. (2002) Hepatic effects of 2-butoxyethanol in rodents. Toxicol Sci 70:252–260.
- Singh, P; Zhao, S; Blaylock, BL. (2001) Topical exposure to 2-butoxyethanol alters immune responses in female BALB/c mice. Int J Toxicol 20:383–390.
- Singh, P; Morris, B; Zhao, S; et al. (2002) Suppression of the contact hypersensitivity response following topical exposure to 2-butoxyethanol in female BALB/c mice. Int J Toxicol 21:107–114.

- Sleet, RB; Price, CJ; Marr, MC; et al. (1989) Teratologic evaluation of ethylene glycol monobutyl ether administered to Fischer 344 rats on either gestational days 9–11 or days 11–13 [final report]. Public Health Service, U.S. Department of Health and Human Services; NTP-CTER-86-103. Available from the National Institute of Environmental Health Sciences, Research Triangle Park, NC.
- Smialowicz, RJ; Williams, WC; Riddle, MM; et al. (1992a) Comparative immunosuppression of various glycol ethers orally administered to Fischer 344 rats. Fundam App Toxicol 18:621–627.
- Smialowicz, RJ; Riddle, MM; Williams, WC; et al. (1992b) Differences between rats and mice in the immunosuppressive activity of 2-methoxyethanol and 2-methoxyacetic acid. Toxicology 74(1):57–67.
- Smith, JG; German, JB. (1995) Molecular and genetic effects of dietary derived butyric acid. Food Technol 49:87– 90.
- Spolarics, Z. (1999) A carbohydrate-rich diet stimulates glucose-6-phosphate dehydrogenase expression in rat hepatic sinusoidal endothelial cells. J Nutr 129:105–108.
- Tyl, RW; Millicovsky, G; Dodd, DE; et al. (1984) Teratologic evaluation of ethylene glycol monobutyl ether in Fischer 344 rats and New Zealand white rabbits following inhalation exposure. Environ Health Perspect 57:47–68.
- Tyler, TR. (1984) Acute and subchronic toxicity of ethylene glycol monobutyl ether. Environ Health Perspect 57:185–191.
- U.S. EPA (Environmental Protection Agency). (1986a) Guidelines for the health risk assessment of chemical mixtures. Federal Register 51(185):34014–34025. Available online at http://www.epa.gov/ncea/raf/rafguid.htm.
- U.S. EPA (Environmental Protection Agency). (1986b) Guidelines for mutagenicity risk assessment. Federal Register 51(185):34006–34012. Available online at http://www.epa.gov/ncea/raf/rafguid.htm.
- U.S. EPA (Environmental Protection Agency). (1988) Recommendations for and documentation of biological values for use in risk assessment. Environmental Criteria and Assessment Office, Office of Health and Environmental Assessment, Cincinnati, OH; EPA/600/6-87/008. Available from the National Technical Information Service, Springfield, VA; PB88-179874/AS, and online at http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=34855.
- U.S. EPA (Environmental Protection Agency). (1991) Guidelines for developmental toxicity risk assessment. Federal Register 56(234):63798–63826. Available online at http://www.epa.gov/ncea/raf/rafguid.htm.
- U.S. EPA (Environmental Protection Agency). (1994a) Interim policy for particle size and limit concentration issues in inhalation toxicity: notice of availability. Federal Register 59(206):53799. Available online at http://www.epa.gov/EPA-PEST/1994/October/Day-26/pr-11.html.
- U.S. EPA (Environmental Protection Agency). (1994b) Methods for derivation of inhalation reference concentrations and application of inhalation dosimetry. Environmental Criteria and Assessment Office, Office of Health and Environmental Assessment, Cincinnati, OH; EPA/600/8-90/066F. Available from the National Technical Information Service, Springfield, VA, PB2000-500023, and online at http://cfpub.epa.gov/ncea/raf/recordisplay.cfm?deid=71993.
- U.S. EPA (Environmental Protection Agency). (1995) Use of the benchmark dose approach in health risk assessment. Risk Assessment Forum, Washington, DC; EPA/630/R-94/007. Available from the National Technical Information Service, Springfield, VA, PB95-213765, and online at http://cfpub.epa.gov/ncea/raf/raf_publitles.cfm?detype=document&excCol=archive.
- U.S. EPA (Environmental Protection Agency). (1996) Guidelines for reproductive toxicity risk assessment. Federal Register 61(212):56274–56322. Available online at http://www.epa.gov/ncea/raf/rafguid.htm.

- U.S. EPA (Environmental Protection Agency). (1998) Guidelines for neurotoxicity risk assessment. Federal Register 63(93):26926–26954. Available online at http://www.epa.gov/ncea/raf/rafguid.htm.
- U.S. EPA (Environmental Protection Agency). (2000a) Science policy council handbook: risk characterization. Office of Science Policy, Office of Research and Development, Washington, DC. EPA/100-B-00-002. Available online at http://www.epa.gov/OSA/spc/pdfs/prhandbk.pdf.
- U.S. EPA (Environmental Protection Agency). (2000b) Benchmark dose technical guidance document [external review draft]. Risk Assessment Forum, Washington, DC; EPA/630/R-00/001. Available online at http://cfpub.epa.gov/ncea/cfm/ nceapublication.cfm?ActType=PublicationTopics&detype=DOCUMENT&subject=BENCHMARK+DOS E&subjtype=TITLE&excCol=Archive.
- U.S. EPA (Environmental Protection Agency). (2000c) Supplementary guidance for conducting health risk assessment of chemical mixtures. Risk Assessment Forum, Washington, DC; EPA/630/R-00/002. Available online at http://cfpub.epa.gov/ncea/raf/chem_mix.cfm.
- U.S. EPA (Environmental Protection Agency). (2002) A review of the reference dose concentration and reference concentration processess. Risk Assessment Forum, Washington, DC; EPA/630/P-02/002F. Available online at http://cfpub.epa.gov/ncea/raf/raf_pubtitles.cfm?detype=document&excCol=archive.
- U.S. EPA (Environmental Protection Agency). (2004) Toxicological review of 1,2-dibromoethane (CASRN 106-93-4). Integrated Risk Information System (IRIS), National Center for Environmental Assessment, Washington, DC. Available online at http://www.epa.gov/iris.
- U.S. EPA (Environmental Protection Agency). (2005a) Guidelines for carcinogen risk assessment. Federal Register 70(66):17765–18717. Available online at http://www.epa.gov/cancerguidelines.
- U.S. EPA (Environmental Protection Agency). (2005b) Supplemental guidance for assessing susceptibility from early-life exposure to carcinogens. Risk Assessment Forum, Washington, DC; EPA/630/R-03/003F. Available online at http://www.epa.gov/cancerguidelines.
- U.S. EPA. (2005c) An evaluation of the human carcinogenic potential of ethylene glycol butyl ether, Final Report. National Center for Environmental Assessment, Office of Research and Development, February 2005. EPA 600/R-04/123. Available online at http://cfpub.epa.gov/ncea/cfm/ recordisplay.cfm?deid=135268.
- U.S. EPA (Environmental Protection Agency). (2006a) Science policy council handbook: peer review. 3rd edition. Office of Science Policy, Office of Research and Development, Washington, DC; EPA/100/B-06/002. Available online at http://www.epa.gov/OSA/spc/2peerrev.htm.
- U.S. EPA (Environmental Protection Agency). (2006b) A framework for assessing health risk of environmental exposures to children. National Center for Environmental Assessment, Washington, DC; EPA/600/R-05/093F. Available online at http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=158363.
- U.S. EPA (Environmental Protection Agency). (2006c) Approaches for the application of physiologically-based pharmacokinetic (PBPK) models and supporting data in risk assessment. National Center for Environmental Assessment, Washington, DC; EPA/600/R-05/043F. Available online at http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=157668.
- Udden, MM. (1994) Hemolysis and decreased deformability of erythrocytes exposed to butoxyacetic acid, a metabolite of 2-butoxyethanol: II. Resistance in red blood cells from humans with potential susceptibility. J Appl Toxicol 14:97–102.
- Udden, MM. (1995) Effects of butoxyacetic acid on human red cells. Occup Hyg 2:283-292.
- Udden, MM. (2000). Rat erythrocyte morphological changes after gavage dosing with 2-butoxyethanol: a comparison with the in vitro effects of butoxyacetic acid on rat and human erythrocytes. J Appl Toxicol 20:381–387.

- Udden, MM. (2002). In vitro sub-hemolytic effects of butoxyethanol acid on human and rat erythrocytes. Toxicol Sci 69:258–264.
- Udden, MM; Patton, CS. (1994) Hemolysis and decreased deformability of erythrocytes exposed to butoxyacetic acid, a metabolite of 2-butoxyethanol. I. Sensitivity in rats and resistance in normal humans. J Appl Toxicol 14:91–96.
- Udden, MM; Patton, CS. (2005) Butoxyacetic acid-induced hemolysis of rat red blood cells: effect of external osmolarity and cations. Toxicol Lett 156(1):81–93.
- Valberg, LS; Simon, JB; Manley, PN; et al. (1975) Distribution of storage iron as body stores expand in patients with hemochromatosis. J Lab Clin Med 86(3):479–489.
- Wang, YJ; Ho, YS; Lo, MJ; et al. (1995). Oxidative modification of DNA bases in rat liver and lung during chemical carcinogenesis and ageing. Chem-Biol Interact 94:135–145.
- Werner, HW; Nawrocki, CZ; Mitchell, JL; et al. (1943a) Effects of repeated exposure of rats to vapors of monoalkyl ethers of ethylene glycol. J Ind Hyg Toxicol 25:374–379.
- Werner, HW; Mitchell, JL; Miller, JW; et al. (1943b) Effects of repeated exposure of dogs to monoalkyl ethylene glycol ether vapors. J Ind Hyg Toxicol 25:409–414.
- Wier, PJ; Lewis, SC; Traul, KA. (1987) A comparison of developmental toxicity evident at term to postnatal growth and survival using ethylene glycol monoethyl ether, ethylene glycol monobutyl ether, and ethanol. Teratog Carcinog Mutag 7:55–64.
- Wintrobe, MM. (1981a) Variations of leukocytes in disease. In: Wintrobe, MM; ed. Clinical hematology. Philadelphia: Lea & Febiger; pp. 1284–1323.
- Wintrobe, MM. (1981b) The normocytic, normochromic anemia. In: Wintrobe, MM; ed. Clinical hematology. Philadelphia: Lea & Febiger; pp. 677–697.
- Yamaguchi, R; Hirano, T; Asami, S; et al. (1996) Increased 8-hydroxyguanine levels in DNA and its repair activity in rat kidney after administration of a renal carcinogen, ferric nitrilotriacetate. Carcinogenesis 17:2419– 2422.
- Zeiger, E; Anderson, B; Haworth, S; et al (1992) Salmonella in mutagenicity tests. V. Results form the testing of 311 chemicals. Environ Mol Mutagen 19(Suppl. 21):2–141.
- Ziouzenkova, O; Asatryan, L; Sevanian, A. (1999) Oxidative stress resulting from hemolysis and formation of catalytically active hemoglobin: protective strategies. Int J Clin Pharmacol Ther 37(3):125–132.

Appendix A Corley et al. (1997, 1994) PBPK Model

Corley et al. (1994) developed physiologically based pharmacokinetic (PBPK) models 1 2 for rats and humans with the primary objective of describing the concentration of 2-butoxyacetic 3 acid (BAA) in the target tissue (blood) of rats and humans for use in risk assessment (Figure 4 B-1). The models incorporate allometrically scalable physiological and biochemical parameters 5 (e.g., blood flows, tissue volumes, and metabolic capacity) in place of the standard values for a 6 70 kg human. These parameters normalize standard values to the actual body weights of the 7 subjects in several human kinetic studies. The physiology of humans under exercise conditions 8 was maintained in the model. The rat was included to expand the database for model validation 9 and to assist in interspecies comparisons of target tissue doses (BAA in blood).




Figure A-1. PBPK model of Corley et al. (1994). The formation of BAA from ethylene glycol monobutyl ether was assumed to occur only in the liver and was simulated in a second model linked via the formation of BAA.

Source: Corley et al. (1994).


1 The Corley et al. (1994) model included additional routes of exposure such as oral 2 (gavage), drinking water, intravenous (i.v.) infusion, and dermal (liquids and vapor). The 3 formation of BAA was assumed to occur only in the liver, using the rat liver perfusion data of 4 Johanson et al. (1986) scaled to the human. A second model was linked to the ethylene glycol 5 monobutyl ether (EGBE) model specifically to track the disposition of BAA following its 6 formation in the liver. The kidney was added to the BAA model, because it is the organ of 7 elimination for BAA. All other metabolic routes for EGBE (formation of ethylene glycol [EG] 8 and glucuronide conjugate) were combined, as they were used only to account for the total 9 disposition of EGBE in the rat metabolism studies and not for cross-species extrapolations. 10 Contrary to observations in rats, Corley et al. (1997) found no evidence of metabolites in urine 11 that would indicate that humans form conjugates of EGBE or EG. Thus, these pathways, which 12 were lumped together in the model of Corley et al. (1994) to simulate rat kinetic data, were 13 eliminated for human simulations. The human blood:air partition coefficient of 7.965, from 14 Johanson and Dynesius (1988), was also used in the Corley et al. (1994) model. In addition, the 15 partition coefficients for both EGBE and BAA were measured in human blood, rat blood, and rat 16 tissues by using a modification of the Jepson et al. (1994) technique for ultrafiltration. Human 17 tissue:blood partition coefficients were assumed to be equal to those of the rat. The skin:air 18 partition coefficient, used to calculate the dermal uptake of vapors, was assumed to be the same 19 as the blood:air partition coefficient. With the exception of the lung:blood partition coefficient 20 for EGBE (11.3), the tissue:blood partition coefficients ranged from 0.64–4.33 for EGBE and 21 0.77–1.58 for BAA. Protein binding of BAA in blood and saturable elimination of BAA by the 22 kidneys were necessary components to describe the BAA kinetic data in rats and humans as 23 discussed above. Since no direct measurements of protein binding were available, these 24 parameters were arbitrarily set to the molar equivalent values reported for phenolsulfonphthalein 25 as described by Russel et al. (1987). Constants for the saturable elimination of BAA by the 26 kidneys were then estimated by optimization from the data of Ghanayem et al. (1990), where rats 27 were administered EGBE i.v. and the concentrations of BAA in blood were determined, 28 following three different dose levels. These parameters were then held constant (protein binding) 29 or scaled by (body weight) $0.74 \times$ (renal elimination) for all simulations. Significant increases in 30 the concentrations of EGBE were observed by Corley et al. (1997) in the first postexposure 31 blood samples. Because the subjects were able to move their arms freely after the exposure, 32 Corley et al. (1997) hypothesized that the local blood flow to the exposed arm increased for a 33 few minutes postexposure. By adjusting the blood flow to the skin by fourfold for 5 minutes 34 postexposure, the model is able to simulate this change in the concentration of EGBE in blood.

Table A-1. Selected parameters used in the PBPK model for EGBE developed by	
Corley et al. (1994)	

Parameter	Human	Rat
Weights		
Body weight (kg)	70	0.23
Liver	3.14%	2.53
Rapidly perfused (BAA model)	3.71% 3.27%	5.1 4.39%
Slowly perfused	9.4	24.8
Flows (L/hour)		
Alveolar ventilation	347.9	5.06
Cardiac output (COP)	347.9	5.06
Liver (% COP)	25.0	25.0
Rapidly perfused (% COP) (BAA model)	50.0 25.0	51.0 26.0
Slowly perfused (% COP)	2	2
Partition coefficients		
Blood/air	7,965	7,965
Liver/blood (BAA model)	1.46 1.30	1.46 1.30
Rapidly perfused/blood (BAA model)	1.46 1.30	1.46 1.30
Slowly perfused/blood (BAA model)	0.64 1.31	0.64 1.31
Metabolic constants	·	
EGBE to BAA	375	375
K_{ml} (mg/L)	26.9	26.9

Appendix B

Text Output from Benchmark Dose Software Runs Used in the Derivation of RfC and RfD Values




```
Total number of dose groups = 6
 1
 2
      Total number of records with missing values = 0
 3
      Maximum number of iterations = 250
 4
      Relative Function Convergence has been set to: 1e-008
 5
      Parameter Convergence has been set to: 1e-008
 6
 7
      Default Initial Parameter Values
 8
      lalpha = -3.17322
 9
      rho = 0
10
      intercept = 8.48
11
      v = -3.71
12
      n = 1.07589
13
      k = 278.325
14
15
      Asymptotic Correlation Matrix of Parameter Estimates
16
17
      (*** The model parameter(s) -n
18
      have been estimated at a boundary point, or have been specified by the user,
19
      and do not appear in the correlation matrix )
20
21
      lalpha rho intercept v k
22
23
      lalpha 1 -1 0.11 0.2 -0.21
24
25
      rho -1 1 -0.11 -0.2 0.21
26
27
      intercept 0.11 -0.11 1 0.27 -0.61
28
29
      v 0.2 -0.2 0.27 1 -0.88
30
31
      k -0.21 0.21 -0.61 -0.88 1
32
33
34
      Parameter Estimates
35
36
      95.0% Wald Confidence Interval
37
      Variable Estimate Std. Err. Lower Conf. Limit Upper Conf. Limit
38
      lalpha -1.10102 2.15389 -5.32256 3.12053
39
      rho -1.07311 1.09214 -3.21366 1.06743
      intercept 8.47695 0.0493243 8.38028 8.57363
40
      v -5.12159 0.285841 -5.68183 -4.56135
41
42
      n 1 NA
43
      k 468.055 60.889 348.715 587.395
44
45
      NA - Indicates that this parameter has hit a bound
      implied by some inequality constraint and thus
46
47
      has no standard error.
48
49
```

1 Table of Data and Estimated Values of Interest 2 3 Dose N Obs Mean Est Mean Obs Std Dev Est Std Dev Scaled Res. 4 _____ 5 6 0 10 8.48 8.48 0.16 0.183 0.0526 7 40.4 10 8.08 8.07 0.22 0.188 0.168 8 85.9 10 7.7 7.68 0.25 0.193 0.282 9 189.5 10 6.91 7 0.16 0.203 -1.42 10 451.3 9 6.07 5.96 0.12 0.221 1.45 11 1143 5 4.77 4.84 0.33 0.247 -0.66 12 13 14 Model Descriptions for likelihoods calculated 15 16 Model A1: Yij = Mu(i) + e(ij)17 $Var{e(ij)} = Sigma^2$ 18 19 Model A2: Yij = Mu(i) + e(ij)20 $Var{e(ij)} = Sigma(i)^2$ 21 22 Model A3: Yij = Mu(i) + e(ij)23 $Var{e(ij)} = exp(lalpha + rho*ln(Mu(i)))$ 24 Model A3 uses any fixed variance parameters that were specified by the user 25 26 27 Model R: Yi = Mu + e(i) $Var{e(i)} = Sigma^2$ 28 29 Likelihoods of Interest 30 31 Model Log(likelihood) # Param's AIC 32 A1 61.856962 7 -109.713924 33 A2 66.476628 12 -108.953256 34 A3 62.170236 8 -108.340472 35 fitted 59.636147 5 -109.272293 36 R -34.183663 2 72.367326 37 38 39 **Explanation of Tests** 40 Test 1: Do responses and/or variances differ among Dose levels? 41 42 (A2 vs. R)43 Test 2: Are Variances Homogeneous? (A1 vs A2) 44 Test 3: Are variances adequately modeled? (A2 vs. A3) Test 4: Does the Model for the Mean Fit? (A3 vs. fitted) 45 46 (Note: When rho=0 the results of Test 3 and Test 2 will be the same.) 47 48 Tests of Interest 49

1	Test -2*log(Likelihood Ratio) Test df p-value
2	
3	Test 1 201.321 10 <.0001
4	Test 2 9.23933 5 0.09989
5	Test 3 8.61278 4 0.07154
6	Test 4 5.06818 3 0.1669
7	
8	The p-value for Test 1 is less than .05. There appears to be a
9	difference between response and/or variances among the dose levels
10	It seems appropriate to model the data
11	
12	The p-value for Test 2 is less than .1. A non-homogeneous variance
13	model appears to be appropriate
14	
15	The p-value for Test 3 is less than .1. You may want to consider a
16	different variance model
17	
18	The p-value for Test 4 is greater than .1. The model chosen seems
19	to adequately describe the data
20	
21	Benchmark Dose Computation
22	
23	Specified effect = 0.05
24	
25	Risk Type = Relative risk
26	
27	Confidence level = 0.95
28	D) (D 40.0005
29	BMD = 42.2297
30	DMDI 27.1702
31	BMDL = 37.1792








1	Default Initial Parameter Values
2	lalpha = -2.62607
3	rho = 0
4	intercept = 9.05
5	v = -3.08
6	n = 1.56979
7	k = 333.008
8	R 555.000
9	
10	Asymptotic Correlation Matrix of Parameter Estimates
11	risymptotic contention marine of rataneous Estimates
12	lalpha rho intercept v n k
13	
14	lalpha 1 -1 0.0097 0.064 0.075 -0.09
15	
16	rho -1 1 -0.014 -0.064 -0.075 0.091
17	
18	intercept 0.0097 -0.014 1 -0.63 -0.64 0.25
19	intercept 0.0097 0.014 1 0.05 0.04 0.25
20	v 0.064 -0.064 -0.63 1 0.96 -0.9
20	
22	n 0.075 -0.075 -0.64 0.96 1 -0.82
23	
24	k -0.09 0.091 0.25 -0.9 -0.82 1
25	K 0.09 0.091 0.25 0.9 0.02 1
26	
27	Parameter Estimates
28	
29	95.0% Wald Confidence Interval
30	Variable Estimate Std. Err. Lower Conf. Limit Upper Conf. Limit
31	lalpha -11.3409 2.55713 -16.3527 -6.32896
32	rho 4.21018 1.23612 1.78742 6.63294
33	intercept 9.02037 0.0937743 8.83657 9.20416
34	v -3.96474 0.470028 -4.88597 -3.0435
35	n 1.39015 0.229376 0.940583 1.83972
36	k 462.11 80.7255 303.891 620.329
37	K +02.11 00.7255 505.071 020.527
38	
39	Table of Data and Estimated Values of Interest
40	Tuble of Data and Estimated Values of Interest
41	Dose N Obs Mean Est Mean Obs Std Dev Est Std Dev Scaled Res.
42	
43	
44	0 10 9.05 9.02 0.253 0.353 0.265
45	40.8 10 8.71 8.89 0.443 0.343 -1.65
46	86.6 10 8.91 8.67 0.19 0.325 2.35
	190.7 10 8.01 8.12 0.253 0.283 -1.27
	449.7 10 7.1 7.08 0.221 0.212 0.366
40	1096 10 5.97 5.97 0.158 0.148 -0.0614
77	1070 10 5.77 5.77 0.150 0.140 -0.0014

B-6

```
Model Descriptions for likelihoods calculated
 1
 2
 3
      Model A1: Yij = Mu(i) + e(ij)
 4
      Var{e(ij)} = Sigma^2
 5
 6
      Model A2: Yij = Mu(i) + e(ij)
 7
      Var{e(ij)} = Sigma(i)^2
 8
 9
      Model A3: Yij = Mu(i) + e(ij)
10
      Var{e(ij)} = exp(lalpha + rho*ln(Mu(i)))
11
      Model A3 uses any fixed variance parameters that
12
      were specified by the user
13
14
      Model R: Yi = Mu + e(i)
15
      Var{e(i)} = Sigma^2
16
17
18
      Likelihoods of Interest
19
20
      Model Log(likelihood) # Param's AIC
21
      A1 51.943035 7 -89.886070
22
      A2 58.944827 12 -93.889653
23
      A3 54.680821 8 -93.361643
24
      fitted 49.559802 6 -87.119604
25
      R -37.662661 2 79.325322
26
27
28
      Explanation of Tests
29
30
      Test 1: Do responses and/or variances differ among Dose levels?
31
      (A2 vs. R)
      Test 2: Are Variances Homogeneous? (A1 vs A2)
32
33
      Test 3: Are variances adequately modeled? (A2 vs. A3)
      Test 4: Does the Model for the Mean Fit? (A3 vs. fitted)
34
35
      (Note: When rho=0 the results of Test 3 and Test 2 will be the same.)
36
37
      Tests of Interest
38
39
      Test -2*log(Likelihood Ratio) Test df p-value
40
41
      Test 1 193.215 10 <.0001
42
      Test 2 14.0036 5 0.01559
43
      Test 3 8.52801 4 0.07404
44
      Test 4 10.242 2 0.00597
45
46
      The p-value for Test 1 is less than .05. There appears to be a
47
      difference between response and/or variances among the dose levels
48
      It seems appropriate to model the data
49
```








B-8


27 28


BMD Method for RfC: Hemosiderin deposition in male rats versus AUC BAA, 2 year inhalation study (NTP, 2000)
The form of the probability function is:
P[response] = background + (1-background)*[1-EXP(-beta1*dose^1)]
The parameter betas are restricted to be positive
Dependent variable = Hemosiderin_M Independent variable = MAUCDose3mo
Total number of observations = 4
Total number of records with missing values $= 0$
Total number of parameters in model $= 2$
Total number of specified parameters $= 0$
Degree of polynomial = 1
Maximum number of iterations $= 250$
Relative Function Convergence has been set to: 1e-008
Parameter Convergence has been set to: 1e-008
Default Initial Parameter Values
Background = 0.464249
Beta(1) = 0.00104028
Asymptotic Correlation Matrix of Parameter Estimates
Background Beta(1)
Background 1 -0.67
Beta(1) -0.67 1
Parameter Estimates


```
95.0% Wald Confidence Interval
 1
 2
      Variable Estimate Std. Err. Lower Conf. Limit Upper Conf. Limit
 3
      Background 0.464473 0.0851405 0.297601 0.631346
 4
      Beta(1) 0.00103871 0.000331559 0.000388869 0.00168856
 5
 6
 7
      Analysis of Deviance Table
 8
 9
      Model Log(likelihood) # Param's Deviance Test d.f. P-value
10
      Full model -121.475 4
      Fitted model -121.506 2 0.0626604 2 0.9692
11
      Reduced model -130.097 1 17.2453 3 0.0006292
12
13
14
      AIC: 247.012
15
16
17
      Goodness of Fit
18
      Scaled
19
      Dose Est. Prob. Expected Observed Size Residual
20
      _____
                                                  _____
21
      0.0000 0.4645 23.224 23 50 -0.063
22
      250.0000 0.5869 29.347 30 50 0.187
23
      525.9000 0.6899 34.494 34 50 -0.151
24
      1154.5000 0.8386 41.929 42 50 0.027
25
26
      Chi^2 = 0.06 d.f. = 2 P-value = 0.9691
27
28
29
      Benchmark Dose Computation
30
31
     Specified effect = 0.1
32
33
     Risk Type = Extra risk
34
35
     Confidence level = 0.95
36
37
      BMD = 101.434
38
39
      BMDL = 69.6269
40
41
      BMDU = 174.647
42
43
     Taken together, (69.6269, 174.647) is a 90% two-sided confidence
44
     interval for the BMD
45
46
47
48
49
```



```
1
      Default Initial Parameter Values
 2
      background = 0.3
 3
      intercept = -17.8009
 4
      slope = 2.88261
 5
 6
 7
      Asymptotic Correlation Matrix of Parameter Estimates
 8
 9
      background intercept slope
10
11
      background 1 -0.39 0.35
12
13
      intercept -0.39 1 -1
14
15
      slope 0.35 -1 1
16
17
18
19
      Parameter Estimates
20
21
      95.0% Wald Confidence Interval
      Variable Estimate Std. Err. Lower Conf. Limit Upper Conf. Limit
22
23
      background 0.291372 0.0594025 0.174945 0.407799
24
      intercept -16.9704 4.29214 -25.3829 -8.55798
      slope 2.77044 0.669882 1.45749 4.08338
25
26
27
28
29
      Analysis of Deviance Table
30
31
      Model Log(likelihood) # Param's Deviance Test d.f. P-value
      Full model -104.742 4
32
      Fitted model -104.839 3 0.192188 1 0.6611
33
34
      Reduced model -135.725 1 61.9658 3 <.0001
35
36
      AIC: 215.677
37
38
39
      Goodness of Fit
40
      Scaled
      Dose Est. Prob. Expected Observed Size Residual
41
42
43
      0.0000 0.2914 14.569 15 50 0.134
44
      245.0000 0.3981 19.906 19 50 -0.262
45
      515.5000 0.7039 35.193 36 50 0.250
46
      1131.0000 0.9466 47.332 47 50 -0.209
47
48
      Chi^2 = 0.19 d.f. = 1 P-value = 0.6606
49
```







Modeling Results Using 1SD as the BMR for Blood Effects

1 Table 5-5 and Table 5-13 present the modeling results for the potential blood effect endpoints

2 considered for deriving a reference concentration (RfC) and reference dose (RfD) by using a

3 benchmark response (BMR) of 5% relative change in the mean. The following tables present the

4 same effects using a BMR of 1 standard deviation (SD). A discussion for why this BMR was not

5 considered the best choice can be found in Section 5.1.2.2.1 for the RfC and in Section 5.2.2.2.1

6 for the RfD.

Table B-1. Comparison of BMC/BMCL values for female rat RBC count data from inhalation subchronic study (14 week) using modeled blood C_{max} (3 months) of the EGBE metabolite BAA as a common dose metric

Model	$BMC_{1SD}\left(\mu M\right)$	$BMCL_{1SD}(\mu M)$	p Value	\mathbf{AIC}^{*}	Scaled residual ^{**}
2nd degree polynomial	31.5363	22.6222	< 0.0001	-90.947514	0.15
Power	41.9568	33.8953	< 0.0001	-52.341720	0.218
Hill ^{***}	17.361	13.476	0.1669	-109.272293	0.168

*AIC = Akaike Information Criterion = -2L + 2P, where L is the log-likelihood at the maximum likelihood estimates for the parameters and P is the number of model degrees of freedom (usually the number of parameters estimated).

**Chi-square residual (measure of how model predicted response deviates from the actual data) for the dose group closest to the BMC scaled by an estimate of its SD. Provides a comparative measure of model fit near the BMC. Residuals that exceed 2.0 in absolute value should cause questioning of model fit in this region.

**Model choice based on adequate p value (>0.1), visual inspection, low AIC, and low (absolute) scaled residual.

Table B-2. Comparison of BMC/BMCL values for female rat RBC count and MCV from an oral subchronic study using modeled blood C_{max} (3 months) of the EGBE metabolite AA as a common dose metric

Model	BMC _{1SD} (µM)	BMCL _{1SD} (µM)	<i>p</i> Value	AIC*	Scaled residual ^{**}			
	RBC count							
1st degree polynomial	474.233	374.108	< 0.0001	-26.323	-1.35			
Power	474.233	374.108	< 0.0001	-26.323	-1.35			
Hill ^{***}	56.5593	32.0476	0.7038	-48.884	0.204			
	MCV							
1st degree polynomial	108.691	76.203	< 0.0001	141.85	-0.223			
Power	108.691	76.203	< 0.0001	141.85	-0.223			
Hill	40.516	failed	0.1768	120.94	-0.317			

*AIC = -2L + 2P, where L is the log-likelihood at the maximum likelihood estimates for the parameters and P is the number of model degrees of freedom (number of parameters estimated).

^{**}Chi-square residual (measure of how model predicted response deviates from the actual data) for the dose group closest to the BMC scaled by an estimate of its SD. Provides a comparative measure of model fit near the BMC. Residuals that exceed 2.0 in absolute value should cause questioning of model fit in this region.

****Model choice based on adequate *p* value (>0.1), visual inspection, low AIC, and low (absolute) scaled residual.

Source: NTP (1993).

7 8

Multistage Cancer Model. (Version: 1.5; Date: 02/20/2007)

```
1
 2
      Y[dose] = intercept + v*dose^n/(k^n + dose^n)
 3
 4
      Dependent variable = MEAN
 5
      Independent variable = C_{max}
 6
      rho is set to 0
 7
      Power parameter restricted to be greater than 1
 8
      A constant variance model is fit
 9
10
      Total number of dose groups = 6
      Total number of records with missing values = 0
11
      Maximum number of iterations = 250
12
13
      Relative Function Convergence has been set to: 1e-008
14
      Parameter Convergence has been set to: 1e-008
15
16
17
18
      Default Initial Parameter Values
19
      alpha = 0.154717
20
      rho = 0 Specified
21
      intercept = 8.15
22
      v = -1.57
23
      n = 1.30181
24
      k = 170.5
25
26
27
      Asymptotic Correlation Matrix of Parameter Estimates
28
29
      (*** The model parameter(s) -rho -n
      have been estimated at a boundary point, or have been specified by the user,
30
31
      and do not appear in the correlation matrix)
32
33
      alpha intercept v k
34
35
      alpha 1 1.4e-009 1.2e-007 -7.3e-008
36
37
      intercept 1.4e-009 1 -0.41 -0.51
38
      v 1.2e-007 -0.41 1 -0.48
39
40
      k -7.3e-008 -0.51 -0.48 1
41
42
43
44
      Parameter Estimates
45
46
      95.0% Wald Confidence Interval
      Variable Estimate Std. Err. Lower Conf. Limit Upper Conf. Limit
47
48
      alpha 0.142549 0.0260259 0.0915397 0.193559
      intercept 8.15021 0.117707 7.91951 8.38092
49
```

1 v -1.75852 0.187534 -2.12608 -1.39096 2 n 1 NA 3 k 206.872 79.7468 50.5715 363.173 4 5 NA - Indicates that this parameter has hit a bound 6 implied by some inequality constraint and thus 7 has no standard error. 8 9 10 Table of Data and Estimated Values of Interest 11 12 Dose N Obs Mean Est Mean Obs Std Dev Est Std Dev Scaled Res. 13 ----- --- ------ -------14 15 0 10 8.15 8.15 0.28 0.378 -0.0018 16 103 10 7.59 7.57 0.48 0.378 0.204 17 253 10 7.09 7.18 0.43 0.378 -0.777 18 495 10 7 6.91 0.37 0.378 0.754 19 738 10 6.8 6.78 0.36 0.378 0.195 20 1355 10 6.58 6.62 0.41 0.378 -0.374 21 22 23 24 Model Descriptions for likelihoods calculated 25 26 27 Model A1: Yij = Mu(i) + e(ij) $Var{e(ij)} = Sigma^2$ 28 29 30 Model A2: Yij = Mu(i) + e(ij) $Var{e(ij)} = Sigma(i)^2$ 31 32 33 Model A3: Yij = Mu(i) + e(ij) $Var{e(ij)} = Sigma^2$ 34 Model A3 uses any fixed variance parameters that 35 36 were specified by the user 37 38 Model R: Yi = Mu + e(i)39 $Var{e(i)} = Sigma^2$ 40 41 42 Likelihoods of Interest 43 44 Model Log(likelihood) # Param's AIC 45 A1 29.145609 7 -44.291218 46 A2 30.744881 12 -37.489762 47 A3 29.145609 7 -44.291218 48 fitted 28.441981 4 -48.883963 49 R -3.574142 2 11.148285

1 2	Explanation of Tests
2 3 4	Test 1: Do responses and/or variances differ among Dose levels? (A2 vs. R)
5	Test 2: Are Variances Homogeneous? (A1 vs A2)
6	Test 3: Are variances adequately modeled? (A2 vs. A3)
7	Test 4: Does the Model for the Mean Fit? (A3 vs. fitted)
8	(Note: When rho=0 the results of Test 3 and Test 2 will be the same.)
9	
10	Tests of Interest
11	Test 2*les(Likelikesd Datis) Test df a velve
12 13	Test -2*log(Likelihood Ratio) Test df p-value
13	Test 1 68.638 10 <.0001
15	Test 2 3.19854 5 0.6694
16	Test 3 3.19854 5 0.6694
17	Test 4 1.40726 3 0.7038
18	
19	The p-value for Test 1 is less than .05. There appears to be a
20	difference between response and/or variances among the dose levels
21	It seems appropriate to model the data
22	The marshes for Test 2 is successful them 1. A homeone successful to
23 24	The p-value for Test 2 is greater than .1. A homogeneous variance
24 25	model appears to be appropriate here
23 26	
27	The p-value for Test 3 is greater than .1. The modeled variance appears
28	to be appropriate here
29	
30	The p-value for Test 4 is greater than .1. The model chosen seems
31	to adequately describe the data
32	
33	
34	Benchmark Dose Computation
35 36	Specified effect = 0.05
37	Specified cheet = 0.05
38	Risk Type = Relative risk
39	
40	Confidence level = 0.95
41	
42	BMD = 62.3999
43	
44	BMDL = 36.2595
45 46	
46 47	
т/	

	Input Data File: C:\BMDS\Data\EGBE_M_HC.(d) Gnuplot Plotting File: C:\BMDS\Data\EGBE_M_HC.(d) Thu Feb 21 10:55:46 2008
~	BMDS MODEL RUN
	The form of the probability function is:
	P[response] = background + (1-background)*[1-EXP(-beta1*dose^1-beta2*dose^2-beta3*dose^3)]
	The parameter betas are restricted to be positive
	Dependent variable = Hep_Car_ADJ_M Independent variable = AUC_Mouse_M
	Total number of observations = 4 Total number of records with missing values = 0 Total number of parameters in model = 4 Total number of specified parameters = 0
	Degree of polynomial = 3
	Maximum number of iterations = 250 Relative Function Convergence has been set to: 1e-008 Parameter Convergence has been set to: 1e-008
	Default Initial Parameter Values Background = 0.209552 Beta(1) = 0.000187331 Beta(2) = 0 Beta(3) = 0
	Asymptotic Correlation Matrix of Parameter Estimates
	(*** The model parameter(s) -Beta(2) -Beta(3) have been estimated at a boundary point, or have been specified by the user, and do not appear in the correlation matrix)
	Background Beta(1)
]	Background 1 -0.71

```
1
      Beta(1) -0.71 1
 2
 3
 4
 5
      Parameter Estimates
 6
 7
      95.0% Wald Confidence Interval
 8
      Variable Estimate Std. Err. Lower Conf. Limit Upper Conf. Limit
 9
      Background 0.195776 * * *
      Beta(1) 0.000198015 * * *
10
      Beta(2) 0 * * *
11
12
      Beta(3) 0 * * *
13
14
     * - Indicates that this value is not calculated.
15
      Warning: Likelihood for the fitted model larger than the Likelihood for the full model.
16
17
     Error in computing chi-square; returning 2
18
19
20
      Analysis of Deviance Table
21
22
      Model Log(likelihood) # Param's Deviance Test d.f. P-value
23
      Full model -119.553 4
24
      Fitted model -118.389 2 -2.32685 2 2
25
      Reduced model -124.691 1 10.2756 3 0.01636
26
27
      AIC: 240.779
28
29
30
      Goodness of Fit
31
      Scaled
32
      Dose Est. Prob. Expected Observed Size Residual
33
      _____
34
      0.0000 0.1958 9.867 10 50 0.189
35
      402.0000 0.2573 12.981 11 50 -0.493
36
      925.0000 0.3304 16.209 19 49 0.866
37
      2120.0000 0.4715 23.334 22 49 -0.240
38
39
      Chi^{2} = 1.09 d.f. = 2 P-value = 0.5809
40
41
42
      Benchmark Dose Computation
43
44
     Specified effect = 0.1
45
46
     Risk Type = Extra risk
47
48
     Confidence level = 0.95
49
```

BMD = 532.083
 BMDL = 333.797
 BMDU = 1475.14
 Taken together, (333.797, 1475.14) is a 90 % two-sided confidence interval for the BMD
 Multistage Cancer Slope Factor = 0.000299583

Appendix C

Benchmark Dose Assessment of Forestomach Lesions in Female Mice Using PBPK Models to Estimate Human Equivalent Exposures

Several PBPK models have been developed for EGBE, all of which are capable of
 estimating internal doses. These models are summarized briefly in Section 5 of this assessment.
 Consistent with the assessment approach outlined in Section 5, the Lee et al. (1998) model was
 used to estimate internal dose levels from inhalation exposures to the experimental animal, in
 this case the female mouse.

6 Peak concentration in the blood during the exposure period (C_{max}) of BAA was used in 7 the derivation of the RfC when using hematological endpoints because of (1) convincing 8 evidence that BAA is the causative agent for EGBE-induced hemolysis and (2) EGBE-induced 9 hemolysis appears to be highly dependent on the BAA concentration attained. Area under the 10 curve was used in the derivation of the RfC during use of the hemosiderin deposition as the 11 critical endpoint, because this endpoint increases in severity with increasing duration of exposure 12 and because it is representative of a continuous process and not a one-time event.

13 C_{max} of blood BAA is considered a reasonable measure of internal dose for the 14 forestomach lesions reported from EGBE exposure. BAA is believed to be the toxic moiety 15 responsible for the forestomach effects observed following EGBE exposure, with concentration 16 (rather than AUC) appearing to be determinative in the development of these effects as well 17 (Corley et al., 2005b). Other information supportive of the C_{max} as an appropriate metric include 18 the findings of NTP (1993), where no signs of forestomach irritation were observed in mice at 19 very high dose levels of 1,400 mg/kg-day in 2-week and 13-week drinking-water studies 20 conducted by NTP (1993). It is likely that such oral non-bolus dosing of EGBE does not result in 21 high enough local concentrations of EGBE and BAA (Poet et al., 2003) to produce irritation. 22 Consistent with this observation are results with other forestomach carcinogens that are not 23 mutagenic, demonstrating that forestomach effects are dependent not only on the dose but also 24 on the chemical concentration in the dosing solution (Ghanayem et al., 1985). 25 The blood level of BAA is apparently a valid surrogate for the local (i.e., forestomach) 26 BAA concentration as blood levels of BAA follow the severity of the irritant and irritant-27 associated hyperplastic responses in the forestomach. Further, this relationship between blood 28 BAA levels and irritant response holds true for routes of EGBE administration other than oral, 29 (e.g., inhalation, intraperitoneal, and i.v.) (Green et al., 2002; Corley et al., 1999). The basis for 30 this route-independent response may be related to the Green et al. (2002) results from whole1 body autoradiography of mice exposed via inhalation, showing appreciable amounts of EGBE-

2 associated radioactivity being present in salivary glands and ducts.

3 Plausible evidence exists for considering the incidence of forestomach tumors in female 4 mice, following chronic inhalation exposure to EGBE to occur via a nonlinear, nongenotoxic 5 mode of action. EGBE appears to be one of a group of compounds that are not mutagenic but can 6 indirectly cause forestomach tumors through the sustained cytotoxicity and cell regeneration 7 brought about by irritant and irritant-associated hyperplastic effects and breakdown of the 8 forestomach's gastric mucosal barrier. This sequence of events is considered obligate for the 9 formation of the observed neoplasms. Strategies intended to control or omit any of these key 10 mode-of-action events, including the initial hyperplastic event, would interrupt the process and 11 prevent formation of neoplasms. While this mode of action may be of qualitative relevance to 12 humans, the exposure concentrations that would be necessary to cause these hyperplastic effects 13 and resultant tumors in humans, if attainable, are likely to be much higher than the 14 concentrations necessary to cause forestomach effects in mice, primarily because humans lack a 15 comparable organ for storage and long-term retention of EGBE. 16 Another line of reasoning that may be used to address issues relating to the occurrence of 17 these irritant/hyperplastic lesions (and potential for progression) in humans is to order the dose-18 response among those effects noted for EGBE, most prominently the hematologic effects that 19 underlie the hepatic tumors and that are the basis of the oral RfD and inhalation RfC. A 20 benchmark dose (BMD) analysis of the irritant/hyperplastic response observed in the NTP 21 (2000) follows. 22 The endpoint used in this analysis was epithelial hyperplasia of the female mouse 23 forestomach, since it was the most sensitive forestomach effect observed in the NTP (2000) 24 study. Consistent with the 1999 IRIS assessment, four steps were employed to estimate human 25 equivalent oral and inhalation benchmark exposures from this endpoint: (1) a BMDL₁₀ value was estimated using modeled "end-of-the-week" internal dose (Cmax BAA in blood) levels, (2) verify 26 27 that steady state was achieved (e.g., no change in BAA C_{max} as a result of prolonging the 28 exposure regimen), (3) simulate the internal dose surrogate (C_{max} BAA in blood) for humans 29 (continuous air exposure; drinking water assumption was that a 70 kg human consumes an 30 average of 2 L of water during a 12-hour awake cycle), and (4) calculate the human equivalent 31 dose/concentration that resulted in the same internal dose (C_{max} BAA) simulated for the animal 32 in Step 1. 33 34 Step 1: Estimation of $BMDL_{10}$ (C_{max}) dose. 35 C_{max} for BAA in arterial blood was determined using the PBPK model of Lee et al.

36 (1998). The model results and incidence data for the endpoint of concern are
37 summarized in Table C-1.

Air concentration (ppm)	C _{max} BAA (µM)	Incidence of forestomach hyperplasia
0	0	0/50
62.5	529	6/50
125	1,200	27/50
250	2,620	42/49

Table C-1. PBPK model estimates of BAA C_{max} blood levels and incidence of forestomach epithelial hyperplasia in female mice

BMD and BMDL₁₀ estimates were derived using the available models in version 1.3.2 of
 the EPA benchmark dose software (BMDS). The estimates for each model, along
 with statistical goodness-of-fit information, are provided in Table C-2.

4


Table C-2. BMDS model estimates of C_{max} BMD₁₀ and BMDL₁₀ values for forestomach epithelial hyperplasia in female mice

BMDS model	BMD (µM)	BMDL (µM)	AIC (lowest = best fit)	<i>p</i> Value (>0.1 = adequate fit)
Gamma	420.56	266.87	151.16	0.5287
Logistic	544.757	444.896	162.191	0.0067
Log-logistic	462.513	329.04	150.153	0.8717
Multistage (1st degree)	177.442	145.713	156.244	0.0648
Multistage (2nd degree)	338.483	202.437	152.681	0.0976
Multistage (3rd degree)	338.485	197.436	152.681	0.2535
Probit	525.521	430.612	161.304	0.0086
Log-probit	470.876	344.412	150.163	0.8673
Weibull	376.085	238.952	151.855	0.3807


5 Step 2: Verification of steady state.

	62.5 ppm		62.5 ppm 125 ppm		250 ppm	
Months on study	Male	Female	Male	Female	Male	Female
1	403	529	921	1,200	2,080	2,620
3	402	527	925	1,202	2,120	2,652
6	399	523	914	1,184	2,071	2,582
12	484	639	1,079	1,414	2,349	2,951
16	643	849	1,443	1,839	2,798	3,501
18	756	995	1,625	2,102	3,067	3,803

Table C-3. Female mouse C_{max} values for various time points of the NTP (2000) study estimated by the Lee et al. (1998) model







1	Step 3: Simulation of internal human doses.
2	The tables below summarize the results of model simulations of the internal dose
3	surrogate (C_{max} BAA in blood) for a 70 kg human who consumes an average of 2 L
4	of drinking water during a 12-hour awake cycle (Table C-4) or is continuously
5	exposed to air concentrations (Table C-5) of EGBE.
6	

EGBE concentration in water (ppm)	Calculated dose of EGBE from drinking water (mg/kg-day)	Cmax BAA in blood (µM)
24	0.7	9
48	1.4	18
94	2.7	36
188	5.4	73
375	10.7	147
750	21.4	299

Table C-4. Estimated C_{max} for BAA in blood for humans continuously exposed to varying drinking water concentrations of EGBE

Source: Corley et al. (1997, 1994).

Table C-5. Estimated C_{max} for BAA in blood for humans continuously exposed to varying concentrations of EGBE

Concentration of EGBE in air (ppm)	C _{max} BAA in blood (μM)
1	2.6
5	13.0
10	26.1
20	52.9
50	137.1
100	295.0
200	733.7

Source: Corley et al. (1997, 1994).

1	Step 4: Calculate the human equivalent dose/concentration
2	The Corley et al. (1997, 1994) PBPK model was used to back-calculate a human
3	equivalent oral dose of 23.6 mg/kg-day from the C_{max} BMDL ₁₀ of 320 μ M estimated
4	in step 1, assuming that mice and humans receive their entire dose of EGBE from
5	drinking water over a 12-hour period each day. The Corley et al. (1997) PBPK
6	model was used to back-calculate human equivalent air concentration of 551 mg/m ³
7	(113 ppm) from the C_{max} BMDL ₁₀ of 320 μ M estimated in step 1, assuming
8	continuous exposure (24 hours/day).

Conclusion

9 The PODs calculated above are significantly higher than the PODs of 1 mg/kg-day and 12

10 mg/m³ used to derive the RfD and RfC, respectively. Thus, these results indicate that the RfD

11 and RfC values for EGBE, which were based on hemosiderin accumulation due to hemolytic

12 effects in rats, should be adequate for the prevention of gastrointestinal hyperplastic effects as

13 well.

Log-Logistic Model Results for Forestomach Epithelial Hyperplasia in Female Mice (NTP, 2000)

Input Data File: F:\B	: F:\BMDS\DATA\EGBE	2/26 03:38:20 \$ DUSE_HYP_LOG-LOGIST.(d) \F_MOUSE_HYP_LOG-LOGIST.plt		
BMDS MODEL RUN		~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~		
The form of the probability	function is:			
P[response] = background+(1-background)/[1+EXP(-in	ntercept-slope*Log(dose))]		
Dependent variable = F_Hyp				
Independent variable = Dose				
Slope parameter is restricted	as slope >= 1			
Total number of observation	s = 4			
Total number of records with missing values $= 0$				
Maximum number of iteration	ons = 250			
Relative Function Converge				
Parameter Convergence has	been set to: 1e-008			
	C 1 1 1			
User has chosen the log tran	stormed model			
Default Initial Parameter Va	lues			
background = 0				
intercept = -16.768				
slope = 2.36735				
Asymptotic Correlation Mat	rix of Parameter Estimates			
(*** The model peremeter() background			
(*** The model parameter(s) -background have been estimated at a boundary point, or have been specified by the user,				
and do not appear in the correlation matrix)				
	······································			
intercept slope				
intercept 1 -1				
slope -1 1				
Doromotor Estimator				
Parameter Estimates				
April 2008	C-6	DRAFT-DO NOT CITE OR QU		

April 2008

```
1
 2
      Variable Estimate Std. Err.
 3
      background 0 NA
 4
      intercept -16.7132 2.64108
 5
      slope 2.36545 0.372243
 6
 7
     NA - Indicates that this parameter has hit a bound
 8
      implied by some inequality constraint and thus
 9
      has no standard error.
10
11
12
      Analysis of Deviance Table
13
14
      Model Log(likelihood) Deviance Test DF P-value
      Full model -72.9391
15
      Fitted model -73.0765 0.274637 2 0.8717
16
17
      Reduced model -131.841 117.804 3 <.0001
18
19
      AIC: 150.153
20
21
      Goodness of Fit
22
23
      Scaled
24
      Dose Est. Prob. Expected Observed Size Residual
                              _____
25
26
      0.0000 0.0000 0.000 0 50 0
27
      529.0000 0.1324 6.622 6 50 -0.2596
28
      1200.0000 0.5145 25.725 27 50 0.3608
29
      2620.0000 0.8705 42.653 42 49 -0.2777
30
31
      Chi-square = 0.27 \text{ DF} = 2 \text{ P-value} = 0.8717
32
33
      Benchmark Dose Computation
34
35
     Specified effect = 0.1
36
37
     Risk Type = Extra risk
38
39
     Confidence level = 0.95
40
41
      BMD = 462.513
42
43
      BMDL = 329.04
```